{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "machine_shape": "hm",
      "authorship_tag": "ABX9TyOREvVcjQXRpPWCeoz1AzhH"
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "source": [
        "# Medicine Identification and Drug Facts Retrieval\n",
        "\n",
        "This notebook tests a system to identify medicines from packaging images and retrieve drug facts using the DrugBank XML dataset in Google Colab. The workflow includes:\n",
        "\n",
        "1. Image preprocessing with OpenCV\n",
        "2. Text extraction with Google Cloud Vision API\n",
        "3. Text cleaning and entity extraction with SpaCy\n",
        "4. Semantic retrieval with FAISS and Sentence Transformers\n",
        "5. Response generation with OpenAI GPT\n",
        "\n",
        "**Prerequisites**:\n",
        "- Uploaded `drugbank.xml` (DrugBank dataset)\n",
        "- Uploaded test image (e.g., `medicine_packaging.jpg`)\n",
        "- Google Cloud Vision service account key (e.g., `service-account-key.json`)\n",
        "- OpenAI API key\n",
        "- Installed dependencies (installed below)\n",
        "\n",
        "**Note**: No database logging is included to focus on testing."
      ],
      "metadata": {
        "id": "WRTS1-hWWjVQ"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# Install required packages\n",
        "!pip install opencv-python google-cloud-vision spacy transformers sentence-transformers faiss-cpu openai lxml fuzzywuzzy\n",
        "!python -m spacy download en_core_web_sm"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "Pe484HXdWlhm",
        "outputId": "e8fdc235-0a4f-437e-ef02-0002c010bff5"
      },
      "execution_count": 1,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: opencv-python in /usr/local/lib/python3.11/dist-packages (4.11.0.86)\n",
            "Collecting google-cloud-vision\n",
            "  Downloading google_cloud_vision-3.10.1-py3-none-any.whl.metadata (9.5 kB)\n",
            "Requirement already satisfied: spacy in /usr/local/lib/python3.11/dist-packages (3.8.5)\n",
            "Requirement already satisfied: transformers in /usr/local/lib/python3.11/dist-packages (4.50.3)\n",
            "Requirement already satisfied: sentence-transformers in /usr/local/lib/python3.11/dist-packages (3.4.1)\n",
            "Collecting faiss-cpu\n",
            "  Downloading faiss_cpu-1.10.0-cp311-cp311-manylinux_2_28_x86_64.whl.metadata (4.4 kB)\n",
            "Requirement already satisfied: openai in /usr/local/lib/python3.11/dist-packages (1.70.0)\n",
            "Requirement already satisfied: lxml in /usr/local/lib/python3.11/dist-packages (5.3.1)\n",
            "Collecting fuzzywuzzy\n",
            "  Downloading fuzzywuzzy-0.18.0-py2.py3-none-any.whl.metadata (4.9 kB)\n",
            "Requirement already satisfied: numpy>=1.21.2 in /usr/local/lib/python3.11/dist-packages (from opencv-python) (2.0.2)\n",
            "Requirement already satisfied: google-api-core!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0,>=1.34.1 in /usr/local/lib/python3.11/dist-packages (from google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0,>=1.34.1->google-cloud-vision) (2.24.2)\n",
            "Requirement already satisfied: google-auth!=2.24.0,!=2.25.0,<3.0.0,>=2.14.1 in /usr/local/lib/python3.11/dist-packages (from google-cloud-vision) (2.38.0)\n",
            "Requirement already satisfied: proto-plus<2.0.0,>=1.22.3 in /usr/local/lib/python3.11/dist-packages (from google-cloud-vision) (1.26.1)\n",
            "Requirement already satisfied: protobuf!=4.21.0,!=4.21.1,!=4.21.2,!=4.21.3,!=4.21.4,!=4.21.5,<7.0.0,>=3.20.2 in /usr/local/lib/python3.11/dist-packages (from google-cloud-vision) (5.29.4)\n",
            "Requirement already satisfied: spacy-legacy<3.1.0,>=3.0.11 in /usr/local/lib/python3.11/dist-packages (from spacy) (3.0.12)\n",
            "Requirement already satisfied: spacy-loggers<2.0.0,>=1.0.0 in /usr/local/lib/python3.11/dist-packages (from spacy) (1.0.5)\n",
            "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.11/dist-packages (from spacy) (1.0.12)\n",
            "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.11/dist-packages (from spacy) (2.0.11)\n",
            "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.11/dist-packages (from spacy) (3.0.9)\n",
            "Requirement already satisfied: thinc<8.4.0,>=8.3.4 in /usr/local/lib/python3.11/dist-packages (from spacy) (8.3.6)\n",
            "Requirement already satisfied: wasabi<1.2.0,>=0.9.1 in /usr/local/lib/python3.11/dist-packages (from spacy) (1.1.3)\n",
            "Requirement already satisfied: srsly<3.0.0,>=2.4.3 in /usr/local/lib/python3.11/dist-packages (from spacy) (2.5.1)\n",
            "Requirement already satisfied: catalogue<2.1.0,>=2.0.6 in /usr/local/lib/python3.11/dist-packages (from spacy) (2.0.10)\n",
            "Requirement already satisfied: weasel<0.5.0,>=0.1.0 in /usr/local/lib/python3.11/dist-packages (from spacy) (0.4.1)\n",
            "Requirement already satisfied: typer<1.0.0,>=0.3.0 in /usr/local/lib/python3.11/dist-packages (from spacy) (0.15.2)\n",
            "Requirement already satisfied: tqdm<5.0.0,>=4.38.0 in /usr/local/lib/python3.11/dist-packages (from spacy) (4.67.1)\n",
            "Requirement already satisfied: requests<3.0.0,>=2.13.0 in /usr/local/lib/python3.11/dist-packages (from spacy) (2.32.3)\n",
            "Requirement already satisfied: pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4 in /usr/local/lib/python3.11/dist-packages (from spacy) (2.11.2)\n",
            "Requirement already satisfied: jinja2 in /usr/local/lib/python3.11/dist-packages (from spacy) (3.1.6)\n",
            "Requirement already satisfied: setuptools in /usr/local/lib/python3.11/dist-packages (from spacy) (75.2.0)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.11/dist-packages (from spacy) (24.2)\n",
            "Requirement already satisfied: langcodes<4.0.0,>=3.2.0 in /usr/local/lib/python3.11/dist-packages (from spacy) (3.5.0)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.11/dist-packages (from transformers) (3.18.0)\n",
            "Requirement already satisfied: huggingface-hub<1.0,>=0.26.0 in /usr/local/lib/python3.11/dist-packages (from transformers) (0.30.1)\n",
            "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.11/dist-packages (from transformers) (6.0.2)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.11/dist-packages (from transformers) (2024.11.6)\n",
            "Requirement already satisfied: tokenizers<0.22,>=0.21 in /usr/local/lib/python3.11/dist-packages (from transformers) (0.21.1)\n",
            "Requirement already satisfied: safetensors>=0.4.3 in /usr/local/lib/python3.11/dist-packages (from transformers) (0.5.3)\n",
            "Requirement already satisfied: torch>=1.11.0 in /usr/local/lib/python3.11/dist-packages (from sentence-transformers) (2.6.0+cu124)\n",
            "Requirement already satisfied: scikit-learn in /usr/local/lib/python3.11/dist-packages (from sentence-transformers) (1.6.1)\n",
            "Requirement already satisfied: scipy in /usr/local/lib/python3.11/dist-packages (from sentence-transformers) (1.14.1)\n",
            "Requirement already satisfied: Pillow in /usr/local/lib/python3.11/dist-packages (from sentence-transformers) (11.1.0)\n",
            "Requirement already satisfied: anyio<5,>=3.5.0 in /usr/local/lib/python3.11/dist-packages (from openai) (4.9.0)\n",
            "Requirement already satisfied: distro<2,>=1.7.0 in /usr/local/lib/python3.11/dist-packages (from openai) (1.9.0)\n",
            "Requirement already satisfied: httpx<1,>=0.23.0 in /usr/local/lib/python3.11/dist-packages (from openai) (0.28.1)\n",
            "Requirement already satisfied: jiter<1,>=0.4.0 in /usr/local/lib/python3.11/dist-packages (from openai) (0.9.0)\n",
            "Requirement already satisfied: sniffio in /usr/local/lib/python3.11/dist-packages (from openai) (1.3.1)\n",
            "Requirement already satisfied: typing-extensions<5,>=4.11 in /usr/local/lib/python3.11/dist-packages (from openai) (4.13.1)\n",
            "Requirement already satisfied: idna>=2.8 in /usr/local/lib/python3.11/dist-packages (from anyio<5,>=3.5.0->openai) (3.10)\n",
            "Requirement already satisfied: googleapis-common-protos<2.0.0,>=1.56.2 in /usr/local/lib/python3.11/dist-packages (from google-api-core!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0,>=1.34.1->google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0,>=1.34.1->google-cloud-vision) (1.69.2)\n",
            "Requirement already satisfied: grpcio<2.0dev,>=1.33.2 in /usr/local/lib/python3.11/dist-packages (from google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0,>=1.34.1->google-cloud-vision) (1.71.0)\n",
            "Requirement already satisfied: grpcio-status<2.0.dev0,>=1.33.2 in /usr/local/lib/python3.11/dist-packages (from google-api-core[grpc]!=2.0.*,!=2.1.*,!=2.10.*,!=2.2.*,!=2.3.*,!=2.4.*,!=2.5.*,!=2.6.*,!=2.7.*,!=2.8.*,!=2.9.*,<3.0.0,>=1.34.1->google-cloud-vision) (1.71.0)\n",
            "Requirement already satisfied: cachetools<6.0,>=2.0.0 in /usr/local/lib/python3.11/dist-packages (from google-auth!=2.24.0,!=2.25.0,<3.0.0,>=2.14.1->google-cloud-vision) (5.5.2)\n",
            "Requirement already satisfied: pyasn1-modules>=0.2.1 in /usr/local/lib/python3.11/dist-packages (from google-auth!=2.24.0,!=2.25.0,<3.0.0,>=2.14.1->google-cloud-vision) (0.4.2)\n",
            "Requirement already satisfied: rsa<5,>=3.1.4 in /usr/local/lib/python3.11/dist-packages (from google-auth!=2.24.0,!=2.25.0,<3.0.0,>=2.14.1->google-cloud-vision) (4.9)\n",
            "Requirement already satisfied: certifi in /usr/local/lib/python3.11/dist-packages (from httpx<1,>=0.23.0->openai) (2025.1.31)\n",
            "Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.11/dist-packages (from httpx<1,>=0.23.0->openai) (1.0.7)\n",
            "Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.11/dist-packages (from httpcore==1.*->httpx<1,>=0.23.0->openai) (0.14.0)\n",
            "Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.11/dist-packages (from huggingface-hub<1.0,>=0.26.0->transformers) (2025.3.2)\n",
            "Requirement already satisfied: language-data>=1.2 in /usr/local/lib/python3.11/dist-packages (from langcodes<4.0.0,>=3.2.0->spacy) (1.3.0)\n",
            "Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.11/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy) (0.7.0)\n",
            "Requirement already satisfied: pydantic-core==2.33.1 in /usr/local/lib/python3.11/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy) (2.33.1)\n",
            "Requirement already satisfied: typing-inspection>=0.4.0 in /usr/local/lib/python3.11/dist-packages (from pydantic!=1.8,!=1.8.1,<3.0.0,>=1.7.4->spacy) (0.4.0)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.11/dist-packages (from requests<3.0.0,>=2.13.0->spacy) (3.4.1)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.11/dist-packages (from requests<3.0.0,>=2.13.0->spacy) (2.3.0)\n",
            "Requirement already satisfied: blis<1.4.0,>=1.3.0 in /usr/local/lib/python3.11/dist-packages (from thinc<8.4.0,>=8.3.4->spacy) (1.3.0)\n",
            "Requirement already satisfied: confection<1.0.0,>=0.0.1 in /usr/local/lib/python3.11/dist-packages (from thinc<8.4.0,>=8.3.4->spacy) (0.1.5)\n",
            "Requirement already satisfied: networkx in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence-transformers) (3.4.2)\n",
            "Collecting nvidia-cuda-nvrtc-cu12==12.4.127 (from torch>=1.11.0->sentence-transformers)\n",
            "  Downloading nvidia_cuda_nvrtc_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl.metadata (1.5 kB)\n",
            "Collecting nvidia-cuda-runtime-cu12==12.4.127 (from torch>=1.11.0->sentence-transformers)\n",
            "  Downloading nvidia_cuda_runtime_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl.metadata (1.5 kB)\n",
            "Collecting nvidia-cuda-cupti-cu12==12.4.127 (from torch>=1.11.0->sentence-transformers)\n",
            "  Downloading nvidia_cuda_cupti_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl.metadata (1.6 kB)\n",
            "Collecting nvidia-cudnn-cu12==9.1.0.70 (from torch>=1.11.0->sentence-transformers)\n",
            "  Downloading nvidia_cudnn_cu12-9.1.0.70-py3-none-manylinux2014_x86_64.whl.metadata (1.6 kB)\n",
            "Collecting nvidia-cublas-cu12==12.4.5.8 (from torch>=1.11.0->sentence-transformers)\n",
            "  Downloading nvidia_cublas_cu12-12.4.5.8-py3-none-manylinux2014_x86_64.whl.metadata (1.5 kB)\n",
            "Collecting nvidia-cufft-cu12==11.2.1.3 (from torch>=1.11.0->sentence-transformers)\n",
            "  Downloading nvidia_cufft_cu12-11.2.1.3-py3-none-manylinux2014_x86_64.whl.metadata (1.5 kB)\n",
            "Collecting nvidia-curand-cu12==10.3.5.147 (from torch>=1.11.0->sentence-transformers)\n",
            "  Downloading nvidia_curand_cu12-10.3.5.147-py3-none-manylinux2014_x86_64.whl.metadata (1.5 kB)\n",
            "Collecting nvidia-cusolver-cu12==11.6.1.9 (from torch>=1.11.0->sentence-transformers)\n",
            "  Downloading nvidia_cusolver_cu12-11.6.1.9-py3-none-manylinux2014_x86_64.whl.metadata (1.6 kB)\n",
            "Collecting nvidia-cusparse-cu12==12.3.1.170 (from torch>=1.11.0->sentence-transformers)\n",
            "  Downloading nvidia_cusparse_cu12-12.3.1.170-py3-none-manylinux2014_x86_64.whl.metadata (1.6 kB)\n",
            "Requirement already satisfied: nvidia-cusparselt-cu12==0.6.2 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence-transformers) (0.6.2)\n",
            "Requirement already satisfied: nvidia-nccl-cu12==2.21.5 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence-transformers) (2.21.5)\n",
            "Requirement already satisfied: nvidia-nvtx-cu12==12.4.127 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence-transformers) (12.4.127)\n",
            "Collecting nvidia-nvjitlink-cu12==12.4.127 (from torch>=1.11.0->sentence-transformers)\n",
            "  Downloading nvidia_nvjitlink_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl.metadata (1.5 kB)\n",
            "Requirement already satisfied: triton==3.2.0 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence-transformers) (3.2.0)\n",
            "Requirement already satisfied: sympy==1.13.1 in /usr/local/lib/python3.11/dist-packages (from torch>=1.11.0->sentence-transformers) (1.13.1)\n",
            "Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.11/dist-packages (from sympy==1.13.1->torch>=1.11.0->sentence-transformers) (1.3.0)\n",
            "Requirement already satisfied: click>=8.0.0 in /usr/local/lib/python3.11/dist-packages (from typer<1.0.0,>=0.3.0->spacy) (8.1.8)\n",
            "Requirement already satisfied: shellingham>=1.3.0 in /usr/local/lib/python3.11/dist-packages (from typer<1.0.0,>=0.3.0->spacy) (1.5.4)\n",
            "Requirement already satisfied: rich>=10.11.0 in /usr/local/lib/python3.11/dist-packages (from typer<1.0.0,>=0.3.0->spacy) (13.9.4)\n",
            "Requirement already satisfied: cloudpathlib<1.0.0,>=0.7.0 in /usr/local/lib/python3.11/dist-packages (from weasel<0.5.0,>=0.1.0->spacy) (0.21.0)\n",
            "Requirement already satisfied: smart-open<8.0.0,>=5.2.1 in /usr/local/lib/python3.11/dist-packages (from weasel<0.5.0,>=0.1.0->spacy) (7.1.0)\n",
            "Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.11/dist-packages (from jinja2->spacy) (3.0.2)\n",
            "Requirement already satisfied: joblib>=1.2.0 in /usr/local/lib/python3.11/dist-packages (from scikit-learn->sentence-transformers) (1.4.2)\n",
            "Requirement already satisfied: threadpoolctl>=3.1.0 in /usr/local/lib/python3.11/dist-packages (from scikit-learn->sentence-transformers) (3.6.0)\n",
            "Requirement already satisfied: marisa-trie>=1.1.0 in /usr/local/lib/python3.11/dist-packages (from language-data>=1.2->langcodes<4.0.0,>=3.2.0->spacy) (1.2.1)\n",
            "Requirement already satisfied: pyasn1<0.7.0,>=0.6.1 in /usr/local/lib/python3.11/dist-packages (from pyasn1-modules>=0.2.1->google-auth!=2.24.0,!=2.25.0,<3.0.0,>=2.14.1->google-cloud-vision) (0.6.1)\n",
            "Requirement already satisfied: markdown-it-py>=2.2.0 in /usr/local/lib/python3.11/dist-packages (from rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy) (3.0.0)\n",
            "Requirement already satisfied: pygments<3.0.0,>=2.13.0 in /usr/local/lib/python3.11/dist-packages (from rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy) (2.18.0)\n",
            "Requirement already satisfied: wrapt in /usr/local/lib/python3.11/dist-packages (from smart-open<8.0.0,>=5.2.1->weasel<0.5.0,>=0.1.0->spacy) (1.17.2)\n",
            "Requirement already satisfied: mdurl~=0.1 in /usr/local/lib/python3.11/dist-packages (from markdown-it-py>=2.2.0->rich>=10.11.0->typer<1.0.0,>=0.3.0->spacy) (0.1.2)\n",
            "Downloading google_cloud_vision-3.10.1-py3-none-any.whl (526 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m526.1/526.1 kB\u001b[0m \u001b[31m9.6 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading faiss_cpu-1.10.0-cp311-cp311-manylinux_2_28_x86_64.whl (30.7 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m30.7/30.7 MB\u001b[0m \u001b[31m77.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading fuzzywuzzy-0.18.0-py2.py3-none-any.whl (18 kB)\n",
            "Downloading nvidia_cublas_cu12-12.4.5.8-py3-none-manylinux2014_x86_64.whl (363.4 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m363.4/363.4 MB\u001b[0m \u001b[31m3.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading nvidia_cuda_cupti_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl (13.8 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m13.8/13.8 MB\u001b[0m \u001b[31m115.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading nvidia_cuda_nvrtc_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl (24.6 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m24.6/24.6 MB\u001b[0m \u001b[31m92.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading nvidia_cuda_runtime_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl (883 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m883.7/883.7 kB\u001b[0m \u001b[31m49.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading nvidia_cudnn_cu12-9.1.0.70-py3-none-manylinux2014_x86_64.whl (664.8 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m664.8/664.8 MB\u001b[0m \u001b[31m2.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading nvidia_cufft_cu12-11.2.1.3-py3-none-manylinux2014_x86_64.whl (211.5 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m211.5/211.5 MB\u001b[0m \u001b[31m5.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading nvidia_curand_cu12-10.3.5.147-py3-none-manylinux2014_x86_64.whl (56.3 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m56.3/56.3 MB\u001b[0m \u001b[31m13.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading nvidia_cusolver_cu12-11.6.1.9-py3-none-manylinux2014_x86_64.whl (127.9 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m127.9/127.9 MB\u001b[0m \u001b[31m7.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading nvidia_cusparse_cu12-12.3.1.170-py3-none-manylinux2014_x86_64.whl (207.5 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m207.5/207.5 MB\u001b[0m \u001b[31m3.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hDownloading nvidia_nvjitlink_cu12-12.4.127-py3-none-manylinux2014_x86_64.whl (21.1 MB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m21.1/21.1 MB\u001b[0m \u001b[31m19.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: fuzzywuzzy, nvidia-nvjitlink-cu12, nvidia-curand-cu12, nvidia-cufft-cu12, nvidia-cuda-runtime-cu12, nvidia-cuda-nvrtc-cu12, nvidia-cuda-cupti-cu12, nvidia-cublas-cu12, faiss-cpu, nvidia-cusparse-cu12, nvidia-cudnn-cu12, nvidia-cusolver-cu12, google-cloud-vision\n",
            "  Attempting uninstall: nvidia-nvjitlink-cu12\n",
            "    Found existing installation: nvidia-nvjitlink-cu12 12.5.82\n",
            "    Uninstalling nvidia-nvjitlink-cu12-12.5.82:\n",
            "      Successfully uninstalled nvidia-nvjitlink-cu12-12.5.82\n",
            "  Attempting uninstall: nvidia-curand-cu12\n",
            "    Found existing installation: nvidia-curand-cu12 10.3.6.82\n",
            "    Uninstalling nvidia-curand-cu12-10.3.6.82:\n",
            "      Successfully uninstalled nvidia-curand-cu12-10.3.6.82\n",
            "  Attempting uninstall: nvidia-cufft-cu12\n",
            "    Found existing installation: nvidia-cufft-cu12 11.2.3.61\n",
            "    Uninstalling nvidia-cufft-cu12-11.2.3.61:\n",
            "      Successfully uninstalled nvidia-cufft-cu12-11.2.3.61\n",
            "  Attempting uninstall: nvidia-cuda-runtime-cu12\n",
            "    Found existing installation: nvidia-cuda-runtime-cu12 12.5.82\n",
            "    Uninstalling nvidia-cuda-runtime-cu12-12.5.82:\n",
            "      Successfully uninstalled nvidia-cuda-runtime-cu12-12.5.82\n",
            "  Attempting uninstall: nvidia-cuda-nvrtc-cu12\n",
            "    Found existing installation: nvidia-cuda-nvrtc-cu12 12.5.82\n",
            "    Uninstalling nvidia-cuda-nvrtc-cu12-12.5.82:\n",
            "      Successfully uninstalled nvidia-cuda-nvrtc-cu12-12.5.82\n",
            "  Attempting uninstall: nvidia-cuda-cupti-cu12\n",
            "    Found existing installation: nvidia-cuda-cupti-cu12 12.5.82\n",
            "    Uninstalling nvidia-cuda-cupti-cu12-12.5.82:\n",
            "      Successfully uninstalled nvidia-cuda-cupti-cu12-12.5.82\n",
            "  Attempting uninstall: nvidia-cublas-cu12\n",
            "    Found existing installation: nvidia-cublas-cu12 12.5.3.2\n",
            "    Uninstalling nvidia-cublas-cu12-12.5.3.2:\n",
            "      Successfully uninstalled nvidia-cublas-cu12-12.5.3.2\n",
            "  Attempting uninstall: nvidia-cusparse-cu12\n",
            "    Found existing installation: nvidia-cusparse-cu12 12.5.1.3\n",
            "    Uninstalling nvidia-cusparse-cu12-12.5.1.3:\n",
            "      Successfully uninstalled nvidia-cusparse-cu12-12.5.1.3\n",
            "  Attempting uninstall: nvidia-cudnn-cu12\n",
            "    Found existing installation: nvidia-cudnn-cu12 9.3.0.75\n",
            "    Uninstalling nvidia-cudnn-cu12-9.3.0.75:\n",
            "      Successfully uninstalled nvidia-cudnn-cu12-9.3.0.75\n",
            "  Attempting uninstall: nvidia-cusolver-cu12\n",
            "    Found existing installation: nvidia-cusolver-cu12 11.6.3.83\n",
            "    Uninstalling nvidia-cusolver-cu12-11.6.3.83:\n",
            "      Successfully uninstalled nvidia-cusolver-cu12-11.6.3.83\n",
            "Successfully installed faiss-cpu-1.10.0 fuzzywuzzy-0.18.0 google-cloud-vision-3.10.1 nvidia-cublas-cu12-12.4.5.8 nvidia-cuda-cupti-cu12-12.4.127 nvidia-cuda-nvrtc-cu12-12.4.127 nvidia-cuda-runtime-cu12-12.4.127 nvidia-cudnn-cu12-9.1.0.70 nvidia-cufft-cu12-11.2.1.3 nvidia-curand-cu12-10.3.5.147 nvidia-cusolver-cu12-11.6.1.9 nvidia-cusparse-cu12-12.3.1.170 nvidia-nvjitlink-cu12-12.4.127\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "application/vnd.colab-display-data+json": {
              "pip_warning": {
                "packages": [
                  "google"
                ]
              },
              "id": "1a807cc1adee48268ab44e1574522c5a"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Traceback (most recent call last):\n",
            "  File \"<frozen runpy>\", line 189, in _run_module_as_main\n",
            "  File \"<frozen runpy>\", line 148, in _get_module_details\n",
            "  File \"<frozen runpy>\", line 112, in _get_module_details\n",
            "  File \"/usr/local/lib/python3.11/dist-packages/spacy/__init__.py\", line 13, in <module>\n",
            "    from . import pipeline  # noqa: F401\n",
            "    ^^^^^^^^^^^^^^^^^^^^^^\n",
            "  File \"/usr/local/lib/python3.11/dist-packages/spacy/pipeline/__init__.py\", line 1, in <module>\n",
            "    from .attributeruler import AttributeRuler\n",
            "  File \"/usr/local/lib/python3.11/dist-packages/spacy/pipeline/attributeruler.py\", line 8, in <module>\n",
            "    from ..language import Language\n",
            "  File \"/usr/local/lib/python3.11/dist-packages/spacy/language.py\", line 46, in <module>\n",
            "    from .pipe_analysis import analyze_pipes, print_pipe_analysis, validate_attrs\n",
            "  File \"/usr/local/lib/python3.11/dist-packages/spacy/pipe_analysis.py\", line 6, in <module>\n",
            "    from .tokens import Doc, Span, Token\n",
            "  File \"/usr/local/lib/python3.11/dist-packages/spacy/tokens/__init__.py\", line 1, in <module>\n",
            "    from ._serialize import DocBin\n",
            "  File \"/usr/local/lib/python3.11/dist-packages/spacy/tokens/_serialize.py\", line 14, in <module>\n",
            "^C\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Setup and Imports\n",
        "\n",
        "Mount Google Drive to access `drugbank.xml`, `medicine_packaging.jpg`, `service-account-key.json`, and `api_keys.txt`. The `api_keys.txt` file contains the path to the Google Cloud Vision API service account key and the OpenAI API key. Ensure all files are in your Drive (e.g., in a folder `DrugBank_Project`)."
      ],
      "metadata": {
        "id": "G9fKhpxgWm65"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# import cv2\n",
        "# import os\n",
        "# import numpy as np\n",
        "# from google.cloud import vision\n",
        "# import spacy\n",
        "# from fuzzywuzzy import process\n",
        "# from sentence_transformers import SentenceTransformer\n",
        "# import faiss\n",
        "# import openai\n",
        "# from lxml import etree\n",
        "# from typing import List, Dict, Optional\n",
        "\n",
        "# # Mount Google Drive\n",
        "# from google.colab import drive\n",
        "# drive.mount('/content/drive')\n",
        "\n",
        "# # Configuration\n",
        "# DRIVE_FOLDER = \"/content/drive/My Drive/MsDSAI/January 2025/NLP/Project/Data/\"\n",
        "# GOOGLE_CREDENTIALS = os.path.join(DRIVE_FOLDER, \"google-cloud-service-key.json\")  # Google Cloud Vision API key\n",
        "# OPENAI_API_KEY = os.path.join(DRIVE_FOLDER, \"openai-api-key.txt\")\n",
        "# DRUGBANK_PATH = os.path.join(DRIVE_FOLDER, \"drugbank.xml\")  # DrugBank XML\n",
        "# IMAGE_PATH = os.path.join(DRIVE_FOLDER, \"Calpol500.jpg\")  # Test image\n",
        "# SIMILARITY_THRESHOLD = 0.85\n",
        "\n",
        "# # Set environment variable for Google Cloud Vision API\n",
        "# os.environ[\"GOOGLE_APPLICATION_CREDENTIALS\"] = GOOGLE_CREDENTIALS\n",
        "\n",
        "# # Initialize models and services\n",
        "# nlp = spacy.load(\"en_core_web_sm\")\n",
        "# embedder = SentenceTransformer(\"all-MiniLM-L6-v2\")\n",
        "# openai.api_key = OPENAI_API_KEY\n",
        "# vision_client = vision.ImageAnnotatorClient()  # Google Cloud Vision API client\n",
        "\n",
        "# # Verify files exist\n",
        "# for path in [GOOGLE_CREDENTIALS, DRUGBANK_PATH, IMAGE_PATH, OPENAI_API_KEY]:\n",
        "#     if not os.path.exists(path):\n",
        "#         raise FileNotFoundError(f\"File not found: {path}\")\n",
        "# print(\"All required files are present.\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "2jMG_y-OWokl",
        "outputId": "55ba96f4-e78d-4307-c5bb-1c2e8bd450b4"
      },
      "execution_count": 2,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Drive already mounted at /content/drive; to attempt to forcibly remount, call drive.mount(\"/content/drive\", force_remount=True).\n",
            "All required files are present.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import cv2\n",
        "import os\n",
        "import numpy as np\n",
        "from google.cloud import vision\n",
        "import spacy\n",
        "from fuzzywuzzy import process\n",
        "from sentence_transformers import SentenceTransformer\n",
        "import faiss\n",
        "import openai\n",
        "from lxml import etree\n",
        "from typing import List, Dict, Optional\n",
        "\n",
        "# Mount Google Drive\n",
        "from google.colab import drive\n",
        "drive.mount('/content/drive')\n",
        "\n",
        "# Configuration\n",
        "DRIVE_FOLDER = \"/content/drive/My Drive/MsDSAI/January 2025/NLP/Project/Data/\"  # Your Google Drive folder path\n",
        "GOOGLE_CREDENTIALS = os.path.join(DRIVE_FOLDER, \"google-cloud-service-key.json\")  # Google Cloud Vision API key\n",
        "OPENAI_API_KEY_FILE = os.path.join(DRIVE_FOLDER, \"openai-api-key.txt\")  # OpenAI API key file\n",
        "DRUGBANK_PATH = os.path.join(DRIVE_FOLDER, \"drugbank.xml\")  # DrugBank XML\n",
        "IMAGE_PATH = os.path.join(DRIVE_FOLDER, \"Calpol500.jpg\")  # Test image\n",
        "SIMILARITY_THRESHOLD = 0.85\n",
        "\n",
        "# Read OpenAI API key from file\n",
        "try:\n",
        "    with open(OPENAI_API_KEY_FILE, 'r') as f:\n",
        "        OPENAI_API_KEY = f.read().strip()  # Read the key string (e.g., sk-...)\n",
        "except FileNotFoundError:\n",
        "    raise FileNotFoundError(f\"OpenAI API key file not found at {OPENAI_API_KEY_FILE}\")\n",
        "\n",
        "# Set environment variable for Google Cloud Vision API (not called yet)\n",
        "os.environ[\"GOOGLE_APPLICATION_CREDENTIALS\"] = GOOGLE_CREDENTIALS\n",
        "\n",
        "# Initialize models and services\n",
        "nlp = spacy.load(\"en_core_web_sm\")\n",
        "embedder = SentenceTransformer(\"all-MiniLM-L6-v2\")\n",
        "openai.api_key = OPENAI_API_KEY\n",
        "vision_client = vision.ImageAnnotatorClient()  # Initialized but not used frequently\n",
        "\n",
        "# Verify files exist and check image\n",
        "for path in [GOOGLE_CREDENTIALS, DRUGBANK_PATH, IMAGE_PATH, OPENAI_API_KEY_FILE]:\n",
        "    if not os.path.exists(path):\n",
        "        raise FileNotFoundError(f\"File not found: {path}\")\n",
        "img = cv2.imread(IMAGE_PATH)\n",
        "if img is None:\n",
        "    raise ValueError(f\"Failed to load image at {IMAGE_PATH}. Check file format and path.\")\n",
        "print(f\"Image loaded: {IMAGE_PATH}, Shape: {img.shape}\")\n",
        "from IPython.display import Image, display\n",
        "print(\"Original Image (Calpol500.jpg):\")\n",
        "display(Image(IMAGE_PATH))\n",
        "print(\"Inspect the image above. Is 'Calpol' clearly visible?\")\n",
        "print(\"All required files are present and verified.\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 704
        },
        "id": "81lLnTwpuFPL",
        "outputId": "88924f65-62f2-43a3-de4a-0e6047bbfc49"
      },
      "execution_count": 5,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Drive already mounted at /content/drive; to attempt to forcibly remount, call drive.mount(\"/content/drive\", force_remount=True).\n",
            "Image loaded: /content/drive/My Drive/MsDSAI/January 2025/NLP/Project/Data/Calpol500.jpg, Shape: (600, 600, 3)\n",
            "Original Image (Calpol500.jpg):\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "image/jpeg": "UklGRqpqAQBXRUJQVlA4WAoAAAAoAAAAVwIAVwIASUNDUKgBAAAAAAGobGNtcwIQAABtbnRyUkdCIFhZWiAH3AABABkAAwApADlhY3NwQVBQTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA9tYAAQAAAADTLWxjbXMAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAlkZXNjAAAA8AAAAF9jcHJ0AAABTAAAAAx3dHB0AAABWAAAABRyWFlaAAABbAAAABRnWFlaAAABgAAAABRiWFlaAAABlAAAABRyVFJDAAABDAAAAEBnVFJDAAABDAAAAEBiVFJDAAABDAAAAEBkZXNjAAAAAAAAAAVjMmNpAAAAAAAAAAAAAAAAY3VydgAAAAAAAAAaAAAAywHJA2MFkghrC/YQPxVRGzQh8SmQMhg7kkYFUXdd7WtwegWJsZp8rGm/fdPD6TD//3RleHQAAAAAQ0MwAFhZWiAAAAAAAAD21gABAAAAANMtWFlaIAAAAAAAAG+iAAA49QAAA5BYWVogAAAAAAAAYpkAALeFAAAY2lhZWiAAAAAAAAAkoAAAD4QAALbPVlA4IBpoAQBwUgOdASpYAlgCPj0YikOiIaEVXRWkIAPEsrd9NFquGi3CoHXv56qoPu77SIueefIaOt/e69Pk/+15jnwPfd/4Xq4/rP+q9gXzN/839kf/D8WP75/wv2s9xn9R/337me8z/4/3k92P+P9Qb+6f8P1t//h///dA/xH/n///uQfuR6yX/w/eP4Tv8b/6P3j+Br/Jf97///+X3AP/p7V38A/8etY+bfzv+7/XzyP/JPn/8X/b/8v/tv73+3P2V/a3+z/ovDf6r/Jf9f/K/7T2E/l34E/Wf3z/Jf9z/IfMz+b/5v+N/zv/l/1npT8bf7//If6b/f/6j5Bfyr+ff5b+3/uV/ePid+t/6/+273XbP9R/3f9r7Avs39Q/1n+F/z3/v/yXpQf4/+A/1H/v90f0X+7f77++/57/wf6f////r9Af5L/Q/9L/cv3Y/yH///+H2t/pP93/qv8p/0v3/9qD7f/jv+V/nP9P/6P8h///wB/mH9Z/1v99/z3/W/w3////34z/13/b/zH+n/bD////T4v/qH+P/6/+S/0n/2/1//////6CfzH+s/8D+/f5z/6f6b////v7uP/v/o/+h8hf2s/+n+l/4H//+kH9ff/b+1n///8iAi6XYsbjJx54ul2LG4yceeLpdixuMnHni6XYsbjJx54ul2LG4yceeLpdixuMnHni6XYsbjJx54ul2LG4yceeLpdixuMnHni6XYsbjJx54ul2LG4yceeLpdixuMnHni6XYsbjJx54ul2LG4yceeLpdixroOBsA5BOpMQYWzgeTOAwAWIQmtVMO+0OgIvl+GUKBYeqXN1jihkmC9Lmn6YmzI2puw+FSlTzA3PiihQtVXkzH3W479TPQbqC37VDf/03A8wqOhHivfjFERyaQUdE9aISgtzCo6oIYYz9lz/P8fhcNXNid5gv//U80nbvk2/efWlt5Cnsd/qWB43hYEGqQ6/OCAdJkh0UWZisqQBMsLPl0+kHZJMFx9xDy4kTVa3lABpwN5cW+zjkE+Bgl0kY3+M+w177vG9H0LGQYsAvChkc1egE3Li6fqN76V7f+f9pUjmak7kwiWYOJErh0i5A56FHYgdn6YbpOObb/GrkiEdSbCH6rwFu+0WMmqvBDh9pfwW2fS7WVRl2dwiyaStl9zDKwA8+LFyl6XZ8zO4LNwRdW8blOyDMc9DEu3aoaJjdIbWzxUtmxq9z24NTd88+v//i4JmdLOgD1DW2nHjO5qyXqL/Ma1qhp1qlb0bM0al4hsDdhTxTNjmT9Ms/rFbU8TzfOS/RXYm/lBkiZiYqr8bvAg2ub3+jvKw1+yrDej2s4SxIazKLCqj496vIO9MF7jWk5+KZUCrx5jbrKgPhkkn5DG3pB1aZV1dHUCRVPIG2yvyBdtViwkUPXQgKx9rGzvdXPRlF49/mmxaawFBNAtjkycGc8/7qhIBye+yNUfu1qArmBmVlyU3nhKfgJiW+vSSHnRcTo5jbAViINlrJlFBDL2FYc2iHNOhlqy4ic/YzIh0GHTbAg4qsIGrpjJzseMyVPtZyobNbq9ZvrBV+0+vzC2jIuV9rUuC4n0bEk9u+EO7EiECRdrmufTOdIZAHxQy7H/xzrdk3t2UT7ndzF/Dgg+ZYk6NaD+N4UjOMfisChhdBNYXpFAKS/eF7SuspppLnnt4gXZof3648vTLypKhV4LqJ9WN/ih9fzxUEYClKfyvuOEVH56/boEccFdfjjEVcXu2pT4aBfwti6ybjpLawKzJao1M1xxzQjFnAPGRQnUJT8m0L4UozU2Grbyj2X2/7wWo8uVrudXObUnU8OAUor2TLt+8Vvxp7xz5yH1Z27eF2cyA1drP8KhhwV8le+l7APcFFIGfiXlrRXdPHloQ2McsEJ2ZKQYp3mxIPgvlIShkxM3vtWxBZZOrYNyuUGJMLfL0A2TLibTTJ53hu3f8KIfGv3FIVL1X27uFji2u3wJbuYTxWEUYstNJEUfrCNevx2JzsZAUO9vzby6Hn5DHD6hFIB0wryCalrb/a3uyC5GVs84WWEzPAZccGd8bN06iSe8ETGV/ZRl3MT6uxWOSROTqvx+fCqzKtfXr1Jnl9NHxt4I/0uphTu0SAR/lRfVK0uh2ZEtmQdREEyAFu/15oKxpwpdv9C+Y7IAciuxJ4DJWA1JSnIWNdIBxsEVFhvaj00+fOJHdIXoUOOSS5tGLekXG50hQbKuWuj29QmbWhv5FFHLkTTp6RKO4GQyh6jZwrIvdH6OvKP9X30PwpFtUHfOIyb++zdIkUE/kA6VeTjsYqmLtVTUKCaRhNNoHXc5aT/fwbr4TklZz3ls8sfzUSsRlCRoq1LqtnuCuK66vhlEcp5mCRDGkBkxVDooDd5q3EpZ5oFKYT1+jQMwVUEPP5jBEOpN6X8ZXyev/39Cm0un2DogIJOFhgoSVBBG2Cc4nh6plwrk2XJ9CYNoXwOgpsCJzWiXO2qsmh87rV2ZXCy1C3ly4KgqGVMF32VMZ+xIbdjZFydFba2G1kfH6R5BC5/XzguY9DSy/ZRNxK1wUKqVJkQuXv4jYoeEpGRiw2OOSKqrUxwMIVUcFM2ZTEEZvSMwLZS2LZuNuUgWf1uPPmK78hY+Lbbmhqxl/L9332FJw3uR57yJ+FkId/7Z3U98iSX043zi6wznCM+g3QQ1qgMeuX6jiyNrZBgn4oUOENqI6vOpIh4qsS4t9uQJEy3hy/ho7ej7HH6SoZHBGrFuSH/5ajV+yEHj5bn/OVmYIMT69mPDRt5pzoRwb7A+vVfSpTLRYthxofqfYi8UvxIgyv2QlfQcpyyG5VffrWobPNOmKA3xsJZBuEg8AtL20QlUMQDoj4fECSkeIunxouPX6ExXws9Q6/QUVekYf5OQn/eZnihygS0xcO8lAJ8/cgkMdxvSeRsGcd4w6P9O6/EOj7ENk0Otu+aPBV6c4+L3XUx2XailmAtYM0JryVVfXPpt2RcQ8SLZ74P5D2aNrotzTtbfWc1jywvzjVewyEfbm0GdiDHYzSdlAjD+EosHhlltKOtekY3FoFjJaQaL5dGD3xl23k4NRmT4m3qnZLi7kn4Ok0XFW5mAJgCT9io2VcEPNUiWMBO6Uuql5lxfIDOJwZEIVSdyRCHSaOUTA5VcC6RLupSKf2Gff83VBwglEsdZoUkgw8TAJa0T+U8DatErk5KzPXQoMTmqcAZvNLhhF+e1zhFRtygoCmfB5scul7/or4h5uWbn94o64Kncye2jnxLE85HgncDdxjXAOaztJd3HyhBWnnueOfYvja0iXuRYopBT0am5ziHmR2ZsNQPIbT96X8V/wExkUMWJu289FIM0NkOLMTZYuXukM4LH8/21Bvf9mffO6kJQvsRRyvZcKW4x0LsyfaDTC+U0HdliNT2N1NxRu5Jx2mQ6ushnJN0e5lHlHx0NzEQDma0ls5CQofoXU4azLRy3SZemDko7YnI8kcfQNC9BLa4ooGhb+d97pYu8tet9TDihoPAL9yeQ2y9BBt33vUo05GS4mq1PSyXfp5dm7d76pPrAJK0ncSKPtPzea5UK1PLD4lr6+zTE9VQWcs7wehAB51XN3ms2Fo+vwIVfXcvp+OiXPWsE/BoSq7+afm6Ho+zuwBRn60eIJuwB2lb7IQ+hYtTKproMLH+bMGGmK7yOhCg6d3hwlmsRMST6UiXS/aRwJmwiuV79X1XFLJ2d/kpOALx37+3t42IQQIj5Z6PykmG35YzZQ0E551dgT9OZJ4RduwtfCitHy2CQ8P8YUBseaLxloWuQhzCRRrgCZpa74MFmkZtYMp/B68lUfg3e522qI4jXGVMLOiy7ghhF39Yo8d2pMdMV9hN5gtGDCvRiwCsz1LeOEmZ78okyiQTglJf3tZsv9DD4NwAUQMFBBePU/2cBULTKOIw2+9Lh6zX7q4ZXfNJlaAX0KrKH4o8yE7HidTu+qjFTIZghOoaNNH+PydnwNo1p9Ps52OtKZwmNpI6V7gDger36pf/RbDQdvclZgI95g0dpEbnhM5GNmVx3MTOyqRrNIwnMWPmVb3XEUMZOGMi9hbMpkdUWh6loftdj+98aQ5d69256J1ImtVB6eHW5g02/QPKv1OJSpOd0gUYKVSmpXiKH/kSIUqDwFfxsf4xIY71coqZQ3Mk1wRIndE033xC526xDqH/Q6MzzK+8as9qpqy3BGLUELrQx4zb9Jxwb9R9KSF7ZLp5u8k60i8sTddCDP/7qcExIhacyGYaZzD+SCjCTWlgWzs1DYAaTAibgh1Qjm3pfN+Eud7mR5BrhExPTW6wAeKn0L8DsuUXPlkj1ZqB79//l/P9mY2dBfaGpqgqeAiB0Ww3Dvb1igbjBH8fBqZw0tLFkScamxK9tX07oYP/O9jTVTgtOcZFLHkFQnytpE/8AVDZflLef36XEHM39Xdnn7S8wIh+mkn5muxpdkPimdRtDeUjBVjp/hLk44g0Ul5CSbmzkyGietiTdJiD2jxcSMa1zCzLgEr//vPTX0yamiq3MV/PJiiV4nXfHy0y8Hl7aU+keZYYtP9z216HCHcEmo78zaN4OB2stZKB3+/1DX/JvLb7Jd77sHdnAelWKfCs3jvSVcPTEW6yE6X5/YFPtIlhQLnuo8TY8JSKqnj2yNZrYC1BxW6zi1t3uPt/vgeuvx1ZzWSxtNsp4npskSKeHtiZvvFQDs2GflUEAsl1B9MPH462yB+/vAuqHOHGUB/IWDeeCwxQVzxGiGpSdowQVrh6Cyt5+VmSYd1RwM1mN/mwKNevULvLaJDPMXE8Xn+EwA8/s6f3SwMpBidzw7JI/zGsN9k/W9358cfZ1vXjxBePRiIdKbeuanQIWJ0rFuOYROhtXFGT/n2YoQazKPZhBitXHWftIXofiGrfTqzX3+ZGk4lzdpISmzzAIF54MY5ecbZKZqX2d89nwHotjJLeyWyeC+1RmdReiDe9sFnx0OSgyGDBV6TDeBw+EloavNL7MlYsoym5Qpz9gfdAp3tWKv6P8y1Qjuo84fXu/txGQETnZAnjhrCyEOR9qmRlrRHULGDPjB1qIuazqbuV8V4sZBO1EqQIWPoOqhI+OgFKibybmGVTWnNOHw/ew6OP08o1xGivplvzfHxUQ4xJO5cDoXI5kxnBaoQlIkzl/ihbL866VAu8qB1bwkBW6FPPbXU5Y8Tv7zwSeWsolgcpYHYIxHlgGYnRUD2GSDBkKZXfFopyBoovJRkU9iBPAcQBBvzJ8ivwLZryiz8a7LwgHRwIsASrXn31OPMg4kQofUVz8op6cRabNXFnxip1L59YpawqvmxTOS6gt/uUkbvGUrln5gZOF6l2k+UTjSPNPetqB0uFlVwS7nKGBtpUOlj2nDe/G/w9P95OhQNi3VjcUGDpFB3yLLeJsvDmflRoIISzdvrIxlbUUs969UUxnNTZR9PD/wM0iUY/n/5yI/t8CBEpHEo9303qTTf2AnhpGkgXUWoGER+F7TID+iCdGSkYM2u1aYxGD9bGGRcRwqXj/1Yn2TE6fTW75ZnlN5zYIV1iL2bEY+XlJUQhrahHUvlrV+MquZIur0rZm+oAFO7c5JYVUHqEoz2YOEiZHZzfg5vuK/dqtR7L34V3gXI0OskbvpUiSXVsEcixudsLk4IZCZkVxc/9orXcBpnKjzzCMw3M5AHCuwLlbqS2KJLId2pUGaRufrsRR8luIF+Swe68heZNuocEG7Q2P2ReeLc7iAm7f6ytgIbpoaEvfwzbZt+rGe0dp/mB0SLhnG18jNMa0Y8JTH4j0d/oTIvOb2Z0SZleCnSZeRm3OGo5M53E65PJAfJYwiMTnzf0KLlHv4pqw8DmlX2Y5fdoQlcD4ZhiopLgzO/fQY7O6wPmip7ZiQW9qv/ze9u79ELd1dad6Ke4Rw34wNpNyJ5SlL2INwCx8uFqH0+1N780TltPh5vixhqcaS/0Sd/v+NgynFKgIpX4eO2YkK5rn8EPjusH/wIq0c/Yl0t7HEPW2JnUcODiIjahpJQIePD5/nOfxd2PQn0LPhFnrJhUNn2VcKFSaKfU5VaTbc+ie0yavp0KLk4XPRW9pPAJ0xXefCVnMHGLGRRAtSX3FPRtm250VdupaTE6QlMJyvNdwdc9WCTMgxAZX1O/qAjjWT2ICAy+t3c0/4Otlu5frIWE2VhD1hPpxTUkZIf959XgAl81KHQYENxMKtIb0PlMGunlc8DF+4oITomnPXbuaCa9WvDJ4jPAMiTAt6V1ed6HB1+EE82oRSTjWhfegJdxJcARq0EqpKnBSMUXfIpckPym6M2mRBgQv8M/fhhuze6zbOu9S1JKcaO9QAYFklCvoWPLLeiqZ21LRgbIR9HTkr0by3GLENq5yx3EiXfHpY6PcHYNxwsgo0a/m0MOEXjN6USEvDSoL9oHYiOLAFtLp0/n7I6PowEX5WhjsUoUsQkzISnRc2Gn+TvTQ7q4LKDPuTtRmEhlVIDKE9958ufTyb51r/IHtfi4R3XBg+lGP8Km1Oqn8/PwNQ5zGUGCN+TE29T1hQ46V5JH8YugRY2LTMYxpN3lx1JBOxi0HsXJx17fN9J29sTXJG7wa4JfIcbMYJBonoCnpPSczdpKK3G/AGPqR5D1fWzeI4hkuytofXHzGjpNEGz8BT7CtYnP1MWlOYyCJIL7+0CYvcwt6Ru7/5fC0YbkDX9OtzIClGFybKSzZGFUzYov+1WQ5qRb5P9vZTwPi9Z8N1JlOTwJjTv6vSe8wmnjt9MlOGaU4JohRCr+K7ZsBfoIpc7/NoAc3F5uGpL/egtEuO/aBVJ4axApyBnUhH6VYdwiKgroh0gb9PwJV6Fq+5eucy/m1xwCdPkuAIRe4uoW73NHgYo8U6nekalXyC0IHXtqcgox4712mbl2LUo4dznM20u8LFomX9nLpCLMrfDU8NoufBjKknrIyiZ2+PYnL/PQ1++AGDeFKovuWhoz6YxuqJRihFLPCoNLhcXDUdTLDFpzSzd1xkS0UNlON5+WFdDkFCPfwHWe9yeH75i1F0WaaQjnldkauCSp/HIv0VFd2zab9LGmGak2YEDA4Z3lbzyDcvTWull4ao/1sqxTCT35DhUZW9vL1NM2BzVSGzIlSkjC4uCsyh5Rex4XOdtoFw3HogLIQ4H+rU5tVO4K2+RqNpBgYqszLfrDPrRhYXaLsxsjqtnlssPhh0oz+pMQvDNQ8FEdElM/8nCIUdRyMurAeoQMEczjpgzADfGGeRsmiRKI1ZN9j8P0NU325PTKrCof0uKhsehyMRpIq8tIW2Y6hhWiLmKFn2HGmykw1CAv/NMhGkI94M8xuCSlnlnJmdmg8r3YZOaEdcg8V4SVqZF5ybQrj0tFcNRYpxgyrUYWK1cMdCuu02tUIQm9equFCDbeOQQWA8C0wR+NiJUZGUaYGqLQOgHt1Uhbwq2vmYtssGioonfgrrbVRnm562OohwrtkdbHn14Kq6akcSNcMU8Z5wCef/YP+of5hL4/BfKeP4INriEQ6Kq7JhVLHdoQXdopacK5Q9vpBOEI8PsO/7q6v9DRD4JiXtvmkJKwvDrD+k73X+f32F3OJNVWIZx3zN8RGnv7qukqimGFhWRTSeRtDIGnZjMr8E6ZnH3zWcRGzqAUMdJvPbYBCOJBsBTSRulh1ZpNLep989qA3nSWu8d+HN54G5raxRuKETFFcd+i3EvEEsLDeWNRgI2EDRmXG9a8jgVu0YBGG0JyTQ4Uj63ScCPSU8i9+6q//o83/mQcj5bwGTQOjjJlVYJ4g1d0yxHZcJGEQPW/xXLblph4LnDCYA+HxIpxn10o227jD9+NDGb95xQPpR1rQPhU4doqAtj8NZ4UR60xxJvdHWpvOukOMm/TtO5BVCSrwHcxsW1sOeq6I0MbF1gkDjNfscPCfbcRu6Krvv8wb2k5PcDpvmkaCfPeR6DgJ+xvmUdGXkwaSEcers8jccXDdJM5/Gc+mCo2JfvrlIMaK/8lUzad7uqka1Q4A+jJX08jwtSJszBIK6/wxUOC+6XhzuaUmdqVXn8zdgnnVcwerBXcU8kkOoIlrJVWuoVum5vh3Q+CQPc7Tp35oc4RVjpHwm2lq51ukatSUHxkHBsNc5lBppP9UyJnvEXZjdMEq80u3K7vsn7VL27o2FHv/h57VvYZl7hBXxaS+o6SSNeUBS443FTpFpnGEXTH4EYD5m+VQHpmrswUXjOH5aboVxy5GLyVp91OjD8HNCwyox4GxvADNwwachTY6LmZJjNpoeEl9O+vD7L1WNxoXDJksJVM92rlVtuduJCZ+AAvAOCglUtEWLObHVV/PDjYP28WEeu985bC/9a4354FRQxh9lPkdBSQ7fpqEpulXv99Z/zuxJh8fPRAnDzKAkStdJ/SSpi7KOkVsJug6Okn922dmngz/4e6lUVfzORed6mIweEfpqE1qnwBy+niX3fLgn8b9pvi4u7DyCO1K9tvMls9zNAlXtm8G00u0/UOGL+LbU1dCAX4J22CLGOokRUkc+y4Q7YVReXuzoTnBx1o9Zp+RcsgrrZP/T/C2L0kiKOfnO2taNmFn6ZhpVdLYfY9OxvsSlpaZpfXDv3T/Nem23YRygAiRSbQmITt8nGc0cUTu7Oao9GK010v4cP4FoXlfViit9Vm/v2YjmJqy/5ctCFaQF1rAVJhqojEmaA4q6AK0yE7RxlSDuYRP2nM2KBwIAyZ28rK3FhmW7X31kdj22aAjq4mRQTPneT9JSOX0VV97RoUD/9zZG4llKzmljlsIo4gwVw1NGeqpn6R4HuWMk6Z5XVnfvhyziDvJEsXCCygJCFKeC4m4pKUjxEW0Kg6z3slHOP9KRqDnEPeOLpt+Ks/3GOuQd9GjfDW3tJ9J6q3NekS3UNH5040vOHtkqwxI2ER2U0gMPe8pvPGbpqworxEP4NikmfXNlWydEIAMHRWbFYRW1XTt35L6Q7G4z+M9DX4ul2LG4yceeLpdixuMnHni6XYsbjJx54ul2LG4yceeLpdixuMnHni6XYsbjJx54ul2LG4yceeLpdixuMnHni6XYsbjJx54ul2LG4yceeLpdixuMnHni6XYsbjJx54ul2LG4yceeLpdixuMmIAAD+/9mcAAAAAAAAAAAAAAAAAAAAAAAAOsiywLiJgZOAAFjhP38RoOqdOhaWivl6tv5EPJdwAdkP8e6fDSXc3AVomLohQuYmcz7fbRXefeRcgU+PJSByUvTvdB6OtpYz2pnugqNqGSUVC14fqJI66wXvHMWauoRLq4XhBK0548RKodLShQ9T0cfy7TahOgmRid2siWj3PkDL9fUxvvCbO7k8yqzE/hKHt8GtG1b8l4PfLOpzbQgCjXIKsDeva9TWYUGaQPE7hxeoM6Ihx4LwgCytanuj+wLuXYy2GOc/lhI+r5h1llhR2S+12Snf9fCPhMek7dz6V8KeVWRhiLh3VA2OeBvFkJ9juA4XcuXbkiQcepTDFl3rlvnNRl40zqY4/Cca8uWcQy9vpU2yyulyHRFBDHj6cELE3w6tpcZpsNCJsJvBe2AN/pz5jG472dHc/zcgMzi1wUOrv8A1/uh95fk/dtsHgaih5HsDVvr7QbcxZYz3zomVzuXfsdeeAEZ1j0ZeTYAKXHyKrx1Dxy878stpan5kObH48VRhTlyvDLJFvhc8wxvoJPH6PRAZ19Al8wUjKigojLFXXTou6LNF5J+x63WPpoCy6YEvCJXm2cBhRURt1BqPUq0wf6BuODKfsRhQuE6MUSc/TbSxsrTF54wfwrVIYzgk1xyFoK/GHwNWy4WUk7zfF7Fr38rdJeWOLn8fJ5KjxZTADJm1pnCIvJnVjBp8dDgp+M5D/x9LxftHBh8Xu9sRxaDeRxyQ+8xgQ653IsXQahUy4sHfFkn7hd7IUG5LaO/B7zWcRXZqUHP99VIZwBOIYQZDqO6DPE4hFzi9MfxNiMyz32LsrEO3Z5TMuUPxo25PGCtStoc6VfkgQYv4KSZhG9rJkOejl7HIP5VxlzcyU9VKod249DzhL83FLDqxxT3XEpxDIzEF3qkIdjjz9gYL/CGgaUURcj7Cot8ksXbk7GrEEroJyb+ClJFAdImbD5BKoEQXspW3rAlO737Zav+yMfLuAwB+EyDdR0Vsd1b30NhAD82WNryjVeUneWeF1rGgBXCi5THrqRHY15pShjdydnBUp3I6XZlIp8VjIw46GKptm568jC2KbhrXn02OUs6kK3I1Cxht2D7frovCEjB62Z9c1bzS7rMoyhZdcenirWqgEF7hps32j9ERreS8jtQ7m1ZR+HJ/ZHpydzc9/c962PA/izg4ZOiqFNCxCy7ZXSIlDFFYwlajBY7zdaK3uyM607OvvBC/3dgVGY9pibiNU/Rqy+e1UOCK+2A7U6sH/cQvsIkNbidBTcYM7Yh/O6Iwc1fCTwtF5XY3Bgosy1VPpQnMchxbqP4g6dvwm4KYMxj1Halkkq8VLatRong21sFdxRi9XdVta2HWe8vC+JwNXT4sYFdMenVP9WJK1mCUpICkc/QpVDgGZGLEMyMb9Cey3v5yDE4nN7YW5Vr6LE54hXUdeGlEexe+cuC017V3pH6yhwdVHlUvhkdywqkKKkDbkD1j1iT2xtBf7uyDFzM6nzPe0NV+EmeY7OWce0WiSUnt3RR8Dwbgx2JAhr7Jn1liY1sntB7AqHZm2jSfAgJeVGFA22rIktwpSql/NcK0ZtqHn+AiJGaSIGbkEZggwmYz2wKr26TkVsr41PO4+BV9i+ZLXdW+fNr8jRCUyl/L+2rn42Ui8uEl3ZiV7tA/uZHNYLQN3qk2FDiMV0BS/E2frwhQJqLyhKSC0We1oSiC4IV2JWmdJQtQ0M8LXMtcgTwZH+FcAELN/TK7qafvPRnoJIvgM8+Vv2855OOqvMbmGwhX1hVjdW4ekFtvEP1MJ7jvSeaVNmizNg6WisQXTY502WkoUJmtVnq3zlXxHUb4Yj5l/hbBCaCYp7mmvBtV24FoYKj3hxVdqHx0VnvXBRLXa/wgSzOPQlEevHZauIGB9ylq6eus24UcAR74k8CSPCwFxXnlZT8NnSqh/bRAa/sWd8yjJnaoCoqWUHFdUpfbnXx72jZvJQvajwLsSjQqLeronnwBZbxcHT6X6cqxQGs55deKU7Nmc5XfTfTtA/utn7SOCCIOCnIi2+qbGR967lDFSVb+uVu6Z5Bac+uyCnRyXgrVL4L87C13rTam0sv7GAXL4fvBPrcpR4PjOGHhbmX1Av8teWeYSDjoIQjGFzWw1r2SYiUXRmw3NJfF/6kiHBPYCOb299G1xEOwFk2qqhk4mSZW/PbC3Np6qLVX4qAkdwvk7Un2o/iU34dD0S0KTZRG922kC/S1JlMsbX3lFnmwyAEA4tdvx7cHUmT24khD2LHxiNCj56lGCzEJwwXtqJ4eGusnrcHglBMdQnxoB94DVdclMCfoh60yUuOd4j1AIdCm1FsSu/DI0ySyYbBhffBHFKajST85MTUYqOT1zGqFjNH4szps+wq3wuYVJ+3MFSqA4Onlf70n8kOjVttzuu8H1+MIgQnrbejQ5bYnA/jPd83ixg0GBJrVIh9SDAzJPpiJdV9uLGH/tKXk09M7hpjby69ow9E/xQecFpSL6shuEiKbsWPO2KnlRf3z6sHI0p2LMcIrl9Hwuv5otXbZMhz2IuLJO2XX+SCFEODq12BFs/gPBtL0ei5PhWADvyvuf2f7T/t+7b/RFNnKBkyTwf93XdxxsW451JYch8omvSaoUGQ3TAH1G/bQLB5bxajGwKxwMyNd7qZlSYgegWlCJ6YiY41UDmaJ6nG5MieBO60SBWOFZExj1eDayU9sX9Z1/WMUhAwKwZbRWgqUFw2gr8CNU9h66JLbuNNWYmhwFkLzrx6a5no1D7vtmS1Ee0WPlGk2fldHLF1/AePRBwd9Yg28xvToQaSShfCIymJhv9wqMHKVJRljaF+OuAKmQOCTy0q3G7UCdIeIaxVahNl5n86dGiNKk/HDaEsl7952gMnSBqDFhSLBvKhdbUox0qANyXj3dLfMMSuLbyTiNm7ZLLjJR8jJoTZa9cSj7+jc1fIse5X8XNy+JUdXxHURXwlbXmtCyvrHVU0tWFPTGG1c3e1JTnxJ1zxndD1mKlB7P+csf0DFyH/ebQHf8z6TOvf2WQ/1AQNIgDlt+YvpvzPXnrWVm+KNqhlAHzTKc5CEViqlEowuJLRl5ZKt7/nPI2LZ/VxEM2e/LFL65BBTvi3b5w7OU3JF3vbzqOdrMeuiRhlkPH5VIHK0XyvKTyrr9/yLeuMz/BvF1HaOji5LnDrs0PYRYFe4VIoACnuFnGF+54lLKS9q+erViBpTxb7rLpHvqUQ8dvJkYKc8X5caiLnJpBU30Tf7p+kB/ulsY1IoAPnazt0YLq5uzrpyn7WeCpg5QC/ChW5Hzv9bw4iebLlK9m6zEJxhKpx32Wf0GWaCJU8fjDXOrdpRXfrkB+R1kOPwTh3vesoFxPvAgxWlFp8i3W3aoUmuzFA25Dl9wuICGX6Mbv4/u+OTsIRprbyofwKqC/+8L2sXS/gZVHL5At54eC+Oqxo6YI7apEC0NTJJV90IHO0o4vtKlxk5nCC+7SZMl6Md8uGooy7IGL6aLYTuK28UYcP5NF7JIGg0RaaVE2F6htOHAIkAUMdV5NTeezKf7ZBRx5/23QRrsHK8jQD7l2mCKnRaarFSfLHtFZXy4TeAufzjsqhkXQDgDBd5lru/TpK1Mbr8xu/a2ACBg/FZT9OrcV6iTaDWJBYKjgFHMtmU04c/ypA4R35y5lw69OUtS+MlGWu08ZZNiay691l855TqSWpPXTardWbLN08NP5pXddzax5qeHzTSmdLMrR/EQtoDagPOomGlGIgz15xZxvkiss84VsnDoxQMEJ1H8WA1h9oD3M9C8ZRuPq7ACPK4NzDbLSTRGq0Zv1Vp48ECET8M/ML8+lEyhPvYFBeRbvPXcf9cVTF40v2lq7BBV9etTQttpl/1L4EoUWSc/7EIle8bxhf7G7Yy6A8gzoYQQo0hvE8Km8wcQtupuLKCczSJ1w3u9XvhUeHvkuGv+o4KZAtNTGkyoYCdx5qRsc0fpzLE1v/bHfumXSsizDg77U9eTr/bexdThwcIvWofDBNb0YCL7IKCDNDy+KM/Iv/RF2T1EDKy1w2+2MnZCOm4+T2QO7Ds5QWlzI3BgHfIPKs+fJSNA/xftBosWvveAi3yizLOoEchbWthi2z4LoPmgPbSza3jfj5fTx0fgZy2ee4z4MHntss6SYDsRMsohhhr2xMt1ptp74DOk8rZBM1E6sJI924ksLoYk6p74MC24fWsnOC3s5DnMGBQ3rEzx0Jwya8VZT2BXiCBbwEwxvXfmRmdxdKUdK61GOU/v+40fzQE7VaE4NPEtvaVvwPvFb8uyyOlBxSB10rbUlzDknLRHJrNmUpA9zCOiyeHmFkNz5xPZ7cqQn4lyiqaAxQHW2u3eH5zJLgeEorjBD5EhEAzLT7OK4MdBC7MROUVGG3eMfifrLAzrLPKPe8Aacg3vuu2IhLcguiJc18Li/YTmDvLmHnbHKzVSfjHcRXz6aBmP5Md1CTghyuegDO+Qa7VgRb1F48z3g4/tsOIMPyYfM5dw0I2Ep+pcxESDWJ0erId4yIz2yyehP7EEsAGXldOerEHWb4guUXPNYTAYyUudGPTImIGNUmdZFEHg6hqAfTIi0mulGMN4/9ovJMlLqrWFMOKxfdjd1lxppnA92tP0VFLourJLkY3AHTIigZwqYmE6HWoGKHTbw4sapg1kaJbXLRmw2mpPsMVWZd5AweWh8gdwd9EuTm8Ri1wDZwzJPjp7VpvSf/ws0TbduFvAzNkSD0mb7fJGsvoTxVv0PA7tsVy3UpK+DpMtNlaIuyWlorwi2EvM3E4LGcGzSk9qwWEG7mtA+Afk7srP0iZjRhaeoC0VbG18AHJGzDdeEa7DSceDLpSerw/lCKw9+Xcp6qTI18xjG1bswRIs6cTEUiMrdRdQMJLPeRDiidRW4v4VvinCYxh8QfHgjz9sKleA+DJBC6cVrZEqww81BZuRRw8B/wJ/Ud6BYZUCboaBM88d1s7y7abLwDgKHss/9pmDjXTIhi9SFqlFVY0dIg1yJDn9xg6/cPXhrel4lvtYkW3nfVhoD8LlUrjaQG8+EwcDchucmJKTTMj79sR0JsmreL2jSDHmmU32aD0MYURbHGSESqAYdPsEYiS0+pDt/ADszSxmOnErsgaEpy8zPH5Tq9lNVNC0T/tWcQ8nuh6a5NzMbazmAofe91bcPIxQuXQYHicObnZypz7C2u3uwzx+1yL0cAYUPvOGkK+SLz+lzSGctf2yh4v32z7drzjiSCk0oUjBDZfka32T8oFsvAX0qf/zgMiddEKxm2lJnKJ1+Af/XkhjWoI/3cp47GVrt33HUCybSlt2qIBe7lpefEdv/5jgtOdb5LJQsDRv+udm3T9jjLfsHFdK4dUQW8rgvQS0H8jPqMfECWjJSeJ2TFuJ8+GG8qYsfOnW7kBQpoQXOMPbZ3TgBA4Iol0A+hrnmFbNZqAquqMic9DcYD+3IUnqQmJZPg40JnmAAKiHOYL+Y2sAgo3ROhi1FpvecPfLjMXjZALVMJJyYm75S/vB9EayZvqv2DHsJg4HTfloo9n1tB4JaqmfUJgSXM2mpLtvnxlqvgG9/wDe2RVmKY63bOZ8k6IOoz1ZbC0q1guWhOe9ABmHRtlNmV9vc/Noe7uCX2MeFidxEZ5jjteb1YZioc2HHokIvifPO/5LnU0eDpIHPsDcDiRGHlhotyb4mfGW/cWVWXgQHZ1mkp/FA1dkPNE3wp2amhXNGBRjJ31447OMrH7M5B2nmLC9Wsu4OWY2nHOss7KqU1kjq9HXtlXC2yT/O/0ZLw7jer6lCRMOc5Wansf+HzGSL2/iyhRnWP/g/LIkb4EfGxXG8Y43SCOizM5cXY6iIHFDRqikPtAFr04/0TWVlFdZyhfY2eE4KkCJQjgNletp2ooWlcePiKZYVhc9dGoH73TI0naj1LqDENe54DAM/fOzfGAz3GwEYe5Mr4DuajqipjEJdEIiRsf55eJ5Pk10DuC07gHC7VT/BkTxGkPUNh5GQmOYh9R2retsnINbwDcrNRKQ4fF/aiJM0GWz7C3Z/8mo67qdMfvcZ9KNcxClxYMVJv9pIr9CoLJSjDg6+LuHxT/7QrSOGCcINwZ/AxR43v+7F9QGbFOHMTMDUgS6C/9HETFvbPqeEYFsRPYyYyZtkX2NXg4LkaLSjDVxoxWpUedjgKwPV5NxBB7eTjWWk3ZWC8FggTge4EhQe5MauDDYjfR5tw4guLeCLq+2G8Yv0tltCnCWd4VIRQvHTOtmgzXvRn+A+PEwkwNQaBpfy5iMcY4hIWaljkWbkS3QLL6ODO2DmvogzjAJnkB6FttjNq5FVdPOa5WHaodDgtrGEBPsEPhIa83sK655/n0O9OoVHngwb1Rl+07lXUOUxFdLOBQfZDiu04X9x6yUB4wRV7gGUSxYmTiXyvEP2bGpaiWY+hqG0LHDXDTfzJ7D4pVuYmqBC0FmirgN2nqA2NZXEJrKGX4KGEFKokvGZY+LIMNvBaUwdCwRDUb/iO5Wi1A7p6KCi0MRj9ZljIG3YOgfx7aSSuGlI0z7grH+ZijNn0fMbphaKoJtituEQoWvEyvYII5D0wsFlBkAH1fqK/T4MW8+arkC7HvCShtueZk+RN1wj9JULzOA9UQHvBKwwhCiIYvGITJJTAWTMgGtWNSOSwScS2FiukqbYcGqPvqVz1uGx9BA4XT/AkGpuzY9D01kjbxIG3jM3qXHrp7Eb/1+kKn4TksX5rRkiyYVaWT6qrlDWmY/53kPbzeja0R2C7N/QSeNaOdMv+q1lJQ7yJyJzIJGmv6rUnPEsWuSl9B+0mK/+s+xqHnApHRPXQgYS5yZSoo/LYddh+ebB7/qP/pBS/3IZ7padALHtl73vl9r5wTKO/DzAZxZXrni9/dj8cT5IfQGDcR9iNIb/5Rm6srXufELv90GzolPvBLzeiqmiG0IlcgjCRwWHvPDEnqNxyC2Yu+nXure/EW+Qlz1peGPI0NlZvcKRUhYwaxUGDN4yLCPkNqREPhCQ2K587Zzvos+bdDr+iPVhUeZaztwEMIwpzMj5Ua/msRXGFTHH3cFesvSF5zeayKolWCnOTeezzbMXvk0oXgy1fumUtVEn7IbltrN8gTRzlfg+JpmKWr2e9C7dk/nFldaoCsUlUQ3ky2CjoaDWP1B2iI/rjeDJ9BJRJJ4ODib4rnwYoXQaXWXFOOdLFTYx1YVLyn1fBRfByMXIvXlJWkPA7C7J7H8Mk6aiF+N090V4LLgXQZ0Gwz0wZ3tpmQUBpg150KNjUqmGJ+XLNmI7QTa0iODbKIvEIQoqglp3DOcXNALJJlqPTxlANR7WYDNGW2aHBlUwo39xvzp2QBSg8jot04UGJVo8/JxomikqLT7DDhmRcU88qCZPwsx8TQz/3y2qp7ZmK+65GCnL7rfeyO3HizpUczpf5Xiud0l+srS2pvp5sGFjf4t52GjORUSVV++0i3zxOr3xKQqjSSnRGtF8Zm2beya3Pcki6nmRtzgqKEtDXLcjY6r8yf7uDgOjygNGZZPNqzgGKsckv2MgMt8+JAPsOk/vHM7TY1ZG1Xn5GY4I0H58TeyChlKW//gDIkN613IEx8xlRDTDYtrTbtfvW97Ryb4XnceMfPdWBayopGUZ/Hm2jgLCMPGcX9wckDjlxpxYMlq2R3HM13LIlGA26DmEmUucF0ZUVoI64qZ0f7z5kaYMZpiUnk0bGDAV1j4hJRThHP1vtu489+6iBI9U7+QavV2TKaSlPV8qOxk7wEOersw5hlNJGsX90/uxk6NzQWEToob0kx0ctMMfYOUlAfbN6k0uA0dREXrpb3HH2B5ebD5Qx1HZYjM3trHv2FwYPxqw/Z6P6YYK6ANHU3Kn9f2HUkRZvsgDURDrhyulDxrAiGebKGiOqS55yxRvmLhEYOg7zzhzdFiLHKOXBcRGODZm1JflOPXA49wIaCnDH/joXkGDghHFocsHjcnQ4hAXjcz0PIYQ3z0fmEHbDFFhjsgPL2jpIR6ijgaXnewDzdmf+4kb9qY3tfnyCXJJSqqBG1lVtdm2g+PQF4ls4tjINNmaRg9VqD25gYwyz6mUPCERCHqLq27wmDYYFtZzQsUkUlDtswc8lTjKu1ZcRcVpRACgmC3t/Ck4SyHyy57wdpoe1wk73RlyEXxjAFg7+2LSAqqrpwbmRYWrsApkTccE4rHiyPMCqxDxbkOK6L9WlwaCQEBT8o0PU9ntuqii5x/sd4GLE6d4vZSqC4ba5bpMRU6PBkwFEsX3AafJsQX0WyeGzr2HapxP3e8S+I1OidtV65TnRld2vbDtRfDGhpFBfIkyrM000tI5lW0LTIiHtNUhvNbvtmEQ+/jO7GHGAFzcT5LOcVAngoSVoHofZTmUInQou++XBn9krIpXBMpecOCpLm62VwKJDZMVineNmzAg1OD84cb0cBVSYu05v0DmcBk3dHh/JXFmMddAjSXngvzi8CZ1KXXHHHQUFwCIKQtd1q//UmSURoHFjNybBnY3vpNDqsGnkttX1MXmap35AlFU73zXurKEVxVkYj+nrt6JheIh+EHEdQ0sklZOmu4vUBWCfkSmm7z738LLoiA/bptUCISOgj7/msT59AbqB7rI9Nua3WG9UlU4CwWsx/V8ZAlaVdicpZM14jjfxqHNHm2Jp1WRYQoPB7p1O4VQ6++M0O+94Bn2swPKMyQGm4wGFqJritrXj2rMMUuWxnoRL1P+h5WFAKBKc+NjJkZd1NBnRSs9t6S4Br4RpIhWuN38ll2wBx47M6C3CKoukivQfg3asi9xTVi8yItIri3VyiTBUeKRGo8rUR/yVcKP9aSG03TdKDvVh7xTZdp/8w5DmKgMd2HwoXgZXjdiqZIwkUY2bZK5r1sxVBoADF/Z3KndqPcEZM5E02s4GOKLY41FICDh+ZpHHZ8jMqkAwOSjIiEOrs1gxb+Cj7/caiPkLkkgd/Od7LgTDikBuYDIDrzlvqkpfl+xjd2mbLakAsN8NcnslLSK17UsCX5n4aRaf2gRh+POot3yEe/02ciE/itBjkE1dhc3UXl7iq2JOD38OyThLt06/Sct77BGEBirEOYsP4jU4U+NoNsNaWTr3WuDquIXcEEE1DDvmZ1s1e4i2tQCoE7+QACPu4MwfAIO3cMUHGrch8cORYhTD2aW3mWRfPIUCDnODgOggGeWUmjYjSN2NrTqToIdoa24q3CS0/vIzImghLKquYz4IaPoOrU0EthoYUoXk//ThHdiDKTdHdIP3HibL6FQ44cRIPelXzhfDcFCj27EOpTI/g84RXQ93De+0XWwVltq8FuYZIeavL7eGsuVvlsxdnlnDuPd8zyaGhVqdo99VQJqdWvHSMmR03wC4GYwdG2o70EHSnweI3FqGhvGDrrG7Fxx3YcWiox4CMdb+hVs6pj+vH8l/ETVOO0xhPmiR8RsKfFwKvEjYlpuvKdE9hQtc+nkszwHbCBPqF2yrBdqQZ4mBrKmvSzS7UhvQTGR9H4cVEt2XcKsHQKVwYELzEtvK+U+rXW+1/GnmhdgifgZzgQ/BNbr0/Kym8GMzaUPeCHyXwMaRPa24UGVl1U8dsI+ygda0Q0Jm89OkW+0vZKo38feuLfqZ25Du2bOCMUNuFhkrogRoCecHaWxYkUXDJIzTvrLv0QXcLJryuvsX8SBIfu7pxFf3QkahimX1KfUYUV3qSehpWY07Rp2eOCnAPkAx8Vf9kqK76dXKPLGV3vIisB7JaiVPRTPSfzSUtk8+PqIKa4dC/MbQUqXdqHQyYBdTHZf778lCGolDpXR0YtRA2LbRuKClhhGPs+t5k6WvE0+41EWR1oiPP9i0D2A03f/fhRX0Fbh7wvznrO1aqapfc1TWB2uV0fTKqbKz6Q3MUhr6mvKQk/4Bqd4Qhtdedf92jteDE1J2TEQrI+KK0Knh4tvT8xz+8G0yrzUzIYJJnw57dO2Noez4x4drXB2NTb0vx3En1mLcohapFLZpPtLIVWCHEKtAnPO+jXnx8T5z8twqoD7t5wXHSpRhtWO53g/dGzC6qVIaiS/5Lfx+46qLdhtyOIWB3sxxOKey1GFPtBIKNQHJz9YByHQ5xyVlHEZjTa558cYLYmNisDGSw1t1b8SVNI2sCHTRqKuSl785V6yFJg01dHgQjhXXvXBv4sNvdiazubIypqHij8F0CtawfkuLKq56o/tQcFe2ajJWPYoDAjeXg9haNKVtx6cg/xRa2ZigkoKuhdjw/pUxury56jVv3VHZO7eZCfjvDake6s0OwSduj/LAiELcL4BlrZu0e+K1EL31Un9BJ1Mkfew9C3ri+QTIvPyUqne+G4vZUQYDTbia8QX4NI9BSPx7Ya8x5TyYYYspwNpnSyx871hCXMXE3yCLR5o6ySJ5kT99MVVUTMz0k/MGAlAE9VfxwJkYsjnNOMA60KjqAckO40NOl29yYHt8x31hbVqUMDOWhTMFmHMIkUAW7nVGwFwxqKRKOHIAcZSrupBNPfief9Gt1Lc+BK/kLwvS7kWNt+x5r0q8cRZ8NQInc7cgKFltWIVP2n5jb8le2D7DaV62gj7RdQzmbL1FILTAx6h98+A+45roECfUoPjxcurEAAEjg1ObwSyDUsMswvE/Zkq80OJYJWm/HMjd2G2QOJOqjxUJ3BNJvLijDHyJ/byscFK+whq41hvf/eAGKlkMgZvqBmjXiPnsWDGr0A46JBQlzbqtvxGwQQKLKBdeTThpRuptCZ3vXdcqdMEfp03+5mFwpfyq1mYCAQ+tlHSlX92tAJWmxe0BXSHJzHEQswKG6Ps386HT4txgwSUarDGv3hu5a2A3ReFUlNCpyerw9/f6R5wv11wS2xc42fBlJgLd6vKHqYzowmcP2dL+cydsIPX3mZliUzqseDaNDtJjUUeqPMmbFx8AmpsB2C/c7N70gti6U59YBXjVW5w8quFAi/Dcd3X+JcvFbtIBGHNm23HMZ6yQv7ccsuFl4+uieFJ5gNGKW/fEdUik9kleKpWXDWSKxl7W5siDG9PsMbsgcRkNhNVtSu0FTFYyvM4eXM31aIZSNelA9KbSbxN5UakvSIqe8QrKDWlbubNfQcbQ/UMdtOvL0VOnjP3MKBvVmrWkR+ToYJJMnp6o+1dnVFPlwtcp+HzftJ0bQvml0u2mCOkfskmw2g1pzk1GSelgcvtj26JxQL5o/6tV6HRY8HWlRi3Fxq8k7SFUykQRDaNI0OK/P1gH+0YiQngs7JHGzTVf4FBmsg4q3rZqpcGJjf12QYt1CkjsEMog+/mhbgfy/O4qnzsYn6vb82Styi7rsFc7S8776Z8OulMpELVEnCspo7qPd5UhxsdpoHXkUWIKz9a1SSDYddAw+mP5yaZ6/wTRIJLFv1vQGOBQixzXRZIOzpdbQnamD8Dk4/sU2571oTejcBAPBTgSV9jEY53t7mMucqgulvXgJTuhPacQCr+7hIjqxSsBOtud2HBOLaJSWaKvEQhEcGsnK10B1ZwGC8mWpwy0TYsfoKWHzWsGfSSxlAYAyU5GwOW7avESynTnHgJeV1FUtXT+EkjnIOid+33rJIV6BKX1WtgCC4rm8RR0sczcnNKF6mmPIlPUZcnMbhRMJRezffzfNrlNHT3b3pQLdDE701Fv2+GLZcjhFrTqiXgq3YhtC7jju0lLzbC4lc6ELCjrgLqLz8uAfWYpAEBxqRoiLA48FJpVVhFO3d0CsvGzdkIkhSQZ3BoA4VzHaCzp4iKdI/OfcOMMGJunLrCgUHt9627q6L4MCl86nbmStk3KmUMLlAA4QNTlvlxsRq5YIF+i3Il8pb/dvUJidro7ZbWxlZbZ7WSzPs7Uk9oQIuRjQZZHS6+wT4EWM/BWaiscuoZ1OjibwpTMws3l/OUZAHJ+J5WtQZeFXjBLNxjC9AqLr9pQAJ8TZPsLSApUIRhmmf1P3MB5zdUYITRCulpIEVTcO57b2dUHD3mA4AULMnHPHstZC0rHC5kScL8WY00B266j5OWNss9PmAgmn62opDL4A6NsJYjaOLxuzBS4KKXzN/NZ2x8cnPh6UgW3wJE+hggkF6K9ydel44mUuzQjF8o3zEZHZWH57TPPRPoyAoGDAkAytr2ofy0/wHJhLvSIIA5ONjyoHDnbcTwYDqpKyZC+fpzXk51q0NZWC3icXSmv0KRFjJ8L4KwAQ/Na2gkKXz+T8wNhlqVSds7Z24yV7LRb0RHeEeXrRSU5ckOiDwZ377JJUvlwSuhVuzeBWtlUnX9xexF0llSLeyM+eRaX8ON0Jao/m3Z8/RQV934vvaFJK0c4hgOdmpYlVf5ruupQF3GynLMd216wzBS8D5dv4FvbYJ02nZ6uP0zTfetP18b+JjRQyoPboSnr1B0oDxQfvZBrBAYJvXnnNtQBUvWmNyqZvcghwNi1EL3gl5i0NQxQWB0kvU5h3xtHL+Q5pRkz1etUZiWMT2+wgvIGMeZkdBmpPeKeb/l1NUtBIshA793XorCNop53yHfPWqXKSnlxQzAvI93IV01BUgRh+51JI1d8oP+631tMPmfkhsiSZcoGoXZ6/liGlkeCaQhdeSE2Nc/mdmjZ1+oFWKr3En+Vx8dYSNuEf1AG/685DOb7DTzH/2TVLgQAMvSRIzSAZTp+6S6DRDinXQmcVoDxufk/oANo+HMHIwnHJDybeJ2w5DY8OQ9U/XAJko9kcpMM0leRRLGxsANcRVAYBIN4+dmsTCNUttZInnkp8YEuCD7j1LRaveN0Iw5y0KwA5IZi/knk7/npcsPfuTUDyq0IbmDK7ExLTVlZEgVjCV+PSCxDUA7zQQMYoaUfzWWoguuf8Q3PMBUNkin51U6GQ++qSXxnZJVPNQTy5DeMMsL8+noEvkqa1RTYLdV8t4qWxyfhugVC/GOqKX+xOBC5sFyZ0oQ1CUIXI7WR2I6AWnldF5zo3D6TVFKE6aCQjn5g9msEE2Y6sGf8uHh/ajzen0HMwZzneIowVq5iMK/DUIalXCnOwbFIzvj4uVIwn7QMBC5sJtaCieX4W91KUMSyBtJn97movmYQGD1hwxl7I5IsB898RJLRqzl3MhOjgk1pOFqrdf23Ig2T4WFDNemc3djpih79YuGUsR/WWJXAy5C8Ov3sJ3yaO2/vc/OMcGakQmxZvFuUXiTOuDimUoFtP4NC7MGAv+N9MWTswAv8A4ERZvMfWYKM/kOKmpeD4MBlkl1omPIbYDD10e1prTfrbm9wzozaqlgzMM2isXBUIUHxblS70O6rUZkuf3Ynh5NEu9dw1MsBm3gO8aN1xsbE8eegQtMwdNaB05/xBqQGD75D/46qoooYrGJ2r/CJ6xB8RxqpsHQmWTO+oV5rGeRlIJQ1NH1iZs6hmsRZlCP39u1Yzt9gP8DjRGAHblgXMq4t4GNba1pWhPBPJSC17gFt09qXfxbyH646pzfwuSsNAvpi50QSVKY5kI6VAXnOyPC8W0AFBLD4a4ZfX3YBOCnMhuVedAua3pgG5cTs0hFgUx9d0VDgieksYk2xxJIf9f3g/mqWW1Ya0cFNdV1jHLOEpOtJwVWfRXV9bTWX9+hhqFskbIA7pREuM+H3x37M5wyodsLVYpN2sQJeM88K6UACtkrVlnf8ATiS7fsqgz1YFLFOdLa15jpNOe1nR2jTlfXIOZ1ADFt9O3HOyhWYV7ITx3FHG+kC2jHa5BmZBNtZgE5qBgWrk75aQNzoqCNZfjHczFExWafDpurzpIMXdQE5Lyv9OzAF5OyzgcDvd2pYJHm6bkFVnRqtZluZmJc+qkvUYYaLeTxTNx8ngLCSxjVkZ/pjFI25CyV5o3Brfw6QoROr/xwgZMm/Ku7K4bQHC1/7bOnB879U/MG8r/jI7D6S2rj7OIrqQMy+pKVm3n+EfnuJAx/Nvs+1Slk+6QymV9PcurrWylGGqiA2+1uGFqFPQ/qfTF12G7JTBzvKz3Qsl/amlPPs0BWslIjHeIuDO+5FPlbPP8+dl0YDxyd7gXQGi4X+fMhVWJBeg6sXzK5jkKQbM/s5xvUUBcgNkj8EaTwWrmpr1yYnS/etdQpEk0VOigxIOnaF5WSuemJiRPwMQ0tLSmFX+NfSwV5v3Lq53NJtSoJwVs12lDOdeWSKpeeDoQJPOL6UxP8/HPDbhRPA4BRBMhvfFE1QQHhKAyaTzivXqHFiU63KsPraNU3xtGRp3SmYWLR80fTVLYoMiHD4t1hoZbTAtM6nOw2aCj83FAXhkb5B0tut6XuGusbUC5wrYWldrv5Kr9WSB7EOOTYx4c9HPlEMyxDND7pU6SyghmlM6x+nJ70yggr32ElCsp6DsUaNl1RkSubUZ2Nam/YahhnafnREiLEI0V7pOt54bott1dEKmCqj1v5SPF7e62TpBIPfRj7AfbBCNi84t7Zy4aUDf+i5sGrVou+DCGm4WQ81DYr8ckn8GiUfPFjpFTyemL8kmRawYeOb2QnAdUR766W+We4sZ52hxe7cQt2DiXwowEoFcQi9Dmu08jB0bdEikhTuMvQcYqC/RK2KVY8QBzAQRn9woIfgvGLu2X3hRpq/ye302NXLTxbppgJKBZ6K3paegqHdtal4+agpsRNnjr3TtpmR03UHhVD/L4IVgKbygckePoKcVOYd+TaoIhxai2gurUD4OOfLLzvx3jZFq9DUeDIkpLgetesJkoOYEVLJ9JdzrfXcn4hqq/AdfYeotivcaL5Gh3C6IavokSRBbFDo65N8RGcI1MLJoIvxfN4RkY51BknBY0pTAjiKWn/zl1ODUMvhS6dEBzDJOTFeRHNL3YLB9VzuPdPdI+R3keYPvEn/0zaHIx0RMKU+NJDoeUtYoz1qLfULPPacjqeepBmIH4rgwIQOzzPAhTIur3NGaONp+93rM9lMLI84vF7zg169zenaeHr6Nu6h+xy+evHv3bYB8Y/JInRu59whBGO3aG/6GVrFimQKUleuQqnBWPGTMlPmedSp0dAtfjC4bmdDRCSLk1LbO/j8piJkeQqgoXG8J5Y3YTN9XOvbHVggyQU1g5EdoPbZLUVgx40/RJzaUxdYJuV9fQV1LB5sCMopmS8EtZDkAhoh5I8es09ChEUlCleOfKRzrJwPbQ1P4a8jpGQ5gfYXDQbsUskmXdW7ZGCe1gyiK05ZJd2ADgws0x13FGSkTHLbZHeggtrcafVlzNST6DZuoLr4rrALL1HK4TpFTfk/VK0lgSyz7VBsEC5Tcm6jLk21cas3RyDDXD0voupwi2MUOZksvQMh3JjbjDQwUm9zuw1G6TEBOfW5hpaBDZVyIzKKTPnEns6osMf4HL8rPsebGZNn5YbCMKKwQxXU7fXrvIzcAoi/eZrCIE4PA/K6UKAVBl3UdQE2zZVmE8ExOX63RHUrIY8xMOBjZZ19vUx6EQOwsHYnhHk16hqfr/GuW3LQTcPCfvotUNBqRKvXU4+8+E+etIBE9+3aY9KNF3jAft1Gbs4Euyjv0b8PychD18y3vK/mXhRLE1x/5La7dFRirWXqNl45P6MK/nGKK2E76pqCAt/Fl5oLvSpasoEehffwxAJG4nMMzSElza2DuL8l+AarW4PISSPcVXdByGe+RuII1Gr6cB/bvtdCYa4wtuRR3YQxnlcdxPsoPJ+nWlvPmX6jp6KpbA1NKPITWd0BHzNjpBQbAhE48QbsO58ljOjcAMaB34k41foK6tlasF9SqhZLLJ2qWmj63eCvTF11PQ8wAlflDbAcONqQaRMQVglgk3I7OLz45zQ9GF+46qS+v5exB1oDp9H/nN1RAufv0EqcZAnvoSAs8NV+7mB77+TazpqCPVHSh6DQ70vp0pFvGL9W1cioNVYjymnFIxYKwEdWZlhJlBdjeZtyvzAFEcl8YQBqoX+cj6mE1drZV9GcCKPALE07dM8LCMVOlwV2GoE6mc1JFuFYjrXw/+lZGUkUcj1C0l3xunM+ooC8H8AGqqOJBVIMg/N260iBEtEadRCLA5unU3keaKg7gzvpula+iyiMMgGAAd/ZRniOYJu3gLg7g/P1PGL5sDWsl/1E9jvg1DGXcmDtIKl3FToj25pZ8KYWebvR7QFA0TS2FO6L1OIZWZeMy2pXinKVmVFnRuLKsNlgHsDR9PkjvIEO3J/uj0DcgmeujaBTihjoHCVqhvpcpl1aH5r+0jXGUsyygB/cJG3wrkgcutTxzuDZSKMFqyH/YI2+BEe3Dnc6YB39hOdPU03OXd/x56Xy94fs4TaaK5a/W/Lo+wJbfdyypbUJ6T8yeGs/H6D7JZtgaTPhnmczRowk8cWLQIWZmeFuW0ad9XNSJPeHp5HO+J5j1xO3CqH8RV1LN6TkmdHUN4s7s8IG+pE8NkW1Hati6ut+IpWYOqIsgHGmVfr8O9dxo9s9d32e6x9dtXpsdBT4Ba+AQQWhWEDSMUkTNeT3ztJVJDFfeMvnvUW47wkkLQYK0gL+LDS3EZRY7w4+5A39vwOhbZJOhtCPsac/VQir2aQY3poZgoOn3i1qmFKhXtRlRUnugJBruvMBLux2Odh7cD9lttYSMA7fgySSwSws43CWbsqEvn0XBXEVyX90gZC2CbI8/a4zgHnkwAajdJLpHmS8p62VhF5VbC7zu24Mqg6nCLhYx+e10Nx0VBVAzdUxE0Wn1vGX7FiuAZWMcgem3vOqo0hvXzXlJEK7Nu3FBguZBVwHcO+55jd+YB3efeeFBmQ4jXbTokrHUmCMW7MxUn++EGAiBqfDSktPwVzmqpIJHFjNDMZAFWqkGkRI/fS1xmz+tpfswyOmp349OwXxaAuwSy1ZRA+kasR95e7jgXThrsoNnDKQ826nF/nCdzaVq0f1Mipqk7DKrysvQNn8Vo+ZhqB+B34rQUy/e0ZAt1rlJxoylmpGYkIhWmw98wgsXJxsGsCY5cwbQAQlKgi0DWyJfdn7ds2zg142hsfXatts8pEo8N9QgmUhR7BNFADN0EmlVnp7D9+i35vCK+bTSsCaQkEsl5jVu2F7kCQRPNfj/cM0oyG/vCtHJMXxqjejuDDtK8LfTeQP4ukIwxzxM8eKgdXP6Pc8UgKve6cmpsUStPA8LxC02jLon1FNmfWfCozHNa//jXYZW5MbUlGGGSopIlGxh6B0rtW+AVYH1oAl92jg/ASAIHhF1tX3/B2Wn3ASK/NMvPy9wyxM6qTogy92R2hg8LakFl/S/MEu9u+H0UPXiMbiGCOhm6ThaiGf58FD6mBd3ClzYlTbl5YOFcDv73X4kIO9c3u7UR9BR6g4J5m7QoMX9aYALm+DWmhpPmHzHjHfNa/YMXHB981fu284FLu3FdPG+LbP09iNfNpvqFP3ELQq6QvCJXpqdpLUdiY4s5T9ZyPMBYFvsclXDbXh3ADsP1NuutW/zmQopRyTUhxFtevxs7mlbOT5bl3j0LkD4GqdUqWo+e29f81QIOLwxfc77tsrhPH96xnan/HyTPIsAhY1fKHQfuhH/zo0fnHGvvDUeiFzlaezMFYrOHoWWriR85M3TDPdu47hRDbPCQp0jUofDLp11u1kFet/aFxIhCHxFRD6xuhdiEZ0xpefrEcN/QdrfYHA6X6SHUsvi+ASfZ9jyi/5gZKpOZ4QuGhzj4eGREjLs6UDQrLYQCsPInCaOh70iIq+8eBEW9BkMfbVMGr0xGe8seIQXwY1ORhAvKpYCVE2TzLd09XGkK1QQ4NlIcEk8R/4/jRoCKCOfAob+z+dZPA+Jr9pJ+exiDGMEvLaBzIPma/JsyWCOxrn2BI4uRnmcMJndy7XaaB9Q9sKhbBW9ZsNZT9bSTXAkFD7Ik8Qt5OZCNrcwarLLH9ejCNFGjEiTtahHGuaYRZ0W00IdaGJ6Dtiq9R0eYMd69uI7MuiyZj539KZ6Hb8+WkiAWy2Q8Rdpa2aFYSCoV18jNkFRSNio3zknGaa7shqxTKfIINBkjurGkJqja1YI4scVvTItdZXdhDTs2LecMPJsOMEBF8/0ATGTDBbUaSK6uGMOL010HjvLswhZGec/52gRs5uYFIpLXF6XLPYDUxVgCLri2yfo+KNiTYt3jFZ20dsEhgvUI2+ehwl6bp2Iy939qJ3UzRs0O8fFDD4PYhjDtqTjF1oVzjBdRtF/2nb4wppUe05nqImyJCkKduHNz4JbanGwO/fVSV7LdRM1wLwVWLbrz0xEKB4oYQhV+FPbMJVKUxWAEGD8NK93FDBsgkPhyUEB8IRbhMx7j9kUyi9AwNJIVBMMGQtFObbYKhSUh3cp57kztTsPfJtdStOLBbC9IS39xLSyBUnCKePKmb9uW0XRdjG1V5WHLBRqYdPMSx2fi8fTIXC/wHgRopQxmonWq1OzJlpS9sBGGbtJEn6GDCMJugcTW6s3GsIRqjO23aVu8C1poVHaFR1dnj85dEBct3ipqkISA9X9uTSoTS2qzarq100oiBKgnJHFJwp8WYEEOtuTT2lN73Bh+b9bUk0wUdPLvTbcGHHc8V3vcD5gI6GSYvZ4j4ybwYrQR/sBN+y/aF/Z+33zG4D5su8XOud9rKZ7/zBYgSMbfR9Ifxtvrfh9wVV+LRuw6B5ndj1Jc8maDtDPYObenCSDMfXwQVd00OkqDqtNC7ZQgdH3UIIDNBmvNghcyqU3jSgOhUlx1tvR+IXQmLzJHZSWEC46Z26il3Ov9AZPzmmRShdHqTQUifw55asuzFSGKSMtwUbJ7pTnVp4pg6IZXc+lk0IMMvMYEwZngOdeZ09zunY1kSRWGO1pbrJicjsTvKRtp3UvzJUpPgzT+d7tnjcmktS8SEdAED4JlYqha9OA1kHkn2EMhe0LuPbK7vvxAlMl2EFg/fLXBB8M9oq0mPxtNF/gh1bt3LLmn4QqTbRrR7rvf4xQ4Hk98nOX8GUxKwm09tNaNTJwGnWAXfkcnyDAKvPt4DQQp3aCL3V1Y4FlRZE/1Q1pZ7Iven6jJQZMzXU4Ry2qxB7TQ6EAuBhzEtUG2smQ0PFOA5WIdnnHSku+tIezgY3gR+8ahpBaVHEwEH5F/+FxcgyBHiFOjtr45lLoB7vU3iuQdLlEAO9AITCb5cUO0RwYcjyN7anEX/wZVPaaO6EL4XMGRq0SrnZBHfu6t65vUF09ulqJNRjISz+kDalZxvXpcJkTyZpGokfe0aOQbxgJA33l4jIEVPgKdp/gVWeW9rlCmYYTy+VtAZmXEQ0ASh8g/EuhOOeslICFgX8AAqYArXH0fSuY7Vo4d+P4EElfpS0RTu5xDc26BrojJcCRgwj959BY9W2G4eDaJy2/+QUZciDQNdQGW8RfanVj5GfC6IuR545Z4raErhyUuM2xO7jc4sR6Xjo1qMbG18n7UtYOyJtiOCkmXC1gsS/WczV6X2xbNb6FUsgHzZrJXWAd4Rkze5FynbggFHGhgPw8UCJUex6puLjSqGiG4NguIVHavBmVEaJnS+Q22gq8zTqssEN/gjYMQIrgD9js8TxMJBymnryHMFPc1gApkECxwr/sGX++wmch2HigvZaiW7iuAmfatGX0SRyqTYFNC0pP7h0T4cUCqWxbS9ZRAP6WVCDWEqBCq3LdVSUntzlK4uFqUdqtaUWDSmO4qRSlgafWxVbrfAHKcC0G/Q/H71xcSZ2nhAD+ASkSQfXqhdQW2aiNHLGG/CMQkB0ZLuWQbhTF/t5U0lUM1bwO3vRIPdZ0XsSMdZADDBNDiCYTOzvZaq5R4QL3AhKveQj6eJZHhPm7B7N9Xo46FPZ545jV3zWT998KLJHrkDFGfSRH+VDmxcwYB3H8U3ZVPmp6OTNsfnYRM/1QUcm9AXWK2SYSd7Kwyu5GEJ9qlzxwz6wQn/9QtWHfYDVeD2gzIxsbMi1r2ekacQaDjH5GPPikLjaS+7vQkSF8Pz+P+Uqw11Nsm0MCWxh7LA7BlRWdBtglnY0BASXtJWoL85Wu/MTJec76VUOShdAsU+RqOYyH7Yhz9kNzskV5i8XJyZfhqheY4idvf4SFy7LIW9aJhyvjh3aPhY2Ru1tSnQ93SHc0eTevXJsdahND6+ku8LIUYPBmSQRAWEoVcw9K42ohPXpd5+cFZvWj6sUyQ6JEKPgFB2XfSL63uymgIoGEdmdhyPMnIYx4O+lCJUZNN310ni4bOut84p0PiNZdX5E8x8amRSOf/hWbhxprmdGyLO7qnPasq6hAf3SBl4n2ArQC1RgMjPTnFI2C7VthUZ917KYdjUM0ulPKpCx2b+IrnFq5PReixKEJ5SLm1EBPY5Vf2XPoqUosgmGEG+pL0dkwHKtPRvWbRmHJgUzHqLE/rEpVBSuWgczK1YoPgL0Ctbi24VeO3/1M40Xgvr1erxoazvrFXTj2U4GhCZUSFetkU+QlDy/E83ncaZNk3S8QoKmLh3+okcz46fLYnKeTco7KwIU/ShKgM2Y8sPCCIH+ixhmT95beYHpB7fzXjY90tcv+boZpTi1PqXGAxA1BD/C/iP24KkqzpvFu9AOhcqVmS/BfABC587OjLJQCWeh9L1BeADNoLB2R2QHPcQQsQ5mNWoKOs4bYwrlT/zvCFvrL7JDKTmQdai96bEEAuDcQZuvmYc7ePXfu/bjZiI6BH2BA69OCk0KIe41AxEZtRS71HiJtCto16djZ8prQhSnnszvrH+1rEj2ZQ4sSen0a+KEpgYW7aqIsf1i65UWdZlEfnSd6Aii5gpfmcVPioudFwQPhwav35U8GGAHXvZixCF6GmjI8+M9IHdr/yS2la+0Zlgn2hIkE45R/j00PgpOnPGbYyBMRU9oocrq0ZUe84PVKCSq29yvd19b5p77QbqAZOGOCGTnByqTVewvi+jgBtDA2a5dK3HKBOVs8RkSaCna+1oyKZnbl8pOScJcDGYqD0VQA7CzkNH7Ayr/jaEI8n1g/Q3e91AhS8b6DNfQxdXa+c09kLgMIfnvUIoeRgB40U5wXiaex+Sg8tklrU87GDbIWksz2WdhCtsl9v47ge1zzkDUac5+tX+u+eJc4y1ItnapDUV29c5dx1wylhFdLi8pP8lk3aF2qczvjKuHX7pMWEtyHPsjPtunE+MPHQXjQHY0lzCR3MSPwhbhDVB5BA5adoveNpAO4U5sQuZay9YjmhIWiz3frGvDclzfmP8Q3UCPfIQz7kSM0kZn2g71H0hQdsHWcLYgaddfVvRhZHCjemP2q7We9/eCI63BG5a61GiVcVORZktW9LunQ2dETyNeyl6IN2elxqI23p3oBDKJseDwMiFIaYNWvd/T6QA1axQeGVXU3/6VFj2gXpfJwGLg2XpqWe0TbZ8sk+DkgAWNHTSWxSz2AUenuxQ00tjcRiwe4xGeR67m01RaLbgaxiKcGr43GB7iE2eqwgyZP+HFw13vd+haG/BNKaIASLno6h6tyYlwUZVDdi7vPT6IUeOwxgl2yZQ6yWMHU2sbSt0QBzsyHoxbJUGy2BxF/zpOwbXR4tXjwHKNFUzPvebhDCZwtiM3gycwQQl1Zg3CuM+7gtYqlYva2fTeQmshSGhzgW1prZ3CX4lwwPHHtV1YQtukjx+Ex/02I5YlmZH3b6j6UBDkbxOk0ldNQdzFU8qYBfXbkWVH3r+erf62UinJ7xEaWQe6p2OBkeY3K0qlZMaUqLhWMytf26NHnA6IK5B3vUg/VV2JAwheNfWW6JM1V9YeojHBNpprS2kawsy6f5oAZ9aU0IbRsIuBJPI4C4DhJkSziVvqdooSUeCCjKE2XYwpTfr1O2IVvMwSHCh7pEPL4vXsl8H5twOk8qDGesVSYkJsU/GCY4kphMnRTNLYVBJ0R/4pf39esTG7ePj2gXE/REKYUwC0TkUEoveYZ3wADl/j/U+qtDHqoYBc6wU4YIaF3ao0f8FwbaaaQtoxNsbk1qaWzINGyeOWcClSWmnjkuXX7NFyPPRkrE3QRDYtaxdbm9kwIiZB/gBqJwXYwdaNwrLixKgJP2BQETy+OkmVg4E+oKsJQ/eXyca7bzy6QXLmxGIZCk+xqdpSBcOfE1dLNZ9FceDkDvtFCUI7NviPiJcM9bcaFphYLKqYS8aT7is3t6yOGtNrH5QFODtSdoNcdDkWjdqcMjthYiMzZ6JIMZxqokJ7bnJ8QsVzWm0Ia/bImAmQHQTqJPSi7Mpd/sqyw9gCgyGRYPBbXNe8wY4HLZvf1InBrOXes/A1hNK2V9KcFJkXe9ryaDrIjghvNv8E2swgqJwNw6bQIrJ8nwA0OykCmpaQ3DSEjXJi8v2hIaiHExksWtLWAtJw7YsBH7KU+ZUtC1ecWoMADjwxLouIoONNXTJAYjrAUTsfcg8vihADaVhdK3j/WrPAVCqUtf14oNIj6JKO8HPJW1bpPxbpa+SrlkkZ3RQMuc0K0C3lUAtleKmTZZm8o5JGYalmbZsB6muPzQVJq002RFH6od4awaU6ugb3cXB5fyFcM5+IXbFKFpgVbZcidlYIWbgw272Ji1B63A9vSEu69bRTYESOC7XOlmxlAxlJDlHFW6Ki4LKRYt5kn0n0NsQg4K5uus2XeXz4qFpYgVlYoap21Dmte7IkgIPsOrsQbDqc0nrJFvuECHSSynrkrouYRmlu+x7y74+icqz8dj3tQs7w1uAiI9lmnydIJkOZdKSRi4Gzm5G36KFTGhdm3W66L8SYpvrrgpG6pkBfa187Z7096xfkPJLAKFd4kSaYlgf/hyCE5lVdlenwh3rEZgqMBF0XrtKNrwAUhx6rjBilhg55rZ6qCKw0o0IDD4cluhJW+YirUy1x4Hbl85G7rRRm/MUnoe2OZa2mE4A0CBWLxofa986IsXWK+xRouPUvECzJGREPj3GKu/dVww1pQ62sfpCIL0uVmyUwCn7MVKADQDAY/r5/y8fLtjCq2L1mC76bceiJhj/N2arrvOdaMzwjZv6SbtHQ9W2TR4fJgERANgnqDoq8Ef+e2lDpIh79R1YZ5CWhPwRcahqctRZPyTScokJXZBqkNwGCJdDrM5opkpdos8F+oOywaAh/kn31Rh4+oVPClGcztF/CS4D/tadhDebUkhq5n/nNN4aQMFTJciyHQ2o/tuDh4XzEMI8IEY0RZIkpnlcbSDi2QCvYNQVhIsAIfFaPm/nHKCZEi9kS4Pq/kspRYtsQsiEsOD5D1P3H1HAM+oUlZB/Yr42xvG/K/ayvZQOrVgg7Fb8jrR2Qj8ozCzZRnnC4SaKavqBdLFj1Fx7f67P8vQCaIIrioKAXmnTRiB0Xcpg3YHTpF328Zv2+YualUAxWJ2Uof/MowbxoENoxzjqVcwBpthObrUXeSShU1LxExiogzvP8Mi4R27eEefJSFxK5EHNtxCCiKo6Qk7OQfA+gNUCd0nxja1UL1JcfRYsMr5qvL/i29Rq7uSMad7FNyRHLcckUmNCO9joh7jWLN8k698GzxpRdDGupmkncbfgHDuMzrNpuFomBTaU1zcvWD3/VYG6p3h7Nd888jSpvxfnjtt230JFaamhb4I4D8jHe9S/gR9DgURNxSKcYn7861VPlCE1nnTCiUNgl6bv0TKD7VYngoKtAC1vi+1x5Jz8jGxsBnYokrVX6kmDU3Z3TlsSZLZxu50weJVTVlQP3ffE3Odzu7XIGnJ2AddG5BioEkgMTvTwhHP6rDJzmHIxYZchwAPgHxl8j3N0+hPmqZp98bqQpGxDPJqGRUSo73dBQ9fpbDXVbB5r8O6qIfQPbDBjP5qbEhotUKCK9HFamHn1QLRxumZTxMtPoLxqSJYuARpKzE1FvFQ3E3Y26MglndxC+DgMktCzspTDIBdsgz2oBnXMeepBDjbsqz//GUKFcXCT+Gu563ojTPuTj6pyJNQVB03+r3zdhiNBvc8fQEPgeTJaF8HmgjCigh0z6acWRzvq3FD7ksgL5eaL9YEbkfdPdQqX+TekTzcKDW/rKe0EkU59NMnM+7SftsiutcrIaG5L7MFDVmIkQeUNCqpku0NYxzP/vIhvLjPxatFp6RCavU0s+NTyBYl93u9eP8gHQm3svhexjiygVfOZo6KvM/QIqo2tfiO2kPpg37N262Jc4PmsLJXf/te2hKUKaU+0e24l6Bb00x7A4qYokPV4hgJGVRneUPA1mAXGQ4mlzt94kMNqpYDS1058epmXbrwXWIsc64NgJjE6hpT/L63BV7O+3P1+PG3fJfpuFCXEbdEjPsRtnN1hFyIhp4ag3R6dKd1nwJ/nQh7zey+fLcaVTd+QtbANl+tDRllW32XNWQNdTkCtKXJOBtjfH7E4UxgyhehTFMTfkrGCuWl1g5hZqk5yT+iWL76N2l/6FPDUxZHs3QM9lBUkor+0mOYFoFAradJRr/xyIpyYsk8jUUX1qU9kBhwp7pV0T78LF9kJE1553DEYl8uMTNj5uKosE/jUWAQ8AZUauiwuAjQPi25XP7h2RwRM8tnOblZ2tUu5UvPsqBCVfoqJGIjL1biIMN9PZi7vpQnlZR3N5aN4ZfFvuN9JVqkbAEBADHQ4K35IwUZjQLBcO/Le9Nf3D96sfme0UgrzmSM/CHBLEDArd9oZeuJilt7LPYIPceFdce7kVk1Y4ya1j221kI0c0H9YHL+0bPA51vfYWtXRw8GJceVDADLUGRZEslUD6+PGDCwTfmqKqHVJX+i0xXHdaEX6ukrziSAaI9AkkVdej6lu6AHnoWzPKRBgRIbRPbVCbg0c3jsvRr2XkoczVMwKTB7Qgf6BcP1dey1nw4niS5uwD7+TRljZR3EJKNAxAUWp1TnuRXELCC7TBS5PeJa1nRuplu7GV+0ucXbJjxXjcHSiuTFz2IKUodGqPgHq5qKaa4/tS6jgtdKoqd/1kKZCTtW24U3AttrEHGAQ8z8DrES6gWVo02ZQ1eH6rRr2AhP7Hs++4CT7UkXdkswfBtzOgDDfoeV7AlxCR2ay7IMCHOHIvLSxkaTJd5Aw6IhTNPVq2qPgsLu/oAgEgNF3nNmk1qQssRD6v4vznNZUPjKajt6VrxOE85Y4v9/1DtYvXYpLVqbs8za2zZ0CsseRUKfx2wWBbr6bCP0efM4AVDMzmXXeEKPbkhfVVH5Hq88ReLxP5Sd0hXBlkZmdPnORlFBRCmUOViEl7QzgPV3Tbz3s/g+Mjfg9MhSF/UfMgP+4N5BnjAAVMAhCxrxTf3M/ARByG6fHL4gFExA3w2wVtQR3WvntJy5+meLwVJ/tLlJKaLqt6JRTXDDes9VzNhD24XRZfzllKUeAUZ5BA+6RYl2r5xQHuW2dyLve09ROuuKttqhb+lJVtkTjFWqigHNrTkuH6qMw2kYcHwAbtJPBHK1DZUKfOoeg5p/NO1orx7px3AQwgZmsPE8N4OZQr53MbyCkPpjVgOxk5Bsvoh/j4rw/XIjNSJwbK3xJc2RP9UISr0qpaWWoH4ohlEEQD/LWA8M2E6sJiqDX072bw2XYdizXGi7di2jRFnBBxjXLXqNel34nXfSfAlGXpAUOlt7CO0I7rMWP9/TZ5ibZy0i4sXJHkvh3Ke4HYGyEG6U5JzfN0nTjrwILkKdWaxCSk6Zq5QJd1sg2FHpwF59IMrBqAy0lWkl56w9OXhJEM+YkisMYvpeW3Y/9iooDIu9gWalH7EhsTmKjMY0fP4iK6UvjGHsafMDBYwf1fTCdY6JZBZClqfhFqo3wj1dElSuUy4ULmFLj3MEEfGdg6stuuWWtvrFgdEFlx3LZPPhkMUqlfm/JQINRZSXo/kP3YC31koLU+ZDAmGVYgfME4aa7VNLplMAYSJmQH47f9k1c7kT+wr5/CA+ohU9DGEL5oR6FC88bTbzU4w9bBlhD4+uCH5eMew7L14eH6EJ/koBcdEpcpZ/SdX8SB2NdUJslGfeHDaNCLOQjuWRyUFUWHad55uq5cszUlnW21vrpiaQuWD2fzBC7k5e+6xzQCsysWKUMU+NmN0SJ5xypQY2TaGEYhQbVa72sJZllYt7j9zrDgNdD0wM6ut8PmdkPSpIfw3FFDnk4H12aBXegzBDYdqbCmdf2u2zPgT3ktKq93O7FbSAuZP55TmLHQfaOu/SDWbs3+W6kmCOpikOu1memkZ5cEZNuYf5Z6zVTQydV+Y4Hb+KX3tiIrhDwL45dxECBaZhFFs1rTYpOKeLeGi+JHwwRTVy36l6ghEJqfAXAFHQ/pPnFhxMl/FQeFaqG3WCQw1cq1lEt1Qm40OMT912c36vNfh+qSQcYSFhIbwOrZ1V36Hb+ijsAXHicFw5rfSVlpP0CQ+8baHu1UkkNZg8vm9cPl3qEnCiXt1om7l1/Z/Fjcl67fXDiiPLI1WLOidC3a0gFfCtQUWjMEFQIf8BpjipREvXmHvCLG2lFAZ92FuwZSwrr+P6XJE0uo1bB8rfA4njmwxLK6PvItm20n/GsOQInOYQSZOw/Rfx5QQFM9avHba8Tfm5ZBIUu9DZX0I8ClY5+Fj0JuegvUAKofL0vGunJ7YkTvZrUR/QwWnOydvWr1rBxvMxuv9LUe/ZmM4nRLlRQrDKtT920wCFkU7qqRyC1VH3DKo/t+KxiFDOOd+JUC/vhtFpqO4WFCIHCBcOxmFU5MDZdTgTAHVDJpg+8GP4gy7PkL1SpxfC9TwGfye4gN9tCthLx8W0Hfra0bltqUeHa4Je7EA8KrZXOzq/CultsUlzvLO/b+sQeqhXoqgCIRRMclBpSDJDja+CM8/6zYQbPill3yOsCtrrgBLiPRhaQrxrb2+kif0g4I+QeqPPqkhJcP3atQMelLZt7us8+MgJQmxPKmAIaqrMEUo+9agNzl7SVGDVOCCylJOhTEzvKYlogNn9aUHa/WGmCiWu6XEq/B3kl9ww0lKo6Ih/McpCLhQQ3/grlYa7CAO4el6aLOFSNbgbHl4JdUIceCnYqA8VZZcCx7A2mo5Arxjnq8GGig/b735pLyokNrQP4llqkXzLnDORUnEMIn+bkFMWFmqWQxl9O6R4Y6bushSW/TW9+SXo4tNVjgmO9rehVsRqgim3Z2pPIyrsP7bJe6ttpy9TfSTfV0zxW2XUyqvZuOKaXw7A16jfH0cL8/aKBDedY3yTKG2wgDnTeVEdJv9/TM05NSB2hMRgneas1P0EcDykcfb1X01tGrMTy2sf8pI4e6w2L5kkLuCAHoVEqhOOylGQL/fym/9r8dbG0XlvNK2YyB5p+rXzUuc4wEr9u7oltadOUB93dHNlMqCPWVQC7HuWeDZ/7hxJNGqVmiQ/+lLFqO0cxU2JBUuuumMHzurzuHoSTgpvX0nG5AVOd6AiImrjnMCO61E9ipUPEHgZb1o7Zf8Yl2DvqI8OQ04oR7JBegKHwpyg/VFJHpaK9KqWdHX9v4DQX4p0YxA7mmYwtFnBePvfz54xrfson9g6C6LM6MQZ6asmdW5fQ/paZ0iRZrOIYx+AR/tIzQSDp5vfGE6bw6R5NGD15Ymam/KN/xpqd8Rqv6FCrOrKEBBmjgu+fA9gruIPsQb0miO6DNQe8mwtxkWlhiDJVWv+Q5RQPrKZDmGokZ7Q9eX2tZ1rNwTT4EJqsvVvKncP9sjifGWFOvrK1BPNkiG6//UbKmlieUXohOrJqnOiFismDTpS5HBdz2sTa6HQwp9zwsb2LDHWjblxJDCpBzQyYl2NzmQysTQJtDVNDoAO+epQEfYuMBBSG+IJDdr5Xy3opXQnCFFa3MuZK4H9Hw62oXvZwZIF0n0I9WxLJkmO23T3NJ9v2BZiGuEML24YH4JjttPakmFRFRgYvcuztL7MWXaL6fSPvt8U8sTsp92iLTCoY75wtBP2yPl3X27AAsnvtRpeX+G11XGWvHaTMPO+74o6+zj1e2iBxWSOoedL1NB++2hwui6b46PsUcnORp8pMFt2moypGLaCaWVKoW44dDJ24t4mneD0RyEd/T0lK7W3G/bO5uP/emYRUBJd4ZmEamSJ8200EOcNk07QVQZ4DcMW0mKuJTs5o+1Q2PKzhPoSyI2SE3cgmZmchYY6ojAUZXLkXQl9RhHXhNL5MYz54G8voVTidHlkMfc1MHWY5J5YniWowdYyUO4pvJyrPeMWsXM1KmsvXH/9Ps9cgjW+k9KwXPlWiSd9NtgtShw4FtW68PY1MeyiQqGZbGt79KmMM6z2BlaqCBomEd/Y5bmITH7G301tYpLmg2myIw8oRGGkDkWpBZxjdo3cHM+7RKXaj6xnNsm03EXnF+M3Yo/vLJ5ntnaeeBHWAUGiarM6ckXLugMDHRpaBSKe1yC/CjmdKPfSDvRMe5xC0zT6Sh0EplPGvAOgLPs2nWVCHFil76M7Y9BaGSz60nouTAInkDDPcr+rn/C3pFcG6favpT9qwqMLVBMJXXBN550qOYH4ioSxIZaK2iw0yXlZKr7lWegB58l3VTgFpyNdjICH3jZ+EAw9S0jdnEhy0YrlfD5lBI0HPvA0JPq7nqNi1m0XDARRQvNs4NRfaCwFFhl64t+VE+K6KFJCUwL4M+K8orEpXgmektHOfD+Am9Ocb1ID5O3/kdNoOTMr+74V+HBaHZ2KNvr42L4BddJArPmA/R7j5Gr5AlBhfyqPkD2yruGMmLl2dMpbw/ZERQGgb4Y8TguLSaYTXGRHZEu2Cgcywe/wkLFjCPw2HK1wS/JWXMBpPXAi0XCr5NFVD6earmSofMJ/vBulEeZShtXw9S+y6WCDLY3GnlWKuMf7JSqCwCbC+GzfhNPIvLTX9ZkynNDDE1B3m6dUtYOuR3v0HqFaTp5mCJ48ajww3MoIPrBVEnQU4zO9Y5CO9YQhLbw6Id2pe4AtkmGUFvDd4YHJO8YGc7PmUonchTe/EoCbtTxr5Zhy4azCuD4UFL3m9Y7uU98UH9XEr4MIyJN4ok7e44M1JQg+3OpeQ1JfYr2ZcjjchuT8VIBlLGC/da2G3yOB1DM4ka56xtNPQ5ShRGCiYOS+zro3z2YMG/d3M5Ls1Zn/aRHkkNCEL/tOWqon7jXpH4UhY8NGj16KcyuoJmdQAKh3OagQwMIynUYPclmAqC4abBjSEOYIHcr3EjUyYkaWbdmQW9JJZJuDbW6xVj8qyhGYgKAvC2TArTcyxzwMM8R8ChMsMl+OoDP6zJWwQi/qQzuqn0BFcGAKt69lqL2zp+YuQaB690KmlsNEv0DeCCJEpTOj7hiEWGXTWsTJj2SUdsL7sv3EJ1CCET5j4EI98HDq7oSVF3XkSUsuGazT0RX1mIfzcgexnbPwXNkrTGw66AeErQFQn8xBBsUWTRsDMPTHD1LeOfli9tV4x6XEXlibM/2LwCsyuy4BCFx3PEqxDWZPWlU4ReE+CT9M7hkltwMTpDS/v5Xn1FW3t8C4ZYuRqlrEnL94VVIrW0tI5hD4ariAwAhAWx6C+B/V+lw2wsL8n9BZS+UwE72mKqcLZc3f7WX/KWunV747wDTt2YuuBFvD1t0gY4C+9EHBaRH6WGVzf9wFgHfVdKN/neqHufNBi0TfiLGisMkkZCPFROxk6eGNCqbGTYKho/wVhMgXNj7AJJUQIlIslkwIJFi/Os6o4BzKNIAIYcvQgO6/Haj0XM6IZH6UqHJiDZXO6eYy6rNiI7aApZfaG/O5k+ZVinjEP/kRfLcBp8+HL1c8hdT63RHPsIJZvt/AaV0QzYY+zupV8JcY8f8CeO1wwK7i+YQznSW3Jxo5hHAUnkKYeTMjNLPxi2Pk/o3AJsWeXBjYhI9gInWeNchDx8IXlo3tXcbk4/qjatatkOAz2YxlD8YJYw0PmI27Zz/QXfsBL8gMXZ9xYa2TG8zeSHwKJXZceDNehRiBLjRLRmt8zJsO2UsUBiKAX0wZ/jsL53xXyzmCpgDMm3LUK84YgBXlk4MNGl/a0acKU4ew0KP59ZwUJo1AXTRQrI7vEYUUiGAznLIgpo+NB9JMTGeD2QUA2c3iedi4bDXKZ142zfhIsneUYFPYByz1UtCigQUEWP7nnLhh7PFgKqzJux+GFmelOiVUckMSRNJfR+ietRxI1a8gqMvg7v8be8nXTs4Y3ELer8GEnhOZ2lVRGYI/gr8UvOMJrptCL91C9GXZW/Nh2bjjtZ4MCZ0W8HnkHbnemHx4tUmJVvUDlXdykCPaAApkpcg07pCyTEQfeG6fgJOlCzcS04IXqlOq0ARGBl3B4bDLkNpNo+KJfQWWS51zAXiEpHHiHsZt24rHFIhueabHtOS45CFLVMNyjZ4e33/dUNW54s/p4IyZv/gUaiKFzL9fwXnjjyt6TglO99uCUi94+TkiDsSaICxqtSr3YkQv5gy6POvwCrgsgJuIANZw8mJ6TuKAZzYzGjckAgWJ72h6cb6vxhWhXi6gaHZAJs1K0CjrFYMwAhfq/TbBJPmF1XWNdKAdVmt7hdBhQKREFIXG4fK1Pg6mrO2LvjqhBTtyAh1Z/MBjeXWQ5Z1FMdeFpnUWkjpzm4ERjvrU2DY1h5+2Bs9HF7tn6/5fwB75vTsoEYOy+B40Xp/V5FxE5mk6SMHmDcR/pGTQuZmckem9UW6qIi/kOh/pMpQTFNTlLZq5XJp5GTBCAYUKTTjx2aLe44lwj4irlCdOZRfWPXBzxNLwb1g82sYlFxsvNErS1WtbIRfR8ZduuafGuA/XaufKnm4ICxJBMDxu4PktH7O9FQXQh3jMIuq88eekU1g4elQHmlc5lRDwkKuzUArUTav3YqFPN7jTmZgrnVQ9yancdJUoZzSuyfSPwApWKmJZIVaMo8bcwa5emf4OkMHSRQ5Y4olKkTlZWavbhCHa51ANwaC1AZqeEysMG2RoZN6pl4CwFtHEhlmvV9NLYoJSKgghdFpW31Qyp8ibeN7u/v/m8+vsa9CIJ5P/skMlNwQxgttpl3X2Tib6enMCtGbiC9wwnmUYdiFt+r5TVYokD4qsSmsTPzUsmB8MQOOrXTfUyEEP412sMdeKqTQJzcIGQmQhFF62C6nugGeIpPq5wuk5Xu8V8KEFDZjSi1GtNcnetnb/CqkFFsyL6+93PKDs9QraFle6dYKOBnsNCfk8MbmLdNjegJtIHsZaO2p+nCQqLS+59NwlcyPo6/PqMDu5zrqcAtpvnwNrvWwH1sExi7/sC8WTmyt/t3v0ppk2AHVbkn9FfAFbDEqD3fbsuPM+LWob9MEcEja3mACO8zkwn9LEM1xlEtW0thSorhPKsFnsQUmjiYx4dLPeJSvDXN4zhdWmvEiRk102KLl5i5KWr0fczgCBCTtatFSnSpES32u6niHxCkHcLSrwSM0AwDDu9J9mif2hBG6n900pWwOx6lRkMcfwuCxtD0GEwhsOGqTerZKBB8iPMv6o4VmIJ+wu1x0nxOba4jGqeDQs3qm7LxD7lTi6y+5QIpfiorg/2vRLXVe23a45mMcyJtRkn7AyLnLTU93bGOKmfeogle3GmV0i1rRBo5b+a86LmTB7r7RLpL/L7dZc3U/1m+sHlteTYDba33Kc2U2WYvUTPGSoyLN6tZQi4f6Ptd2Y2kfsfRxSC/DFIjT5oL9onH+gFUMYk/mGxNZ3KWv9av5iz+TzOF9b3QRpbqgvuCxkkEY1622GJnp4hR6ugeViS5eUAWWHKSD0BOvpyg7er3gdYBBf0Kc3aaPyWQFgtmQ63QLvj3KtPa5k1C+lrP6fCX+DuLj4pMXaOdgwwp9MJpxHK+x0k2Oxr1Qccwhu1dHSTHZ/T2lkb+cusWl2fGi/lccMGpGtrtRYd554XkI/7YlqIvo3h6Utzc4nCbY5yap+6sj2ZuYfzxbq9XJWarif9bYgwJLPOq0tbtKYrLYiSUF0doIiwpThxewj+Q4IvlC1TDWs1zy/zWHyScGDZ8lsOx1RSSIs+TOcmB7RghwECkCAqadzrj6fvWv1qV5qhvZeAsdp01uX/yHqexNCGLuJQnGhutGwfZf3cDO0D1JF7rWXyz4tTqsdN/hihazFCVPbPeGR8QVBD5m13nHm+XHH7K1Jd9GRCcF8l8O3+hW+GaaviNVBSIj3m3Wu1SR4y//9pu/4mtBCJTr2+Y6bF+ggD+dvDxTYhngRRQh3L4BUHQnzS9OTEyEWbDgElwsnBzgH6Qk88emkck7GmCvFKbSXfvrt5iztJHl1qsx+HfDgHrI9UXAcXugwXFph3ckvDHRAlCk/WuzWNj+uwSaLum/fKf3F64D3nm+v1qb9i5ZrANTjqqxuXSeUkkq+7rlYOSiT+viMIRNa39qJvTQlrlVOPn+nvjBRlp+SWmtfF0FOGFMFrIRefZ5zxg0X/wbIeE48skEY9eFbPlpe0VgkzQjDQ/6lMtCLMpaxRuaMNZ1oCrKZ7YEZbPgdyHbYoyhdyJVrhZZzJ3Yi5kHSd3Ei7yqPgTfhAQ+aI1fAHsBHnSpmJmHuurBUgau7zUsAGKNiwXXEw9+cMzUKaVJaxfKew+F3z25amCm64aCA0enUq6B2aDDceFQQm0zE/lPiGVY2ZcpX/9bJnfoyw2V6KYbE8YEp/nYQVP7XInvOYwnuwMfMk+0qwSHnAeO+pw9KZjjWzbRECBcCB/MuVW7FAFMRyBjP48OQUHkhoffRIs48VgRje8i2TrNHQyCLY21B+ui0viZC/CjUCDd87XUjjSX/Ak1G5shJGpYGoFqKLdIXEegzgetdgtltG6QgChEwXFvGGsAPdr4hulcrkPe8jSPpqxcwAN8mWI7vtSnTTMIi1x6BeKUjXyZY+oXUekZLPZjxzGq7ILLwCLW+8TDSNLzAJfPFYjDGKPeueEZJbzf5nMQlP77DqhX18RDHe7IVAS+/NyORsE9YJRbmxf25y6a+2pKT1QXja77UcbxcDWTmZ9wBFLQJkyR7iLh2tqzJrR2bkySWvwVKw4fvboJatrzWxAsJXAyseBZ5r06HKct0A+jeWwdhKKTXA8FpQG4hnT1mI2ci/eNKAQtHghXSe8ep/FMf9RRvGF/4rmsa59/jNFcm+ni2LqlqDtC6tTXxNrttZRBl3aMTzrVwKZQ+KYn5I0DquN78sz4Ly/0/B6Ro+amGgYjttiI9bDSeRcIHyXeKtU5WcPNzJBw9qSB5gWPgSFG8V7COb4/roqeh1qxemtXZe7jAW3F3CyWcz6/cAuHuq4nyjDtK67gRCLcMahcvuIhGM9C7ab2Evsg+tRyWogzUYmQAuZBvxiHBUy+wKpkfjNwbE71GexW3/ORQGF50d+oZ8693RL2TV6kvpJjt3vH2yZJiCU7KAMkYTCb57auM+4/hDdZovjIaINvLLmO5zif9uF/qpxh9wGgIX3G+XGYpNR0VYo/MnahfizMVXNwTJ6LlsynEmCur8KaV3WEi8RL3VifMWJis/6dG/+FVMBh8QdGQcjBN7HKvpWFmHbnIfsLsD31nsXCc5B9diLB40cb78XA0elk7LusX79B6hlQ+NSr8Vi/CznE+hN1KqfcBTfCZHKsiLA+V8sM6lA3OX3O3Be8eNH1p2prES9AQ48CRrTfny/NlO16koHBcxmaLCUAjHlR549YV6DIGfdh/10fAIvFJbGeXDJoW2q5x+6quhPZiUqgwo0AflY/Tf7T9ImYhV0QTgpXqfHIwc+Qb3tJNfVPOBMq8Br0XOWY5ZYay2lKZansCae8xuepPAxjGcQZRBIGPwpcJOEyEQWuJJqsiJuqo5ALPE0TTqKCJWGaroojNiPAMnakaOhEzYJZonTZDyWOX689Ohx8UAemd50rSjpuNtdP6mD/CD3NbLO0N1HbgVZWlRBXNhULzsMAPrlZigdu+xevooqcAJ0Qj6AEn4bnpJCVUs2Q980Fk8tuJNClzy3GPZxtPmis0J4NYf2Bn0unuMRpxGg02AbIKRfKkYunHun5z9VeO7xSZUPEwT8XAH2EL+3uEOjPC6Gi4/EFnklEfilX1OjXemPnkRCABEb2QwtWGaw3sHzQqtikz124a8nGPrTfeXRvyFKa5aB/c766OKY/MUcPpvuFjYo2FuNQaGaiBCXVVBGJVLLstZRMJHt+6/4HajJxNfBuMmdZeL9ywnwxu9setwuSvrbK2MRCB5UEB84CXxt3g+ZRsGBcQdfivhEN7YwJLn1BWFyo8Js5JSA/MhVdxD5HezstOWXE3NrzbcW/Oe0lIkgiL0N5hsF+cxCrXDA4sDyk53MLtn7lRCCkn4oRn2JKAeixgWImJyAbRp5+s4XGJ1ABsH16enfhejGYlhboWhWQ+yhLtqJmc1LaUvH+6AI2O0nlpUfRkae+V7V+cCOcqQUcNFKLDmYaOCI4T5BI/oM8zR6uQgFrkulYnvHZO59/0DPX+DoHlu+4LGVnWzCXtbltqHBsyuGOrFDV3ZOALWzSGSwjgv5rb/tr+hbqB+h6VZ3G+LVPEo9vrSIOL7454FGNRTgyWXJSc5IQ8gSN4t9qQm6nkfrzuZ5ghVznY+82Sv8NT4xJ6/pFApZLCngQlVH/+NXweCNLM6EIP8GRrYP711+LPLjFue+m6mVmtO78YgXA+5xr3fmLOsFUOCFeOj5ArieBqFKFe9foDZyOqTqpdc6hn0DEobPYo75OaBULPY1+5M1PWrapzC/C7EoUmMHqOvhvI3J+EtsB7at0lJ1bUNbPahPuPSEaTGY6mrjZy5+3MNL0WJhLMCLB/NejzY7g1N7qOchm8m1SSoNUf05Nd3IE6dKmPkWW+4J0RwrSC89iaoCVY7+MzC7Xea8QyhHXuwGPGttMbikzsOFL2qP3AYn78MyZjIKYhfGA8XWoheIssRatnE4LrodasN+ZpqdIlIFXn3osR/pfWBDz1daJ+zwiMsWPok6cwAQB6LtBVrdq2kSmcwaxh9wj+iEFkhX1WqPSuLp+2htzv5YdpMix0MlRSHRpOwYnG3OpdXWKsW77YL1152ehlNABWZKMKCPM1489KAnOPDBJm+u1czOMU/ViJ0a/HlbWFKo3EpeS/NH8LW/lLKyVm+0XCiM101qUNZknjeNc0IwTeMzpCf8sgvcjc2vIPlndK/NH73UqacwrStXFJGfSvM3U7+3GypUZypOePfZwT8Oue9MnqLzm+WX6wKe6TbvlghUk5bRz5t4TsevMLYZCxyBijnXIsEezkyNGzi6U54H9CdTrkKs1J+AfDQGXOnr1lsNHxvkjToyVbG9wpfgmlLmr5ORwh1uaNLaoV6qdA1/pGYRTUSoLAXB++yflxlmWAlg3tP2XR7xBrnLcCu5rGsw87yRjw4YlEy8ldFHu+sMnp6arXyhOMGY1R/BtDzfyoX9hQf6g/X/Q1QTN5Huj9CRXdsYU1AwAf2exyJNYa1UA/v386/tMYyHSRzrT7G/2M76kdSL/HN1TjOhq9maqckuZxvjO0iv5gNrEuceIdk4kYL+dwYa/k9al7EoMyb8A+AfPxX2vUyHPtT8jbnoDJrB0WpsDGFNmatgj7E2YJCqyJ+AwUfGTjqxJlWOLoFHMu1cYUnKHIAKxCSDDqZgPeCcuK7Shv/mE0tDhx8myD434H/8iDgVLWnzsfnnbwByYh6T8z74B/MFLy29AqyzjfGTU7r4scCbhVy6HiPV+2jOWG5y88wmutz9qrIkyCYTRB/E1BEj1uDF+Skndq1Zd/TsyI82u8xinOKHblamGBoypi8rPgAJkmHp/ADX39seOlGcBupecwe1XUOEyoWnkwbaOpyfJSRqLR2fN/hqCtL7nnMHGLrLW/+0Tt7H4j1t8aCoNn75Ul2dXoPIDFKktTSPqajaxPn5kN5KK5HT7MaSvrnGwUPH5NbvE/LANBqrwNxZp9oWVxlheZ+qDxgfDDDSVPMilidY8j0m9NamVDD52giqQfwNNWgWjFH5PAEQ7RWQ/XmXNZ1w02Ts2J6IncPfZie8Wr5ZOA+CnBKwIgaNx1HhbrY2iwcRmbFUbKHxyVjpiUv1U6K/LF3+NmEWJC9xYpXNtXHMF941ISfzfMTFOdZTWcL6YnJcQZyyEJyuUfpn56XkPMoGP7kZoHQOyReU1Em0LdleuYIogiCD24R3Tmtkeauvi11QXEYVS/jxUOEtbuE+p/i07/vMSrwTuw+u8DnYRdFV9+RfxpfRbpo0ELBlXzHL/I2FFFpxDvwlMv84zzPJuk5A1g6T2uLBuLzL4HuE8OuyjI05zHvSjcNcFz5VPR0cPvi4j7O4IAUm00rtTZk0O79ImsyPC94sx6LosdrU80WsmJxAPFWMOVjtFXTVtyvAQKK0cvfvb5ncZpcpWEW8wDSOlAMDz8Zwp28VutnQfZnpt+mvyt85PbqZU9pwvLb66fpN3mZ+Dz3cq5Ob0BGROifBMibr80bzjAlh7VCwW4mwiGQHFvp8PuQW9lSaJVxqAH7cSiSpw9XJl2w1bqP/V1I3CnA25Bggr7WcDW8uqi5PDbFFRtPgSN19IpwgfUlXF0NVuPQgJkR+vX3ouccJVz8zdkjZ0zkcRN/AQmPcBc9H4GJg8P0iwDcSLnOEeVx2fJlcWGis92V2CKMSe/fzgv+rENSXrmtd2/xSrTvO1n/kzs5aQWjWBbjx2jnsf2mhfH3njDGbs3EjoXT0lHfNiVNoiD6Bkwl1/bMkRasJPZIR3U9K3lrrbjIlqrfQLyi34yh6RndNSTzaHDgkT8/mZoaGdMf8iiGazz1IcdlF7U3kghpWORMB8gH0Jcu1Vu2mhj/c8gwVjSiD07dUfj1Ndx3nE+9cuJosNoOm5PLyyZlItxuAaZ9p5BJdWNi7WcTlMIguu8dAiTP4RHLgEyoVqhUak1Z+WtaMdDJR/g6ZU50Zv2T1MJJrFVwFZKnxlworaCspqCagizhaQBF4eUXayAoDV2cHzDiN1BSWcH6yi0FfQLOf9yNNl/ffCGpcLE4PgJ43Lye0HhgRt2EACX2i1IlGZWLef6lztayaWmH4r87ccqs59iN0qV2bC9feB6ges0VW9UFotzrkzDeJ/3WJlVrvvwiOE/GJwuK9nxg+FfB1+5R+ZN9OlVzZxQruAzEQHGubC1i04KkXd7564Hi8PzYxJR7Y4Xa5+Gnnq1BbNn5gMWX2XRFxtiFBLK8ZC9e+5Y0m4cYDp0RAA1sES8IVbS9SUwxxCR+6ljIoHzRvhA0hjX7eiPHZ/uAGdQJNrTPiAdS8cf5l/8dbho77IVvgWffllzDNaStWEoZ4Q2OO+HT1h3grxOTEFgiL4k6lnwiliDIzTqe0Skeyl9vF6OEPPVgJOZM+kU3yBzEovM4s2K4WLY6xTa47L4uh2mlWBrCLsHDgCVfFMOqx8szY38ymEl+NhUpHSPjyclkq62zSgrVrK5vyo4g+Wk5sHOg/5bVDOBRxpVdXmRc2kQuCCHVNLVoi+oV26GiggE/CjJjBkxhVp8SEaj2nkxed1PooU4/d0PbJ9ah9zcW9MGg4A+jeKCUTFFmaGi93AdNxk6R8A9MZh1HmHc6/LLdw+f/DEXw/Fd18P4d9qQbq1iN2bNsBHq7jJO6BDBLe2UeNLCoclT8MepNi1eLqtplCDK0pAjYzGSf+qSFqKvtmS+PnA40HDw0sVw2wu5aEecR8KSHo9AGsYjyydRUQFKx2xNKz14AydbKvt/4hQYreMGvgy+F/VtGl9ZEfFVlkh4TGFN0Cq0GSrbPIZrYKXAO+gow3CZ8YYPU3MiNmNtSGe253OY5wRD5tTKBwvNam2nZWUQf3r03a4lRcSD5LSGCQR3nBe++EuPAsBpZ2gYu+5K/UHukht0cVKfBfb62pRTuIxWpohzkEk+L+esLPOoTXriymfU9ao3HbiaahesPKpyuz1DP7PagifVP2KNwQg0vzb4ed5k7p76mPz7bKxl23Qph7bbGNhDyIiWB98WcBTWtlb/iAUit2sxhUfEtXed4A/4Vg14vyY7wdLmoTfFK3JxozQ+56hBZUk+pF8qhifDiO+u6CzCwFbUIYb61N64WsMkd+egrFWIhmWvg9Agb3d5Lz9g2rikRb6LLd+Hrj/CzfzPoLsw4qW0DekqO/ZS6mLSfx63CrJKUeRFoUjxNg3BDOrVKqp+Dm3OdJYPYY34O6tfXoyc3L9jfsbSOwSDJ48hCQe8HKmjzKLgS+AcsdKWiIfFIzCEbILfd+yL2JxNi5E3Sz5Gysjz9A8hTUmbWa13XiNMcqYYYLdGJijwOckCi3qXeBcd+PQtOpn7dM7TWWgKvdbAFSgZkJp1Xv8YvbOR3H/nE4wQQPZumUwBCwDwxH32RddBxSUVmyi+zBhq6wrrnDbQUU4C8slL3uEMcIXr2TRRT34yIDA8ElUVMu3Q17slDvQhjsR0iHPREaflkjzkDoxX6Kmub8ad78id0ktS4Cr5HiL1b72Ra/j+mo9WOGa11Cq4LvWMtXUxnlhPBSgB/WUlxmNQCuvJ+xhML9N5Iahk+lj7Xq7HbT6wKsy3FoxuU64h7eQfzLntMnf5e6QSjZtSSQtR0FGH6mYdUxlDYLr+VhlmOtOABEZYApgDi/8M1YWME/W6h7Pot5ULTc0VPx89THzEQs7ViiWlIsCCsKy4/tMQXTmv/pDmNC+WtWMc3Fjtr6WENjC/8GHBWpAiOCsZxotX5huXQgaWz5boNkwPvHIF1AMURd6AmMmyezRUozCCW91DZvgtV6FeLiKakJYVLzt8HFL9hTTzMBVH6Zd3h81jsWC6iZQiNoVNcoz6RSokHgSeRLecyQt7GokLFhNr9azk/1QMBf6qRKoWUV/vOw/hYTakvwCM0ID2ZceQlfyfmbg1D8Pky/quMAmypgzMCjPaznfWFjDzgH309CfrTNxRn6BMp7uJTtSTI6g+TfVt/b4pm2yVPWRDn0PvMg3FTuKkzze04G8dnW71n86iJXPLNTPIvn16TteGW+DFK/j69JBr4WEWfi5+wqxKYVYdWySqo+01jLGOeE3fZ0y7LX23E6NDAadZNppv4Xv4BLnLPj192CbQ7T2H3NQFAJCtu/Y+51tgvYV9f9mS4MSpfT6BBazSaL84we9JAGJQ9igy7zjEQ+WppyxyYp6btYn+s2ZKPd4Ov+zgesNO/22ufUPeQAXrmvvmFIWAh/YKdegkREsktLwHihrxGGq0JP/bWe2nYEwFh60qY7Pzy2y78XSzOfZRGHiPpB7fgY46zrBzLUTdhy4ieM7lGX4VROLp8/QDTCIaNRHgDpX3OCDe5rZ9YfRXZ0XwRJqvH0kJ2g2+kdLuWmVlgYhiSdcgf6MQYJOFDq+wJQPX6OruVyUI19WNXCsbmWyPrxTLSNdb6VpAg7T2xdHafSfo5XFka+v9TJciy5HXgQZiQKMP/wLPuVMh12opGbHXdqb4+7TNEM4XrTaURCpu8jmsAABvuODpKmtwkbNq4ueM8AlrtdU2x9wD0hDs7tT5KxJbzBstUasP+lst2O+UnDYEORHvJRQ0At8+pPgqnp2lyjX14k6YQjm6CumKN4k+7ZHded+OlyQm7+BEOY33ctqPaw3bvUdt/wBOzmATSYKj+kvRW+rL4mKoFFZFSKnmkbEu3JAQUnCrrwZa0q+USnKkq9eD/1BJHk6AK1hvn9DXe8Zn990lcVbAsypdvqkO8tjs+JMqCWFkfgBHU2EF4rWBncHNoZQ4nuhbUk2RBhjHYzgKKEvpRek49MwYTpnjKfH4eliDKp2i7p0nlC8xIddC0yR6HRFbsNFoyBklJP6LNCF9BD1UPzmyac4je0QZIYqzQiYBOzpkXjTW4FmBUem6LrrtB9c+6o/w+nI+wOU8U0y3nY/uAMLJl+WmtRAmdeJdx8UO1J2vvH5Gtr/m14TY9XbjsEamw2KEOLSQo1KuX62srFiVYV/HKctsA2X8bttxiqj/SrRK/rJHN1LGpn27Wbgawqg6b59eYPPrc1/UCgFLycBt9YOurBsGfjV22CkJTsHI+8bf+yICVBT20hIlHky+x85ZNhacpyiKkX5KpyRblKQr3FBrIii/QNLlivxxFr/u7rOvh1RDnBl3wdeDFRzb8J1vQ77Gya6OoG+zKZqHACCrpPlBY5/UduKU+phOx7l85UUUpOTsyKEwenzKnUyCcfIK/mfUBcfFAqOAQq+hFJxN9FlTaIAsO74JGszDyWn6Ym2KrCAyvwVCUpRmP7G14Vzxfp4bnyffOOEp4ptGrG3eZj+f9vu9v+ezdnuJRz6HraXyxGynmWOl2HZhQ38sYAUmHmbPUYAKKng5RtAriQsedU+xgbTJIv0Tm33JhMvj+LGKioMV26L7IUvVDcD4BFp1rZd9eHFkE4ALj48g8Jlx13EaAP0WA62l3uPwGywEGs6G6FuCUjytiImjz+zTggesTgWExfawxnzNr3rp3/l30Moc5toacE+1kE3T0Dlw+UsbbqJnTfnKsjz61grwldNCA1SVQli2/N25BojkOnsdo+0CeeYU3sERnvbWo+A0hZ7A5ofM75f9VSpLiHz/21eeHvt6Oue1td2oSIqlq4AQcL1cFaqeR5XGV3lNkobaGmP6WYTBsjftrfhIcIJ08g/BdQvci+0SvmW0B1wQLIYgh5beQcW38AkHN0WpT7AJtLZFfJKUm/J1WccfM5f93aqMzzzRthSD5p53isIPyzdFGGAoYqGS0dnop/LFQHS4poTT3vuekHgRjfuaEZM2q8ZfgefBoUrDWbMTffAhvHnBVy3+/4rupJ00+UYMGXF1qaY9Rexw3P5WliIv4NkfYWdxJY/8frPCFMuWEO6hjeV/tTxDQxjroxP+I34d3NYBUP2SVcdRDrQDhqdFC6nImrSXIMYb0NRP/vOJgs9XloxznJYQj3eNTF8xT7WOIkPVpe2Ix4/B+Lu1K9e+24n2xzDv05Z/5sr9EGtWlSrkWCDY8T6X1QIUo9XLhBH/2Z4AlGGcxq+dcHXX4458gotiasl/8zp54mFY5d7EK89vIv7XBPzp9pp2vZLCaN0cbsdSzqTchdJm6nhumBVTlk3wXfu76jah3aAD8zm0hLEou2XsX1BwaXLAJtbLM1sRKgIJyVjXob1NTtplUuZRHp+SOP/tRsLZCjimabatnYsxjfHcgCjz8HEWolseO7dMvyP5dP4lD7dxsfvUIKLrVfR0b6NLvbt8C4kUJC0LmQxtfctJPrDvibpbIpw6ewzHxE1zrCvQXk5XUwrQia9FfvNlFc/jzY7BISrxJ+QNkhPJh3gXzXJJC1av8paMSsSonFMg80a9e1xI6A9Kp9ARSX8xTVdYWGBp+suMCh+AITS7rEE85mK3oRbaoMPh7SKNs30zY3+Mfjm76Ytka+qdPRWsz39Q0SsOynIdaNb3r86eUHu7ruXxaKXU+x06D50ilSqG6CvBlmguIWPJ7AqF83ITTuO9A4dadVO1Ro+GDm8pDW5py8ncPeVPMRCV1rnqnkJi6VA4tV+R4L1PDg5HMX5j/XxKnpws30p57iOnZuZDf5eTwR/FOXMuatMSkW/4MVqKGUgXW6E+lPfitKbTRAiHwceUrKARblWlOZ6iG1rAsnZw3itvXWGENSlw8LrVNlUKXK31RUQeQ8Emwsr34esZtmNQWeAaL+BLuxJM3ugwN2m/NLs6A1Q1gXViOa57nNcioBxtPm7+QdyZ2lCt4AEvBt26ao+1c61cn5InC9fEm4aG8KRm+d5hD+8yCkiSWWidreIzFfjES/ya0m0uNsdmphdjMgOfyj1O4UztKRaF/o8O/+lzmYYmbAYrvTr9smvcB8sYG/hHJY7c1MxLeXk9p1kT9frVhxZoOn9nV17fri1oY6EQeMhYJbQmJizEVHXEDgmKE9zRc1LQi10dr13Ijz33KJs6Mzrs7PfJCGVc8x7pEr2m606XvakITGEyBssyhAK02OBI2ifai/oK69u+mmDVd0Q4UVetFw0JR4ep1hqdOtyTkihbqYfXHhwwvLgQiOmDZm1+ol/9KOqMHmEmIqGiFub6FuIDdHqPioQyzf0Et7mCBtBzRWKAUMgASbDz4CROcnHWivIMXii5YklGW1gZPfyxBB3llsJq2fimhw8vEjm0aWcoR34nWWZzPGywraRR20GKU4uNpXhUtV0Qj+WhoEDq/K29Gj2i19RHns1lNnVfaaUnXe/H80N92CR1B5ioVyRvThJo3eTQSOCHXxEYvpwzf8PwjlZwRs7FUrQPXPGl1K4p2PGbTx7M+w89e6mlaQcfknexZOwdS0WYzcb/hv60r7tS3GOK0fpV2FLZQSctvIV8lxbdk8mOnzprmuot3tDb8dadWKO38fpjdXthRF3IEqTU55sA8JwJiuKp9/cwMLVP6LmlLkFaRcz0qv4dPhhuo+crz+CwcQh5LoSUjB+XETAVevHzEMxH/2Zk1IyqI2IuUzd7azti41m9o0EAK8RqNC/wJ/6D+zUz/MbW7Tl6JYZcbuPNX4SqIM7hIOIBMjYL1e7gE8l4iO0Vg4Sotq8WWSfs7i24AmEH2LJFNzrMcKHe4kEvPh+RHs83e3ixFhtvkBchrWDZTS8YnBBiREhgiW8uJZQhDYvIzLMGbV4+kHhit0I16G8Olv9Xoy+fvFzK8CldqV1nLb9Q3TVjC6Y0SlWzpiDtunnBMlseJvRmWVr3EerLiE7b4soxMOXk1iFvKspCbgz8B/XvOYTVXqQCOvWxQM2/7ro0MbUwrgqHW3Y3FLEwcw+ntq8BjVvWbAK7eT2sh/+dZ72sWLkhpJOQIlTso1pRS0XwVOhui0NSOGvhD6B/0iHcHy4upULQolmq8T3d9tdxafu/8jnfEUijukQ1tcq18ANUUGoQIep1ZUT4pnCwJHUrvNXJRUQbV5Mfv5oBgd9kmHVxkmk5pNp9sGfDLx+O3doRy16nwnZSHccRiWtxdl9sgRBGnEDJr7eiugTnDh0YAa3Wl6giU1eLuysVT29vWn0tcu9ahOjqJCYJ4kWiD9hdUGSkPWrXFxIzNjIB1jUo3Hp8mi6AHEfdE9VKfZ+nUyTSbqBhGEStVkLbJnVFYZ69GEzaaUhWDYi/LIDCMK5lJuWGiniL/4zCzpHTa4Dw69DJDXpybUUBmaBfd7XHb5+/lby+Jsb9bdfBwUTKdAbq6nvge7oq2of8Px+9G43EvSui40rZxoeao/RnsI0tVotQS5YgY3GXDCx88bUo7o+OtiOkBgi/HkBDp6bUA2cvF00qOa11q9vItyE4mt1avQXfwxbvMdbx8RdvwPmPnW6DiYu2O9lkJBA28A4wPDcooCNLI+DJK50BrOxvXAoDO5vHAG4ndxOEdm23iunsbm+5EkMp4NS9NiWtoIBR21VNVIsnUQq9AczspUHRmLdsOPSGiNuvMvTDIvGtGrh/Kvwlsw5Qk2X4sZBUwsOSIbvVC3xPdz8KRtf7kD5fRwmh/g79wYlPGGgkEynERKA2m3QuJW4L21CcGF9CPMGvqlUCjWGisugrn7eH6hLy/41DYNC/zzjPEDcLe2lBwCgkBy+dioE3hJ0s2eHuzmvVrWibCJ53BVJ/V03ldP73mzFP6+z89/NaadQ9HwfDCtdSuphI045RRYXEHqiY8MLrm0RB80iDVD6C355ZXTslMpi+0tqt8BI9LYe6JErFQvhYA/llZkmM92cDDnsreoTvqqcWCKgE39ZXBrTVFkPcW/ZCmej9Y1OUwRJHW7dSR5copjR/E8i6drf78F5YK7Ijg9pNlEJfmLcm8/ltiAVcj7+WRYME0Had5+EEO/PcLnP+NuF9jkbZErLKH4EdXXI+o2ZthSqxAA97lqoe0aQxPrrD9LcMCvYc7pOPGgN53Jhew1POk2OyAMr0L795XeCr/aRRaIVW3M/o3ibovQnYIFsguhmgLLDNLV/QGtaHdwY6mgKwfaebktB0ATlor1hzhIFVUWKCqGyw9SH61tlCerL/TiqmEk6HWr1fwuRa3z6QmJFyrCtxffj9TwlVeq84zrEtF18TTD1UmQHoozQLFGunsM+hiO1+IOlQNd/fkKaXYaN7QAA6JJCNN0n6n9RA5NKJt6SKbAsh2M5uNuX77UmKel1Z8BEg5JZUMJ2PC3Ie9NoAQrm15ii2MMwZkJJkuWMEn2dq9S88Lg3wkWYh7oTtVhn1ylb3K69Mti1OiizpoTugsV6BtKeL+alNwqfklMlCvSCoz+ziC0HB6L8LKGsaRLttR4aNvzDK6tgTx8B6b/aj7u2/6juKhCItFJgjRm9evWyMhtBv+CHoya/wurgsMk7mSplgIMjQNxhapVTtSz+7irteaHaPHplvdD1Cx0kEcppXDSimH6LT3wIFeqI2/CNwreu8NvTRx8KZEaw4tnI8/SayA+98+wgr8WgmF/IpxFqiBSi8ZH6+ocHH2e6nYimITHBnyGUHhoQuNR/XQg+c6kBBMsfuqwhqSWpVslaMxJaRYxOlhUw29P9NVkjYXLecd0b8sB4UFVLGrTJW3iK2pw8+OooFZHWYgHU03u2Bi2Z+f7fspMONw747wqLwSpFgK88nJgQr91NtQ0IKcLBTBvL0/duSofAfdASiWInpKhNqQ5/l/owzYzqDeTlULyl/z5AzCloxT2Yrl7aufTcrLjyvZa+T7RUxVjn/soKOnv9IqXw2v7+LHB/9C/SUMxPx1LznzbItE22Q90rGOe2FrhJMpApmc/LHU7/AjwD5Hfij+ivkeFQJoyaO8YgRiHlZwIz/NxCqEQGLu7LCPFsyFRIkgsgRvIjQP0foVL9ciBWgfjD03buHf9etbVyKiOp3h4/gzcVmsPrFkA7EkwCDSHmz3x5E0oMrSJs6R6qs9g4zbCvQ3m8f4t9A49ant6Sbpem0yv2/r2haUfpfzGUeplt3e75UJmJsd9Kmao4N0qgRC6uk8QAR/Oaiy/gUJJsfLoBpETVjkLqvQTZlqzw1NCxqeO9SAXKobUr6p/H7a82WAZ/g5sX/BSonFY/DTSBVkW7HTbCyNofz2Q5FCQPdKA/SMqg1WnxQvBozdmgiLzIp1Qz3rcA9Xqdn2lxr/W1s9wRsc6+IXOi/jtyWCkjP37gn5IYAuE4L0185dop4D/ZzrWQYCO4bi53OAGLZS6zi5qEp6icg2mArFP1DIkJN1nffvMD3YKkKSPwp5fkgGZ9HBpSeiWBeqMIRYOzPVAUZqwBvBaJoVxQ16hoM6I+5zP5+efx2e9Kkc5jEt1w9u/AeAQnXE895g9o9Bb20fcM2btMrVtgzGOktrasesZeq/TBj7cvDyRsUzbCCZM9JlOpLesihiDIOymK/Rz+kpffMaaXtWPn2gzT/0XX3zFX6MgJQwbzPLKU7AvueiagPV0X5PRscC2KIsgrqMNXykpJpDsbbtn5Ew6OfX8G0Qw8Ghnnn+ZnOcCFKKRSV4h8WMIMok/zLAS94e0/+a3Hm65FVm35hW8LUyE03LrKAUsRB9kgB5Kw7YDc/RzyYKl/cmRxYcBp3KWUuPiZJI+vBZ3okzlVE28Vwd3s3oXgrxHfn4XHPd9nHfJfzZ/qGFG08YPiF4dMgQK5WmTaZvzTmlArwcgQ6O7S3oaSsegQ2/tQM+B9Qbxca3dk7STPrRyvE/bS9QqkrsHu8cquzQjElSudN7zaGmF53fomj3254eDGGk802g2RIvc1BsJmFvrcJPnwHHvtX1o6F/bMS/NHt8zfxQkYhKYWZ+iEskqO/zNWRM5iIxG+tFgZwhuF+pkaX6HpsVcindkCeEwILxcZjo6QEn1W0h4loxjJSh+HuQytOibzhzdVEBaboGcVRyMoQYLu20i5IiD8TumV2MvwRnSAhMSlMG7wiLVFHivpV0LplJkPWxC1zRfA38T7wQbdAR550a3dUMPt2HGQmZfU7s5z7f8b6GwFR0wxLTzA6AWyVvpBYleBG6I7qois2yiQOg31UBj+u3tHOqmEOF1IpY3XKET6LMwVFnr3TLKOv2840NplVJvts8VoQ5YdETcm0E0cL10OzX2DGEp8IXWfsW3XVY6eEDVFKLUF9qMz4UzNad2jeodYmng0CnmS4SP4X+SjKGXRmwVLP8Jeq/V/EfIUwZextiv/XpZ1rPRHLW2QThH7pWy1bEtrChwtOpyVJGno8Lemu78Jr8Qq6ZAlhJ4w3p7UWavIeVQLCUW0IOPbM2iAdjCdHIcwm6O6/dR5U1FjFXhdXcwyMvmxyWS3e6DmUv2GlcdKQeoTI3Sy+U+FZl1vkFcnE9TlMj1vv7pZ+Xj5/J+b+7QDjlNDO2tiZb3gpBQxtfo/DZOd7jcPZfkycEviYRqvmOrL56CgJ9S4k4vJ0vL9XUie7fRnREMoJS/Y7Cu2frfWThVuydt1QMcB5pNzYdEXmzzmVNI2A12nKUyddJztQI6WIhBbeyDHZWvlkV3SCSpypqF0xvzd/0oxyOuUWHnsK7661sMzZ4fcdVEHftIGdqNBWfe709eIdvMuw9ze4MgaJAmkSArrp4RVUfba+h+1FsaIQQDoQAspUaSYJCBOOX73COr/Q4dGDr4DM02ORTWlTvLfvDDyNEfTLAwTGaI/twkHbxRNmbs62lebNv8gVj2vcpzwiu8c2gfwulPOkvVoxYTN4psC6JZrj0CphAJM5dOrcTKw0yWFWnCtWH8SyxrXFXB4h/kBPai95w1Vbn42LT3AOH3ZdGHzqrOvmNY6tHN2UsGgYt+FnPCtnrYIZr2c3Mi2TPGpt2JYEm5i4GVPQ4xexWs9xSWl9/4MLhzYMA7V96P1BFpxq4YFOY+qtbgSKHjTomWzu5hFj0ZtmxpJ6VezJMl6usY1em9J3G9Z8TCpw1/xBqSAysRRHhdaHJtJOSnw0Yzi8QHE+dwSX82aZjqrEh8uhVvdJw/gicaGpMUoN66cd1BlS6WxODFlWC3KWVc8wqkU0Fv4czFVaBTzRjh/92DkDh+5VyPwGrm+MaUyGLtLCEU0s304Wqy6H6wdZbtshIgvNhCgJ+8TT6UnlG3mC1Ksm8qiuTp0yVjUbmTMq7V/L9b9BPa8u0+qrxBx7+XP7AUDefVFyCAfPW2pjw3fGl0yBsESu2MURpqk4p0+ag/ftMjOWduvEBfGyYNLq/5y4A2gbZ+WoVOCYrjpXSgh1smZhLAXmmD5e39jII667/wEWw6uX50D/L31CGXbE+9OW6ZvoCssQfY3nArafLY8Op+ZZAsmCfRLxM2kkmMW5W2BHAtA6T2bUO5QpTP+kZj3BURNE7Cq4f7EQxEEO4ehiyBaOpw0vp5NYZcyZrvMrWGrgzHG8nbEQKJ0tRyr7kF7PpUhwyLrDtG+ZsDqh/QcTY8I6E5Kk6V+NA0q06jNwg6Kj3K2y/o4chE1Kvx9mF6nEkCr4sxcET1GDkFpoD7v7g6t0MNQqaimGXDOMaPnwAKmdFKoNun7OLDZbQ1tFP0/SYdHdE1lVykIXdU7ovbpWOz7uztfMzZo7LtmDbBMNH1AGC568EAHWPsPn+c6BkxLxur00bQLpjvtOtaK3WSX8iP8YyivhIXTHzO6BWlaEagUqAg4kMFkRiUs+cZLf0pvHO+ndi4Bgv2s1pkt/Lz1zXmQ+vDkgz4MbOyIRhWNTqYbztLPFk08VX3QhlZTdmanUX20nhcY6l1rwLBoC9LMpk7n9rz1PHXQeSZGnR2zwrIVzwI+HBrKgM+pHmHRyKA9qk2WuHtgrUmVIgklWXti55EYGGPHMvGUYRjAMF4XhdmAlqwMxyFiLsBwHheglfvQTsAVizdPuIjpK3BF23H07ez+7dtvUyrqKMVWhVsFaiOZRGkalBuZ7jrtpQ0+Th+NkYCp0TIdbMcMMfJ6jhsVjjQINpP1dKpGrPZRA0rQq4UCatisl5jTbowrO6sgexnyfQ6fxKxfmVk/BSa3PSPH20mqRXmqRgUDqH8TC/fwyZinu8zBdwe2gCARzyncy86QYBc6d66lqSxYFGKEYtLI8Kn1oub1yZIigjJ30E9quIngUuAbswMNp088MQ1qzTgEVfFBLOZJz+kGxSXhZdkrDfuszlUh9yXdD9XMYgifljNjxVsCpaycRXT5WmREbBNJUQiVEyRWxSc9uf/zw+zFJVk9plsB/G5RH/CsV1FWl4PNAQDZ3eohPQoasgSvAFuTebuacDU1YSSMlX8/mkHpMQE7S+YwPOW1I/CBSdWfuJvPSjWtqLM3NL7O7XwXfa5r5ad5pWd2Y6yJfA4V1+jQKqDgeuG0Qi08HKeFl2S9Fy/g/KPlMUmuXyPzovhlAJjNDQZQ4DOTMRxL1yauVYFx0hBE3L53YorVToNzwmIfx+cOmcHsUj8eR6VMQ1BHlUdWl90uZBojj9C6cMMmq7vBa8H95RXu0Sdl+/RemLBYGARjHEWdrWCLpcNg8guk8cSywgVncd/OlvaFhwoWdYUfVM8bkWBkmFwv+zqeOcfCLyF3UbEYoMpKY7hDIJSiuslw91DZBeokXUbXCaS6EuG9hQ6ac3hybRhMQSx/viZ/FqCNIzJUtK78pn4A/SVezngGJJjLwSbaxdGrBAGhWpd0bL7IbihpGAqDokbBbOY3agCTjg0jJP7fhcekyQZ8y3AmOnXGOseXQgNNEQ4jCuKDLe5YqOdTYPw3zz/h0ixvn4JXgNXn2f7SRd4nuHWcc8gTe/KaEHrtGi77K5LeIM/4g0NJ74WjdsxPcQ3/GucSrQsjYwcac27mCQkXEuxDH7POsLWg3pjDbHcCrHy/LOEDLpBS5H53C4IxH45wc8rJpvsRseewOxOssOI9FB3NxWHHPJBaJ34TarWpmuUuJEV0FFGtcW1s9MfndR8RCubuUCWWNosxClo8svC9Gkfqms80GlClXBA8Xs4BF6/RJtD5djSNscO4CV1HgTdwzELVdgKFaSk6aYISrWHMGnQLXh75Yls3+tuZH38FpVt8Uz+ZK/UN1Qxn1JnkqaQYm8Qf66xK91oHAm7pyjFpEyWvfwma37/Udc1IHGNMVcgjD8cDCy+60aotp8l6JpI0cayrwCr3xI+zopnJTfP0WSdmvVA0EMV2DtHL9RR1QQp3W4kIONZiUsRKX+JRUfosKMUuH2+AVUxPJBoSclPx2A0EUEdF+GK7/7xU9ZKz9huToufHVTPR4Qfz2GOKAiIimuRw7S0BH2rHdEygizUa1qGFuaL6vlfZkBICiazb3VKV/TJIOwHs5gVaYGIBEIWRNJcjirpDJTc1NEoi5OjL3Pu+Y0gWmDjluPTgvb2067HqT2rGyXsf2ptCTQRnbAEyOWi06vY7VXKVfrLEq0QN4ju6zWSE6RAo239Y3DvpdbihaFxhVjBwEI/T1qSjO8L56dFI3nWThoWKflMysTOrruB1EbGk7TSiXhOVk9FHzpRujSK3lUe3Xj64GtCEgXjA09TzxG66px9K8cS60RCDU4bhlMkA6aWpAmbvlCS76LZgHnEI96LnqK831D6J4IjFPdkoBovKgVkdBy4We/NsdTnYEDOo3/Dh8lZA9Hlf2UlQpnLgEnEciWuQo8Pz44ZrPikGka/etbpteNLfO/FihS/Densvv2FhD653gghlNgieAzRncBdbSRkKIGkw5820uQ7o4SzvWKBk6OKzE1AQhOtZee97fe8S9AhEo7dhiM4gZrLBHNCM5NUBGmhqdfZ+Kx+klnxdHCMlUeifpybPmye4VCx+F0t4J2UiPj9hoI5OszxPM4dmTsoO+751uJOvCgu6/E+HtfloF+u/KbUNmbfJTzCQHL3NDVjr4SlMFrXdB9K0jaB2zWsVOBxTyoZPse4w+OVF3zjcxjBlkjoxXbaHITYT/8LuTlQUTN49Ve5pLC+7EXBl0CFq7MWQuu0vQ+G1e8vjU8CW7quV82LeyJA0ivwHu7Hfb3qvfg+uuNB9g6sA5iMjJvXDynRE4f15nc5Uuue+vjIueBnejk15SNDaD1vqzW5CZScOma0czK6F8ADCSptpm8tq9JraF2ovtEnJc4Hw7B2X3AvH914AInBQLbugzD1J4w+3iguM9ICqYdUsqSD8xKo16IhHS2BjuJr30FsWbm+3bOLjpOiZAdK2YjbMQJ4E2yXWcKE1gvW8TegR4O89Pl61+h5ztF+/ftggz0hz8GastWWXe5SSrhUnTODjaKXQdFl8LBPhqPGSfzS326BpaP+Qj26Uod1tbxWrc9FdNAbw9ZFPHpLlDdac7txLx/YJyLb8nd64Xe/vQp6+hw33irXDLcmo0a6ZE6nlvElqN8HnxAQl11Xn6R8631At8hwL2hUAg73tBe/TEOKOEmmPBqfaWgzqJV6LHRihKwCvHzEiSBCRxAjwuIRsU6TSJeeGr2BYGqRoJTThjm5WweJynW7JJTWS4KQV19cIJP2UdE34XYCfxI/kSmOAvoqYTQiL7xDAQ2VgMwnD9xJpyupynZ4/m1+MN6Bp9QAZ2sKuYpaaqqhhG5Yu2Yy6Fl31s+uhPpKvSj7HE//T+NRYeCHsaybIknuZ82ZeUVXg2PHc/wE/vA9adDphsnmg+vgX2WFA3Bnb2zVA9O2I9AVPLzEgX4JtGRRMUlWiF21tNPkeAGEJJrXtDs4FZeiI3nQhQlKl9Xo8sV2h5qWVXDenxotES5RP5kjBaC/sS9wgCghpHA9TQpEmTISn3j1PNLsD0LMED0Wn9Od+pAoiCnddeHX2qOVnbiiwhruNcfgasDnCJ5XQOSLaVIDa1uwcf8Z+tkSkbH98cP/QF/ZZWk5tYA5LjCcsgPU9Q4SwSFDksHnSY/Xvuc0bSKXH0FEmcCrnaO21gbvZdhBFKYjMg0e4mY/YYRMzZrD0VJfBbb72oV4iKj8rmF7lu/r87e598Rben/Pu6g1v0zPX6U22PmAQoHUlm/gu1xI6MbVF6HEdABozxYHwXVgCmgFJ90XBc/fKpK4oS7ljNQ2e/Q8BM190BN0UkAT4UtoOS0RP94rNACAjIUGnJidfvPCTQHvKnzqBv972IswNL02wCmSSaeJT6Zy6T9lLicHdT+zgmarMOUiYjD5WLgOqKCMxlw/7x9bJzoKtdkpQOCsKGAE642aJu8WabkznAz4xkT/17uLzYgPl1gSzptUPjCouPrOyksyrCmCRglaCIg+j2BN+PXDOdcBJUT180wDzw/PjspT3uXpLoqaAwSvNwGIR45wvChhj0J4jqtp8So9lwKr5d7kv/h3wPrkPdtuaZPEH373Pm63uOttyqKFXOmHBXEvzdux55CBpH19ZVeYMCv/H188CpP58nAukL5x9KjbsugI9fcjvOtKmedotz3fobXxLCCTXaqYURgPNVG8AHQOlmO9auvRvrs82v+wEFtPW9D+qdvRbRXcEg7MT07gsywV+J9JmQf0y9agagPW6B0ztjNtHyNubqeNzggFIvBddOSses2fnEiF3fSKHlkizkV8xT6NdZ0OQMhmX8meavxTrFFDOm4+xL4VL7dzMMcm1IE6fFO+cS7BiYKhvzBkqiJasNntvfoOIbr8c244l2x7qx6ivBwbsO+iEaHwkVJa8j9KohPOVyywLcuQ54OeszJT5kUh0SwLo9gy8zvixGyipNG5ZDBNgAjVuFfwxqbkIpCuGb4RD6SLK4/Iqo2O/sYD6TPpv8KDn8hj1u1EFSlam9m/GWYob0xqFZsjJCk137SdJv7cv9T0WbqAipB+wPg6aP/QMufgb5Wwau6cxv5b7vHFrOQk7Xyx0GdMDAfdthHtCYMubp7PcP5EBbz3hZGcZYSgMdH+TDEQNDqG70x7U2mIvHaZpy0Q9XF3Tk/5bCpJaFT7efhnJ7erhobpfqIpF2QY8SpmZyq+/YpWxFY9WZh26QkU5uaAiLaXb/GZJ0sa8hCrENDyJvJ1QYj9FV6cB41oDugbai9WBljwOQyYtTuISs2t7Vv2fkh/JRrL9yBJ3bUAYZDCAuBuYKxI7C4tpAKA/5zgfr0OQIHb9vd3Z4tny0ORs8Tzh4dq1ktR64+N5AA3VuN3hzmW63k/H7Mog2TJgRPYXvlAPfMefVFa49pky4eMLgB3yYtk3YGx+x6nx4rvUlllaRJtUBz+/g/OJqLWqB0VDYpsrMAfcGesciIjAbZ4cpeenVj4vxPHI2kWBEm1Gj308r1BRBJO1Buw4G7rCWVcBj6aX9xwFQyi21OKn1qPNSmHj3ZCJWq4w9J7UQcHNo+4OnfO2IZaDOBUkl+F/q2bfGUvo4fjuq+5fdLHcnPZQMl13xCKReFpeFIsZAEiXXM4ojDlPb5SP41VhHFuximpSGx0M/hIZWwpnMhb8Ymnarq3VSfez3kyIY2NJTojYFrneXhRhq0Pj6DEvPWmqlHiRq71pt8nXSZ9Hdfrth2SVuVmIlFQpN+yUr0t+xjESloHAYOoCZUDRT5yia1NkGmHqx2rzg5iXSoYQG+q5WpiyIFRShWHkYuBcg3NLfSpvv4zsKaszaZcvJWASxORTCrl69RUAo0/RimmcS2OZLYFOkco/EzecGdduHpNol2zt10kwBhGydvin9pOirt6vDI2nUlMIehePrNMTCeERuEvQ9FHBBzArB+kY9SLnMxbJYqJ5Fk7NGKnCy1wRkEn7maHMxpWYUXNKFWhrUmFlZgAI6mUolsPgI53abgwwq0ddbS9EKi+++oSby7YFQd2lG7WsQNQdrKK8S8scn9/pyJSq1K3NNTUAZHNfSF5UjQtA/jDa847W68z4s8WyaOZ4c0IRopA82CogIOAO2Wtmjrs9RPK1mNYWn/TGwPCDLw47JPRZSlvquHIZTPLMDCBWNLyn4hAXth4KCAGLhjA/q0R8WwzZuxsOQuyXooYlM94RMYRSMoZY7YTG1nSlg4/rgpQ+tV7y3qhijhr3oU1+gzs7ursFnaNcSGJVk3XmaY6r2/T+XDSQmo8ESapMkpkSZOH1UgjUjE10DCcqHtY4N/QCSw/djQg1wvlSS3UI2nrEF7wymdUoZQwhfNPRSDRXcXnxAfg56BJi3wgOrUBhJY3ECjaGjZp8TiOVY00KzL8GBwa1xp8vP2mtCd3lnieoc55aZwsCOO6i+XruhvgoMA45HmVaEThCv+dMqvOIQ0+1SfBlIkm3DHGyf7WmVQGVlbxBx77BuDwGW7U83ArZfiTNhCAP2qv5TsAslf2SVNa1tbbhsjMu0ZJicKLKEMxEdzEfKIl50pXsLBK6DA83997ANab8KneVf3mH8s1upKzeikqlrO8aFwZi1Bnj97C717VktJKIAdj5q90JVipPEIzqwdA1xxB5WeXgKlVzXNQzNv9ZQACkXFMWeAdEPx+la+hCaukPIy6RjR0F9VudB84MPtai28/8wv00CqZj7dB3VetD8vuMV5wDg2r464iwIqiCG2mcBaAphBbgNVO91eNI6GAq6ChAed2WBJOLRjL6yBmTy5FY/rxR1eGc8fTsdZzgFymwF5rkh/cwF+jAatkpI3Ibv6IGwRvAU0spuJ5DOBtCiBdQMBjdUct/z5e6d8drU9XLa57p7Iza8xHkNnPxTHENDlpUNRWXgcbAoE48ynSscZnepxtY2fRlVHZ5F5eAlKV2fUh7v+XX/6LppFmsEET+tWGIhERiJee7DqNXDDwRiLg2S+/GEldjYZVvwpj0aYF7VkWn8nD6q6N4p2Tva6iCogZZqjzp3FjWif8uAMtnkPxTOnTrWo7Y6/c2uLXrCVCIPE3n/aNb1GL8ZxQuRP5Bz5J+2FVekpBG7QYC6Y6CFO1q4ZSudcNkxLA9MzZ/ffvXD+ra87A9TdR5QotYJePbgh3SNYYRqI0N7w+pWb66XkC8OBCRofHm5jlcmbz6hxtDeSFnuJF/x+Xt8B7WwgltWJVOpFj4+rnBKpg8VOQpqL402rA2CANSC+DojuoVAzc7eRcEDrXngkjmO2tbThfdQh0zCXulrVmN4ubFvJ6UVaox45f75B9TH8gURytMwF1yXFzfAAT/4MQaYFBDU/FIC9XVdMaGT8cq3Wdvekr2KYFNT8/cfL8GmvaQyLipFgBrcFnM4ON0LGxi1zTKsu/5Z0F0BnnxR3XG0332+9B1qIjP27hywbLxEbt9zk988HB9/QgGeY9W+SXiCvBxIpDtz0eWoMEjwz1fpfeHra2HQWRjEW26Yu5uLy3h/zGI1EWLm2/Rc5suE58RBge1k89ZgbIlQzxAKzsT9Hh01hMpL8zfiEOPzjkfHQ1mkwMLvWpyfHdcchJaXdAEeWpLqT3zNMEOq88iCkXwK1787iKY7UEqeH8zO+/5gK+w9qN9XpDoka1SgLouRaZkRf8djAxvmAPlkcJuF7SgwK/xr41nfUmvjuBVezM83HNdYQ8tN7Re1q30Tkgp81emqLkbn0GtPTup4Ftjwf+7KELqE3OHhBmg8snfNY6L7beKw9+iLi+8MwngdV2jAG3v50a3l4VNgQGTCA5kFwaLGapkl6GhkS13OyRkOGjzhLQas5i64zYSGzLcIzdAOmLvA1TtsVTmJxO349F2mA9umKCSNx5TK3dzzeMm5ukFfHdQrya3//zLtTZF9Odz9W3BVBqbipKqVEW88wMKM3Ev/Tie8gp4sJPmY+/nQRALvfNV41MIwbbp1UKep9fPTS6g64p8bwU/uGKpZoNJd0tahgNGhVblLxWvH6VkinviR1R9zQjVfgGCaouguTPwR8ImprSX6xgXb+IOB+5kPfdg3gEuXAfHdvqE6zgFh0Kt/DLw3YM2KFhjrcpuWEHsGa/j3SySQ43Wa1MIGE+XKdJ2p4hpxoXjJyCNUDL0+0uEGSBMHjr039xnayrvvmlEWAkU0XmMMZHxMjV6nlZb83FAFnk9XqSFU7RdIU39V9+kwHh1GZqalQ77RpvBF6fSd9/WMcn/Z4pZrZHGHr6F3ZUCiBBMy+8pPoSyheEZt3aSyyoaw5f23WcZVn0VQjRsrdxticd+MfC4KeGJi2eAzqp79H/5AMNAn7IveBQPg/eXCFRITlcMVEhS8mgwTwULHMZ7NWX0emxx5QCqOtXW1eFXnKN/ZoygsOLHlwJaCSxnDH5wVwergdMe11iQld7LAwriUExLDFhmwM2ptGvHxdvUFJeFxcnYVJtsUzQsCicNXonqwJojRt9yC0xurJUPYJLTxr1ZTBbBH09hyvtBoJ56aBSVPAE/8q+5j9NJkoRM1YkKbgKXMMjskEqN/wyY8QQpcLGO9/XejzqgsOvFEYtpLu3JlZBGs53BSaS1qL0bo2CWNFuOraXg3CbcvX+7FixgqnqTtoeVYk1VldnMys/DDMzxgb+8gE2/mv9pWn8bzWIDnTUKFFx8lnAsV7JB99SFAzlYD6PR+A9tSwErwuhoWJtOF1MNys1jjZc1RsECsLaKfZvJx/9VO522v0QEfr6AmhQqPbhxo9mlr1XVw3FeJmHBlAHulzixyMkiaSGM52aN0+CM1S72SMh3h4BlT2gBzlTanj4GDbpiSa7dVYvPVj2Z41kWfYoLoD6Nmv2iQYCX5wkF4qayRHyAqFXwO0wkk+BskfyjbSMN4PhvkoMMu7iw8I66E/VIPpi99Gdpr85EKkP9gbmRfLx2Z/BLtF1XHlFg+NG4qD/UamfYA4vuUFIvjCv2lmQNMKJaEaL5VsFUYpP4BMFeKeSFm19Z0g9Y/uLYU3N1lDH6omVywSlj7aM+cuWsOM4uekJs06EdGxuzF/mAFVnvs13JVNKRlR2m0MRKGE8mAUgUzFYg4naz8jJ9IQmdm61/dF/qMye/G9uS3qOpLjIhrXd4OS4jyA5ZZMrHEjYh1+F8VaUUpaY1C/CjdZoloxxoTKmEhV9z1ekHDuaOyn5emEzUeVzM81uSYglDJ6zUm13gp6QU7zm3YQVkHVTVhR7r2umpr+ip5R605/nH6/5yZxGZwcVTWzeIdMLzGfJz4ww5VspimCoQvbWxvZaoFnwmHUxZ7h0Z9F7K5Ca8JV/GzvTJgdwphHdl6z2Bper7abmPyAmrXmGqHbF3IjZUtAWtZLz+mJ3QBzx8QiABDMhwfpnTAPfwQMPQWicY/g1tk58tYo740wszGBPt91AARUWrPYGCdwruw9Jq1ks+fHYhQdDkQp6GpHhyki+I+6BN+8FvR5gJknsKfySKK1VhPZLDjmGXlzEWcee2uizAwBav+ZHMUh30jGVOGI1CsR5gAusF3XL90BlDtDGW396lJ3ENwBQE9qIf1WTPWFcedIFbAkrM+GPpd2udfvjCYiy+F+iClgPEPLVJiQIz+cJePm+QpQIf7p27nCuaNwcMFbp0q3xjrQY2GlL5EER0n5S8e+tblDtysQuIvPw9O3NpNCeiOx2r3lyA9JqJ0Dea0pxQ78BivJtuSQ/HH/33M0yky/ORVsGRRUv2TPs935JVTgPFBRespDk3U9zuwQV78Nny94mbEJjelypNE+qrLo9kF0XshmvU/UI5tqRpTERiHWLkrjN6MhmgTpJIP9I3wA6boQyfJVYToO3kRAh4AjR6pmwOT/uh6dxt2b7uPasowoFpWXcAEqIjTgM8F7I1ONi/7hK0dn44o4RcWAWEzsdHq80rc9OPclhZZDLskxS5N8b/4mYfE5row6xE09+o1bFbVOEU5empEYLiufOrpp9R3eIClKGUBUmPQ8uVv3YD/s+/pUt6jkJ508HBhfOFk7WMf73+8S2xaMZUZL/UUOxXTmpFGhi4FKgJTIA4L0smP3Dux1XMDvHt2Q7Elcn5NML0oCRcXND3oReTc1+hW3MGNAwrncTUOBEGJ+r3JdYfDET97xWR3VQH+HlEz3jHHyzBPpajy00hhoxa0g7lBTQMixga/3Mu7X8qAWzQ9KCHizX+iEAn9I595BVOxift314j860KLySt6JsmzDEgBNs5NOj4jj1l/EBT3urxUg5KJ0qEOTiME8c69CTSlBidTDyToBH+cI+zBjIK3OktgFREYq1CUKpqwRMRCp7II1K1fBk1RiWlM+WFOoEq1ET04NCPivnQdd6mCmvueuuLRjFHUq8Ck5zVlQKtC8nYLSx4NCWqA6p2t0E9og6j+b9melqsTFSHwLBcezT3A+e2OtUwoA1wyrLzOPxWYaofxzdIqFJH31/+W7t/1NnN3MdtGeDl4EInIjDxvat5rIa7nwOms8H/k88fkR5BHEZtmSiMbilCinH5aHDWPUsE0OT8JRJFG8D7YfpIRAGU6HoVhHCvOIDOQrnflhgxRoO59no9XvmVqrrFR6gFaGcEljPijMBRQrdJD9rKpDcAtL/lxo9d8BhQIcvt8SMZzS3llxPmfn3ZBliNkLSFOiO6QFWEpuJtnLEALXrZpCEgzsF70feeiSQu7PmRc0h8k57eycriJDUXb9UeR5TmPNy6C9brRchJPxQfPfrsaGOW9CyYJaH/FgPI7BoyYJEoFAYI++qIuO7XVdyFceN3oe9aigP7GxWfeBZaoUqGkSLjTSn/fZuWs2/JW7ex0b5wK/Zex7PeNIFGqONjJNNslQUOraQsQcX9cghgFh27RMZ3a9ozriejfLxkBbjjJIz6/rmvVYwYXHYPxXt+hdX0HN9ee5nZ109ple6DmU7Wzgs/maftToVaZ02NHrC05doutpIB6aetsoWkB3Hb0qgU4uBT5Jo72bHiRAg2qqnJyUUNQn33/t5PRReK5B9MVN0rVgPnw6yeeiBKVS3oUG7t7EGUf8bIrWPQ5eeMbZS0ghm5l3Sw4wnMbdIJK0k91PUUXoTn2D0ItNeQUssUpU9UejUy0Py9EEU4SpsbGbuzYTwtxxQ7+UK0X+EULy3YtQgQ9NZtRR3YEVWIRjeX9PA5lT3DxPO+gPsgFfcsMPP021n25k6Mc1GOX+H0jGTmoNUhkweJ5BT4k/CB/o5OfIdPY6D1e9T8ygbRkrQs9F2LpvhMclhP9chyeVc+XeIHY49sAaW9dIRZrNZvyJsDTB2dXlmVnIaNbxw0Fk8ugnDx8wWGn0GZYPYoL22po4FVo+sIAFqjYGuW4gQ5Fv0jCqBhC2Qrbt5OpCvN+v+Tm4EGm1z6CIrCmV+LbV2g3t7ygMggp7rGlQGW3Z6QH1gmc4odgNqxTT5WUwj/+HB4AM9N1fyfLmg2SIHFRvtE2JPL2sZTiweUJWO7H3CE0xwwYe52gxaiFwfvmNsnLZjtilY3pgHAz+SN5QDmi+lC0QrWQqHw3Kzskl0DV97pwZw7zDH5rG2zsI+W8xDeSchjhY/h0tMBVKdgpI0HhETRrvOId1I6himo4qOX0Kb91sKGnKOY9s4mNpTvfhsAzw3h9x14xd46Y/xIFMnxsb/7uwbpxbNuDt12+4UG3NDE9TUDyzUKUsps1N8k9VYsD1qGcekHhWhHrm7A4d+u99yYl1QCvTVvCuQZ7aiTvdLxTzsfJnBkoC+M8aroPyxNYGk6jhyu9H56t/0OjWQziQkjR0rfjG2S5/nYiw9PF7YKu5t2OMgah0KB/EZ5fynu3EFvrcjScLNveLnK50SrKrz+ZbanP/gNBKiEgp6MjsonSDF6Os1SBrVo1B1+cuu33Ln9Ly12TwWdfMUBwyHqXoAILPVTBh4cRyNr+KhmbFZ4ZWVud5MWHDnfWIuKFb74veQfNSUrOkYT0WBalx9U/E2aRkOOLG2s4RBp65LPTaaZ4VVMkg7EQKrG778bkUGWx6IuTHfBD7O7P+fyOwIY3KKUffDtZ9F93A8oahCAPcjbBeLFwMGDSwMNaPfkkmxoM5E0J9JFupxuJeuqa2+VNeDGjvf0ox9r7aXNMYl7lkCdQf0KO6mZmRd6OM75LHuDpm9GjIwWadCt7SlJMy6vfPbMs+EUHVhuBuZFHoL8Ydl87AXcU3gnNt5nXlMIJXG7+2GasGp9bYRjXVqqvauv/toGtPuDFTPkybgitaE+8qztPgxpTF+SEFXdw5NQ/bwPnYzYFEdy5ZAGIJyoOMXlrUw57qQ/fWx2pkccKXnxpcfG7dUII3eXfpIDwMIBqmKwMnp6TjgasUDJsiXoUxcbHQB7CWZl94kww5gFJdZqQ2ZKQEnrzWMT6zl5mblwxxGm79vMv6RHtlSYiD8zAGBmdxWgOZUrDpH2/V6oSVS8ZO5dFLPIukydgie2JTJUHtdcF7e4dTgkx1UrvFWDV/AvMWY8yt28PYM7P/EMlnE0uLdcd4UMRIihIQYlUDMA9/v1DXfxHNSeoh0N9o0pk1uJtVAgKaDkXEcfj5B9CfA56wT9es0arzXjMKd3dqx0o9m/QyfYjFzQINyuiHKQerA8gF12DS3x6ghnyglOyE8oc3nKhk277YZ1UyT+d3FbCbTv1xjEHmDnmCTKu+LiwumWnS3kykE1IBAxJVhLVlm9Fs9dhnYN2BcHC+G/dyyP5Oeu/72NhpbruNEA4m33+r5d19Y+c83/cUvbrBwLHknmwrOuHp10XgoHzv769BUaxpXv+lHkMP/QBuKbY4X+VFdLOYbF9nKD1GBTqyGGIzShkRnEoGCXbBR3Dfdn5wQ/+3tR03rQd+7Wl/3c0pDdhWwql5nRvT+z69C7ayej4i/t0/aR5wo0CyO231GMy7C46k7k8pNOBDwsGgV5NhfOnF7fxCN78tTxIQF+SDR/6wat/KBw0+m6zGEcePTgBo2iTd4rXsTZDHnTfTx/Wf2vFOwvOjif6swAEIM+JxbhkxHCHmy2VUQgfxcT6YOTABzIBvXT5XOA/r62zwyTKs75d2UBU+vHuVAM5rduFghhLXj6315+2B9KKs62fEXtzPvip1d9kZAxpnlX3BFAu+vGMGiOstulhodDIUYptcws8GZpiRW6l1OgtqR1rDVgQgYoiCFA4O8dkgk+Pk0z7tX53OIGZkeZUBPvm4EhCs4LufRbY2UVjsNjFz2J9PdmCb3WLP/OzgZGkQZI/sOsSakFMl+jVmoUKiclnyWKDD6IBEPQio9mHl7H/Ox6bpEryIigo2awECRezVvOjMv8WlJzRsYbAspURc4rhmVyGDZ75Tif+mnCTVSX0IdLG/0oohTc4JdkvsZKg6VAFpe9VciFUANxpU82ujSKbR29ShkUPwDDYLy/ezkmdg+j/K+7OtuXCK05X2T8+5jcTp/xIrpyRc4FVvG8wshfgvjJ0BJ3oWu7noKRjB9W2DPRZRL8/jCM948un22Jd+Yr2KlT+yTfaXpcAe+N36Zj5FkAsqOLOfgBvq7cTKjSD45bY4Viq75gPUP/h5C7270vRF+y/UcmU7CE4jfINR9gLzHm+pYpxtjUYaUY+azDUsxN0p20qaRxtt/J/pQQ44IvW1yXPOW+NwQPiFYp1NxU1BwdjEuZu1ltNDnJbM6nqaNYmwOuFQwxvffxKU9CrZMTSDNsGYHNgV/VHUk5I9/rncjPnIlWKbXq99NA/0H81SHAYsSL4lpu1IlhZcfOcYk1UMk4oN8PL0I1aTtPnVLTIPIapDJmehq5Gdc5SVQKKDPnfP1siVLR7ee85KEzcZp9GuV9T9HIgwd/VyKTLYaQa9i7ejJWz9oYyqJ8c6dPCYYhB3uNGiF37/FrwzzwsZg0YCFykOpqd3K/D74we59JMc6ep9d6x7L6ejliZin9XxWMuUYjy00t32wWJ0VLaZ1NHMbuptmAUPFssL11D9iqIfbHunNFkxUbTAn/dHG8tFlX34htB+ttsyDEwRcRMr1w6wymuasGA0Sx+g0+vmL/e6frFdoXljc2yk+MUyykYeetEdo/S9rc4pNkRfDAA/9QZWNwdKkLSTe+jcnyvkwifqYgpKA2YDVEGUpbbxkrciR1cx2UVViw5ZJodueqEEWz5VGVoprc4es0EQLY1R9Peput3Yuj+pE4yT6HI0yihrn9Iebr1GygkGPCDeLjo21FO3qQarjAmMiec49f8Xx0gO0g+JklY4hAMYQmeZlwi5khHmU6bTBolChhJGorChv6lf3dOagUW7bMu42oztTadvLnOFTnT5X1UtiTkiWri/Y8TRs+3LK/FVFyldnNjHUb2Udg73fwJvN+oPKroqn7ebsaDh5Tbju7ovF4wMVtndHFvh+DBv+l7eHmu9mEwUZHy1BPQcG9+tAdmGovo87gPcQn8RrpM+K7Ij1f5Np5xMPx1IC6Vz49a/+PwfXhA4dpg2HOFhLTPiQxDf4nlo8G+jA1t14SVDYwZV/O/HaAYivUh9Zks6/Z5Cg4GabT6KucETky1kXuA5SPofgcVwN13+jyv+VfrX7KBW7CfOZ8tIqXfaGqpravzke0E+edh1faPueebjpK/t3AGasU+6n0sEJffr/kqw5FJRRxwLmfNY9zxppxN2+6GqC9KAajwXPTMT/b0Qlq0uJprLPO8gaaPs+rh5NGxzHLUpeLr7ltAuaS0F2fhIFiZyWmrf4qxzxqcu/H3gjVWPJq/Z0cHTfLcCdzBfaLeMhuBmEoC44l776M6Zfsss2D3rj1HUNUNv5Sf/UjltMr18ZZtiC4FOBltR4qeeDgvpXPEoDNA3oh5R1qXAMtE+xyKaMBxLShPSLcDy4cx2Tc0/HfieFbrKedu/e27vHU+z+PC0DI5raoPbnd95pgNC7Xo7cwkzbr2ec2jgH6WJcrJRflGLLHn7vnoY0P+51SGlBSKESvG1nDL24pF4dhhBa2bH3DkClWDFvQMgM90re8vXnxNMB1QdAGRqyI5LWH5EhrmMxJZd5uy3RpjYVnBtUTjHrKLImVaLVFDtx1/+7cc2SF0xy0TGqbG9OYkTDd9Z8UWMatYbsBV4C0IN4GPW3s2hnBRKEA7SVYTSJ/jcbEU0GHHUp++er+Xj4ZZel/ihlq3NN5NP+6laId3zksvbLKEY0Bsu6UICEsxiOg8MxI/DQGYMMfAyivJNOb5ta8NQxI/3R09M4oxSQwmoZ1e8VuIiwp1/dlBmU3liXDeLOlinT5a0qWVblYBm69PvYqQDFuHtAuHsgyuLTBioC6fyf4DgF6hG9rx80Ug3t5XS8cU/QNlWWDGbGoSLX0cvu1hN67KOvStDgnn8jNAOJOmYSawX2dh3uDDf/6eR/hIRzsB3FT5uNYvq3WzkOcDwpzzS5nIGnl6XQNZQysdRp4vk/Rih8E9uQNOmKjDJy9ODalmaOvlqRTubV9PtTVRTCzunJrgeK1dm911kF0ccKNWiO9DrTDZMRjYOxIiO6JNxAj5eAkRByYDw+Rv3MU2zgIkGlxEHnffDFm7QKZgjsrN9Hdya2psmCQIMzgdN/lZqbeTvABdk4ODGS2a42yyYEUkXdXXwN4RzpMV9go3L2upwMb9kYp5R8lt6HgLivX3VBFgF7pLVgu7aZUWfBIsL6CsVawipsqoTz9RTDuDEZAlXE3Z/oKQuyrJpFkASVrGLM1lZfIwLE6oOYzO2qsTSpaVrW1lc2iRN9b0thqI+HWjTcvnGlK1lDvvW0n90o8gYWCG2794WZvesgg/2ZCKVV157PNH4+z8sA2c6o/+9ifLc2RHfIbeSkWTasFRFjKN7gsDvxDzakSGv9Po5eGuxrDd0PIn/Z42zqUbW6CKUZNQgDxy7jZRAC7IaDtgV+UghGEDDw00GA/wGCtTh4pKOrJW9cx1suueSmtQ2oi+1uZXOWzGX0MORRPVNQNeqy8iQ6YTXnmeXiaxvomdPM2O9KBysvV0AoLHtXZ2LTZjPMD/vuInrYWi6C5f9wu8GskZuoyE4d5KfFcVkaMZW6I3AvoFwqN3DoNeDquZpoxomQqMSDP5s1czdXoGolpzkMijNwcZW6g/DXddUWEjLLHZyD56uOD8xkrSMj4DV1JZz/LbMsqLU7/plXBlaAjTtTHFuEyUAzdKrmt3vNRwgeNMuDSuZfNs5YkItoXiHQpebpBEM5HEWQXuuJt9yYNJ+hVoP0vKm6M0NOjJLgE7tj8t4lHfdT1ru6KkJ59EtLHrVAdxX/6CZk45I36X8S9u1K0m+QCh9ala/5o/BCpIGzoMOPHe20UEL+MWZEee1RN8XhIeq3v0hqyPSiQXpQvpdHI7sSiYwIn7/62ZFNztKYIcE7oYPOs0crKJ34IF7Dt+KRsvw9A5rWgMv0WQAomMYQcjYleZTG+zyH2fG1RJe37rMBTlKE/fQNFx8O0yPlhSMB8x/8YhGwU2jGi2MVewgRPWe+M96ogS74s02j9LtizQpqKK2OsEZjoA1rHwU+7cd5qjRY/wpwjR0lZzUEGazncS2zY3po0YIQoxVdfi8Egb214R4Ca8J0lgilS0D2BPxSdAXI1Q+91u4WZhdTGMYOefaAWDOM2gx1RpoD7V8RCpLBdzr2USOYF6Cm000PC6AChuCcT2wPFSiMB8ZhRzniHPW6SPU6BvJ4tedkV2rOMferrbdmIyBRf+s97YSY5hfGyFwkOBPD5nngygAc0iy2QihoZJsPFKTGGv3ayBdYQEiHfKeJ2nyXZYkeBEMewoZuP2bGwVwK5fdZ1CSqnFxb4P7oHk4MCVLVFPNm5rCIuX2DI/+FiTB7G84RTeoCjYasVJBsjAWP9dW6oT2Bmwgti8fHC88dP9qOmdH4K5TfyUs4AqJRutgsTjCAL4qp5JnU8VK/NCHKARw1T04zs6VA2kOjWmNIvRKKQrLo453m+C1oiSu3xCpwOD95TzdNfLl/v6cKPD/IbE+7GoXwPkPQTd4v8ZFP9al+m6M1329ZCLjxvHPP9FIu0OTYpD7+OhRvjixw4qvns//5pFg1wrdgdX9n8Ey0HKjb14gRcG3mE3LY4S8lhX3mUzMnp3qa3gbStLaIZ18OvJnYiIIq/aV1O7Nn4I2t6hmMWZCWKYMLCsgPIdxQxO5EV3ufR7PHBJbtTbX2rJdGv6+ms6rxBg6awM5ZoXjBswDRvvTWelTkFmpB7YebQECv39dxUzhu4nPQu98uoV3fD7CIVkczzmWnW2uZbS8aJB174Ohi0kco3xVLmgMRaSXhR4ERxaLtT6VhIXx5wwkiRsEP79d8btxTfZRo4V9WYNdg2qWnSqJadHx6Qze/0AeGZmre8900KGZ34dQg659e9Vz0cbSQ0cMzFIfeSgEokUNzrhK7chkeWr85Ilqj40h62lEmcU5G8zrJNnOdhlB1RRC8o1gxw9EHXIBl4S6Ur9V37mleVDHqSOP/zVhdw6ifoiB7T4lcVWbyp1smohiFPysHAqxwwtemnmObsL2Nxb4uFqMWHzCRN4SzzMURUA9M0nAEN3kHryaNS8SDk0wUmKdMKKJKqawGktguyNUamf+LsSa8hyW045TkGVVaUryP/wPO8UTfUHA28z5BEGuiAExgK+3kns9usS7ANK88aoNnzyHkyWFSNNIz4+5HZddcnGTg/tQL13g4aaPWbLvJjExMn0QX053F5ALQDbwDI88t0RvDbxW6SIHd5Ho/ohgl/BDpw+xFQok5j7ysvT+zobz8h39dqIJle2A070J8d29uyu0hZKDpFBbmRyuwm8JCbeTEZKnwsQF9PRoxgNNoVWH890BfmjvqqHkq4q0VMVytDOUt8lsnqCdXbGTGE9BWoVm1sRUQekh0EdL4rveUC6mbxKL1l2s0HXlhXQ8o88Ao8S4uVl5JlJ5kWoGlr1WHmKyhPrGc9v2I4ohkYb4uTJdYSPJq5e9rFfQ+VX9EA4He9SUpNDvnwmQT2NmZSO1wR3s/QyF6I89eLakRuGn5CvtKmfS/8FCSbLRrFOQEDkzrxxpTjrvtr7QUm8Ak8+G5Q6ResTjaeS3V7HdzYlk46HXewl+1oCNnTRdc5y+xneYsXdlnYu+1YvxlGWFn0fmxNq1HEMEeL/lgN7C5PYv784Uw3Pcb6Rs+mt1pGGp00MPk1HYVTF6VLBMQOPyZjTKzAgEVxzU7qjJkeHPf0j5YP2BwfVT+bALdk1vfZWt6Jc8eIQ13Ikcl7fDJuIN12RfpwkKHbPRRcFYabayT7B+afIruf7px0TRNge5wbUzahs9AF7moHWcuQc2dcdi6Rn5crqV2x7OSsUjFdHO8ZbQZ50SHE7rNuHkI0boMH6I5A+B89EYEt+qNHl31ymeurNdRSr73voJtbPJS24AhFxes8SSnp47MeXorCFTYSSS9RgdapGkGxePWtEHncup91UzuV49FwzFKUP1KpJGB4wjY/oPiVz8IyDQBCi9LViq9dSGpGXPBeUoL3Br5tBi5I9oVb7kel4LaCsoXAF571CcLJM8vjpaFNH9xSUr3BsRmSTRpfmMrUj232URnkgEC5WEKBNAgYr/fCLlWp2EkJicC+8GG9s6h+IJVeIEVeFE0wwefVbUhnTWCjirwmYZQdWgTF4rgcnQzwjoga43WKm2zTyiTEXdgZhv+4aI/h7+VGaVuOlY39iQMrO/pITyjOONjweFjSu1768DZabRxYJur6B4tzzfbKY+bDcyXWDUmDFljOG7Nm6Z5IATAseMJ6NHEmMles3+3g+FSlEwLSAo+bs7znVXYgALkwC3C4W6nSoaep2JIM7Mc3A0xCLv3NJG2JImLuuEBEhZTU7wQDC9jlMufY05gK2/dTW5j0ymcNWoRbpY/KFiTBtpAX6VYbgYN8ze6aAqmlIcfimxEi0vsAkbSpLF7C/y8ijh2kM3TvPl75Ze7OWtMw9Dx5tqiFedp5ItJylqlA3QRJ1i+zBFXwzjLjBRj1g2LPiO29odulfoWVii2cbNnuHWMl9mm4ClVHetJeXHg2thfdz/gT51a8uvG5gC5q7G4GAOIps54KMjb2MHb2V74QfPCs23cmBEJDUP2Oom6Irw6IPEKL4evv8lxAUfQ7+qxTWFrPsvqmjgMoj62fdFtN38fDIecly4E8CUAtYNvrw8+09CZxvF9zwoAZTOKXU8rKo/vcv66xHTVUj4iq80DQz+B2/Ij1TnIbKw/zO0HQnFMWZaq1O92FFtBFVCQ8q0ymZ+76BMa02N04heGSqGzxH4rdmoRlz2a4Cz4ysahP5BIKWW9sd8d02KVOc8MlHu+kaRmEZOsKM1EwshcnQpekJGp0L9bWy0KXTCnDNA5eqWPiVE+or4d3ReD0szwi5OoYAM9QCerAnEdYbzS8L7XAiwkVNwsLBmfFt7jqNXB0uZ+7w5fpuFsPxfhtRrD4iXQll5uNOKUX+bzUz8hE4A+6YMcucxwLtIB/dekec8uXUGYR5x+TDkDRQbRHUkNZBCdIYmK1qgRIZnUXDFAOmks5diWAfGE9sRj2ZJkfALbSdUk26aeOo9xyt7Kc0ErSbOv5mizT8D13Xj/ir+5t4nBeqvW3lGmfD4nXSKDKT6dP6BmONzmDsRmF6BipZ7xLI10fntN8J4QcVjpAjW/Bme05/edkbp+TCSjyBKWkvfkvNvPSgWki86Ff9zmqvHJ0ETV2go7q0DZ+Qe1iXQesP2Rt3NpOgEFJFkXBtiPvGsD4WMmPG3n5UQFQthXYF3Dr1sBJuEvRy8O3minAHQY+XD5S8ykh0cB7hjpRL8cqyON84b0u3oGdkRW2xciR1BDXKc1Pz2DGzKLSOShstFMOj1wfi0YKmVjAG01dctZF3JKzCWYLhHdZCGv7wIrZ1q/Fu1kNTvBdw1Q+o6i/2Gjw9KldEoEeuuo+QfFDDyy/Ij0XhqOXWjL+DmrpS2u6tApBAbJ18YS0bUG3zMCoKVDZR3hB45r3w9QFTGeUPcZDBGhaxDwuA1SGJYVjw1octysU50oU08FTyKzmyJ8sSsemsNc2jjY5uKYaA6XpzcG5mR8fBo3Dc/sRGKXgZ1K+E9gFupCPuusRqzhKlZspXtvQQJ1EcMJC0mgFkTlFhXN3Vz8UNyJB5pcm61F/C+yqVa3adVVrgm0FEsj1pI47/Of830ZhmmYa8mAmq4qZcO8TCUX38ZVNj2pZyykLIRtWB5ApiyG8ne1bkHfTxDbhRg9h0cYwlHk4zkFL5A0Oh24FHoksVxDePF2IVOk0hbtbEULVwyohB0FSRzH591kUv/GAavFSkZJrHxvAw2Fgpj1Y0dsvFypRv6yMeIMo4UQiSoSs/glie+HfjsjrncK1d6kumz+t5hPAxCqelNgX+pbgbcexHzCznr/K9BMxK1C8DSglwhAEbKovac0VkfW6gjaz+7/0kz/B6RnZgUqw7aNui5OM9r7M+ZFPm6rQm0cxNBkgLMuF4+UZRTL+FSiRzpj6x2aAb/Qr2fvBp7xzm+drP6eRsqSIHT8YE4HLP/KLG2Qq/x87qrBd9Pt6wJwY5qhlNYOven3LJutQvOEMh01vTICDiSScOMstF8P2VkvVhlLLBxkGUcAbqrwizQGUMGgWfS+JF4yNqLhjyto+WYqdRhj6nFKmymGJA8cuEBnrbpUlc7Gw9zFXMYRofk1VlROC5LahDYG2+8prMIvPZjGzXNxhr7bjOYzHgXt0fF+G3sSgxmFsaDqAqlUJuVpKHONeoQbclsT1zETwGRlLaR8jeuVmrSru7ihBFvtQoXFlgSVMXMLQhPvv14Goaemce+jECl5mSgQkQnVspFs2S4jOhQDYgoHe8rxbEbH2awGRmD3RxkNZ4CpJjqo/KOtc5hthvfh1xNpUb0M2JQzVv1JvqCAthy5yUOl8UEVdzUNMhee04NmixxyLPbjWbgugxMkEJoI25c4HQ9yCqvqW6fVqkSqLNeDg6JitJj5RSw63mSFIadAAKWE+/sC9t1Y+ivr0UEw3P9pIaLIUBXahHJL7DdLWPnGVb3LiQq3wSP+CG7jArkRuztLIkULy7sGegAX+un/SMVKpEjkW9w9amIFFIaVb6acr0CC78dBSvg4jT/el/G8Uaq2idO3guGLm8+WpyOiU0w8GeEEZxKfKFrZkuXhrsxYMcwDL7rgz9rdQvDIdCzSUr1b/1p4hTUqXAAueqolX4SZ+LkPCZ9R/NF+LSLa6Nk28GfawdCq4wDs4vYtJANfOv0TYllMWqtQTY6YKF2PWJjjnDthrLVJqQsB84WUC+uphvVuwW6XAECR5Jy4282euwiz/7Nk1yE4xE07Omx4uQUk5VtEy3tzisJXLwiAGaz9wOGuMA28PPkcI7qu3ujbXeZuWANaL008IxlsAq7idVC7vFEr9jmSkn6bGd+la7fqZkDA6ayVws7s058lLaBtnxZcpMohDHImlDfeh4tOTPibshy35I4VQXB5ppEBD7aULiA1IZtLjRQ9hcxw/wTpERCLiA+YnoEsubgJ+xoIJZx0XvUaQEby5foPpNJgsAJH3Gz3MMbFmGjgrLmCHReEMyhX903cbglpADMWT2Ph+7+6hV9GxQlHfSKsOyReJ4d670/x+faglv8gAgt/UTZ7/kCzS26UExttlALbzL2PSoY8SGiP8hoUq3yY9jYNqb8XWrdaoOrmZFvH4DSYShHEupcYGMBFtfSRr+cNEZMwG0WjJOrXFBYrbUZ50682flk39R9bmYSewlOZrbvVkrmKadxjbZtFAVj6TmZ9KJoAi+I39ns5NEtHXu5j+s1AT1wWP9Z/wFaCcogNgjqmLDUfi/j9ysZ+ZHkCnFerQq20+xsVRS38glN+pgNQ6m1BccEGIS03as6i2rp84T8fF+WUt4la4va+wkc4YRuMxvqj9mnH+dE+UMpkl0+y02fbWHoy5Rk6DsD9xJheghyHKE2FCL/XXEiMrdNXanaMih9H/RzowUA5TbE6BFLCELmAhlwChSmqinUDMhjpdmBNQBrrkU0B6E//+SAh3LQ9ZmmB5iKfwod5mDcGDBjn+3aVaa45STmkK3S7pJSjPQHvJLDZuNze0sn7W1bP79HUjQXYP1Uc2vcVLZpzk8fp27K9omh65/Gfjn5WWcmMA4PiVKYGsND3HK0U1sX/PN0s8j0ctALznlUDctEssPWdE8kmMMByZ6nrbO22sqZoV5K6/NcDV2XeoOarqHLvQ1z0GWszYIWxbb6YwQBf/bLOS4U4PjZftRLXw24kMdOSMH6mv6x72sSr2Dpa8zsNCAqpkweEfsplGotLcC5gWQ0x/rZ4t5WfDmQGDxHotXn18P8nZh7tn59EY+86NQKpMJ0J5RBZYeNZDB2C+2CJi2YFMOGcktDwhIEbhM2f3fj2rfBEW4TS+spU5UqnlWT++GgZzopdbeMjCMU5qt8uAg72daoJSFbYH2u4SFz7s8Y4Wf+yhJGaZ8WfPScwDDfA1MiO3vjBNp6nRD5CQunqloK0XcAe5iUNGX6Cs4jgf5ZPK7n2Krb9UAq2OlC2hdlp2CLBhzqeRvTbq6B+tVyYoI/ub/0dL/0Jxm7z7Eb0W3vbBidQpBFo8HfNRbbfg5atw3kEtlfhGKHHsLWv4eMF0+JQjIouHSOmXs59WZtdtEMF1cr1FjZ+iN4ASfKfQO84ld0mAzmEddcBWwJX/351cXPP7+cQB2l8ibwqUJmunGoV5uwhVGTdKsUPhwFndrn7Z2dP2hwvYGOV+qR+c9eC3RIqhaGokHQ0B7HbE8XLWHUkzBFsa3J/k4FkO39KRBqslBFUziEKCF+pt5FxVLSBzMg7Djb2PLpv4BCpRyuTxu2byPORcO5aCX6xSFD2pb4qRfcHUNJ7V+zP8gAmzJ3IKIc8fVsRcpPa6BYY9xdGpXdkblkgBgRRUY0X50tULW7vbP/1KOIh85e23GPrzDs7C9NRwKD6jaolBAYDABwo/CPuq+X4jeeGDRaimhAA3o/JBX63kVWKWSucfrlY4/drG6oM/PRPBwa5OKFW/QfVHQO1viIiA5TJ7yJSJaS8VySdy3zTQCXIYb6GxPCqbeDzifZO9kn/6aLDQp+BpMy4L8UsoG5bDJ/vc9qDVUR03d2WBBY8JjBJltVOVhRv83uNNbqZO6Hf5gdGLfZobat2CZ6sHaF8ep/DWTWKou9xUjXGc7658/PW+vJ2Gv/eJ64DG8MvEKqwsNAFzSFgVvYeu1ByqUX2plxG8nC0n/d9ueVHUXA4JvGgFSyK3NxmY/Aj0m7w1ddVBAPLKwROgOB0wchbXTbcmwniMjiIx44Shh+BnCmtVHWWtkRUA1179Nmy/4EQKfdewQbOFc6QPlk7ajXW7BdnO5Jyw61ioWMYtqUdwFk1+nbL0loqNgxxeE43tuunYSQ3tOrivWcPQiYNpF7M41PYIS2PJIikT6YprTEz6+neWTvrBH8o3suiLKjyJ0IPLSjM8qOgc4jhXnOXyQTUVYzjROGSI2XNMI2uTEryeNUvg81BPTWiU5O7HYqprCLJ1yRJq2XDKhHA8m1rlBs8YHlyqhrRChglUY3yDmXgVDrm5W1eJYYuEgFV7HaIQZ0+2YxOxOdrtS2g5ddEycwuV459LJz9CChhS8I5/sKTqjhN81Izs2CpvWVKLjiI1z2VYNiwiItLjM3Y7iGC/VThtRbccSkNlj0HHTd2gGy9Uo+pwu8Jal+mMPDbq4NHL3rgoOnCBzG2+y5XhqSp5sfLf2uuUpLtREo4xwvFXICdfXMo9jjcW68v8fOZM1vxaQMJobtMGZIsFH8Hc2TKMUQU+GjJKRWPBYD9z1LM3iuwdrXHqfjm+gRS6TAB6ji6P+UjOhycl0ZePMiFhgAHy+iVDHTSU8/iHShN0Rm7+uPove9slzwy1DbEBgF4rsXn1rRlT73EDBw5sOLE75pK1Qj2mzX81peE0zpcXyoqWslV4NyBNSlFR2WEFAKVmsqs3z8sfpwNYSj+JRorgIOcAw4iNqC8sCHHKf7dqEGVU5szIEp6+p4YWYF2/ENjIaEuevF2LVfRc1rPnsAUSdUF9lNt3DvHQENWA7riuRLtOKPQwCUvnlKa4i6zNI4XQvpJyCIgZRVd1Dxi+ylBT+1ep6bJMB4hndZpRncRCTFIoKb83n2OTYScX4SgkGEBjc5A+SMAJhk3vmVdJZEOzsoeW6G1kpd7g4/L56mz2ujOKm6Kah8stB2tIBJgDzbEGRJ3VnhjphDyxHBYZCTrKC59II3zXZXwvSRvh/mOCH5xQU7709hBWoSrhVvdati291fZ0rPWEL/VN3HqH7Oa8U172Akv+odl0smwJjc7N3EGtjg34iaw8XtCtqVZOx9Wi60b3UHUlYcX+6wozxk7DQ8wuayXXQGfSzWvDuVwV/QhpxHZPGznxI6Xz9FrCyRcvGGvmYqheKF8WqnHylR58buiRS7Ss/9aZ/yooLlAWJnim27Zd9tDU+LDMvtoWAULHwPPP4SZAkUJgeoSgCGpQngfP7J4KwE5usUnyX5E6wUB6ZGnY60lpor8/CIgqQiisGLQ1zMeZ99IreR1A5pLxjlaeysl3t1ecqWKVAXOV5GOr3bnNxsXWRf9IE8oxdqWb2/uw6qllCa+SzCMqu180+uG5bNElI69WhTcuodJS0ykXETMRaxE9Q6qcNN8tqsLAaMu6nt6oNFwabApcHSq5WKiHfyuMsE/DHKCDua7k/+z2D8P8wkUi3xRac5EavB39kXGJ/qFJLS9HdpGhQtbZlFJM3LUS95ROPgAtTqaKKrNltIb8AKptD5kgCFc2V8kdf9LQR6gqjv/EeMEKBgETXsaWWb4MDEfGoVCuzC7RHPOECH2qpj49TvrzFpxGxT6PY/9wiIkixWDguNuLXti3L3GfzuU61yaqPidYGmRTY9BSuwfhDvWWA5Vpj/DHgcOyXxrG9gNEnN92mytzZ+HPHJftf/e4NU3gRPDy6QeKKVwtYlI5OgXCuBCuqkKNDac7FIJtxCfx4tLD1HpSMs7J1/Q2Zmr5a/lNQK/TfHGfbW6lmtYU9VrP4W6dUi1op4BY/FrxG0WGubwwh2zwgAsOctc55bCayMXOX0R3/UyxDqS0CXzNWtyPzBTALApHAZhX4KX7ldsB28LCurgWDVKHYYcTS39m4rgHJ529RLTSkQqus/hNSDsHQsGz41wQWXRcsaCCTRBz3txkWz770xjULjqXVvgzqboWgxHMWk8r81VAcmYcTjCmOf9FGHGMucRO07YfMN/j2aK97VGwAE4us0MUc3zw7Q6ytcndBZ/PTtp5DraUzFAI4jVYh2PEu6ZyeOTBINn3NCCXEsZEvi/i7pB/D7XivW8bVcNoxg2+9Vtumpqev9xQZuTeo2+2Pv+zzf1VTwDdQ7UbNynsRgooJBnwGX7O4zP5dQhEZCTaDZv+UtJ5ZnESYiDOnPV3xyiS13x7H+3xv9BnTyCMmBf3epud693aJ8iabQzT+hDG5dHOzcJhsphdAxtJSSJpUwEJaejTZP9TqZGOLUviZ6TinKm+Q/P7DqSGsTBvwH1p5jzfc6RRsv+LwUZtLno3WqJiKfcg7horD9Sh+1EKU/v0gUbkq1JggbDbEf8pGjKaWrQW0VS7wOBsf/VHAUg836+mmOy6l7l/oAf+O4PoZSjxMkG7fRdT0UACJ87YsehQcKF3Sg4nF7SRBP+mTwz9ymNebIXVo5Qaii4cKTYv3BKSbAZDwpq71cGKUeHoo2AxDkQ1Vq1S3BFmQ13j/CSI0iA28ADxG6mjBMtITUh13knrHU+v311lF3RoNcyJtjLT7m3ZgLF0A6UjtsIh7OeGhhFaUg8KF2Z1i5eYC5d8ORXD9kMGFJuHh8/NlN5Dmv3ELmigQ5sOSFF/7KAW741BY/OZkXG4wCrS48tqIhI5lxGwpJlJDUB3JT1nLZwKkur5O98gPG/zFpRC71sUJVAcpoh0/8rU5gOg7gfPBqYz7OG3UgmKKIskAZdT6eygLLwQy2Btu3xVUrCbQEEH4pI3HTS2kr2+SU1Jp7Mn9tRVRpjCYvQpjqSX8sLFy9jbM4XAPGzUGXg14x4cUDYCsAJ+fJ4EGeNWzuiKFW5U5Ir+cnshr8hW3eLlpI/er8jHAJg+nGs9aYu5W2gd1VhcYui+TcolyBxH8AT4XTIfZbOK1v6JOgLMEVjxZp4DxV2MQ0lzbhZYTcLx8Tl8oCss+Ign7vo4CMqKhSIm1scjUONhKELxM1EtR2aAXItEzkS9fB2u6bmYTX+Lkel+r7OhF3TyZlT5U0/ew2/YZViz5vH2r36cd8HnFI1WoVmjOynTfl5FvuK5vwf2lYlPAgfKm/Gc+Wx28+DzFuPwUzNuOI5Wg++DBTiJYAX6RyUgG8YSFiwB//kUCnYFdce9/T8t7IQoHVSqZphl4CniSU19OuwDCB2z02WDDBEXCxNhpn27m1a7L9Utt2LZgRxfIMw44EgS+NmcIEUlIo2DXsWXyNJCusHv4f/JpTGG3BVufmQAJl8lww46dBbMfblupbzjafIKNKKaiItFXPEQyZkOMY3cGWAJvrX5RKzYDpUGoyVXLvGcaUoKYMtZyvM9xwztqlVTtB56ZEqZVIlCDWQX9SOpRiCnfwhZdYK8noVPLcg9J2d9MncgArcxNo9vhdJNF+inEqq6adnPwN5lJaFkQCLvBBTB8yAtc8ArqjS3zuYlSc91jhgEXgkiotOeyWHp4wyolWTcG1fHBeLt/QyXGFyJ3VdrqTPfuQdfeXqtdmGkPVuec7GrYonL/hmeuoXLPnzMczpFpWlqixIUm3GrYSDEifbwHCyrgwrH8/ixKY4cV8vOe5oF4j/DBRxZ8SVE7veNde0txPIUE3a8Tg4/L5akxxRgeE1d2DBaX8wtVB/4dblaE4EqljtbTglU2EN6D3vgPDAhJLhig5G65frxlwYoawUOveo6BB7tKsl0hxo+CCRFHGNr2+xX4ToA4YBdum+RUo4+IWTCwulXBW4JP4FdCS7GBFwhClq+Omc2owjudSoUl5UrvKabFcsNGYT+JCv3he0Ea3f25UPUhNRT6irIyDwlMj7NTs1TIqj0WYW+8Nndz+ijTEziYK1FdEgdFvCuY0U+2VqWGWCqFy+BVk63IhdPS8A9ARwyys2otbWWb4FWuc2CUdDK+tUDfwaktvNsMsIbvrT+ZM2qPrtDfviXrB9r3ptIEqRf+a9fM72Z6O5zwbnrEEMTj4aZpTk8DofTqigkKZ1lELZrPvkoC7NAyfN0UlcXR0JVm5XgcPvBEn2EcKhxfl07I4hYEjqkntobP0ro8BwpB1DMOuesHLPb8DzvaUk+eCWMF1mo68Y4HYNuuc4H1deJy22Ktl1z9T9VGqzIRjGogM2xDGzpY3F2OiHm3FRn2YZBPROOoWpkyq5bg3mx4D3BxIHNNwuaIc01YmwjkjCtO9rY7yTjqZQBlO6BAbALjyPNlCBzUWwHZ304DcdfAMp5BJEFhvGPH61tEEARzKvy2D0WeefaNRMS34kCuA7ZgUd7FoB2J3T40lZ1QsiawtLBdUnQSBQcSUuSuqmQU6yUsd8otx33iQzU17IHuMvT7Qdg8MdLyXnIHbUyO84jhxk6t+++UsjD9KqAeW1dz6T62f1pBGZrw5CezjXpq9oiGOVcrAWtM6em7ULNSqklCHS/50sonzxNsYIYgsqeEt5x2g1L56AQIVD98cP2MKqiB4wETO8jqkpzXx57+FWJ2HAagz/l/MyH6hGxQ30dXuNeHwrEqufSwrHCLDVgMmEJGoR6wGt3y3utOAHFF5Pdw4xq5akd+HSsaxnGTQps1uCWnDrKMIYIP9hge+gcVJVXU98sAHJXm38J+OlKDVSEwT8IAHuX19E9H2GR69eYeIV/GfR0rpZmy90BUR/YD+dVSLbIihGD2wHjL05MODBHBPlH+lpZlhP//exSS625YDYf0H83CHJ7qrIqS83YcGyAL426aPVjqygAV8pKzylyp5J2lA7LTwlCnYc/jKN6+22hJE5C6LlkpewYA54wurshd044Mw1Au8UI3EeoVFvDCW8ZPcMnlc5feF/CUbc65Krl8/dT6q2dlVzRR6Up7HK1eaTwXEI11YuymEOrGtvg7FsIMdzqfqaD/p3DxmJIH2wkmRPL46tfoM9ESQDLbmpYY/rv9Pbffm51GHX6HoAk6maCmvPTp6ybWZHXZsagcRnQu+h5Fc0b4k4VBtHv1tnWl4uw9xnfJ3+yNxSXjnvk2qwOcfaf5wl0ToGSam9OtSEzC1BUwOQKViKhcZwA306Cqz4FW9JsARFTNXI++4gZq53EfFJ/5mA8t7r2CRQInOas3foH3iu4+m5IvhvAPJrYgMPq1D5dldZgHjhmtgggpgz+G13MaJI/q4aBl/EFfdpaRyij72PfwGRIdWNwIin22TZ2eX1AjR3XzAFiXTTqi4OgfiCDpDpE/XoltFjMcRcYJ5wlMNRvVLQ3OTkQxFPt3iL6ydxpij1QauprXpWVBk1yzPRtlace2VCLZRX6gJ6ImW4ENk7yttnomzHoJnOBpsn0l2n3zxt6SWEagtOyaeoZpWqMZM+6Y1bnTkDovmNhMY59CQObRTlmv4PW4dQTkU5nFjk48VUvGz29fPWOi2QMGdn0SbEKoXkVwyu5uhfc3W/J/WcWMWSju0TyM/+3X9jK54f8blTuoaR2gfdKTw+yTHf3awAMuHnfpuAE1sOLx63UZ/stf0TkHV2SDUa206GS/et1bsUsC/7nfDBM1Pz3NzRUAmi5v4l7s79vFDeLI9B5TD9iAHDnQ9aksM8s2HDxHJ+Jj8bEqDdV/F2487VGBQeiIEj46O52dqhXeFbbuotQlGb4Kj/prNNtt2fQHDgHoFbGvc0gx90J4glNMR1ksWdttLVRp5XqlrtSJ66Jy5+IoRRNy+2bgg/4aq11wC6D/K/A4sbl16xVvXwO4zCXNrCg6F30I/j/Yi42iqffFPcMDTxF75oQ14d8j4koceoSV+HmATd6z++NIDhkHNBC7Z+kx+r6T/JsxvZbdAwMRvId+r+FpNxsoBowkpNA/V/JAVjgsSloG3wFhPX8Ayev94/g3tcfSp6nWYUlNbB2i4Kt9wUv7PVJLQhIZEZM8/T39NLVfbiNug1Rp5mCdWfip6dN8WR/inmk96mgNyrJIPDI8F06rfoUlf1toZai0AeJKp2CgLIpRu5tH1toLKFXA8EBgp0Noedcn7LMc+l23yCPceqN9V2DKhZ3Sf9rpJR1qI7JtCb9k4RSRNFlwuuR3HofXMoqAtNlavq/E5r7mkczR3gb5g0VuZECmJeotXl47/RNiXvmmVieG7d6cfKXkx6Bl8ZvhwjeIjPnAPylyRWwo4eNMF3J5Wiw4G+e2Ba9/QWnckL6CoLnuMtM6d4tCclzB9YyAZQcIKss/jiE22N3g3t5/R2WDvUxq5uu1f73qqs3/kVP1m8RCyenndLw1r3ir79RWRVqPF/EVQxJDfTlZiIoh/5djkh31k3itRG/AR3x9avDCE4YDGJmmW9UCx9TwCvFV1FSQmVCUZKryq+ANGu87SoyX82venE1r0iGhdHupmV7ACeJqls4haKtqb+yz7c9JLui5QYit/y9wPw9A6lmi9nZXy0975k1HhLq+R9uYIRcpRWmcF7L5YQZ5pLpeOa7FBlVMXENDNx5fG/OHeq8j6NY/m3xyS9fCkIpoUTXl2inu7dsCgGNdpGjyghtSNYnwfMe/y5ok/j+dHOEvuTAwgj6tRm2H48N4M/sUdgNfjFPpT7tCBuV9g11w/P9wfFiIXBpv+yHiOVX7oDxD86ntlCI4R8EoTQnxadKUD+jE+2SdkB6Sj+mDEBc51S7fvrWZEwpU8byvaEBY26BVmZ2OruXGIEX3s2Kj9EJrm3/6IhUMcPBO3tjN9llgw3UuauDPEvUBEOYeBQbXAttQLyAey6MkvFI9OnoaFhfH5+7Wvc7tFIwLypQpXG/t2ieUC10Gx5uRns0ooBqJYcBnNNGTvMQJWyd8301KYFKxv9gxNJge9315oMrfdEPvXjFgyZxMLPp6f4Q/PgwVNQoMo03LLnrqMJi88JNsKPs0J4EtFQ4uOji8S7bEBavBVSMC+zkbGpHRU7JW5F/YiosNlLS1NnixVjcFtTB2cDkPCBODXOX8VHGWWmqcmzGULKaH7UZ2vdhZXbi0ZWCY+RBzdbCV+m9bO+TJPLiFTisFOJOREAG3vGdaD/e7sBXqZjuMsFhb34MlNrY2yrX/dKRVtJj9Detv/U3Yw0l5dmwf1yRjaRVsr79B/LyERfPvn4Lvb2LxVpcDzS0FS3/50bCvG+08fm0VdSnl6KXZzm8Lgy+tGlDUPVcdqbYI6CcwzNgKwGv0DuuFjBJqTJrLNTiBBwsKFNHA09rtkSTVLdS4QW9ii9Er8hY8bmPwp1Ddiwizrl9ClIEMTjkKwTQSZ//Z/x93sxUaZh/K2d8KMelqgMb56XR5M7nzcm80aC1JQ+sBrFn0VXC+jag7YYSrd9zxfo/gCfgBABIN7oR2yWQ0suIhELx03ThTYGAKQqdiz5Z3AdeUXN0uplDDPBvsTT4Y2/N2/ISDneFszmrp4HkGCg0R9+huzQ89j8PEvmRuk5aGIcgmnUJ4K0icx0ccWrmz+kIsmK2nnuTRon1w2naRR15t9n73NWhkCaB/GcsE+/KH0yXMcDIJSNUWerR12P7qHE0aiZMCCLoohjaVREiexInZ8Ys9sDYErhIKE9LDsi3Gn0xAP6cIQ8LIWogv793B2bd5w7oXI95+xSuvu68ukwoA8nvK7YnGFTC4/XGdpjOgM3Lt3aTnI6SSNkuyDm/k4t7JbvvKzubftJm0YKxshYAIGGugqlWasFeDUN2zFbvOKFQb+RZ1uFX+ZcKsFOM1aeCdI7QlUFZmEDLtcxBQ23yen/Ac6rAfUC6/3ZKku/s7HY7S01jCNKIcItlvrNbAvqQcEApThR3A/Etcpi328GO1AtQCO0CIH6uRNH6p6hXd/hc+ohskAwR2LcPoK9bfwyH5dwAJpVneCwdN/XcsECwf5AbHbv/NW1vdQRVWAOQvNhdvaZKkUiaPTkReuYM09yecQL+hoFk5NMFeNcvXRmYoU5viFlFeNkcMJoNzwLG6olvfqBQNo8/kBMwvp6O53tsq5O9JcQNSbIHG2/FsMrAmDkxyw6HrF0yt35YHfyo1k6tysFKPZR6LJeH1A9PEhBI1Vy/QKH/H7DkXtNynYoPFS59vD8w6Q7SQFOJ9m40I/YD/zHBZ1/+k24WSJ88whvCcdpJ3PnGFRLCJ4GiGahW84AB3RkHi4kJFOg7N7QZlyBvYyzSQGlmNVjIQhKMOevcyyEkAtOgcESOCAtsMWhZGHVsTB5JMMg+YWetvMKxbyqYNFQ8s2c/WCpuJDq1UjXf9mdi2HCnEvdVzVBGrAny4HmaDVJ8rLsUaXK4FkPi3CfN608m74rZs2yVsehZ6lT9QmBWzziXZ+arKVkCZDcfLahizPYnF4CtxWSLnaHeY705ZkoT94ciHHUl82hbnItC+vl8+T/f23WONXA09JZfj3faYqIG/15OI4DS210kcwCMadqvcFeQu7KhReFKxIxoTZQ4LNsI+3yeWY07VNqSnPHOW7gYlGFrkyQfHEuEvN+uoqkBJ2UO9QUIlDo8apRmYVkDTk6XTrnkZ6fTRtGPcX1B3Bg1B22AEekvUYlbFDFqdmaAvh3Jhn5sVv6D6hHCGlIM8ZR1L89mcOJHs7v5O8tkOrQLqo2yICmOLZJs6vzHwDPvndyA0gNILnb0KUVbBH3fTUxu3rpP4ojFZyptYt9+kmyKY6ZoqmwM6zMN7ju16dNsYCXLi9HlEUk8nCHRBlNJQxZfMQnYfTmSD5qQpN7lBTlbw68vxBdag/aecZMUHYbvGueV2bVj6x1riVfphjWnW8gOtG4P2VeiFIDfuS6DxLRjdrdnBolaA+qw2FAIEkU18lbJojXZPY7YEZbJcvtVd1JqssDao6Tt6A0oncMkS6H1C/1B2hTCiylGoddgHULpn3gwy22mCOAzID3oYq0tgE318qsLAiA6cKIdscE3Y1i5nEbJZR3zVY46WwamtvYXAHjwymHSnRMXQ3SxlvxZ1sKEqDGI+RrNbULusXwf6WdNIumoiEADoBl7Cl3aFt4Iutycnel8bdKMwDaJbqYr9mo9nfw4JubuGDNmOajQWBcgv8eQs2bt6VYaQbU65aKKLYF/bDw3/dY5WcDPQcESUAdlKR1zsH6+IkvqfFl181jVOCHStSbHqtsKjL1w1T0ILgv4AVSmhCuIrTYGNSWWPWIYNja0jWDQ1pkUMMzkaeJkyqkzMdQNWI226X9+U0KDs85IORnfXctvM6s+agnuZ3QsrrCq17FSGaOY9ho2YdUQQE5d/eG/qNgT1WEYCtZxQ595Ga/rTzPJ7frUJrR1aFs2fNpbjw4ytJYH5xlyjDH9eFpcykXVWhJKFcyNNDv5MbF+CWJiW/HHOkISctdBR2hkdoy/K7cA2wtfwyftD66Jb1tvUqdXk4LMxm9wcJR0tZrGTgEVE6z2azllbNWZ1gAX2wTzEVEesQL6CHChbg/hwxgdGjwhiPQ0lbaUvfmjEZmSGlXVN9nN3OjYw2bxjY6Zie5at+0TPJJUUr48rmGab5fB8f4XjirgV7TTtlxF4cZewl/Z1+Ts1WfKe4KgoswEBTVhW1zPnjbKhLGX/txVDi8P37HWxqfCQAoflPU2CnzsMSJy7q8d6xx09kzjoRBvq1HHWTTEt711Za+32FBUdQgKKx28yKxVWY7OZ5wy3lM/pbmuKgS7jb9PMkHVgG+qEIZakLeIp5QKOmlmaGsiuUhOTyAKFXfX2wvW3ya6AmBzo/qxzfvVmXwlqPw8hn0zDBtvlG1wF5xDU5ke72bT0uTlTeoXnUIDweuuxzr2WgOaCR0pIhWgUuOJYHWoGjFdnGSWNL8vIK8zXn+T/CFzlulIsI5g32NfR056NUp86eDXPQpNIxOIznfxHb7JSeXMsPpVg8G/q+1jhagiOobQkw5trQ+DLBuhWLhbZJIuN0In6n0XZIU1IglUQ2B8bg5cLFDn6mg07HaljoqpuFxP06h8DBg4oaq9nqC2NKvl4Wk7XpcKL8o40OMCRryrSa4f9cH1cA9FQR9mzT8Ys2dY6A0S3vmnDKfcjiEdQjF0rnoI7t2ccyxbL9vK3K9HvXObiRcXmv4FCDP9ctBCXBOc60JPy/UJ9PIbel/07QsyGd2PemE4+nbc06ceHHA62xV0x11M2n7vrCjj3BA0Sy2QcBlkafhdDke6SqUXm6Vt/FO80vtuSza+S7LZfXXP0/uMyVuo5dQ9ToSyL1dsA+JyKIqKAEp5mFmlWrzXugY0B+fKTTKFQIj6BjS6epysffMRm8rKXAD8ZKM+dhKiQV48aFL1RmoCkQHkbZLkck+dKLl0Y3nDSP1+cn3c/XHDBiPdcEzNU1ygK3WBxwTHkbbqkqbgM+/O/jNWs5iZqdxlE49OCSZuC37Mfuk3J7pMPnZ9y5GgjARDNs1CFnKAvnNnAv7eIEkmS9TkyW9glcFJBXzbuWbmjTzkD/dPVuldp1C1xnVnq24I40l6ksj6JGedx1+OVRJjzao578vKQ2UoQ/ZOCFCOg52ZIeVsSJv/N9iCGpCvmr3zNiLP/yqWkF20BJOir4qb3NocGCRwEkAihkAE7RZmb+UcSX67ur1GbDX9Y2RwuidQorZBQUQ+uW/gFpgtLTF03+vMhFJvDRAy398MbO0Rdm2lyZTh2JCpUXallaEZY3Y4AZv+Oxc77MBUgmvwkyxmAKTMjZCkXCTClfsj1u08MLXqD0EBY/I4damGcaIjJQF+UZ5UVrja0IlCihgiXZFOTLjwnHIgZpmkBMCT091j4IVoGXdYG3LsE4Bxepjlu2eaATufj3VuKX9Qd7byAvncInOTebbJmYwNEoy+hHu8oE+WToQiup+n/e0UncvKF3IcZKwA1rAGd+9zrs3szC4YJ6CZ1HmTvwkOULsvDqT4p5iaCtCwWU6vhtZuZn432BftDtN3lIuooOeWyddixouJvtkmJBtxxXE5Id+M7q6Q5UEtochyzGC2r0V3ndVvlVXPHmrdEE2jEUR7PNDPtcwD9yBRuIDHuZ9I+1rLG/BC8S3+Fd5I9qLg1yu8Vu5QT/Z0kiiKVfTt747/g3mATSGx3mac3XkShfpAeH4ACKqM5TKwtipgaDLRTQCOuzzEEZvvfxotbQMu7xV3yxiz5o9NOA/qGq5SuI0H4ApLR7IyIyVSqlAXwIO/NErOW+Bwj4/7tA3MPE6tbZJiOaRDWHiELAM3anshcwr+/ARMPZLUHADniNCmpKV2jOKSyi8RmTPIbBxWLfoh56avTXUEGAhLa4nwkeJAxTLtH98J6nu9YYw2wi3hyKuAVgeXeZgi/L/QK7l9jVkNbjBZckSultgEjywZoH12OaSHACBRp9gR6mmBlv8/iSlXMq6l4Y+O0zhmasiVX5gVgjPOwckiXWQGnlMXDjxLxgrbZQMcHNlltbcrQRnGs4uE60OQMbiUwdX/ThdXqa++33NPQ9lS74UtXkFtd6zij8DwfRBrF7f4g8rug6Obtz5p26bOA0JSWtz1jHT7RDUS9OnV0vpQL8sV99cPBoj8075wHAmBXIsqjcFvplTJWFv936aoEoUjHADsffBEYI1WUtaVUS4jTtY7tIJB7U5zzYzpYnq0rnvMikXB+dwfID7DRiOCUmP+gQBg5q6GVl9SbiuSacpHmGoGrXCYCS6hck0k+YbGpkbtr/NASHYXtYt2DYZkWZJdi14BZ/wquT9epGnYofAsQMVJlb+YmRc6INLBxuA0bSeiM34HSswRxXzb8s7PFMj/dov8TKykfy/nzTjvEnWsOEY7Pp2TNUPq5XMmzKG9G3s9JFxoxbeN7HUo2U4LvoY+voBAsx6MaJ/WtDS/GFiGxzvfJVtJzr7MNoZ+ZPr1ZfNGecLPZCLP3QrpOZiloZLyWOF/IaBzlfYKN/qrxZKtRb+4DAS2cIWjRuRmEz6vOUanMXV+/m32+sC2Bq8mCeum0Gs9d6AKljAHC2ia/ua97W8ziRJ5b1in9Wi+pN4emScird0lzsqaQHzV165NbxxPhpSP7Dup4Pls2KzWlXODShv8N6ieeruG59dMZVRmqTMh+v4R4e9s5BYVwKIxLG24p/nr5ume3vpEBZtU/e/n2P03H9yIYD7jDieJqbVx8VMaM5djkO7MoJccSGb9lffWEbRqDOPC8BZwejR304hAEJ+BjEJoo8rAUGV4ziJXLejaoyw7rnrRCchS+pEJHPom2+bViOCu4S+r95NgElO3PSiaWv7F4eGvi5fAb6I96bQX0kI3pXakmuHb9QgCPbMeDJO7kPOhmx2DVEYQURI2k5P9MNVhsQfaEPctUQu6qKk3bw591FdNFb7dX2dTPZQvi8RoCuQlk+O1ywNKFzqar2hl/MCpFt+KUKxXbjwi17O+dwdSBr4YHrWIAmJZH7vUjDJJi48xdUlpTBc0CAwxK+6fE3siAmNSy/xsbho1jiIM40VOmuUhjAGIEmFXUh+2M0Wemlkxl1hICCex03280ypiYNFDVVGBwtVu6LhOXjzZm0fOHG6a85SQHGczpZM85fQzb+bgX1EIeuS5rRWzJMm/2f1gEW2SrQiQCI3uyKncJe12MTDpX9PQZHLUZddP4RVXmACgbjy9QkaUKMha19zy2kzYwtt5diKHYwelTvZf5HfglgavuHQ68BXKv6jAGlzYR19VPm8PPR1EYALNmqIaId9j//8V1uzmKtq4HK96cmoXhU+IQPyx2dlgn1oTbJpJvqiXXBtAuqut7gdBpkEOoflpjVUWLTYHy1ZI6P6pFb2qcyshIVtJQg3o46lf8F2c/v0Wj4p9/Cupcpsp91pTweXerCQHJHkaxHL9zQA39OW9Im5rMWIO8aQhfjxLcYaC5SJJp90YYdAtQEWndrOIrm5hcJvuV19ZUtNezXcvLDp8lpDlYNOK29PfaFdzrJtVHDzbv+o6Np2GRdqcAk9O8xyN0XqjF3E6vD4tFAHuCQEP90R2WhLhzVqki0v2+R833IUK6O89+T/tkvsrQSiiNAa19ptcDCw5mn1qKKtkKXMZG5XH6A3ymwWk6cYAGnTWTgIGJmBSG8ARY+hc+YmueSzmSGWg4piMRHZvdnZ5EihSkESsIfXDwe8x5SuEmGb8aH9CnYhp+qHfFeA0034f3nCN9j6L1wv7WJoUQzirKVNud3dDfnos9ypGQx+g9X8wkU30otu+9MKlHb9JhB6NpOwJrxMe84RQpCpT4wniB16S0SZmaZDm5ARgM8gta14JkgFsPZKwrJUL3xiL0fqoDmxB2PKh0ru/MhQaslzm1dPwQ8GKwO81C+llAd3nr4rpzDOU1O/5xrV6e0Qi12QM3grlVRAtqKqgRKD4kIaWl/DQNv2UqrSaI9HMayik93to8g0npyhdd75Znok4vuXO/90E1uM7h7NWqAgP9KuCFg+De/5PcfhvP21YOE/AU9la63ChzONVCtumEKnSCTzzQW9LmvcBnxFVyTIIeXdfho9ttV/OvY59Hnpn2Hw1Oi+O0t32zK+1wxBsndhw3yWR8MGQSK2xq1a8dOrQIVr4pr92WlX8EtcxNvElSb04snqK0ZMYg+WKWnuf9Q68eJFSacnrGYt3PhM9kgfZ8BntXsXknCzG1b+VDjIb+fKpluCpQmEYz0Bklk/BpGX3Q7p06TeIbQjVExZyfFDeJmCkv5b8r2hjMSbqJMbcRkQli2hqGvjDjyZBD8TzI5nq85EM6ls73RGTXfz33QKGUevaedZCak2SDfu52hCGA0Egd4hz8WN43zwVDIHN08vegW8FIPbcZiuVq6XCDpSVfZrUqcQ1zO2XM3Wsckoc1V/qeni6yWckdFqrEOaPXpNp6cnaEfa3LRoJkbYhDHiLUkhIfQNMMDCQXLxzRRH/R/5Ya9eaTXb+88mKzYAwrkIjUN62jCld4iXHID3f2VTj44IuSQAh+L6pkvoMZDAA03DUItkzd5DZJ3QCA1Ybbw5inB5Rpx2HVNhUE1hi87dhwJG9wRg022m+VIl8bUNN28E6tDHuzV85bZuox2X0C6ZZ126XDdrNS6rfZgfvpkOPrUQxhEiQEtvQD2pMcYt6Gu590Fh8ZvJvjvXn+RqdHcJ4ah8ArvQRhK9kTmcv4WSdhTN0WN8tkzhUENWSiJYonHcsHeSqColRdeCwIiGyOMYA3MBi5UqB50vEQ4OTynTxmHsiu3HJeJFmqeQ70Yv3/n3/Qw29pErUnSx3rtfZCNV0oaH1ZLEx1msi1C19DzkL9SO0+8QlQUhcLTWtJN0CoXDwX4UrOVuWrL4T4Ep84Tu9TVA1yw18yub882ILYsbWfySsihin65td5A0dHiQwPlID/vLfjDN0Q33zID5BSU8LX2UNlybYnJBKX/Eaf5PGTY9+Y1aoMeVZD+/nkFX3q+Fpa+zu2+IKxpkriWRx3C+1nWJtYVe93lShJAhdO/eROIoygPQwW62WqHKEAH13kYgXwqd3wg8Cg2vGj6xaIokTyfFN0wVXoANSqX40a6zu/ad6JGgJF6mjVXemIQKaUalNbsF4ptcU45U2F+pm/+LTfAzAdGf72vqJijTx5mgNOxhQqsGPsQDjKQpltRg4oAToepo7VfLUP9NelJnP4hMrS2rvkO7Gzqx08j8Fu1mC1Ia593tMlBEUuyvlC8Pz0nk9k6sikqv+d2OwlRcrOy6jw4/U4d6zIAsCR0GEJtxBXsv7GRUkrh7Bn7swL9N5HYYZe6enWHKN8agfPi0UlQVJ7oVermwz+XleGoAVKB+g4rONuO62BCdcarEi0hN+3J4BPSfV0YBk6rh+Y7GV6yoKFQ3IkdnXNSf93LAaF52eqxw238xyuvLLPpU+TGXVDc3tWGAe2VBJgYV57J73JspzmgNIxxQvr4mttpncKMfjhhJYR9O9aNDVabmM+oROBujNI9JfASEEO1tj7dXB6EVuzX1ZuklrjkdYuRor9t5yMWmmROXqeBjHxNl07xwW1inZJ5MyxHe2PcjD3Q+NDd0HMHaHAbWBcY6kanTsdMLH7W4SDpoAgTOGPd9SawRqUenhM8PkTJST53IwJzT/Yyst+INWnT/nxQqqq8zlDjcNN+6YRXOKhUhPjTAxXWQuce+60JqhPaaDlXyAfZAkSvKzhDRN2QYp0TBCjb4KrGlLbGn6tUtBafDQf/B6jzQSGju7N+PauSagY+arRdYGbio2SyUl/vXBEfcD20FDe5ytrBoCQDZ3c0SAb6IhOB+kkXkZwWW3e1+gInI08xsN/8fvDE0zHPJy8yL6UB6P+5kZxrq3fTa3KkxLMB7srEyCaivbQyYLaf3qdRFYmcJ1Q/2aKmgYd4IjVTakaJ64tvlR11W2JUWa1DZ5D3kSxTDJPrUY0ZWeJ5kM0fb5oZXch7VhvhNPK4tI8JvXDS5Eteo9gQiyBv09osbNZwfYWIWQYqrUxLedwycj/0LXnjmRuEfsinf6DsX053BvjXdryAR7TbqqBz8Bt3i2HtHFK6NRP/EON51UWjd8ST/1HUsRRP9Ln+/GxL0tJSLi25vMicD7ccz7AGmBSynT2AyANxCPd3pZUzwTSBVq4SBjTdSsiSBYv8xvfYPpEGx7V18f1Yzsp25IvvufVpf0bp+JE1QquMHd3s1inNoQZolvwRFWGcx9wfa9q07TrN9edHTwbLDVPsDA6TbXeX7c10fCT1nlYaMr0hl+sXmndmZo2joybhtqLzHVpa/+mSmIuLZmwaFILoke3ObTK2diNPyWHWQ9GHn54VvbFV23lyXwLvRu44om4/N7hhn8CgrshWOwKJLw7fI1I2svgyqgnv2ZiFhz3Uvewj8vao26p/LuDM630LY6yU6Dc2TSr9DsxO1nUyGkFGt6EVVPizKHyqT+dXqXKDrWCvJm/kvIX41fUoAnWSCIaq0v6SX32QT48P+RqRXAGbJik9xE5gt8hYrMvLlve7EmGsUsNWu/CfVbN2kl7ErKMJYnnX+/TsIbZGgTRLjyQ6pzcNZOcwC+2fg2K33Y7Rpk+Ml0nV+dBNLtcCJXwND2VPKcW2zG/OENCmxzT0IqLw4qjS5vWDZPpXBKsbWsmitp7+EgmBeixKO//Gf538nhF5XToC1gFHerrlcXFUBRPUFvPmTpTNQdP6x06r1WdRtpUzvAht/ZiAn5C7kybRpkE4HbJDpVSVb+so0wB8m9NFwx3YIzWjPqSCrxm0y8qtz2ehb9/9IEJDBwr47qufr15L+6gkqiGYRzIAZFs3oEqFwMjfgKQ5hTpGXohXIfkLSU5UTe9JCl1sUWDpACB2cBwhDmCXb3CTYdxC9G8VQ/xD9wbAuMwsUPW5aoSQbJGn4NjcjNL/A8fJmT11xOSyWHWtw3ZvHrsRP72h6obo2P4j1HmEQ51QEtVP3D1u+qHPA0Ybk2dRVgOlJtxlMLAv+zAPz3Y/bdxiRA28nenjn2au6WnWQZxNofdgXVPeTyCZPv/F9ModAKkCN7w7tmUvMCzQuNJMEaTQJhnpdssj+r8TiGZY1FR1Wja3hD4yjIqlR5L8+cC60t2SKSSP2Yo1P15K65JwkuhP96pBf8IvNAEzhoFosRWAH/Ii6ZLP+2oJZm3SvUlIrsFLGlqWciux8hZzLzMHwsfOFV/1E6mIS9UMJhu5K0Orjj1i3j70Y1tU5p5f9CeKFTGjrfRrKQoekxfoBc9O7SxsGTrCdY3gdza37BAexFy9pJBdZTU5h3YD+edjQk/jHxLcBWr8S+CdyRrafTQmsvMiN9AV8ooPanksIFSQy+JmjalncvW3NKifYK8OBhu0bjKBd1/i4mHl3WMgRs3ZGlYk3atWBdfSY88EP8nKuMHawNFDGxU1Hk/8Z3A7zV3WKpNS9Ax9Vww3auYr3/f8mAWgMC1HLZTvmaCjQUYOxwzg55p3u5J6yLRaM/NsuSFatUGT+0qY+03jnOszCQbFYqOThremZF4n3gtTMLKyJ+zy8cwl4qMRaIDGfBQy/9PsU/1sP53QggppAvCTTUXlxIepw8fj+KnlKIcnS7aWV6KNqyiIkrq3kazKLzjQifW8SATwnQLT2YUL1HvlWSpcoWElCLRAfnvd6Yk0rOMSo1mYPm3vNitOYf8b43IrD0w11cnPVdJv0/5eeIzbchXtFonjPzF+ZqmvXjoYpQQkL3OPgOSu6ubj6420cDHS5dCPepn/pD94V39IDfHAPhMoB6nv9mxNQRL3BF3p305LIqi8CI4+nZr8769nPoIAy7gtY3NPf6H6kAahwfiUcPLSb8r0RIq1U7mFfGv2njUAQkt8kLJtm1MqUmOSVfCRKhIymBBPOzSxBw2UuZQyEFZXePogaYuJDZVzwawEfdoP35OxTMWWQPQeJmaqO4UCKwkXsGsxsJwZKj48I65627cwjEIlYXkk626HTWgMSxM7C9Rd5ZYy5gYby3yJaz2nnuhIeK98ErhBt2IlLGnXhE8m+v4qxhLl4f/32VQ9ZMzO8uLYJfkZeEl+zhr+zMtAk/LYS2R0dmBsy8WJfBuTBcicDiraNHBhmQoj1HvAhTIoRvqDM03KLZsCuJvG0pfiHfCk0MqfqiwH2TcBOn8U5n3d2vqAPvEdYhnAllRB04aAZzHUpcoyhXCnqHWfUcoibyBbFOyH8jD+CjQ8mWgFJiJKArMDqQ0DTrJCaC2eeTfziPHskEZwfpVqmKQ0iIUgTvlAnbStO6LRaLK9vKGVnKh1kydsmvk5WPV6ZY+5dW2ihc3z3Pg4hg9VZHyPi7oe5rIWZeonxq1+RO4N4OUbmGvrJN3vzTTKqdD98jDvx0l9lpVGeTla+ajB1e+w6zQgiEphKkTddhOACXiia6C6xOkDWGgDPjB8RBgX+IlyNXVqYL4fQ2Cy2cUnlmEeuKGtDa4ljYIr9IXn8jfUTLybMFpR7tuh4IKnBYStgfUX2draxB2kOmCqEKrGmDd82c299V/g5Le0j7kgid90YsaX9PSbQl/GY6YJF31wskmF4R79SQhN+7FujfKNN9fpiF8bZ6o3WmTQtXstZBZNrRKCFbpzv+aWj5hGfPQnZloadTrbAGyFxPWLncYXu+bVZ93cZc09T+1GNH6sp59m1uGyk5/gSWYCNSMG0u49F60745eXctHO52cXpRza1SyH2SYgEnt66Dnje/8ZpEqjylXAdWiNngfNF+MTh4fvWZhShmcz+fiXAfF5rAgNtiGWq5Pn/Tvn8WbdlxNJ9hLjTAzssRC7/qiFdpr3gw801Sa4jV8o3BrChQergi6h1VzRR0pBjhcmrBDNpjVQxQmfdQGh5zfvBE/4aQcbAZXKsNWryhf/ndKA7jfKDf53aVC9YEdL51Jz9C/k9563rhvj6B31XTzAF7lN5zObAegKEzXphLSZLYdiLnK4m9QnIOed329lH74Xfso9nsem1HjU+ewhnDiaadGXng6v4tnp7ASqSmxuJEHAv8KscyUOGGVJSjCnMKiWFbl1Enfp9mjPy9nxAL9gkKv9jzClYBt6X5Vxetq0pWrEY4Lu6p7OnzgScA+VEuO1tPrnCGREsFiDIQvM0+8+Ju8Nu6dSCVlrsrxgL1gcp2f0gXgOLIeD5ZtCVa1lNqBgpwO7Z3KF4f6LvFQYeSDTh4Ry2ftYelW0JCUaa2J2Iy8rk462EsH5riCWZynMIFIRkpeke4u1inT4zYpbNT7imOApBd5KXS6mjJcrGZteul1vQQHqvcRTZZlncRFTxuSwUEbOShHdMMo5o1QOhX2glwUrhP9GExvdDyNkYR0LU9XMwoO5JY7XEVItbLzwJQ425CVxKXE9tBGbWZRL8sYzPIaY6vfJHAvlzWCu+dn5q8YPVE+PxpaLRJ1TNddXSo3RKDF4lNAwtSyhMfz51UXlwGoEtGmAI6Uh2QnSNjaHSyFOvdOn7KS/vJWXgT6adN+wEk+LRPTPIWFSnPysPLjo+8X9CabGqsNWcduRHWYUhPTRGoi2mVoG5ky1qpC6r+KkASdJIz3xMnSdp2TNfQP0VNlkNRS8Ky9KqIMqwv/4K5lerl4SHPDBbmCN/S7bU49MycRkBS9RShP7WBkhhY5Xt/GY+qynE80l1LE2mCILa0FkTtAM+rohXru6JcOvZo5slpxmOSF4V3AQxihDImSQFjxvR7TH7jkKTuNAKuuLKHdM3LhIXsHyS/0zErBSrRlZtuAOnAnrNNhKuqbgd51P3eIdZiy75B9t1+WqQHCmP+9mtf9DhrpIYy8rhbf3pedk6PeQBnhvWTRN+lele3s2FWmevIzBqdIUotB4rpSd4oFTgGnNvBN9FiCYjKhe0WJ+fkfKPUW3iTmcU8kgi6zkM1OeNpHPz+5kH34WR70RsN1mQlsQociYZYWjRkxcjz2dOSe9BNsLvT3SrnmR8FFz9ko5j4pjwPPcTF/EGnRJsEOeJCa5/AwB9+r/X6kU66b7tpZ8KbXz8UNcd2B9EWV0Q8Uo3+wYU7K/Oj1vLMVSyjdQ2/h9VLWp9LR74URDWyks5VDNK2qJlvvne5EtP+TAsd5dOJbVW9d0pJUh22SZvKGzQ+3ZPDo5ii2PHjUpGlWgijZDpC31sq2iUoOG2JYdemq7jT4MvVpbVUwH866l4Gr7xJLPzmdoGZqNj9rgXm/fmJ0J1K0Yq5s2mdNfFl5MjLc7uiZtm7/PBIRwAqJE8jq65D63Rk8DgKbwnYP/aiF8oEYV3y3gfBt9/VqFSNxIzbIV7WAvMiGdYMKpPsHKHtJGpxl7my5kkDHePjcXvWqhUwQ4X1zAie8tb7g8qo40caK5xYSuxaQDSoZQRxrzO+qENAeyMa4Y6Gbswuvs+E0B3z7+QmPfOAAoZSPGnIeupYfuet6ax8ymf8yh71RwEjHe6d4kYpexnsSexHPTDsLQmKJFz6y5NC4UDhEaOOQzL7boadJOWTd7Lx3EiG8HczxiUKEOilXXUoSICtvnTgU8RdsRUhmciNtuhkjgQkD4P1ANCKFNUW4VZvnQdxbvfgbZrA0JO8gQYjuNEiYSegw+QRXQek43+pmKK/EC96yb8cKCEodPWuN1a6THgCiTBnTtU2Y/k+1VSvozitRJfCCrqMR4SIYRtk6p/WIHZ12ZU4Df2uk3J7nvCuY/Bvh/pKJoo6DmEei7dvbnknil1sxwpw5RNgWh5+LmOcAtAA7C7hn8lF/k6m8ZzpnBlAXIIdq/J+UVqko0GE7YM8wgOeihJTzN7bURclcpcBOc1sg1AHkN7q1CH/3XElZ1Azbtw24NWx9xJYM1vjfx9MHPBdY/ye4AsY77keqSeyq+Yv+RWjJKQAnbL4T0JMa3QUDtCzA3hjPk0jQoZSR4EgTuyXeu90DKW433vBuV9ej5RphUD2yVpaZ5HRCRl8PWk3Mlt4dWv/o3OR9m7Dqi3R49UdqkwDEyn31EzTkFIWruWH5r/YLtKQnmjVDBTogurL8Jtp6iUWqN601A7QAo08/d3YizYUZoQgAzRnFEBKdr9ij7CJz4TGW1A3wWMZxZOLmiIn1IXMDH1QMXlxhc0NvyJgpYJnTeL8corGdEQLyEZNxW1vwtK0k2mBuHFDkmDccx8inL+MvwqbFRv/QoFSTFhksQmfvQohPBSjLX+PqGTbNMLTE5lnwNlT4qpyz7YRa2rUboeX7aOLfFSSZdUgV0/WtAWP772r9BBihKmBheTJ4/yeaUBKIWTsbg6ARBjf2vFFCGckJdL/2PVWTJMcM3I+R7x37OU+iRdHGe8DWOyTy5LnH8XcoYQEM2A0jzZvkllXsLm2AtulR+WlgDKpj/t9s4XHKMV73Xvo1l0CKleoZ+CnReXHxmk450a9fUAgfhoChL7f2nvv3FQ/otQ7wz4UZGHrgwJ9cok1cH1/OU33JugFyA9imTtVrchvV3uMHha+ZGTx8caOPGzssrX0VJODPnrW12+6/+ldUJB+iYRXTNKHwOcjZqof+iqqhivQPI6kus/dPo34J/bgzIJCTquLe+ZidHf1yTU70SoDwmSFoIMbavOjvyQPTbPYyt/n5yLTVNZfgHq3+NlTwsPdrtKzxvd/r8xQggSDGd/UUCBrmOdqk1hCFqNByPcH2qNE12aYo9QOAlKXJx+UyJOGaI08yH5MjMAMhb9yBeYVCdaMDDmz3DPLc3z52nJ0poBgOmKj2uPi84+37RsHkwiBIy/mGbdjgurdzXeIVanp+/XohbxCH3GoJBUxsQksa03EExsTzNqffzqQd6JD7SjhtH71KowcRvaGRhB48UQ2aCEemZD/PE3do52++0aJHe+SN/fnNPMJqz3SQjb1K4iwntNJbAWS57sVVsM6X2y9ym6SmlkNEU/mmvMwuNQO41x55+lt2TRLeTLW2FD/Arr9Ep7lh8Tomz8DUg4t5A8DPopw587+62yrPVegM5cx0qwTERXbZblXxz/712DgPtMcilv+/egbJcs+7jrSZaCNG08iZm8IIUUY24inVw90fxrsSb31iX97+iyuo0mC+CcrydpKED41ueOKjJhyfeGRfC2UwCPAqSz9nQkrTItU58iv9na7JHOfujdtzoSse5erz0VbxzwUnMC/0CK0VeoQ2EtY9Cou6jRx0zA/GXC21fK8B7rwKzvpI7CtF/9NExkdrifm0sWlSz1jdl5nY9XKNmb6H5gXK7LMmZaNGlfUBmCDZowXwVzheKNkWwsp8xMq1abBi8oQI022VP6Fm/z1G1tgQtkrPYgnIGAVDjHSX3TUr4JPEAcDeML6eIWYfkGAHCmxIyVDpfDpbShCzyprJDXT6uTRKBMthg7ImAvcqEDPeNxj240tQw1INEMWn9iF+pxolZM6YDZzfNXEzOfw7Rnmy3eHcBeW1zqC3sQ4oPgVko6z230BxkLrkn17S/Oole3B5pyA2ScBtkBBXKrOrp+Ny2lpq9FSskcVQm6u++9ptftqDilhwwOw4g3LtUSt8whh5VbY+sRn7rqU2aVPJ1TJcyLROclluhYsYwQ570vuw3T5XjSn3mamc95i5gb/r5s/Wln33qeOM78nxIPP0s2F3LtWQG5hLPh2jXCgY+CmWoS2h1tp9nj8/PGXFOZOfBWBj1QGJftm8jwGhes+5bVv3ozJB/L+tQvk4TWJZ2VN1t3KpOqG41UpGZejjsHlo5qG0xmPQm+njyK3DRKMe14dmufyIfO1U4rl3UlMdw8VUjYVz8GyKyK2IIAe9zpmBc/vE5df0Sq/NHtD019hQ5SWs5xf3FlvisuPDR7IS3UZAsVW7w75kVpzZJf5GHRDf0pOHPLBQ4VNKvyBaGtjNwZ4POUEon1J89UOLlbaqFmZH/ZlfvnuQCthHarzZ6JKPlUDwnFTWNBSmszBSfe+2nnouxGf+u8qVY/HO1OJc/Dsht9yTS3Ixqbetju4iuxLyB0baOJliPnAcVZTr+J/kcadl2X45YSwDGUHVEBeg1nNk96wW6ZditQ+OsGLYH1JCfyH3ZqJFPx5R6hescOFAcrd6aaaYt+lHmPAjK3YoPYlOiIFI63GYQYgsLTuwnnb0q0kz0vmFoO9w08TpSGKLjsLfceM6rNx2SNjRYuRlQA5o/K10/zrFyBy1Dsb4EUydykDDriWdm8ZppjHIaNCS/sC0mJkh00biRjI3glcy5MjdFYW2tON/ph9BskBH6BTHDzadKQsf/Hcl9hqKz6vEBomEXp1ppzTczZfC+OUpC/KvO6vYLjK3nyQ+rSpx6PBI8TmZa+fxoZfMc3FTIKQDx7uerfCgq6dV1lgMIFfZ58UrTnJ+EAXAW2ElxVGo8s6u4b7drU/ZQqGRlLfVy3mJc34oEYwwSu/bMqt2RMb0quuST/7QVm4OXEgdbgVzBOxnI2W14CUBCaVGR5zGrrri1Nf11iGYnTmMTiv8ld9qb/jXaxh/8a0kNDJKfiNTpYrQb+P8tBSdRbodhfviVK5xJP6L8x6hL8WLKY48swb1xDIauTYt4ayiWk1/et99nh9FmFLkxOKCzcpG5tJHz2TzNa+iw+1X0ixu9B+0vbBXfh66KKzlPxg8cTazE/2w1KicdiEsbYENDyvqh9mYrzPs8AfpRuEn/ggqjBUeke9mdNFct0UvEAtGbteZSr7rmNkT1+1+it9z/VE0+HI6QB2TXBrmBno9pJeXvmdjMbHxuZKDaI+cumql4xXWRkIrvkyY1WfZ9c21eqJt/0T/al4/4ap+CBuI1x7leiMQs+6Ct2DomIElFnKzINZO+s2Q0y/1AStFpzbJaeQ+DQXmYjZ2XdxmoWXdXLMv2iKLUHoh3qvMK+OI3QaB6+6mMH6bme76LR9lp6+BULXoebyYUwZfFRIwcBL92/0yvY0vlAiWPAUKPJT9h9FeicA84FE6ThRyCoLeK23Z16qMtDcpBKeGDvGQexDL5V005xaj3A9o4rNGs84YwkPVB3A//grL+2f21zwCsTSdfuAfIqsw5pFvKBGyewWCh95n3EgQ3PtpCb5FOp6IAIVRIqylqRMOzJYbNFr40uo8JJ0XH1bsF8STHVUTSKiwdF1ugFzh0q2BxFZw27z52/72NDJnhJFc8Cn3H+P06rJwLJ4JSiVIg/nWNOpjPmdYfGHOB/r2g1ENkmMqmcvmjND95DEmqQulz+CJOTIHGhp5FF+FkXvoRM3NOqTzRoQ05SC92JqZhP8kEknn/5SWh3K9jcJHfiBmtgeY7gv64JwN5ptLJZFkNqqMCv67ZVaKLGnisTAmco4mEYnYKnjsl1nqoOumIjJMGAopH9wE5kZWrX0A2rb50MjSHddjTthX8omeC+lDmKurTHHuVLAR+KoWcsGapMjK7ygA2DW+IUZVqmCWjcFEJC6WFUB3GebPu/F1ZLvQs2CL+uGXr6Ck2k1AyjFf+dZGu7h59T3EVNEBNPfkOUu9Lg5NZq6pOPKCvFsRmhwF6qknK7pAj0APWOQrUIy/ROZ6mM6+agnzra5M2ia9KABtx3RWCmgZUEHmC2EetDp4pgrdiT9yDbS3IejtI23sdSh+or4KvSXnBasahGF46cUoA/Nilxk1wBr6ngZQojbdA7GOqeLUEXRNdKHoXR5j2s1BlLr3MKGIZzcwR6GGcuP6Px5nIPVylCkr+qn1beetMtU65EELYwu8jJzxudR7NHkCJNxH0aC+0liyq5lpx+DUSGoX3KbNY+iwLA5EcIYntjTpuyuAhhOIh7uEC5dIIkQwjjy+0B1+izxwVixiJmIPg4dkZd8ZsSXi9gYnjlAjIiySeuAaz2Cuvd1SfMFo67sBosCdsPaoBMZP+kOn3Uy2oAWUf9QtJgj4/A3RrTPR/tGRTM5JBGThqsOYB7mzE4usBSWztZeWOoMFLfnImNqBGakauZQjEr31pPUHe+Dsjr70gAm+bzJBvPNYX/Ngy5Cshhw4G0SOYi30QZ8T3OlKGxb2N1wZPtDCI2FmOwod32Y3dUKKI0uzSGJodFNsGzmPjdpdDaCb/6U49WYLca+rBVyg91ncEhY4Yd0ezv9udq0yrsMRCdfZEYwJXlFZ+RSIkbIDblA6VMDqLbO9tNEreVXsw8I/zwtsoZztI3LlrtyRNpi1i7HKNbIT62H5zzFMU9Uv3FfAu8zrn6sjzKBe3xOuD8r6vPHAUmBmD5NRG3GT/jVt1tAiiEcGdwy2Qsq/ueFLsFHEN3SeSCRhWlIC/aApPeE1BPXDTzzpqQ08kau94Af/XsBDEithenf1jSwvirgVLkHjpon+MTHWAIp+foR8BrBZEa9Mn9fkzwEweumhyaGAsiDqoHVfxg2iO4/SH7v2NH7A7bOl1ZUR9aO3tpzFQo9G2PotNzisMOrdJ7Iiv8FzOZ20amvGP+e+eJARrYfEcpw1E0xhjHmMVPYf0YU3XahyiqAXV8Sz4Hrrx5YuFnBW0kWx6DNayiuLjTKUabRoFT13WRPcDX5NWeh8fpLug6YwP3ox+2nHRZFOOQR3DPMRybj8YPHbogHxy4qS38nE8YTihp6Aok5sTQDjJjqqW4AXRTaDzVFql2xuZIuVJnw7vJllX2m9laKeQZ0FTMnfKaGrfLejRVZO7li2L9kS4elbebZVBcn4BquFhzeNGO8qvR0Mzc56/SEUlP2udmmJV96hDdi5gLnJIed8Wm4D3gm2z8/k+RA3wquG4lo4DHqWOX5+Wlvz2pyfOH66X4mM5tCJGvIb7/o3NFWoI2qoQaG5dvp34yIsd2Olom1yPipsktLgUZsJV+U+2TuxtzchQ0rt9K86JNopys7YHpgaAdBfXQ1gI7KUZdprm5AUzMNh0DA2IxtoHFtFumMu7yAB/f5IW/HHrUj4odmWTqzUwKBQeo6GA6wZ/D0GLbA9htjYjcfA8xFJtSsOk+rovYoew0y/ARoahKwSFGKepxqLjg9IZdfJMesAKLypULg/5e13hFV8GnqPJDR7cAI2guzyJGiYs7or4RqwKlJYtrtNsRipJCFFml4V5hjAvaGzCpWJLlUSHcIQyf8YGR3nEECSH+zNIwjXt0oHn0MBILvb3Y37Lil8Kydhy4JE1DN6MDV36oDj6J0YTwbLZBuFEW2zjVlZ8td3HVCZI7g+3RQ+wfG/gCnC8UAdeE7QdJhgTfUL3BE7HGb0K9f3EBQ4uHsl9ZBZyab6FDHFGzNdefYzMhNFIxNr3wa7pgh11hguzO3fMrAH9fNOWXC667jnBG3rNuVJ6FdneF67njV0eQgmXsWxzjAmJ06H8QbSlNwJRCy+dE+Q5CNnceOE+IUcuv5j7eyxE2EaNDyMwC+RrtF1F1j1t58U+WG9iC9nt+rL7VoZr8sD8QWMGAPuuEzr4TgmG74iIwx4Ij+nHepf+beviW65hx2KDGK7uaxOA22LY1g34pa/iOqRHVa8+LyPlMUkzd167fT/Eg8+pgavg5ddxNEsmF14IFb1xqXqoOibrM+RDKAVIKXYPcvqDQGq8RqsAzSlQO/jCizsVgCYx4GJOr475vgAPqnBiPaQUxOGlKPPKMEtT6FJPF4QLVWqrpB85SCwaivoYI9cKRWi+J39ViuVKUEkCzQ6tC7+6hav1lIwhRZksr9KdR1aDiO3pgEEWlpZEwRPvh1mPVKvpf1E21B0lU6F0jU6JIr0ZWsI4UUe4tvT4JXRxfBXPfQfK71h+RYpfTKsPP9Qn1IrwhristlCdyaLP1lXQdbJ7nR7tLz0SigHrU/wBu9sX/aobcWn4mNZiWzzqCp3dhck2MZG9gQxyabf5dSCwZ4yqaRnWMGl0s6D/fMY6XJHd+c/MksrDRAWAuVGtW/pxL80edVZhW0sfMhzhWfFQyg3ZNxAD+k83MupYL1pIJYh0LldNEkl1EKDVJeIGYG+8N0Vgy2n3dZUcaNuG799gcPmDyyN1dfp+t3+mbf4YQHgLsglfQ5v4nRWpPkgRq4yBzSxJWatJwq/fnFMjZ4rK7Mh3EA468a/WZJXbs7TTtiyu5abVqh26Ef0/vjdiin1BYg6iA5eDUhOS0F9sfNW3z9GTTMrKWjaxp5knvUyHP1xzgv0FSyEzmbyJOeR4pdSFeUei7K7EZ/YPdAgWXywVlMCXzpRbiHPDVZc/3NjfSK7jKWhpk1ZARIm+yaSDDsi1jujw+ZozwA6HHJXedL9XM67I+Y/gjm/gMcLUwDmw2jIGY9HFOmvr5ThXSYsceq4lNLaEgi463HvUgT3aax7+38E1QFevlojUbGwpgJxAOZAlYuFmbF2BNxSbA0NO8ocbm5fY854QO+ejVEdzxnvcxocAWXrb/6zrlyRd+0dO2nFgQDITh8dM8qul5uYYIyDedTvbzvONg0BXNJv7lhk1DlVV8KHFMfMiydYYfeug7XuCqG7cP93aXOkTMWUVWUbteIxys5EvXMR2m0GhrjOjlJxxtbfK/7f6JXc8adVHHwZ/4oNwiEtKaY5Xi8skQCxLdijO4XQp6/NGmXzvSU4cUi2FwdD6006tZ5cIvXW4Hcf5JpB0CKtvnFfaFM93BvmYOxh6q/gsO4VeXJOdiaGXME/ZXjY1LihwfoGMTlfwsRxhJICPlBmcJYwNsQIXmw14iDDgOeqtY41hu3PCU8NTqClM9SyFDCJzGAv/0QM7Ibvz3gxTst4XPUYsOcT1FHt/hn6dVqA9VIFIKeas0pmVfzj2wG7ukMuOpJ7n8V5EUAXstu9DpP7YKWuBQGuEBs+Xbo0anMftZQOVGUYC+tUX5bKJ4eq3c9CNhCSyPu2f9CBeqbmrL6GhC/0KjUD6spWJAX9pHQ0hCz1QdoZErLMZ0gpcG93fm0tlQEFvWH40qgiFBMvhiEdpvo8yZyRnRnWzu4/paa76uSDMihWIs5oNM76mqbYjLkKy4oRgerkgaeQ7yX3BwwMwlA7pzUd+znaHAJGKvUZVDr7vO7UJXXyc7elCcbYMZD/gHdjGA2RLcmUSAj6WLuC3TZ6+AD0ZqP9bv09VycAoa56/AoBzDFf0teuJIzGE13zMLiVSgxDvi7Q1VevmQLwAzHvAGI5bgnQ/zOFbQlHC/MbF7p/HUFoTk9CLbZ2OXQag/HCEQhfznozDw4VcnW0snAhnPDP3e7feS/ibyGISg1Pczm2a6FKf8AUptcDuggfPU232ajBoypbvSVN/3Ile4TQKJxnYGHxnUoJPHJjlRL/xtotcXdW2oHIIuI/rGaG7k0w+hEofhGRzxhwVbRdYWBj2pC9kvran4zYjwlICZW8iU3of+N8A7v+x2Y2Fo2Jx4GpeTcvR0P+r07wiPS3L379zQ4R5bddTDtu/hBHij55fTJ/Ok5wxxkop7VwJbEeHWdJ2SgY4jEnAU+5O2MFj7SmnTZ2kJ0t2UF7aI8ZPZbp2ttoZywfnrgr9SMEMCW4ZsuJj+M2P8NhU5fc2kMV7JpW52OP4PlH4kMskkokJAEXuwHni9spt27PpQWALmOjOXMyU+Ur1ASPFTZpMEaGAuc7FrO1qlsyOk4PF6pSGV4jijBtkCZuv7bxBHEBoZlTRGRw9qLVvleYZcT9TPE9RUqAHfBm3MswUNQ8CBDgRsgyMkpmLB8ACxgg16DNVcNC0ziLmgTpeUMT3yX4p7wSV/Lr8a99Io2noQXJz6SRgCux+U2br4sD9glvjQnDrHUUI+qyosHSk/ujeqfuk1NGffa75GwRLrY2Oa7skxj2I2Zey4NGSX8cJPeS3ckf2LcGcLdJHOtUIoRnmOPW/amHDyLRG0Msoc/GPVPtOHc6mRaZOsp6puPvka2sQSBbHnM9jehnpYKgR91lZjxuIi/xqo5n4N5Mniz2k59RQ39Y0OhjFB6+COTKuTpuRCVeD1hNwJQWT5pntBjemq+dP170Nq7yARakg4BYR2eIbFiTxhF9pNO6vU/jCHMKj6VnHKDD7MgAOFL8c2NWGFoTBpDRANgQ6tSPCm1MZT6+pTMgH8dbnEA4D1lSFnQvKiLaVDoyNjTMmciJuRb7vl8YS835nfpTy6Hw/cNl+UgRE0qS0DC0REpH7ABq2Sq4eig3cEPlKBoefhfohjkX/eF7+w9ozuqAE6GoDovXmdQetogGQFP+hnjHxVYoHarVGvpbbsIP6NvOryxwVGEpGbg5oP7l5yigARs2jHcwG42Nyiu9iHc+MLOaeFRYcruZVWZ8rukADpGyGVXJZhdf+Sj1RTtmKqJIR9cOP0jQe4zQ2nU1MHmbIZf+9E4G/gjWhom82dL1YNt13km3Kc99tM/e27FyiypxBzwAMQyoH63UCcdRQN0GdhMwpIrYZm0Z5zy3bBvpqi06pbS2+/v+PJucPMklaK3arZDVnjUvSppgTB5pO/IEbYROpkvI7/g5M4g0bQa+ippueg+MgF5SV2dTKd81xKh9AAj9sH3r22VCEd0RbpZ7K+MjMjgHBqcZUn8lS3OcMRFjXngYuS2S/yWmdTzc6p1lFXaTkMpr2sJkG3NQwF5OLoSVeDJiVa5OLryKH0irgNPSDUThp63RhNGCgTIwaQAjyWjSkuad+bTdUid84DvPhWgF5i//s9k3Inqz59jxIbzQQ6dBP09uUoAqTX/wRLK3EfDgVkL917nI/+iWN3hVsyMblopbn/f+3dUhlco/ZsvQcGFsrgSlx4jSnJFgznJjKg+ZWhVeLwRiCGY2i+4z9fogC/Dc+5YQZdqq/gh6h2OyJxEhL/6UtK0Jf7iZnq3o41gWEitnr4oppmZMkUaE2tGyCL6cPSEnuYIu/ylZrSodYMiaGYuqHouGh4WuTSZ/hLWYo/Rx8vSxAfS/QEYzbRNNpFhtk6bNC2ewNfYUZ01dedAtnsFCb7kZsh78PoV/eVbtRfaXN8M5rcyIn2M5cjTuBOeg15xX9bpyIhk8N9ULRGRfd/bK7mjwe3r+F+H+PgjLMQmH1SW+j5Lh8T8jUZWCaski1wSFO0I9ZEmeDXZ8HHVbetY0IL2AN2f4VaOBMsRxaELI0GQZUvKuKydwSlcJ0oE+BmXRk5RWe6c+KYJlu1nu1g1aEUbKCKvQV9GlOPTb2KKkzrrhw+4968Jq7ePQlczHcQA/c6DqorDw8JGpvVt5QCMPMEzHSTSPo0rimmdlsaAEpccqXN40Ecxp96XVhuwalKaikTCm0ionJGD3Y63TcRiYMOU/VcdzaomlpNciv29GYfd2F7oVri6NqQBmz6BURtktwXrR3xEFTVlgw1lw4KxNpUCbKbcoY1JI1u5mjwoL0GtcZzJVSgGJQNO1XsL22P/7bcpQCfv/xEHswDYHyH+xg6mFASrABeZU67mSvTM5ICJHDVzITHRkOFb0PWGCr6BoMFQf4GtTq0Sh9lA6p/bIaYYbLP/azRJ8jtqsg6aToOkVLnsK4sZZST2s6tA/5hzBf+c3e/Zw30/KTBK6MNAF80S0Yh0TK+ltTNvbZm/dnweZrMh6HPlABWN/UKk/EfuGTKhl7i1o9Dj3idgNpmzo8Lhecp0VriqxKrwyynOHp7rOSo5H9GJIw24X5vkyxZ54qevvqsoYy8nCYrkTqQieLhPNqLBcV4ojtsGCuuDAcD7WnKHvLGsVo1gKrInNxfh6QPmKDzkkD+oz/dCIhv1N6JDeNPFoA2k4qEmY+L4R1ynpPcB26s4lM1tMBUXl/c2c1kjUR9huospBKOUa2vJ5RUzfq6wBTdDxR4USZrX3r3W8r2jsMlEfNvt3aZsZ95+zDdjqHdaW+6gVioWfEBPNcTAWMLgvzh25+yJSQc6ihYlLP+WR6tBdElofVlwe7owCPqZpLqyQYgO0xkOVR/GnoodoohG6qYrJqL3woZYE41iZ4qymUdHIp/FghblMHyy6r2FYfVevrwk9OBx9W1leFJzR0abnNQp10/tR9h1rKCzAU7EYwWFh3RyFL1bR8qjn4945zEjvJif8kQl2DkIKjFDg10/9P8YyHCk7GFzTzCLONB8glBdduCJl4W0IM0t2GlR5kI1zCT+Z2j88xTZy4sF37/S0ICQXerCIQ1vv8Sx2bZVSdug7d8SaLogcPHKH3GGujkNt1E4RrGsQHG9aaNos1RiARBdxlX3EkSxWTdxn8gdDkaWhvJJiTwSgARVDLos6Q2HS5tHsxCrX6BCRsBiWlecxMD/Ua6RLZweEAvHBWvXD77128148WisK/yJjo8Du9RbC5P6KqcVLXawk/9u3Pzvb4GWh2UedLKfXcyCdbq7Zt9r397O/1GQqavvyu3vFhu4QR/y1idSemfOH5WtoHoLrlGeKom5PRG9+QJjwtBteeoNNrxMMLLU7Y86rRh8SbWWrYt8KukFgLBRfowxaJdqIxRF/QsuXWWoWcv7WBdh14K9zPxbwjbao6HbEXVAwJMoJSlFZzOAHuwpMp/l9S5dZI7fGmWJWu0NLwX20UDBFRGc2FWKpUMv9r4XMfFYWD8BBSHw3ewz659zROQAa9R/fqPji1OAddJFaH2gmTa2hDpnTK+qqklaU4WlqQtPZ4skBLWxwoyv4nb4Sno+Q8MTWhKq+PE8wWn8N72q3098Qnn7cj5dxPx7gmi28VdWuJ+UtaWL5+b7kRE6UqUmoQp/TZonCBnW1pLDnyGHOnJfam8p6xAbePXN+fgGb1XU91DRtKPnfW95sqFWGgPgDRTTJVQVXi8tM3RNrHvaXgy/m5csAdP+Cai+AGUH+QhRRRgOkkR6Ze2mIdrr8Dmr846oqPsgF7JWKYxZENw7NX3vfHSWJQbCqszQvTOsGxVCSLhBeV56BjcR1wljc/0sTYmt1yVQ7O7lUhgbPzKjtLiOTpuDjrX9w82LT9YZAGBqfnMgguEkfOxBxJNVENlGWdKaAYs+OuZjJtmvDZHge0Kh+fhfNfU9gBcA5oThDoqUPu5cYJE12ChO4Yxw1d9UIjqcQDHmxEMXvOsEvAyCjOPbD8jx3Af51dr4n7/G/swlBd4pKzv5eaTZ/xyUyGbSP39jIpQU1QJt47RS5/ZICoO7oxBI7EvOIOc6ZZD3Kizs8fbjLI/IjVCLKdgrcS61fpBGtVaW3AxVyutHBKWqeiHuI3K/7RzpbeQv2AVbil/85xLyHv+nSLpiYXaK/6MzvBEhZecR20UQ4PVA8Oi7z16zxJldlIMCtdZJuSkSFz5Kosd83lGyafrxqFqy6yednGxDjkQKr2YtXmmsICKTehVV2wwyypI0shBaqkLKZC3C5EfKJgadfmI8kgMicuwtohTKKJGHzQ2vRh5xlCzmJA0qTMP5egF6qwPfXfpFMCedajrTLxETAG+L8E/tGu97j8tskOi7itgR1Mkdfhv02/O7bS1JYYWm1GtSO7JvEGw///c9j4rnqRmtLZreKwFm3hmgtfyjamCNl9CqZc15cPjsMXUD1Xb0W8McLr3kCBu0/DUqpDXhJlkcyPowHhn4eh1p9dNt3bj+Nqdnz7/tNW9m9hg/5z93XU1iOR252GjjQMfL/T1CsZS9s0W957Dh4AH8InyDK4JO/6R6E+vch5DvFtxAX3lCEWlbPqzArGnW3yWuidGcZ/pO3V5mQO7+D189aoP+mSQ41ZayWInDjefsAYSjQmsJI3vTwnWfBsdIRgiDgpjIXHKsVT2Pjw2wKXBo4fW4W6GBaInFfzgWv7OxfldpM3LFN7vCykMj6Aauw17JfOoYZ3sqnSCroLBxG9e3/yu08oFN19TdbAr9IGkbpK4ZpgLCck/enfcm7iAbxCEW6/8UwB/ua7EQn68zgb6kM6YONoIlk8p2YBL5ukXb00n7UZQbUvgtSVXkNuHazfQthSRaY/TI1OoZyzwrk+Ijaomh5R6HMsdG5bzqn+0GxFwDbpcZ7y9A3KyOiuche1FFis/rjltDwBHSdjepSifXD8+QibVpOI2Wat9fcFizg/R/jaJOyOoIORiQU9oviHgV4SwdI+Q527LjAV3g36T+ntg2iRZCTN0rvqQobNztBnEwdAHN11QEbiHHaziH1DYw/5iKjalmPBb4dQXdXFIvTjXWJgSFdpBTAgoG0TuW8TKn6g4JM65+nfzBEmtdErXXS59924Utf0jQDhvy3pSfo6u9vugHzjldzqgmG56/r/O3Oj6PD49rfEGGxaD9ylfSZhA9qDHhU/EftWBKHIFB6N27rkAOCnbKMsPqDqlB3oMXKUwj/vnfJ/sePuGUObOWuyh0K/XKAM0f5SXp7ftNmXrCUY3ClKMiOIFLJ4Na7skedVWZceq6dMhViZeLSzBcCUKcZguXn3xOIJRWOOVsxswOa6mzxFsawxNETCTh1InxTQoQz8iOeysPHoyYQrUj+WK6DbV1oTP66V837NzauPeII5yv0rBafqJ2q0lYEtC5knNu8/UvzRadpkGViCBxzuPzCiatWLFcoPW8/l+vvE+cAo5MlNJXShevRA+YxAj6HBJkNF7DB1SoIsNIP1AmX5U5CsfMWC8R97UGnho5OCpBplIYaLX0rl5/6fMqDxYtVfHhBlP97cnHNwa2GYae3E/WdjSlA1hZGyfdfzfDiOGaKZkabsn4b5DxG7rxsujqSSGtdwEK2up3QvSqo8F6wZBzEmmL2j+bIHmRSPUVe+Hm2iXQ56nt2N9d6aOtheU9gVKYvD80JzUmagZX1qu+UjJziZlQZhAlsj2Scck+kJ7nDhezWspMYj0l1D1G067M+8pWI7kzt+0pIenVZVPz3GNAQMA/l0Icf39RdFLMSwVb0O2JBnmZISLvVjTOofbfmzElHFkGUdCo44TM4A97wcMKzU6ip42mfHfGVRwt2Hc8CDnUmdJyG0Yvk3ja5lQuzoGUVp8+9rJhRcDuu6UYuudNZyRXv+6khQA6DBf8LSuHPEcuaGtA86rFrktdLozb4ay4wXP+yGeJG4wdN2OZvsrpnR81WblgqIHIjfUYrYX5yW8WypypXFnxoLE83Hqmn/Q81tk6YMoTQsUi7B3OmTKFPNhdo8w0b07Ax1fcgMUSWgYK4ELGqxS53byj+K0ky/iVhH69OO2xKAuiwLAweUjj0WB/4hHiDEKMA7VxATMqXk7MKz95xzdlq8PNuuhXuenIElr9xQqASF1+wQa49/O7m4JH3jNrN71mLSY2+RtLAqqxgvQMCeZ31o/46LdUiZPWeWqHFarCunGl7/Hqgevqbz0oDIjncTYh5mecTe/Mnz82uV1bt7giW5Ndt0Iw1RL6R9uKpq+4hOScDxp7DUgTfWVmSfO3+aJ8eXdIRC2w3P3N1XIz27grkgLdd4QPoBl4+70TWLptbUN8CyHqhH0O2qxztVyQFwOcb4XlDgvjVmvEifE6uasH68OrKFWuUaJttWq4rTxSra+bOQUWDXvfPThwSfngF32TUUl0oZ9Zn9tknI38akvb8jgFzRcHIPr7Xk1JmIkVZMoQAiqzI1cnN2DXH3SC9BD2bsQ0lcjS3hlYFN0WZr6HxtKqllTNGsYCualnU0dIIs3L8U6NfKyxP4wpvCOUAtzQNrerWuCA6YVvrsBBLzbE29UB8UynT/wIpniTR+0sR0OdCcrevZcECMzG1CytS3OoBWv4uoGTY1jPhp6TZNVUSziC/3gpDIpabVtRbFHho5K8uucBqLtxS/CWX88JAqPdK/JUrIVU2cqYifwBODk1MqHbxF/k2tnS32jD8zm8bzcifJZcs4RBsSLQBPNfpfjnFENWgu/xs91ezaDqajI+McPVsyRECMhvrxBfYhe9xq0e/X+aidngw+OpDmYAQ/wt55THmY2jgj5F47AA6eaMVrPFRopMHhWmFMh1ThNULBsSGuA3uHlXm2cOREjI9yJxRgVvxkvYIp07R9Err3TuaduL/gpFOAI8Hhizvy7M0l9K+b8/tstTn825OHsJwFN1v9bNnkA7ICrZRKwaCgqylgznZLfE/yNMQuRtzcHlvdOFJxE98YrBSeUSdDWuis1ErYhK3SHwPQZfvWjdn3pJKAnx+dcycTOduTz9uZIkVRV2wabTvdM+CBrZ/B7Z3FtlaUMtDwMyQlB2ToAvzDiRTxvT5ZXgKrV68iN6Iuoqah7waK6G5Wxh+SaHfknwpHRqbLYRel11647AjlHj6BvwBEVWD/eooqwLo3I0S6qmzwyS/bxQLHHYitGvG2hlkdjB5YRFFfcAlhjY4O95sMAW0kaK95ZC2dWedyn6zrNcgAWwcMqK69Fkx3O5KSL7dcPT9jY3y02ALiS2dd5r5lHafoWwesq7nhukQHX8A87mudwzoF13p36jVAcD/9J7pES6QnQHxnjcf1HbBonTdSGVhJ48/TAl3iCBYdtKCC5iRuWHKG7cn9/eqDVCoNNnjywctD11jTnQeZwSdvcb277kdOgI45uQ2D+BsYqVjWJqvpPEC/U4FAvMRVZI6UvvfCANWtNQyhOWRfXQvhzMwfQAnpvwJTk0nBjx3CyJs9Lb27zB3UsEtN4q86/mibC48pbxrj+/FKf7ZlMmQ3aFm/hgfBIxQOK7qixQzLsM6wjPTCbi0U9Z3JtMXKPS1FIAARE0kkMvOFiwsBSjyE3f2p4p5sorr4chf2Sqy4z4sINjNvgXxa36Gfei7Roxq3VtkKVAXFmzu3YlH+WIcKJgJpVtMlcV3mUGbn6E3lpN7qJr0HAg+rZJNdxrHTjr8w6hU00ZJdsE7bwKSAnKcWaO0En0AcnXPtMCwmgB+IDD30P7NpNPVUJR6zaghfZxNg025asBKfDCyNFZbajT5TmSb2XjdX5oDSDV1Ry6ns1bWJZ/xLUyMIjdw89fYiQx0kaLf63h/KkPVWdSJ13w2n+TPJSjWKu3Rva+0s19G5rFsjZLgV9CoUTztZnms4xgJ0h01bQTMi3j6JfrlwPRgnmSb7BwizCFd7OWsFdndG6t4M4LCivVyMmXWNMO+0cmFtUFRrjf//LXcZGsJp8zRrN2aCby0aUQvS12NDTvAPRg+TCWF/fd+yZhDCRggevuafw6MacXjPAWZbCGVwryvb93vrZ0Gg+bShr0EDKpWGPAUZJDvQMFqkuyzyGDBkUzmmdeLC2XaiCRglJIdj6lR4azAK1ooLNsBQYvVzEzjPqlsRvBpwGjWndXHUhCHm4rlcE63SL/JQdfU8fvfpbE9jYI22lc4tYxSlIeXcvUrD1jUKCZuf+EStBVJyIESfBCT7/k48Y9NDxSPuWK6g5Flcrzc+rRrEf9B3fUf67MCamoqkKarDlPs/QAfDzh2vt8lGlAFGQU+LqZh11DTVtKDABWSJHeYAAcbJhUA7ZsuQG7I6spk+RBoIDmixedrrGqwPKhjLCvI5WwLypqNNovNZ75wn3AdwcyPTCDBHj+9zIUknib2Ost32W1fTaD0OKbXEK86aeWkCe8iE326I1SDKKNv87JYDV794T+f0oAvVaVXMUesIyBDjYnygcsWErPabXZ5O2TmlBaAMKO0JzzCnV7w63WOqAFiPVkK/LxwirCoIVWvUL4e/VpA34BPN7jIT372411sNZ4FgqLXV9al46Eu10dY3QkXAJSN9vXqJdDZZJgdglMDUud8t8t9DMGeqmHn4LH1viGDXGeA2q9KlJG1G0Cel1YCwjNbwCESPQe6VxhOxjtkgh6T+VW/ODPEaUhy0Vjz3aI6GCq8hzvRGqBvnEvXnaoJUaSAC/tT5doRDjmLVOzAswllZuCFrrzodRlevJVIC5nJ5xD3j+KOSr8L1+yBeUHhyBljrL4vfHoHVNkH02ZVTomO1aHng+xioTLxkj1gLlKBdfQNkhI16wXzUOGA+YC9zK5oRMXEBTVO4+ml7fgE9Rwhhl2Au657OH/o6j9q+X33HqJGGFRmaq8UTAlz/GCJRHJD9v3JzDyziN3qEtyk+STWo0Vp8a79whdlEA1tzSjYK+7DKy0JrKSNbNO7YeUX6QyXJ8msLoYHaIHEUH6sd2w3AalnBnGll6n4m33wxOgXfTQySpeOKVoKoX+aF4HR4wxZsbK1uj0zGgogRwABByRqjyVnaDqBGOkldQkUTqH9KDSDXHyASNHETt238O19aPeZYMyXtoZwFI6cgDfTaixpduIR7lu2PfZ8t13G+ZcNlUH27hpCmVEFLCaUQPGdBEj1Jw4+1iuuu+RgDB1ULh8ksQs6HDDsiTt0cSPBjFIoQf57h9MNP1zO5um+Tbh/eVb1C9PnQDu6og0YaROOsFvnIAgZ1Tm5Oddt9WMowaf9Ke+9Y5zRaZL4ozl2fr8khE1/va1O4SsCT0DuAZmxRiwrWwEUOTPvCGnb9gMNdxc7AYNf3OEPTS8QW3upGdm89iEPlo+Xx+usY/FSYiB/266M2d2jfOWxnpVJQFRGtHs4/pk8kweJmlxkwBNr6ql5hfJXkVXCa2FWJJ0ALxwB6hxhuO94oUeLy2o89m1Ein+3KBX8WO/yc+cEILvA04ApNCkQeL9LiG304QXtA67omFaZmvaXSTqwzA7fCgRkoEsUBKG5ImVr/dMeFvsUGibVdSvSX1TRNPV0hoDgUlpPyufbSEc61OgX8fW4XhE+QH81p4SmVVzdQtf9b3Ww4CM/XClLr4Z0kSTtVLJZOnUtkt7QD8ccDgS+TeoDzCkjPR7mygggVMJ/lj3qOwui5HX+pYqwK8s2afPreRBtwBD6Sca9pnhKk/QeZ5zYr3b/t9uZp8b9407EeeYUDNtk7OWC18vHFjK0IBx7Hre48eJG24iKJ3xUxsD1og9Er9BoMO4UgMFYMliqPze1/zviKAw+GPJAQFaM/gRe2q1CeFYC75p/f+GQRPQaQnTvVFDqr+aLuIJOMjPw4g7nIXMdR7/XUI48vFlW6dHPiYEgHR9Ky3zV88iJi0yDB+HKImSN0u3PlAzhajwL8j66dAq7YsPiMfGH44jg8WCpxBOuy8EtwbFtUTPVo3L4VypyA9l87iD35JWqIJMW0v27vGHOv/hdK8m8LOsIGKVIKl44eD+LZrMbKtNAusWIobyHKGesuYBCReklbjnplNS31ZYYy9o24O8zy8tAmgOa2OjzW0wrD3sX2WuedD7++NZe7HUWIADClCegGfi9IR4jBFEvs/JUZS8memYwlNKcNsLbOo05gud2G2d/kpkooJ560U0di6PRRqyhGGFFShKNOHSLov8BhoRcCW0RJf+sPQjn/F6zNhsTVuCDN1lJ3GLyh7lidfBC2WUOSe9b4adjmGLlSPfTV8I1egPo3F8qXFv+hxoeZbLQ3Dv+CSv3jOQ2QG1wuhimLQMA0yMpw0Sik//oKAsJLOrVn60YVpgMVFHWNAj1/odCfrVLdWsk76Qp4Jeaah+dwmhow4A4GCKbhcYtwkla63KvgNv/o7FoLl5Ud/b44QgDR3Q2h1Ldy12K4Sbi5H4PxOBCaKHJ55OLAe+ZrtGHbV0k8uf0stCyAmkfXNBQIMZwOfgWlH5ABbo/BqpyPfkNWbyCj5mvxhzV2+hgDHaCFP/+jsXk/S1EYqPg3RBCG8HCPvy2EirCllfJJvYQbL81bF91FAUp7bmdSju+qDFY4sshrtdn5x1h3Eys8sDPdFRKbG+sZp9g9TiTYgkPzVEIgmU17D/mPgUr4IjLWFHa9OpA+AcoIhi1LVG+aLUw5uFCi/PUdSBoClHwcsWcspwrZ3ho3gW6BgwY7WpY7kdDMjCs/ykBo+SYENRfgsv1qO/zu4tKFUAeGaI2tVYo0eWpdcsfFlMKV4WzYODcqPbvl7M24X7sMVFD78+YweIY9S43BVk4S/Ap2ddG+ZFj2nEgMX5W9/DMkz1N6XdAAWuiynrdOe0t7YNjkSqJkQp9R/22qn2UtxbhMAbDKgUf/bDDytgauTsaDmzeCxszwHvCsliEdsLkgZt9sWnXNqqwawfoWwss1LUywlNLqWxPOowx0V27xYZwMt1OCwB1nk5OF9w1Tz0INrOWj+1A0skLy8KrMaZ9hzPm2OYUIy3OKm0Z1S8NTwuaQ0a+dWKkrJmzupwQvk/H7mZC/CVqaH/TYYyDHcT8XairocWG801KlXoRbACzjr0ouBZZEwMb7AoTAo0sWMYqk3cGn2VsUUHaMRI3cei+qhLU6K9kcc9iWAUzUaG80vA+f32u3nsEcMfx9LAS+8m+5JCtZTORK4EieJ7RuQiprG0VYVIj77EVnbZtZJmYlefKpdDa4TZDckM/GH9YhshVR70rV5H6CYRqX/eYIbSrF/ZZvwf37RtNnh6QJuuOGQP/QTamlmsqjHFR9T3vL48kdFCUa9hb30+MvJDHL9i3prhb9uBn5tLx3vqrlkFu4N7ESPANR4Z4Qj7xCCskfC/t8yHec/CoaiDqhLbBdk8rYjeCpzJA4o+KKC1OxpwITzKn2asVvfB3lkWffNiKbGAkpmZtHtnuvHOBDYtzS7ytFwA7TMK35cZQi5LS88Os+RVE6ELmARdHGj2Rz+0u36UUKBvpm9z8GSOOet+HBwv0floWfi9Wy4aZJ6OKgp/qOrE8nbc/JKNtVFk+aAHs79YxR2gkSzIkmmjZcH0+XL5nlfKfrZgRlwRa/Q7FTqR3Cs+PxYc2bzDYUaUd9ghyVbq7iBMx+/SlLBWu8/xZ03MMvQdSw1ruOEeYxfyUgcYVnq6g6735rP31f3DUipl6Hx5oMIDjgCph12/1IVggE38HKqwdJ6u/kk2pPBVbqd1yGyOOn9Noln25prTCJfCLnBw3gRjVAbiIHXCUNPEsB/++KbJz+1FQwNPJexdP939h+3WglFS6bBtBIPiKK14cSquQMDF921UK4t8TDM5AUl/VjQ/c5JRAqE5UXh0JLC29prRMrbZwNx9wDCrny0n10jumGUk7YoI2ODoBwCQMO2nSOtjDoOmAHjaIDLIIADfAoB9LQSH29lxEFdX142Yvb+ffHgsHz/j3DFPYk+sUQ8mq5SVP/yzay+ahu8710JDydBldFvLYCLJD3i9o9dtz7AOzSmHH0qzLTvNaNzreJ/MF0G1zUx8bNnh7ZnvB6m/8fNUqhXNVwpC6vbbNkGbCodkUWIP2MD3qIupODNDFL+4ehC0aar1PDVVscxgCNhU0J1QhHt6xWT3+4Fhl94mPXFyMKllQkW0SHu3jrNioBHU0XlAwSRgpxckeUgXbLcj3Gr8AFTmBLq0j7DLsN+ermZKGC1hiaQDLuSuaB2Hbf8oQjUDfAXHf0cDI4fIfIoAkkKlvsNru91pht3zp3SgMzkmzJnlpWNXoFbkQYefvuMjf3BKg/XUfvRQSwSd/iBbsSDMjmPMqgU8qsXzRdR2MUFFbMblqflaUcsiDGsSBLEWCMInawkpfoQuF8vxaZxic2Hd3tjD0ly2jxXS/rFeiQBj2dxLnis57rxEoskQRiyohO1hEcGQmjhXYKDEk3GmFORsyGzAsEmvCrvYhvM58ZKq8MFHJpknoNd6i1w5JBGkPbbiGrTmvSOFCzr7NVPTRmJEAqk0zGhiATHC3+QxcuW5vdDhpIeGqNLAhzAL/kpiJvuRC+6gLx0Y7rLo/wsO5QVLREUlJlzVPWI55YLv9GnAO87nJ3yRrdicQUx2RSl6MlBP7TP+yOiqBUo79awShg+q/AcshkyhZUCN0+h4kTcNXhrFGTRNQFahzNhvrqMEQmNpvZOTpnd3eDaf1iG4BoHiaEOdV2+noQp3VMraJIgKXLy9bOxYWetyc2JqBOmEaa/Mm3LH4YK8becy0k7Betd8wTRW7h8dI8RpWlpOQBIy8qPxbO5z3FE7L5qOLxWjG/UEp+rc/YO4MZN+vQb7oldbDkUxG5GFduW1NqN6ZUmpaaXcRppwdFk6g9jXskTIEi7ZKVJM7K8LYQlLsEk0f7Zo/1VNlMBKGnjtyRJyeCQ7nj+1Kd2EqyOKdahPSENYR8mlS8N7qWarPLKxIK5S1iQb2d1Lgejn8kexNLQtAhJP6K4Hmbswpq08UBvJDIbjQ7UjY77dwo7QeqEn15mqiBGum22HOYt9Pg61eXDAibs4cxASX1VJSb43wJy6R0mqyqGBeWvfU6I8TCG8LKMrpTyhHbk9emDDg8OWkwW8n3y3scDQUseP50BSNjoBFZZ/cICDrpWh6bQSqmx3thjl1hAiTH1zUJcLlI9cBDFSGSDnZF4kT81/c70tlPSo4qZLtksjdzoCXKEzT2TAiT+BcYO/cYrjpnlK74cba3tmeCGryM1uHomoKhU3Vmq0EtU50YIaL6uSV+e/hSj+xK/uf+SdhIZhCcNf2EEytgTy9IkLkmgp9cR5upqp0pUQhnpYzahW4jPunqxTGqm4mn2QImlzGsBBSL80BNe2Hj0iQxsjscAENSEF8aEKfuXjCwjzKHIKbkZjU2olyFyASezKahcM5JB4KTX64fzo6gObywX8iLhhaJqiJrFQ0MiVDkKSgK56Kq993gV5y52AYjCdmMq7gik41cs7HMMtPMMZoJzq4z7TJfRApv8uktdIEi2ny7qpZhKKiOcY5soK4hhdXNSTr3C3gU02TZb08TEzV2gW7P5ZOSTaQkmE7Tn+QSO1qduYPBMp8mcixb6NpbbCBVe0eVwMoDb37GfMYA7MbLuzmbRUEcz8Ee9cSbUogUFiDNbcsh3EyRc1MXhlIc619lDBzZ9KF+LFK89itecbwrGQEkVBzdqxh0WJEzJBveaE+UsUe+mclgTYmZacHp+Ejso6SW3ZwESP1MnwLVPHYjyYv4Q9NYOHXPOjn75PopQVKHJHOmhOA4CkQVAYZ+VOMfLnKTNOEfw1Z7LvBpuxfFjRs48EZcGZr599Tp+8x1rvsU9QxCkTapQZEMNX5qQvRswkHk4A/L4/KftS8eP0mnON8vZa9SbKW6TcdeBIMkEQ8HMQKRYkX5cznSxcW8Gv7xF3fvg73HJkogzah88ig66yvoTBLuMVmy+ohifeZDzwl+HTTXOOXd1Ohl+yFhGdjFV77Mx1mKxQzNrFpty1x7s/PRELPorZNnnUWh+JpdM+m9V/xhiZjMc2JuihMd/DLw5+cs96/EEvrlQ/JpgbwfemVX2rpPmigwNcSg6J0H1iiPudRmvPzRw9JHgJI/3DRMshLZAiuBnvWnKfetI3/v1aFE3uM1mhkpgZy9CjubFDNWsrBAXqzlyxx0Blgt+tsGnTeA75bVJJLDKmZZyZpmQlKsVslOAN/AGOCI2KINMJFiOxLfTeIFQHCbH5Ld8XilfRfUDXTLhNdu5hbTuIIUFmjhQh+SGMbAU4ihtyXmY+3SAM/2u+XECy2fQS6BIcxskgxkPbeyFZFw5mNDQHETgbDYbjEaU7anYfiOfE9PNW4gvHE1eysEf5ELytsgQbRY4IKSuz8bOnECSwJcDqiQLxE+MEgptXt2uOjX9HCC4fZxELSgn9PxUwFaiBzbF8ovgs1Pfiu7kBx0ngl83nwAvAALXV5mHvTuolhHqA7JDqhp/PxJleUQZRunSaieLRuD9mhpuABdkjnErhYuNdzQHyS8Q8MjP47nxmQ1uBA+WJeCuF9Z1jiCGmXQCIeT9V7X62HW2sSiI8Eo4ZxBT2EKOLEPYIL23XjulWQ6I/IhtOdHjH/nw3SIDEFJPpa6xbYOJsH9mYipBDjhQAZw23KHmGDsfafxLtg/UctBSM5a2otlAFlqDarZ53LhU31lA8nqC9bmhkOTlyLoykgcPO8w1gI99/+bC3m3M669rAUGr5e4JeQcxEmhWZgoW7qSYlKn2OuumM7/MCLsRxLzkKe6EuaV7gZ3Wiufpxv/sk/S8aI+R0R4BHlqn/wQW2JyF4ilzzyCuyyEUImQ4PlopF1OK7aS9wXrYUoNt/Pie0CpFjiy+KYGkMD2kryqgxXS8XuRDJBXSGx5k8OAEUtO31rsEpvUtYZAix5FJjLxHsom0ylpOA8EDRGoDFXkrGe/4xHYwK+RSoQKjEiL/5DZ5505Aw5Fn6eGmAsLvHoaghKqOOKTq8yneRYyO22v1uvRaBimLCiqEGUGDnXW/Ebw7eCh1/eXX716oeVB2WA1zdGmkXz/BY1+FFpgpkjg/gYqvmApDpM/HMyyU4LC0Awp1nB/vTb5Q/1ZhYKMFKjrR0ajCTK1FwvR3MqDc9ST8Z3f34tKEzoD4pfT6NnaYpvDhArYVn6ff/GudBEFLfGx6nhau/l9Isu74grodSf1IUg7gfsBWRSYi81oy9gMsVHZP62VoV2E5o70umbduoOwbErXrnh803YH9L61yplQCFFnMyS1eolp6nw+/I6NbnGMinm9dSYz6o1KlIZyle0IsBdFaYUPnwNtfRifNlkK0xDa+Yhxf3R7TKsLvpdoHi7vTPGhdwJsyk1THZzVg7cuqO510yv4/SEXFLM/f2VhxZ04YPsOGMZn1Vn2vJVUXeGzANAGV3+xsaFlUxHvAE1glF+NpsRQdMEo7hBln8mL/xsHywVcvTUtPNIZh+S7HbILzP4ZrRfPa2rBkE1hariAvjyNIa3tHM6R19PZEwpCEBEeLWNW7p2hX7bv+SDdnhCaIuCSebx4LMbUBT+MKg3cfkuWlkei7W1VjR7D68HoNedYhity+LiRO+QUqKyh/RXmPfJRVmAolStd7H38x6JhsldgoXfo2DtM6JRmXA9jJavcfvCyyS03gu1oqz+fo/8ko55+ZLzzFT5T53zeNsmPg+1Z3LOpgHJdcBZq32jMyz5Bx/TVYiy2ajaCBuFVt1zaoYZijbaOcLKqnHymd40L/TE3K/hV5b47TDWwzavPxk0xWePpbZnnMtTQ5OV4PbNECkHe1xVrNKDxHy5BcBddys71U8A8tM4EvhRpdTiyxlUlhbTGIPyADuDumJtVNFobwTJouJRUPfcTwhADBFN7VuNvBbgEflLKgbrXhRssTcgy9x2DpSRgtPYHuFMNYu30gmzOhsOJp7v05lTe/QyDYBk3mTu5+SHeGwBJVmKzbJL7hq7qCJYOuinN1hkgTnTrIUWHmjFHhAURa7qprNWg1AShkiKxoR829Ud13tGVusXtqoHQL5y3ywC0535iHC+Ex++wcxywcjoiDAhGuj1FYx3GwqJB9dhrCq8qzSxVa6HsyHV4JTKpRnC+kAMf3icoE5gReOmPy6KpnhOW8MxQBm31o0vrJV4GWfsVwhPMQupdU9FvqLnDYlXMClmdwjdIMu2zMvn8Gi/CMt/qr8eCACPuM8O2+Ezwt81Fg8DcO7JB5f7ZHFTjFZj7RFEkxzjL6EF8c3/xkVqXCjFaspLzW6KlaPrKt7ajSXduzAygNMfwyM53TN7YSTnq+zv8vPUIhaRvIbXW9IOstKF3HjwQawL3btCikIm9MSK0Sjgqs97vdxddWENPM9nXX1dhWYjzQhmfpbWlRqIGitrD7UdO0DhaLlcsW0wfYKJWcxfZw6nmNJONObJ0ek3afaxsVOzcC2y5bJtpHH83YPkwxe0D+GWPExRssvni5IH8O2JecnvNCyXrxNYp6QJmhQBkcdcnIxUHc3M+kBruH67iT5t0uaIayANYgGd38S7WpjL2J82Ygn2NkBitKosfZCbBJB/AdVT9PmQIN6PVeB+PHEmus5TDZ1OHKLoa4wevYGODN3eFobpjk/qIvs3Ecet9Li3axet51MWqfoso3klVNqfG0N3688HSRRTaD9auUtAZ5epwrnwkwkT78O8bZS5d2sLCCEsoAygA2utrJf+Jwk6kPG9F7VXPgedX3Eni4CJ1u9tN+k2zw2Jb8JGUu+nV8dh8EnRvA1VeKe0U6nXX0RzSM/jk1aNyyXXsSN+L2i7siP7SDH1QLxgHhxKcb1woMeSIApZ2+vErlG9qp4S4pPyQLFSZJ/XAUm/t7Wk45MPbqbqt4VSB6b4/y9MRd45fIKijkal43XgAaXv6jWIRdqQ3wDwjtbHdy3S9Hi8+AWCiZBPTpWyHWb3l9BoVRgkkbDv4Hi0FUo+KWv6U1Tu8wBlEJ+fli6JFHBmreIAT8yr6FQj35IhtKl1fepcDGgW+yPBwep27lIiqp6HB9rWsNaHLMsBGSxru+HaWb/b5JmgZRMUB3eth5vAYb4KhoAy05AGJG7yOfIvaJzsoZgc9fRTv07Pt9CqomEud7iFRGPUP8ZB20Lslgf2OGIpsZ6KlvILYcQ/GQfgykkq++Hz8Weev8C0Galieo3piTkroeUWVEyiCiGXqqACPFTH+wNjGqgNYQOWbEAl/zplqMzA2G2JegE9q1VOiUjjIXznlVPAwzbi7BT3MH89N8o1X8XH2R7BP1CQLQkQBwlR/RR4SS2A9bigGCzVNI0dPYul9dKWyF/ZrEqV34wO+nPTSQJQxgvfJjmcBFaPTnSWqCwXhjjoTZBL70T0ryePgxjL69CWeAXMQFZrA/dE1n4vv0eiAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEVYSUa6AAAARXhpZgAASUkqAAgAAAAGABIBAwABAAAAAQAAABoBBQABAAAAVgAAABsBBQABAAAAXgAAACgBAwABAAAAAgAAABMCAwABAAAAAQAAAGmHBAABAAAAZgAAAAAAAABIAAAAAQAAAEgAAAABAAAABgAAkAcABAAAADAyMTABkQcABAAAAAECAwAAoAcABAAAADAxMDABoAMAAQAAAP//AAACoAQAAQAAAFgCAAADoAQAAQAAAFgCAAAAAAAA\n",
            "text/plain": [
              "<IPython.core.display.Image object>"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Inspect the image above. Is 'Calpol' clearly visible?\n",
            "All required files are present and verified.\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Step 1: Image Acquisition and Preprocessing\n",
        "\n",
        "Preprocess the medicine packaging image to enhance text visibility for OCR using OpenCV. Save and display the preprocessed image to verify quality."
      ],
      "metadata": {
        "id": "ozsv8_wVWq9m"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# def preprocess_image(image_path: str) -> np.ndarray:\n",
        "#     \"\"\"Preprocess image for OCR.\"\"\"\n",
        "#     img = cv2.imread(image_path)\n",
        "#     if img is None:\n",
        "#         raise FileNotFoundError(f\"Image not found at {image_path}\")\n",
        "#     img = cv2.resize(img, (800, 800))  # Consistent resolution\n",
        "#     gray = cv2.cvtColor(img, cv2.COLOR_BGR2GRAY)  # Grayscale\n",
        "#     blur = cv2.GaussianBlur(gray, (5, 5), 0)  # Reduce noise\n",
        "#     _, binary = cv2.threshold(blur, 0, 255, cv2.THRESH_BINARY + cv2.THRESH_OTSU)  # Binarization\n",
        "#     return binary\n",
        "\n",
        "# # Test preprocessing\n",
        "# preprocessed_img = preprocess_image(IMAGE_PATH)\n",
        "# cv2.imwrite(\"/content/preprocessed_image.png\", preprocessed_img)\n",
        "# print(\"Preprocessed image saved as '/content/preprocessed_image.png'.\")\n",
        "\n",
        "# # Display image in Colab\n",
        "# from IPython.display import Image\n",
        "# Image(\"/content/preprocessed_image.png\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 834
        },
        "id": "SzYmGWl0Wsai",
        "outputId": "0111e780-84b2-4d14-e369-297b39b5b059"
      },
      "execution_count": 3,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Preprocessed image saved as '/content/preprocessed_image.png'.\n"
          ]
        },
        {
          "output_type": "execute_result",
          "data": {
            "image/png": "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\n",
            "text/plain": [
              "<IPython.core.display.Image object>"
            ]
          },
          "metadata": {},
          "execution_count": 3
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def preprocess_image(image_path: str) -> np.ndarray:\n",
        "    \"\"\"Preprocess image for OCR.\"\"\"\n",
        "    img = cv2.imread(image_path)\n",
        "    if img is None:\n",
        "        raise FileNotFoundError(f\"Image not found at {image_path}\")\n",
        "    # Resize with aspect ratio preservation\n",
        "    h, w = img.shape[:2]\n",
        "    scale = 800 / max(h, w)\n",
        "    img = cv2.resize(img, (int(w * scale), int(h * scale)), interpolation=cv2.INTER_CUBIC)\n",
        "    # Convert to grayscale\n",
        "    gray = cv2.cvtColor(img, cv2.COLOR_BGR2GRAY)\n",
        "    # Mild blur to reduce noise\n",
        "    blur = cv2.GaussianBlur(gray, (3, 3), 0)\n",
        "    # Adaptive thresholding for better contrast\n",
        "    binary = cv2.adaptiveThreshold(blur, 255, cv2.ADAPTIVE_THRESH_GAUSSIAN_C,\n",
        "                                  cv2.THRESH_BINARY_INV, 11, 2)\n",
        "    return binary\n",
        "\n",
        "# Test preprocessing locally\n",
        "preprocessed_img = preprocess_image(IMAGE_PATH)\n",
        "cv2.imwrite(\"/content/preprocessed_image.png\", preprocessed_img)\n",
        "print(\"Preprocessed image saved as '/content/preprocessed_image.png'.\")\n",
        "\n",
        "# Display images for local debugging\n",
        "from IPython.display import Image, display\n",
        "print(\"Original Image (Calpol500.jpg):\")\n",
        "display(Image(IMAGE_PATH))\n",
        "print(\"Preprocessed Image:\")\n",
        "display(Image(\"/content/preprocessed_image.png\"))\n",
        "print(\"Inspect the preprocessed image. Is 'Calpol' black on white and readable?\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "bDrCWAwZuWcg",
        "outputId": "6ee081d0-cb8f-4d53-d059-2b62f6300fb0"
      },
      "execution_count": 6,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Preprocessed image saved as '/content/preprocessed_image.png'.\n",
            "Original Image (Calpol500.jpg):\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "image/jpeg": "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\n",
            "text/plain": [
              "<IPython.core.display.Image object>"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Preprocessed Image:\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "image/png": "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\n",
            "text/plain": [
              "<IPython.core.display.Image object>"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Inspect the preprocessed image. Is 'Calpol' black on white and readable?\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Step 2: Text Extraction with OCR\n",
        "\n",
        "Extract text from the preprocessed image using Google Cloud Vision API. Print the extracted text to verify OCR accuracy."
      ],
      "metadata": {
        "id": "SsUJC5kSWuOp"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# def extract_text(image: np.ndarray) -> str:\n",
        "#     \"\"\"Extract text from preprocessed image using Google Cloud Vision API.\"\"\"\n",
        "#     _, encoded_image = cv2.imencode(\".png\", image)\n",
        "#     content = encoded_image.tobytes()\n",
        "#     image = vision.Image(content=content)\n",
        "#     response = vision_client.text_detection(image=image)\n",
        "#     if response.error.message:\n",
        "#         raise Exception(response.error.message)\n",
        "#     return response.text_annotations[0].description if response.text_annotations else \"\"\n",
        "\n",
        "# # Test OCR\n",
        "# raw_text = extract_text(preprocessed_img)\n",
        "# print(\"Extracted Text:\")\n",
        "# print(raw_text)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "FrmTOELbWvrP",
        "outputId": "c10fd822-d4ba-45dc-ff22-443834cf1dd6"
      },
      "execution_count": 4,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Extracted Text:\n",
            "The\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def extract_text(image: np.ndarray, use_api: bool = False) -> str:\n",
        "    \"\"\"Extract text from preprocessed image. Use API only when specified.\"\"\"\n",
        "    if use_api:\n",
        "        # Call Google Cloud Vision API\n",
        "        _, encoded_image = cv2.imencode(\".png\", image)\n",
        "        content = encoded_image.tobytes()\n",
        "        image = vision.Image(content=content)\n",
        "        response = vision_client.text_detection(image=image)\n",
        "        if response.error.message:\n",
        "            raise Exception(f\"Vision API error: {response.error.message}\")\n",
        "\n",
        "        texts = response.text_annotations\n",
        "        if not texts:\n",
        "            return \"No text detected.\"\n",
        "\n",
        "        print(\"All Detected Texts (API):\")\n",
        "        for i, text in enumerate(texts[1:], 1):\n",
        "            print(f\"Text {i}: {text.description} (Bounding Box: {text.bounding_poly.vertices})\")\n",
        "\n",
        "        return texts[0].description if texts else \"\"\n",
        "    else:\n",
        "        # Simulate OCR output for debugging\n",
        "        simulated_text = \"Calpol 500 mg\"  # Replace with what you expect to see\n",
        "        print(f\"Simulated OCR Output (no API call): {simulated_text}\")\n",
        "        return simulated_text\n",
        "\n",
        "# Test OCR without API call first\n",
        "raw_text = extract_text(preprocessed_img, use_api=False)\n",
        "print(\"Extracted Text (Simulated):\")\n",
        "print(raw_text)\n",
        "\n",
        "# Uncomment to test with API after debugging\n",
        "# raw_text = extract_text(preprocessed_img, use_api=True)\n",
        "# print(\"Extracted Text (API):\")\n",
        "# print(raw_text)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "bnUQsKymugUi",
        "outputId": "fe63792a-921d-480c-ca15-9547f7a04635"
      },
      "execution_count": 7,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Simulated OCR Output (no API call): Calpol 500 mg\n",
            "Extracted Text (Simulated):\n",
            "Calpol 500 mg\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Step 3: Text Cleaning and Entity Extraction\n",
        "\n",
        "Clean the OCR output and extract drug names using SpaCy. Apply fuzzy matching to correct OCR errors. Print detected entities to verify."
      ],
      "metadata": {
        "id": "OUYa628bWxMs"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# def clean_and_extract_entities(text: str) -> List[str]:\n",
        "#     \"\"\"Clean OCR text and extract drug names.\"\"\"\n",
        "#     doc = nlp(text.lower())\n",
        "#     entities = [ent.text for ent in doc.ents if ent.label_ in [\"PRODUCT\", \"ORG\"]]  # Adjust labels as needed\n",
        "\n",
        "#     # Fuzzy matching for OCR error correction\n",
        "#     drug_list = [\"aspirin\", \"ibuprofen\", \"paracetamol\", \"amoxicillin\"]  # Placeholder\n",
        "#     corrected_entities = []\n",
        "#     for entity in entities:\n",
        "#         match, score = process.extractOne(entity, drug_list)\n",
        "#         if score > 80:  # Threshold for fuzzy match\n",
        "#             corrected_entities.append(match)\n",
        "#         else:\n",
        "#             corrected_entities.append(entity)\n",
        "#     return corrected_entities\n",
        "\n",
        "# # Test entity extraction\n",
        "# drug_entities = clean_and_extract_entities(raw_text)\n",
        "# print(\"Detected Drug Entities:\")\n",
        "# print(drug_entities)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "TbvGq--ZWycp",
        "outputId": "c98120ee-e308-4e7c-9c6c-b7d82febe910"
      },
      "execution_count": 8,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Detected Drug Entities:\n",
            "[]\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "def clean_and_extract_entities(text: str) -> List[str]:\n",
        "    \"\"\"Clean OCR text and extract drug names.\"\"\"\n",
        "    doc = nlp(text.lower())  # \"calpol 500 mg\"\n",
        "    print(\"SpaCy Tokens:\", [token.text for token in doc])\n",
        "    print(\"SpaCy Entities:\", [(ent.text, ent.label_) for ent in doc.ents])\n",
        "\n",
        "    # Broaden entity labels to include potential drug-related terms\n",
        "    entities = [ent.text for ent in doc.ents if ent.label_ in [\"PRODUCT\", \"ORG\", \"GPE\", \"NORP\", \"PERSON\"]]\n",
        "\n",
        "    # If no entities, fallback to token matching\n",
        "    if not entities:\n",
        "        print(\"No entities detected. Falling back to token matching.\")\n",
        "        drug_list = [\"aspirin\", \"ibuprofen\", \"paracetamol\", \"amoxicillin\", \"calpol\"]  # Expanded list\n",
        "        entities = []\n",
        "        for token in doc:\n",
        "            match, score = process.extractOne(token.text, drug_list)\n",
        "            if score > 80:  # Threshold for fuzzy match\n",
        "                entities.append(match)\n",
        "\n",
        "    # Fuzzy matching for correction\n",
        "    drug_list = [\"aspirin\", \"ibuprofen\", \"paracetamol\", \"amoxicillin\", \"calpol\"]  # Expanded list\n",
        "    corrected_entities = []\n",
        "    for entity in entities:\n",
        "        match, score = process.extractOne(entity, drug_list)\n",
        "        if score > 80:\n",
        "            corrected_entities.append(match)\n",
        "        else:\n",
        "            corrected_entities.append(entity)\n",
        "\n",
        "    return corrected_entities\n",
        "\n",
        "# Test entity extraction\n",
        "raw_text = \"Calpol 500 mg\"  # From simulated OCR\n",
        "drug_entities = clean_and_extract_entities(raw_text)\n",
        "print(\"Detected Drug Entities:\")\n",
        "print(drug_entities)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "sI_dHtt4wgq-",
        "outputId": "8a0791ab-566e-45f8-ec1e-ff2c7f3a1b82"
      },
      "execution_count": 9,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "SpaCy Tokens: ['calpol', '500', 'mg']\n",
            "SpaCy Entities: [('500', 'CARDINAL')]\n",
            "No entities detected. Falling back to token matching.\n",
            "Detected Drug Entities:\n",
            "['calpol']\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Step 4: Load DrugBank Data\n",
        "\n",
        "Parse the DrugBank XML dataset to extract structured drug information (e.g., indications, dosage, side effects). Print a sample entry to verify parsing."
      ],
      "metadata": {
        "id": "P6bLof3oW1iX"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "# def load_drugbank_data(file_path: str) -> Dict[str, Dict]:\n",
        "#     \"\"\"Parse DrugBank XML into a structured dictionary.\"\"\"\n",
        "#     tree = etree.parse(file_path)\n",
        "#     root = tree.getroot()\n",
        "#     ns = {\"db\": \"http://www.drugbank.ca\"}  # DrugBank namespace\n",
        "#     drug_data = {}\n",
        "\n",
        "#     for drug in root.findall(\".//db:drug\", namespaces=ns):\n",
        "#         drug_name = drug.find(\"db:name\", namespaces=ns).text.lower()\n",
        "#         drug_info = {\n",
        "#             \"indications\": drug.find(\"db:indication\", namespaces=ns).text if drug.find(\"db:indication\", namespaces=ns) is not None else \"Not specified\",\n",
        "#             \"dosage\": \"\",\n",
        "#             \"contraindications\": \"\",\n",
        "#             \"interactions\": \"\",\n",
        "#             \"side_effects\": \"\"\n",
        "#         }\n",
        "\n",
        "#         # Dosage (from dosage-forms or routes)\n",
        "#         dosage_forms = drug.find(\"db:dosage-forms\", namespaces=ns)\n",
        "#         if dosage_forms is not None:\n",
        "#             drug_info[\"dosage\"] = \", \".join([df.text for df in dosage_forms.findall(\"db:dosage-form\", namespaces=ns)]) or \"Not specified\"\n",
        "\n",
        "#         # Contraindications (approximated from toxicity)\n",
        "#         toxicity = drug.find(\"db:toxicity\", namespaces=ns)\n",
        "#         drug_info[\"contraindications\"] = toxicity.text if toxicity is not None else \"Not specified\"\n",
        "\n",
        "#         # Interactions\n",
        "#         interactions = drug.find(\"db:drug-interactions\", namespaces=ns)\n",
        "#         if interactions is not None:\n",
        "#             drug_info[\"interactions\"] = \", \".join([i.find(\"db:description\", namespaces=ns).text for i in interactions.findall(\"db:drug-interaction\", namespaces=ns) if i.find(\"db:description\", namespaces=ns) is not None]) or \"Not specified\"\n",
        "\n",
        "#         # Side Effects\n",
        "#         side_effects = drug.find(\"db:adverse-effects\", namespaces=ns)\n",
        "#         if side_effects is not None:\n",
        "#             drug_info[\"side_effects\"] = \", \".join([se.text for se in side_effects.findall(\"db:adverse-effect\", namespaces=ns)]) or \"Not specified\"\n",
        "\n",
        "#         drug_data[drug_name] = drug_info\n",
        "\n",
        "#     return drug_data\n",
        "\n",
        "# # Test DrugBank parsing\n",
        "# drug_data = load_drugbank_data(DRUGBANK_PATH)\n",
        "# sample_drug = list(drug_data.keys())[0]  # First drug\n",
        "# print(f\"Sample Drug Entry ({sample_drug}):\")\n",
        "# print(drug_data[sample_drug])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "LZ4ADqxMW2Np",
        "outputId": "49518121-4cbc-42aa-bd7a-d8341ed4088c"
      },
      "execution_count": 10,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Sample Drug Entry (lepirudin):\n",
            "{'indications': 'Not specified', 'dosage': '', 'contraindications': 'Not specified', 'interactions': '', 'side_effects': ''}\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "import os\n",
        "from lxml import etree\n",
        "from typing import Dict\n",
        "\n",
        "# Configuration (from your Cell 4)\n",
        "DRIVE_FOLDER = \"/content/drive/My Drive/MsDSAI/January 2025/NLP/Project/Data/\"\n",
        "DRUGBANK_PATH = os.path.join(DRIVE_FOLDER, \"drugbank.xml\")\n",
        "XSD_PATH = os.path.join(DRIVE_FOLDER, \"drugbank.xsd\")\n",
        "\n",
        "def load_drugbank_data(file_path: str, xsd_path: str = None) -> Dict[str, Dict]:\n",
        "    \"\"\"Parse DrugBank XML into a structured dictionary, validate with XSD.\"\"\"\n",
        "    tree = etree.parse(file_path)\n",
        "    root = tree.getroot()\n",
        "    ns = {\"db\": \"http://www.drugbank.ca\"}\n",
        "\n",
        "    # Validate against XSD\n",
        "    if xsd_path and os.path.exists(xsd_path):\n",
        "        xsd_tree = etree.parse(xsd_path)\n",
        "        schema = etree.XMLSchema(xsd_tree)\n",
        "        if schema.validate(tree):\n",
        "            print(\"XML is valid against the XSD schema.\")\n",
        "        else:\n",
        "            print(\"XML validation failed:\")\n",
        "            for error in schema.error_log:\n",
        "                print(f\"Line {error.line}: {error.message}\")\n",
        "\n",
        "    drug_data = {}\n",
        "    for drug in root.findall(\".//db:drug\", namespaces=ns):\n",
        "        drug_name = drug.find(\"db:name\", namespaces=ns).text.lower()\n",
        "        drug_info = {\n",
        "            \"indications\": \"Not specified\",\n",
        "            \"dosage\": \"Not specified\",\n",
        "            \"contraindications\": \"Not specified\",\n",
        "            \"interactions\": \"Not specified\",\n",
        "            \"side_effects\": \"Not specified\"\n",
        "        }\n",
        "\n",
        "        # Indications\n",
        "        indication_elem = drug.find(\"db:indication\", namespaces=ns)\n",
        "        if indication_elem is not None and indication_elem.text:\n",
        "            drug_info[\"indications\"] = indication_elem.text\n",
        "        else:\n",
        "            print(f\"{drug_name}: No <indication> found or empty.\")\n",
        "\n",
        "        # Dosage (updated to <dosages>)\n",
        "        dosages = drug.find(\"db:dosages\", namespaces=ns)\n",
        "        if dosages is not None:\n",
        "            dosage_list = [\n",
        "                f\"{d.find('db:form', namespaces=ns).text} ({d.find('db:strength', namespaces=ns).text}) via {d.find('db:route', namespaces=ns).text}\"\n",
        "                for d in dosages.findall(\"db:dosage\", namespaces=ns)\n",
        "                if (d.find(\"db:form\", namespaces=ns) is not None and d.find(\"db:form\", namespaces=ns).text and\n",
        "                    d.find(\"db:strength\", namespaces=ns) is not None and d.find(\"db:strength\", namespaces=ns).text and\n",
        "                    d.find(\"db:route\", namespaces=ns) is not None and d.find(\"db:route\", namespaces=ns).text)\n",
        "            ]\n",
        "            drug_info[\"dosage\"] = \"; \".join(dosage_list) if dosage_list else \"Not specified\"\n",
        "        else:\n",
        "            print(f\"{drug_name}: No <dosages> found.\")\n",
        "\n",
        "        # Contraindications (from toxicity)\n",
        "        toxicity = drug.find(\"db:toxicity\", namespaces=ns)\n",
        "        if toxicity is not None and toxicity.text:\n",
        "            drug_info[\"contraindications\"] = toxicity.text\n",
        "            # Side effects fallback to toxicity if no specific field\n",
        "            drug_info[\"side_effects\"] = toxicity.text\n",
        "        else:\n",
        "            print(f\"{drug_name}: No <toxicity> found or empty.\")\n",
        "\n",
        "        # Interactions\n",
        "        interactions = drug.find(\"db:drug-interactions\", namespaces=ns)\n",
        "        if interactions is not None:\n",
        "            descs = [i.find(\"db:description\", namespaces=ns).text for i in interactions.findall(\"db:drug-interaction\", namespaces=ns)\n",
        "                     if i.find(\"db:description\", namespaces=ns) is not None and i.find(\"db:description\", namespaces=ns).text]\n",
        "            drug_info[\"interactions\"] = \", \".join(descs) if descs else \"Not specified\"\n",
        "        else:\n",
        "            print(f\"{drug_name}: No <drug-interactions> found.\")\n",
        "\n",
        "        # Side Effects (no <adverse-effects>, using toxicity as fallback)\n",
        "        if drug_info[\"side_effects\"] == \"Not specified\":\n",
        "            print(f\"{drug_name}: No specific <adverse-effects> field; using <toxicity> as fallback.\")\n",
        "\n",
        "        drug_data[drug_name] = drug_info\n",
        "\n",
        "    return drug_data\n",
        "\n",
        "# Test DrugBank parsing\n",
        "drug_data = load_drugbank_data(DRUGBANK_PATH, XSD_PATH)\n",
        "sample_drug = list(drug_data.keys())[0]  # First drug (lepirudin)\n",
        "print(f\"Sample Drug Entry ({sample_drug}):\")\n",
        "print(drug_data[sample_drug])\n",
        "\n",
        "# Print raw XML for lepirudin\n",
        "tree = etree.parse(DRUGBANK_PATH)\n",
        "root = tree.getroot()\n",
        "ns = {\"db\": \"http://www.drugbank.ca\"}\n",
        "for drug in root.findall(\".//db:drug\", namespaces=ns):\n",
        "    if drug.find(\"db:name\", namespaces=ns).text.lower() == sample_drug:\n",
        "        print(f\"Raw XML for {sample_drug}:\")\n",
        "        print(etree.tostring(drug, pretty_print=True, encoding=\"unicode\"))\n",
        "        break\n",
        "\n",
        "# Check for Calpol/Paracetamol\n",
        "print(\"'calpol' in drug_data:\", \"calpol\" in drug_data)\n",
        "print(\"'paracetamol' in drug_data:\", \"paracetamol\" in drug_data)\n",
        "if \"paracetamol\" in drug_data:\n",
        "    print(\"Paracetamol Entry:\")\n",
        "    print(drug_data[\"paracetamol\"])"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "4JOl7Hx2zz3-",
        "outputId": "5ce058ed-e871-40e6-c102-5fda911408b0"
      },
      "execution_count": 11,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[1;30;43mStreaming output truncated to the last 5000 lines.\u001b[0m\n",
            "ea-230: No <toxicity> found or empty.\n",
            "ea-230: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "lactide, l-: No <indication> found or empty.\n",
            "lactide, l-: No <toxicity> found or empty.\n",
            "lactide, l-: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "trimethylene carbonate: No <indication> found or empty.\n",
            "trimethylene carbonate: No <toxicity> found or empty.\n",
            "trimethylene carbonate: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "lapuleucel-t: No <indication> found or empty.\n",
            "lapuleucel-t: No <toxicity> found or empty.\n",
            "lapuleucel-t: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "tuparstobart: No <indication> found or empty.\n",
            "tuparstobart: No <toxicity> found or empty.\n",
            "tuparstobart: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "timbetasin: No <indication> found or empty.\n",
            "timbetasin: No <toxicity> found or empty.\n",
            "timbetasin: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "sotevtamab: No <indication> found or empty.\n",
            "sotevtamab: No <toxicity> found or empty.\n",
            "sotevtamab: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "redasemtide: No <indication> found or empty.\n",
            "redasemtide: No <toxicity> found or empty.\n",
            "redasemtide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "nisin z: No <indication> found or empty.\n",
            "nisin z: No <toxicity> found or empty.\n",
            "nisin z: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "enzalutamide d3: No <indication> found or empty.\n",
            "enzalutamide d3: No <toxicity> found or empty.\n",
            "enzalutamide d3: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "genipin: No <indication> found or empty.\n",
            "genipin: No <toxicity> found or empty.\n",
            "genipin: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "giredestrant: No <indication> found or empty.\n",
            "giredestrant: No <toxicity> found or empty.\n",
            "giredestrant: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "r906289: No <indication> found or empty.\n",
            "r906289: No <toxicity> found or empty.\n",
            "r906289: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "radotermin: No <indication> found or empty.\n",
            "radotermin: No <toxicity> found or empty.\n",
            "radotermin: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "ralmitaront: No <indication> found or empty.\n",
            "ralmitaront: No <toxicity> found or empty.\n",
            "ralmitaront: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "inupadenant: No <indication> found or empty.\n",
            "inupadenant: No <toxicity> found or empty.\n",
            "inupadenant: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "relmapirazin: No <indication> found or empty.\n",
            "relmapirazin: No <toxicity> found or empty.\n",
            "relmapirazin: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "remlarsen: No <indication> found or empty.\n",
            "remlarsen: No <toxicity> found or empty.\n",
            "remlarsen: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "renadirsen: No <indication> found or empty.\n",
            "renadirsen: No <toxicity> found or empty.\n",
            "renadirsen: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "rezvilutamide: No <indication> found or empty.\n",
            "rezvilutamide: No <toxicity> found or empty.\n",
            "rezvilutamide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "ropanicant: No <indication> found or empty.\n",
            "ropanicant: No <toxicity> found or empty.\n",
            "ropanicant: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "sanfetrinem cilexetil: No <indication> found or empty.\n",
            "sanfetrinem cilexetil: No <toxicity> found or empty.\n",
            "sanfetrinem cilexetil: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "scarlet red: No <indication> found or empty.\n",
            "scarlet red: No <toxicity> found or empty.\n",
            "scarlet red: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "batoprotafib: No <indication> found or empty.\n",
            "batoprotafib: No <toxicity> found or empty.\n",
            "batoprotafib: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "suplatast: No <indication> found or empty.\n",
            "suplatast: No <toxicity> found or empty.\n",
            "suplatast: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "suvecaltamide: No <indication> found or empty.\n",
            "suvecaltamide: No <toxicity> found or empty.\n",
            "suvecaltamide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "evexomostat: No <indication> found or empty.\n",
            "evexomostat: No <toxicity> found or empty.\n",
            "evexomostat: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "tetraarsenic tetrasulfide: No <indication> found or empty.\n",
            "tetraarsenic tetrasulfide: No <toxicity> found or empty.\n",
            "tetraarsenic tetrasulfide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "tanfanercept: No <indication> found or empty.\n",
            "tanfanercept: No <toxicity> found or empty.\n",
            "tanfanercept: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pf-07038124: No <indication> found or empty.\n",
            "pf-07038124: No <toxicity> found or empty.\n",
            "pf-07038124: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "technetium tc-99m maraciclatide: No <indication> found or empty.\n",
            "technetium tc-99m maraciclatide: No <toxicity> found or empty.\n",
            "technetium tc-99m maraciclatide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "baltaleucel-t: No <indication> found or empty.\n",
            "baltaleucel-t: No <toxicity> found or empty.\n",
            "baltaleucel-t: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "limonene, (+/-)-: No <indication> found or empty.\n",
            "limonene, (+/-)-: No <toxicity> found or empty.\n",
            "limonene, (+/-)-: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "mecapegfilgrastim: No <indication> found or empty.\n",
            "mecapegfilgrastim: No <toxicity> found or empty.\n",
            "mecapegfilgrastim: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "nuc-7738: No <indication> found or empty.\n",
            "nuc-7738: No <toxicity> found or empty.\n",
            "nuc-7738: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "nyx-2925: No <indication> found or empty.\n",
            "nyx-2925: No <toxicity> found or empty.\n",
            "nyx-2925: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "arketamine: No <indication> found or empty.\n",
            "arketamine: No <toxicity> found or empty.\n",
            "arketamine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "arasertaconazole: No <indication> found or empty.\n",
            "arasertaconazole: No <toxicity> found or empty.\n",
            "arasertaconazole: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pyrrolidone: No <indication> found or empty.\n",
            "pyrrolidone: No <toxicity> found or empty.\n",
            "pyrrolidone: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "mk-8189: No <indication> found or empty.\n",
            "mk-8189: No <toxicity> found or empty.\n",
            "mk-8189: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "mocemestrocel: No <indication> found or empty.\n",
            "mocemestrocel: No <toxicity> found or empty.\n",
            "mocemestrocel: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "nalotimagene carmaleucel: No <indication> found or empty.\n",
            "nalotimagene carmaleucel: No <toxicity> found or empty.\n",
            "nalotimagene carmaleucel: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "ovemotide: No <indication> found or empty.\n",
            "ovemotide: No <toxicity> found or empty.\n",
            "ovemotide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "zirconium (89zr) crefmirlimab berdoxam: No <indication> found or empty.\n",
            "zirconium (89zr) crefmirlimab berdoxam: No <toxicity> found or empty.\n",
            "zirconium (89zr) crefmirlimab berdoxam: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "p-boronophenylalanine: No <indication> found or empty.\n",
            "p-boronophenylalanine: No <toxicity> found or empty.\n",
            "p-boronophenylalanine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pyrrolizidine: No <indication> found or empty.\n",
            "pyrrolizidine: No <toxicity> found or empty.\n",
            "pyrrolizidine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "quemliclustat: No <indication> found or empty.\n",
            "quemliclustat: No <toxicity> found or empty.\n",
            "quemliclustat: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pudexacianinium: No <indication> found or empty.\n",
            "pudexacianinium: No <toxicity> found or empty.\n",
            "pudexacianinium: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "(r)-propafenone: No <indication> found or empty.\n",
            "(r)-propafenone: No <toxicity> found or empty.\n",
            "(r)-propafenone: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pf-06835919: No <indication> found or empty.\n",
            "pf-06835919: No <toxicity> found or empty.\n",
            "pf-06835919: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "phenazepam: No <indication> found or empty.\n",
            "phenazepam: No <toxicity> found or empty.\n",
            "phenazepam: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pirepemat: No <indication> found or empty.\n",
            "pirepemat: No <toxicity> found or empty.\n",
            "pirepemat: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pixatimod: No <indication> found or empty.\n",
            "pixatimod: No <toxicity> found or empty.\n",
            "pixatimod: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "poloxamine 1304: No <indication> found or empty.\n",
            "poloxamine 1304: No <toxicity> found or empty.\n",
            "poloxamine 1304: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "dexamethasone palmitate: No <indication> found or empty.\n",
            "dexamethasone palmitate: No <toxicity> found or empty.\n",
            "dexamethasone palmitate: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pamapimod: No <indication> found or empty.\n",
            "pamapimod: No <toxicity> found or empty.\n",
            "pamapimod: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pemrametostat: No <indication> found or empty.\n",
            "pemrametostat: No <toxicity> found or empty.\n",
            "pemrametostat: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "ectoine: No <indication> found or empty.\n",
            "ectoine: No <toxicity> found or empty.\n",
            "ectoine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "emoxypine: No <indication> found or empty.\n",
            "emoxypine: No <toxicity> found or empty.\n",
            "emoxypine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "gamma cyclodextrin: No <indication> found or empty.\n",
            "gamma cyclodextrin: No <toxicity> found or empty.\n",
            "gamma cyclodextrin: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "emi-137: No <indication> found or empty.\n",
            "emi-137: No <toxicity> found or empty.\n",
            "emi-137: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "hyaluronic acid (non-animal stabilized): No <indication> found or empty.\n",
            "hyaluronic acid (non-animal stabilized): No <toxicity> found or empty.\n",
            "hyaluronic acid (non-animal stabilized): No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "boclatixafortide gallium ga-68: No <indication> found or empty.\n",
            "boclatixafortide gallium ga-68: No <toxicity> found or empty.\n",
            "boclatixafortide gallium ga-68: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pxs-4728a free base: No <indication> found or empty.\n",
            "pxs-4728a free base: No <toxicity> found or empty.\n",
            "pxs-4728a free base: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "osu-6162: No <indication> found or empty.\n",
            "osu-6162: No <toxicity> found or empty.\n",
            "osu-6162: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "luxeptinib: No <indication> found or empty.\n",
            "luxeptinib: No <toxicity> found or empty.\n",
            "luxeptinib: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "nv-5138: No <indication> found or empty.\n",
            "nv-5138: No <toxicity> found or empty.\n",
            "nv-5138: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "er-176 c-11: No <indication> found or empty.\n",
            "er-176 c-11: No <toxicity> found or empty.\n",
            "er-176 c-11: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "dapiglutide: No <indication> found or empty.\n",
            "dapiglutide: No <toxicity> found or empty.\n",
            "dapiglutide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "onvitrelin ucalontide: No <indication> found or empty.\n",
            "onvitrelin ucalontide: No <toxicity> found or empty.\n",
            "onvitrelin ucalontide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "cv-8102: No <indication> found or empty.\n",
            "cv-8102: No <toxicity> found or empty.\n",
            "cv-8102: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "bifikafusp alfa: No <indication> found or empty.\n",
            "bifikafusp alfa: No <toxicity> found or empty.\n",
            "bifikafusp alfa: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "gonyautoxin ii: No <indication> found or empty.\n",
            "gonyautoxin ii: No <toxicity> found or empty.\n",
            "gonyautoxin ii: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "gonyautoxin iii: No <indication> found or empty.\n",
            "gonyautoxin iii: No <toxicity> found or empty.\n",
            "gonyautoxin iii: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "cenplacel-l: No <indication> found or empty.\n",
            "cenplacel-l: No <toxicity> found or empty.\n",
            "cenplacel-l: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "dpa-714 f-18: No <indication> found or empty.\n",
            "dpa-714 f-18: No <toxicity> found or empty.\n",
            "dpa-714 f-18: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "londamocitinib: No <indication> found or empty.\n",
            "londamocitinib: No <toxicity> found or empty.\n",
            "londamocitinib: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "valiltramiprosate: No <indication> found or empty.\n",
            "valiltramiprosate: No <toxicity> found or empty.\n",
            "valiltramiprosate: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "methylone: No <indication> found or empty.\n",
            "methylone: No <toxicity> found or empty.\n",
            "methylone: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "cfg-920: No <indication> found or empty.\n",
            "cfg-920: No <toxicity> found or empty.\n",
            "cfg-920: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "avx-001: No <indication> found or empty.\n",
            "avx-001: No <toxicity> found or empty.\n",
            "avx-001: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "navafenterol: No <indication> found or empty.\n",
            "navafenterol: No <toxicity> found or empty.\n",
            "navafenterol: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "minigastrin: No <indication> found or empty.\n",
            "minigastrin: No <toxicity> found or empty.\n",
            "minigastrin: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "efepoetin alfa: No <indication> found or empty.\n",
            "efepoetin alfa: No <toxicity> found or empty.\n",
            "efepoetin alfa: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "substance p: No <indication> found or empty.\n",
            "substance p: No <toxicity> found or empty.\n",
            "substance p: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "abbv-744: No <indication> found or empty.\n",
            "abbv-744: No <toxicity> found or empty.\n",
            "abbv-744: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "luvixasertib: No <indication> found or empty.\n",
            "luvixasertib: No <toxicity> found or empty.\n",
            "luvixasertib: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "tamnorzatinib: No <indication> found or empty.\n",
            "tamnorzatinib: No <toxicity> found or empty.\n",
            "tamnorzatinib: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "acoltremon: No <indication> found or empty.\n",
            "acoltremon: No <toxicity> found or empty.\n",
            "acoltremon: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "azd-7268: No <indication> found or empty.\n",
            "azd-7268: No <toxicity> found or empty.\n",
            "azd-7268: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "gb-115: No <indication> found or empty.\n",
            "gb-115: No <toxicity> found or empty.\n",
            "gb-115: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "mak-683: No <indication> found or empty.\n",
            "mak-683: No <toxicity> found or empty.\n",
            "mak-683: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "ono-5334: No <indication> found or empty.\n",
            "ono-5334: No <toxicity> found or empty.\n",
            "ono-5334: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "me-4(18f)dg: No <indication> found or empty.\n",
            "me-4(18f)dg: No <toxicity> found or empty.\n",
            "me-4(18f)dg: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "zed-1227: No <indication> found or empty.\n",
            "zed-1227: No <toxicity> found or empty.\n",
            "zed-1227: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "ruzinurad: No <indication> found or empty.\n",
            "ruzinurad: No <toxicity> found or empty.\n",
            "ruzinurad: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "sx-682: No <indication> found or empty.\n",
            "sx-682: No <toxicity> found or empty.\n",
            "sx-682: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "cp-778875: No <indication> found or empty.\n",
            "cp-778875: No <toxicity> found or empty.\n",
            "cp-778875: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pf-5212372: No <indication> found or empty.\n",
            "pf-5212372: No <toxicity> found or empty.\n",
            "pf-5212372: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "adam i-123: No <indication> found or empty.\n",
            "adam i-123: No <toxicity> found or empty.\n",
            "adam i-123: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "lb-102: No <indication> found or empty.\n",
            "lb-102: No <toxicity> found or empty.\n",
            "lb-102: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "florquinitau (18f): No <indication> found or empty.\n",
            "florquinitau (18f): No <toxicity> found or empty.\n",
            "florquinitau (18f): No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "bo-653: No <indication> found or empty.\n",
            "bo-653: No <toxicity> found or empty.\n",
            "bo-653: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "camlipixant: No <indication> found or empty.\n",
            "camlipixant: No <toxicity> found or empty.\n",
            "camlipixant: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "camizestrant: No <indication> found or empty.\n",
            "camizestrant: No <toxicity> found or empty.\n",
            "camizestrant: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine: No <indication> found or empty.\n",
            "autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine: No <toxicity> found or empty.\n",
            "autologous ex vivo expanded cd4+-enriched leukocytes treated with the de-methylating agent 5-aza-deoxycytidine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pegmusirudin: No <indication> found or empty.\n",
            "pegmusirudin: No <toxicity> found or empty.\n",
            "pegmusirudin: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "2-(1-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-sulfanyl-3-piperidinylidene) acetic acid: No <indication> found or empty.\n",
            "2-(1-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-sulfanyl-3-piperidinylidene) acetic acid: No <toxicity> found or empty.\n",
            "2-(1-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-sulfanyl-3-piperidinylidene) acetic acid: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "thk-5351: No <indication> found or empty.\n",
            "thk-5351: No <toxicity> found or empty.\n",
            "thk-5351: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "thk-5351 f-18: No <indication> found or empty.\n",
            "thk-5351 f-18: No <toxicity> found or empty.\n",
            "thk-5351 f-18: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "acemannan: No <indication> found or empty.\n",
            "acemannan: No <toxicity> found or empty.\n",
            "acemannan: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "cocaine esterase (rbp-8000): No <indication> found or empty.\n",
            "cocaine esterase (rbp-8000): No <toxicity> found or empty.\n",
            "cocaine esterase (rbp-8000): No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "hepcidin-25: No <indication> found or empty.\n",
            "hepcidin-25: No <toxicity> found or empty.\n",
            "hepcidin-25: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "human growth hormone-releasing peptide 3: No <indication> found or empty.\n",
            "human growth hormone-releasing peptide 3: No <toxicity> found or empty.\n",
            "human growth hormone-releasing peptide 3: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "zirconium panitumumab zr-89: No <indication> found or empty.\n",
            "zirconium panitumumab zr-89: No <toxicity> found or empty.\n",
            "zirconium panitumumab zr-89: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "omfiloctocog alfa: No <indication> found or empty.\n",
            "omfiloctocog alfa: No <toxicity> found or empty.\n",
            "omfiloctocog alfa: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pegloxenatide: No <indication> found or empty.\n",
            "pegloxenatide: No <toxicity> found or empty.\n",
            "pegloxenatide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "quaratusugene ozeplasmid: No <indication> found or empty.\n",
            "quaratusugene ozeplasmid: No <toxicity> found or empty.\n",
            "quaratusugene ozeplasmid: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "recombinant human kallikrein-1: No <indication> found or empty.\n",
            "recombinant human kallikrein-1: No <toxicity> found or empty.\n",
            "recombinant human kallikrein-1: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "rozibafusp alfa: No <indication> found or empty.\n",
            "rozibafusp alfa: No <toxicity> found or empty.\n",
            "rozibafusp alfa: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "atexakin alfa: No <indication> found or empty.\n",
            "atexakin alfa: No <toxicity> found or empty.\n",
            "atexakin alfa: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "hemoglobin glutamer-250 (bovine): No <indication> found or empty.\n",
            "hemoglobin glutamer-250 (bovine): No <toxicity> found or empty.\n",
            "hemoglobin glutamer-250 (bovine): No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "beperminogene perplasmid: No <indication> found or empty.\n",
            "beperminogene perplasmid: No <toxicity> found or empty.\n",
            "beperminogene perplasmid: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "arazasetron: No <indication> found or empty.\n",
            "arazasetron: No <toxicity> found or empty.\n",
            "arazasetron: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "zotizalkib: No <indication> found or empty.\n",
            "zotizalkib: No <toxicity> found or empty.\n",
            "zotizalkib: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "tigozertinib: No <indication> found or empty.\n",
            "tigozertinib: No <toxicity> found or empty.\n",
            "tigozertinib: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "cetuximab sarotalocan: No <indication> found or empty.\n",
            "cetuximab sarotalocan: No <toxicity> found or empty.\n",
            "cetuximab sarotalocan: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "lunresertib: No <indication> found or empty.\n",
            "lunresertib: No <toxicity> found or empty.\n",
            "lunresertib: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "eragidomide: No <indication> found or empty.\n",
            "eragidomide: No <toxicity> found or empty.\n",
            "eragidomide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "padnarsertib: No <indication> found or empty.\n",
            "padnarsertib: No <toxicity> found or empty.\n",
            "padnarsertib: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "lixudebart: No <indication> found or empty.\n",
            "lixudebart: No <toxicity> found or empty.\n",
            "lixudebart: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "bacillus cereus: No <indication> found or empty.\n",
            "bacillus cereus: No <toxicity> found or empty.\n",
            "bacillus cereus: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "bacillus coagulans: No <indication> found or empty.\n",
            "bacillus coagulans: No <toxicity> found or empty.\n",
            "bacillus coagulans: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "bacillus licheniformis: No <indication> found or empty.\n",
            "bacillus licheniformis: No <toxicity> found or empty.\n",
            "bacillus licheniformis: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "bifidobacterium longum: No <indication> found or empty.\n",
            "bifidobacterium longum: No <toxicity> found or empty.\n",
            "bifidobacterium longum: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "bos taurus colostrum: No <indication> found or empty.\n",
            "bos taurus colostrum: No <toxicity> found or empty.\n",
            "bos taurus colostrum: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "cesium cs-131: No <indication> found or empty.\n",
            "cesium cs-131: No <toxicity> found or empty.\n",
            "cesium cs-131: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "deuterium oxide: No <indication> found or empty.\n",
            "deuterium oxide: No <toxicity> found or empty.\n",
            "deuterium oxide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "ecklonia cava: No <indication> found or empty.\n",
            "ecklonia cava: No <toxicity> found or empty.\n",
            "ecklonia cava: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "dexepicatechin: No <indication> found or empty.\n",
            "dexepicatechin: No <toxicity> found or empty.\n",
            "dexepicatechin: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "fallypride f-18: No <indication> found or empty.\n",
            "fallypride f-18: No <toxicity> found or empty.\n",
            "fallypride f-18: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "gingerol: No <indication> found or empty.\n",
            "gingerol: No <toxicity> found or empty.\n",
            "gingerol: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "ginsenoside rd: No <indication> found or empty.\n",
            "ginsenoside rd: No <toxicity> found or empty.\n",
            "ginsenoside rd: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "ginsenoside rg3: No <indication> found or empty.\n",
            "ginsenoside rg3: No <toxicity> found or empty.\n",
            "ginsenoside rg3: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "glp-1 (7-36) amide: No <indication> found or empty.\n",
            "glp-1 (7-36) amide: No <toxicity> found or empty.\n",
            "glp-1 (7-36) amide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "growth hormone-releasing peptide 1: No <indication> found or empty.\n",
            "growth hormone-releasing peptide 1: No <toxicity> found or empty.\n",
            "growth hormone-releasing peptide 1: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "transferrin aldifitox: No <indication> found or empty.\n",
            "transferrin aldifitox: No <toxicity> found or empty.\n",
            "transferrin aldifitox: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "cannabidiolic acid: No <indication> found or empty.\n",
            "cannabidiolic acid: No <toxicity> found or empty.\n",
            "cannabidiolic acid: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "grifola frondosa whole: No <indication> found or empty.\n",
            "grifola frondosa whole: No <toxicity> found or empty.\n",
            "grifola frondosa whole: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "orellanine: No <indication> found or empty.\n",
            "orellanine: No <toxicity> found or empty.\n",
            "orellanine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "ovatodiolide: No <indication> found or empty.\n",
            "ovatodiolide: No <toxicity> found or empty.\n",
            "ovatodiolide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "phytochlorin: No <indication> found or empty.\n",
            "phytochlorin: No <toxicity> found or empty.\n",
            "phytochlorin: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "rhenium re-186: No <indication> found or empty.\n",
            "rhenium re-186: No <toxicity> found or empty.\n",
            "rhenium re-186: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "rhenium re-188: No <indication> found or empty.\n",
            "rhenium re-188: No <toxicity> found or empty.\n",
            "rhenium re-188: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "romyelocel-l: No <indication> found or empty.\n",
            "romyelocel-l: No <toxicity> found or empty.\n",
            "romyelocel-l: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "oxb-301: No <indication> found or empty.\n",
            "oxb-301: No <toxicity> found or empty.\n",
            "oxb-301: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "obi-833: No <indication> found or empty.\n",
            "obi-833: No <toxicity> found or empty.\n",
            "obi-833: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "yeast beta-d-glucan: No <indication> found or empty.\n",
            "yeast beta-d-glucan: No <toxicity> found or empty.\n",
            "yeast beta-d-glucan: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "taiwanofungus camphoratus fruiting body: No <indication> found or empty.\n",
            "taiwanofungus camphoratus fruiting body: No <toxicity> found or empty.\n",
            "taiwanofungus camphoratus fruiting body: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "streptodornase: No <indication> found or empty.\n",
            "streptodornase: No <toxicity> found or empty.\n",
            "streptodornase: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "streptococcus salivarius: No <indication> found or empty.\n",
            "streptococcus salivarius: No <toxicity> found or empty.\n",
            "streptococcus salivarius: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "stapuldencel: No <indication> found or empty.\n",
            "stapuldencel: No <toxicity> found or empty.\n",
            "stapuldencel: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "stachyose: No <indication> found or empty.\n",
            "stachyose: No <toxicity> found or empty.\n",
            "stachyose: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "omilancor: No <indication> found or empty.\n",
            "omilancor: No <toxicity> found or empty.\n",
            "omilancor: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "zasocitinib: No <indication> found or empty.\n",
            "zasocitinib: No <toxicity> found or empty.\n",
            "zasocitinib: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "peptide-t: No <indication> found or empty.\n",
            "peptide-t: No <toxicity> found or empty.\n",
            "peptide-t: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "meppep c-11: No <indication> found or empty.\n",
            "meppep c-11: No <toxicity> found or empty.\n",
            "meppep c-11: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "licochalcone a: No <indication> found or empty.\n",
            "licochalcone a: No <toxicity> found or empty.\n",
            "licochalcone a: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "lacticaseibacillus rhamnosus: No <indication> found or empty.\n",
            "lacticaseibacillus rhamnosus: No <toxicity> found or empty.\n",
            "lacticaseibacillus rhamnosus: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "honokiol: No <indication> found or empty.\n",
            "honokiol: No <toxicity> found or empty.\n",
            "honokiol: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pseudomonas aeruginosa: No <indication> found or empty.\n",
            "pseudomonas aeruginosa: No <toxicity> found or empty.\n",
            "pseudomonas aeruginosa: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "hemoglobin glutamer-256 (human): No <indication> found or empty.\n",
            "hemoglobin glutamer-256 (human): No <toxicity> found or empty.\n",
            "hemoglobin glutamer-256 (human): No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "human colostrum: No <indication> found or empty.\n",
            "human colostrum: No <toxicity> found or empty.\n",
            "human colostrum: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "fs-1502: No <indication> found or empty.\n",
            "fs-1502: No <toxicity> found or empty.\n",
            "fs-1502: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "ophiocordyceps sinensis: No <indication> found or empty.\n",
            "ophiocordyceps sinensis: No <toxicity> found or empty.\n",
            "ophiocordyceps sinensis: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "xanthium sibiricum fruit: No <indication> found or empty.\n",
            "xanthium sibiricum fruit: No <toxicity> found or empty.\n",
            "xanthium sibiricum fruit: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "monophosphoryl lipid a: No <indication> found or empty.\n",
            "monophosphoryl lipid a: No <toxicity> found or empty.\n",
            "monophosphoryl lipid a: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "cancer/testis antigen 1: No <indication> found or empty.\n",
            "cancer/testis antigen 1: No <toxicity> found or empty.\n",
            "cancer/testis antigen 1: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "vcp2292: No <indication> found or empty.\n",
            "vcp2292: No <toxicity> found or empty.\n",
            "vcp2292: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "cdx-301: No <indication> found or empty.\n",
            "cdx-301: No <toxicity> found or empty.\n",
            "cdx-301: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "japanese encephalitis virus vaccine inactivated: No <indication> found or empty.\n",
            "japanese encephalitis virus vaccine inactivated: No <toxicity> found or empty.\n",
            "japanese encephalitis virus vaccine inactivated: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "platelet rich plasma: No <indication> found or empty.\n",
            "platelet rich plasma: No <toxicity> found or empty.\n",
            "platelet rich plasma: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "linopristin: No <indication> found or empty.\n",
            "linopristin: No <toxicity> found or empty.\n",
            "linopristin: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "human placenta hydrolysate: No <indication> found or empty.\n",
            "human placenta hydrolysate: No <toxicity> found or empty.\n",
            "human placenta hydrolysate: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "7mw3711: No <indication> found or empty.\n",
            "7mw3711: No <toxicity> found or empty.\n",
            "7mw3711: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "interleukin-12 human recombinant: No <indication> found or empty.\n",
            "interleukin-12 human recombinant: No <toxicity> found or empty.\n",
            "interleukin-12 human recombinant: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "crisugabalin: No <indication> found or empty.\n",
            "crisugabalin: No <toxicity> found or empty.\n",
            "crisugabalin: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "solrikitug: No <indication> found or empty.\n",
            "solrikitug: No <toxicity> found or empty.\n",
            "solrikitug: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "recaticimab: No <indication> found or empty.\n",
            "recaticimab: No <toxicity> found or empty.\n",
            "recaticimab: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "bemiltenase alfa: No <indication> found or empty.\n",
            "bemiltenase alfa: No <toxicity> found or empty.\n",
            "bemiltenase alfa: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "rem-422: No <indication> found or empty.\n",
            "rem-422: No <toxicity> found or empty.\n",
            "rem-422: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "jnt-517: No <indication> found or empty.\n",
            "jnt-517: No <toxicity> found or empty.\n",
            "jnt-517: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "xk-469 free acid: No <indication> found or empty.\n",
            "xk-469 free acid: No <toxicity> found or empty.\n",
            "xk-469 free acid: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "human anti-il-6 monoclonal antibody (pf-04236921): No <indication> found or empty.\n",
            "human anti-il-6 monoclonal antibody (pf-04236921): No <toxicity> found or empty.\n",
            "human anti-il-6 monoclonal antibody (pf-04236921): No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "coptisine: No <indication> found or empty.\n",
            "coptisine: No <toxicity> found or empty.\n",
            "coptisine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "imm-0306: No <indication> found or empty.\n",
            "imm-0306: No <toxicity> found or empty.\n",
            "imm-0306: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "rhodamine 123 free base: No <indication> found or empty.\n",
            "rhodamine 123 free base: No <toxicity> found or empty.\n",
            "rhodamine 123 free base: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "farglitazar: No <indication> found or empty.\n",
            "farglitazar: No <toxicity> found or empty.\n",
            "farglitazar: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "sipoglitazar: No <indication> found or empty.\n",
            "sipoglitazar: No <toxicity> found or empty.\n",
            "sipoglitazar: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "salvianolic acid b: No <indication> found or empty.\n",
            "salvianolic acid b: No <toxicity> found or empty.\n",
            "salvianolic acid b: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "nemonapride: No <indication> found or empty.\n",
            "nemonapride: No <toxicity> found or empty.\n",
            "nemonapride: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "zelasudil: No <indication> found or empty.\n",
            "zelasudil: No <toxicity> found or empty.\n",
            "zelasudil: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "budoprutug: No <indication> found or empty.\n",
            "budoprutug: No <toxicity> found or empty.\n",
            "budoprutug: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "kt-a261: No <indication> found or empty.\n",
            "kt-a261: No <toxicity> found or empty.\n",
            "kt-a261: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pegtarazimod: No <indication> found or empty.\n",
            "pegtarazimod: No <toxicity> found or empty.\n",
            "pegtarazimod: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "enisoprost: No <indication> found or empty.\n",
            "enisoprost: No <toxicity> found or empty.\n",
            "enisoprost: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "influenza a virus a/thailand/8/2022 ivr-237 (h3n2) antigen (propiolactone inactivated): No <indication> found or empty.\n",
            "influenza a virus a/thailand/8/2022 ivr-237 (h3n2) antigen (propiolactone inactivated): No <toxicity> found or empty.\n",
            "influenza a virus a/thailand/8/2022 ivr-237 (h3n2) antigen (propiolactone inactivated): No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "influenza a virus a/sydney/1304/2022 (h3n2) antigen (mdck cell derived, propiolactone inactivated): No <indication> found or empty.\n",
            "influenza a virus a/sydney/1304/2022 (h3n2) antigen (mdck cell derived, propiolactone inactivated): No <toxicity> found or empty.\n",
            "influenza a virus a/sydney/1304/2022 (h3n2) antigen (mdck cell derived, propiolactone inactivated): No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "influenza a virus a/massachusetts/18/2022 (h3n2) recombinant hemagglutinin antigen: No <indication> found or empty.\n",
            "influenza a virus a/massachusetts/18/2022 (h3n2) recombinant hemagglutinin antigen: No <toxicity> found or empty.\n",
            "influenza a virus a/massachusetts/18/2022 (h3n2) recombinant hemagglutinin antigen: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "influenza a virus a/thailand/8/2022 ivr-237 (h3n2) antigen (formaldehyde inactivated): No <indication> found or empty.\n",
            "influenza a virus a/thailand/8/2022 ivr-237 (h3n2) antigen (formaldehyde inactivated): No <toxicity> found or empty.\n",
            "influenza a virus a/thailand/8/2022 ivr-237 (h3n2) antigen (formaldehyde inactivated): No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "influenza a virus a/thailand/8/2022 ivr-237 antigen (uv, formaldehyde inactivated): No <indication> found or empty.\n",
            "influenza a virus a/thailand/8/2022 ivr-237 antigen (uv, formaldehyde inactivated): No <toxicity> found or empty.\n",
            "influenza a virus a/thailand/8/2022 ivr-237 antigen (uv, formaldehyde inactivated): No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "sabestomig: No <indication> found or empty.\n",
            "sabestomig: No <toxicity> found or empty.\n",
            "sabestomig: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "vilastobart: No <indication> found or empty.\n",
            "vilastobart: No <toxicity> found or empty.\n",
            "vilastobart: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "bleximenib: No <indication> found or empty.\n",
            "bleximenib: No <toxicity> found or empty.\n",
            "bleximenib: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "azelaprag: No <indication> found or empty.\n",
            "azelaprag: No <toxicity> found or empty.\n",
            "azelaprag: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "tomligisiran: No <indication> found or empty.\n",
            "tomligisiran: No <toxicity> found or empty.\n",
            "tomligisiran: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "daplusiran: No <indication> found or empty.\n",
            "daplusiran: No <toxicity> found or empty.\n",
            "daplusiran: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "zifibancimig: No <indication> found or empty.\n",
            "zifibancimig: No <toxicity> found or empty.\n",
            "zifibancimig: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "abiprubart: No <indication> found or empty.\n",
            "abiprubart: No <toxicity> found or empty.\n",
            "abiprubart: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "nelistotug: No <indication> found or empty.\n",
            "nelistotug: No <toxicity> found or empty.\n",
            "nelistotug: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "peginterferon alfacon-2: No <indication> found or empty.\n",
            "peginterferon alfacon-2: No <toxicity> found or empty.\n",
            "peginterferon alfacon-2: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "zelquistinel: No <indication> found or empty.\n",
            "zelquistinel: No <toxicity> found or empty.\n",
            "zelquistinel: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "nesvategrast: No <indication> found or empty.\n",
            "nesvategrast: No <toxicity> found or empty.\n",
            "nesvategrast: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "tebapivat: No <indication> found or empty.\n",
            "tebapivat: No <toxicity> found or empty.\n",
            "tebapivat: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "maridebart cafraglutide: No <indication> found or empty.\n",
            "maridebart cafraglutide: No <toxicity> found or empty.\n",
            "maridebart cafraglutide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "tabirafusp tedromer: No <indication> found or empty.\n",
            "tabirafusp tedromer: No <toxicity> found or empty.\n",
            "tabirafusp tedromer: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "englumafusp alfa: No <indication> found or empty.\n",
            "englumafusp alfa: No <toxicity> found or empty.\n",
            "englumafusp alfa: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "streptococcus pneumoniae type 9n capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <indication> found or empty.\n",
            "streptococcus pneumoniae type 9n capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <toxicity> found or empty.\n",
            "streptococcus pneumoniae type 9n capsular polysaccharide diphtheria crm197 protein conjugate antigen: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "streptococcus pneumoniae type 15a capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <indication> found or empty.\n",
            "streptococcus pneumoniae type 15a capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <toxicity> found or empty.\n",
            "streptococcus pneumoniae type 15a capsular polysaccharide diphtheria crm197 protein conjugate antigen: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "streptococcus pneumoniae type deoac15b capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <indication> found or empty.\n",
            "streptococcus pneumoniae type deoac15b capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <toxicity> found or empty.\n",
            "streptococcus pneumoniae type deoac15b capsular polysaccharide diphtheria crm197 protein conjugate antigen: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "streptococcus pneumoniae type 16f capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <indication> found or empty.\n",
            "streptococcus pneumoniae type 16f capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <toxicity> found or empty.\n",
            "streptococcus pneumoniae type 16f capsular polysaccharide diphtheria crm197 protein conjugate antigen: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "streptococcus pneumoniae type 17f capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <indication> found or empty.\n",
            "streptococcus pneumoniae type 17f capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <toxicity> found or empty.\n",
            "streptococcus pneumoniae type 17f capsular polysaccharide diphtheria crm197 protein conjugate antigen: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "streptococcus pneumoniae type 20a capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <indication> found or empty.\n",
            "streptococcus pneumoniae type 20a capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <toxicity> found or empty.\n",
            "streptococcus pneumoniae type 20a capsular polysaccharide diphtheria crm197 protein conjugate antigen: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "streptococcus pneumoniae type 23a capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <indication> found or empty.\n",
            "streptococcus pneumoniae type 23a capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <toxicity> found or empty.\n",
            "streptococcus pneumoniae type 23a capsular polysaccharide diphtheria crm197 protein conjugate antigen: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "streptococcus pneumoniae type 23b capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <indication> found or empty.\n",
            "streptococcus pneumoniae type 23b capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <toxicity> found or empty.\n",
            "streptococcus pneumoniae type 23b capsular polysaccharide diphtheria crm197 protein conjugate antigen: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "streptococcus pneumoniae type 24f capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <indication> found or empty.\n",
            "streptococcus pneumoniae type 24f capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <toxicity> found or empty.\n",
            "streptococcus pneumoniae type 24f capsular polysaccharide diphtheria crm197 protein conjugate antigen: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "streptococcus pneumoniae type 31 capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <indication> found or empty.\n",
            "streptococcus pneumoniae type 31 capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <toxicity> found or empty.\n",
            "streptococcus pneumoniae type 31 capsular polysaccharide diphtheria crm197 protein conjugate antigen: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "streptococcus pneumoniae type 35b capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <indication> found or empty.\n",
            "streptococcus pneumoniae type 35b capsular polysaccharide diphtheria crm197 protein conjugate antigen: No <toxicity> found or empty.\n",
            "streptococcus pneumoniae type 35b capsular polysaccharide diphtheria crm197 protein conjugate antigen: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "hydrastine: No <indication> found or empty.\n",
            "hydrastine: No <toxicity> found or empty.\n",
            "hydrastine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "chlorindanol: No <indication> found or empty.\n",
            "chlorindanol: No <toxicity> found or empty.\n",
            "chlorindanol: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "carboprost: No <indication> found or empty.\n",
            "carboprost: No <toxicity> found or empty.\n",
            "carboprost: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "salicin: No <indication> found or empty.\n",
            "salicin: No <toxicity> found or empty.\n",
            "salicin: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "chlorisondamine: No <indication> found or empty.\n",
            "chlorisondamine: No <toxicity> found or empty.\n",
            "chlorisondamine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "hydrastinine: No <indication> found or empty.\n",
            "hydrastinine: No <toxicity> found or empty.\n",
            "hydrastinine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "latanoprost acid: No <indication> found or empty.\n",
            "latanoprost acid: No <toxicity> found or empty.\n",
            "latanoprost acid: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "aurothioglycanide: No <indication> found or empty.\n",
            "aurothioglycanide: No <toxicity> found or empty.\n",
            "aurothioglycanide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "glyceryl monocaprylate: No <indication> found or empty.\n",
            "glyceryl monocaprylate: No <toxicity> found or empty.\n",
            "glyceryl monocaprylate: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "mephenesin carbamate: No <indication> found or empty.\n",
            "mephenesin carbamate: No <toxicity> found or empty.\n",
            "mephenesin carbamate: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "azaribine: No <indication> found or empty.\n",
            "azaribine: No <toxicity> found or empty.\n",
            "azaribine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "aminometradine: No <indication> found or empty.\n",
            "aminometradine: No <toxicity> found or empty.\n",
            "aminometradine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "tiphenamil: No <indication> found or empty.\n",
            "tiphenamil: No <toxicity> found or empty.\n",
            "tiphenamil: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "amisometradine: No <indication> found or empty.\n",
            "amisometradine: No <toxicity> found or empty.\n",
            "amisometradine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "mitomycin a: No <indication> found or empty.\n",
            "mitomycin a: No <toxicity> found or empty.\n",
            "mitomycin a: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "methylhexaneamine: No <indication> found or empty.\n",
            "methylhexaneamine: No <toxicity> found or empty.\n",
            "methylhexaneamine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "nithiamide: No <indication> found or empty.\n",
            "nithiamide: No <toxicity> found or empty.\n",
            "nithiamide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "zoxazolamine: No <indication> found or empty.\n",
            "zoxazolamine: No <toxicity> found or empty.\n",
            "zoxazolamine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "phenaglycodol: No <indication> found or empty.\n",
            "phenaglycodol: No <toxicity> found or empty.\n",
            "phenaglycodol: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "octodrine: No <indication> found or empty.\n",
            "octodrine: No <toxicity> found or empty.\n",
            "octodrine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "chlorothymol: No <indication> found or empty.\n",
            "chlorothymol: No <toxicity> found or empty.\n",
            "chlorothymol: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "salicylanilide: No <indication> found or empty.\n",
            "salicylanilide: No <toxicity> found or empty.\n",
            "salicylanilide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "santonin: No <indication> found or empty.\n",
            "santonin: No <toxicity> found or empty.\n",
            "santonin: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "megestrol: No <indication> found or empty.\n",
            "megestrol: No <toxicity> found or empty.\n",
            "megestrol: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "syrosingopine: No <indication> found or empty.\n",
            "syrosingopine: No <toxicity> found or empty.\n",
            "syrosingopine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "parethoxycaine: No <indication> found or empty.\n",
            "parethoxycaine: No <toxicity> found or empty.\n",
            "parethoxycaine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "azacyclonol: No <indication> found or empty.\n",
            "azacyclonol: No <toxicity> found or empty.\n",
            "azacyclonol: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "benzoylpas: No <indication> found or empty.\n",
            "benzoylpas: No <toxicity> found or empty.\n",
            "benzoylpas: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pentapiperium: No <indication> found or empty.\n",
            "pentapiperium: No <toxicity> found or empty.\n",
            "pentapiperium: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "propionate ion: No <indication> found or empty.\n",
            "propionate ion: No <toxicity> found or empty.\n",
            "propionate ion: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "asm-024 cation: No <indication> found or empty.\n",
            "asm-024 cation: No <toxicity> found or empty.\n",
            "asm-024 cation: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "miramistin ion: No <indication> found or empty.\n",
            "miramistin ion: No <toxicity> found or empty.\n",
            "miramistin ion: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "acetomenaphthone: No <indication> found or empty.\n",
            "acetomenaphthone: No <toxicity> found or empty.\n",
            "acetomenaphthone: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "ion356: No <indication> found or empty.\n",
            "ion356: No <toxicity> found or empty.\n",
            "ion356: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "ba1301: No <indication> found or empty.\n",
            "ba1301: No <toxicity> found or empty.\n",
            "ba1301: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "azd8630: No <indication> found or empty.\n",
            "azd8630: No <toxicity> found or empty.\n",
            "azd8630: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "fosigotifator: No <indication> found or empty.\n",
            "fosigotifator: No <toxicity> found or empty.\n",
            "fosigotifator: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "evalstotug: No <indication> found or empty.\n",
            "evalstotug: No <toxicity> found or empty.\n",
            "evalstotug: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "coramitug: No <indication> found or empty.\n",
            "coramitug: No <toxicity> found or empty.\n",
            "coramitug: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "xempritolimod: No <indication> found or empty.\n",
            "xempritolimod: No <toxicity> found or empty.\n",
            "xempritolimod: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "influenza a virus a/thailand/8/2022 ivr-237 (h3n2) whole: No <indication> found or empty.\n",
            "influenza a virus a/thailand/8/2022 ivr-237 (h3n2) whole: No <toxicity> found or empty.\n",
            "influenza a virus a/thailand/8/2022 ivr-237 (h3n2) whole: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "cx-046684: No <indication> found or empty.\n",
            "cx-046684: No <toxicity> found or empty.\n",
            "cx-046684: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "bnt162b2 omicron (kp.2): No <indication> found or empty.\n",
            "bnt162b2 omicron (kp.2): No <toxicity> found or empty.\n",
            "bnt162b2 omicron (kp.2): No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "mevonlerbart: No <indication> found or empty.\n",
            "mevonlerbart: No <toxicity> found or empty.\n",
            "mevonlerbart: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "bremzalerbart: No <indication> found or empty.\n",
            "bremzalerbart: No <toxicity> found or empty.\n",
            "bremzalerbart: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "atisnolerbart: No <indication> found or empty.\n",
            "atisnolerbart: No <toxicity> found or empty.\n",
            "atisnolerbart: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "azadirachtin: No <indication> found or empty.\n",
            "azadirachtin: No <toxicity> found or empty.\n",
            "azadirachtin: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "tnb-486: No <indication> found or empty.\n",
            "tnb-486: No <toxicity> found or empty.\n",
            "tnb-486: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "mosliciguat: No <indication> found or empty.\n",
            "mosliciguat: No <toxicity> found or empty.\n",
            "mosliciguat: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "dt-dec01: No <indication> found or empty.\n",
            "dt-dec01: No <toxicity> found or empty.\n",
            "dt-dec01: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "epoetin beta: No <indication> found or empty.\n",
            "epoetin beta: No <toxicity> found or empty.\n",
            "epoetin beta: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "l-lysyl-l-arginine: No <indication> found or empty.\n",
            "l-lysyl-l-arginine: No <toxicity> found or empty.\n",
            "l-lysyl-l-arginine: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "pralurbactam: No <indication> found or empty.\n",
            "pralurbactam: No <toxicity> found or empty.\n",
            "pralurbactam: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "sabirnetug: No <indication> found or empty.\n",
            "sabirnetug: No <toxicity> found or empty.\n",
            "sabirnetug: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "atilotrelvir: No <indication> found or empty.\n",
            "atilotrelvir: No <toxicity> found or empty.\n",
            "atilotrelvir: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "firazorexton: No <indication> found or empty.\n",
            "firazorexton: No <toxicity> found or empty.\n",
            "firazorexton: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "brenetafusp: No <indication> found or empty.\n",
            "brenetafusp: No <toxicity> found or empty.\n",
            "brenetafusp: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "petrelintide: No <indication> found or empty.\n",
            "petrelintide: No <toxicity> found or empty.\n",
            "petrelintide: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "zuberitamab: No <indication> found or empty.\n",
            "zuberitamab: No <toxicity> found or empty.\n",
            "zuberitamab: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "duvakitug: No <indication> found or empty.\n",
            "duvakitug: No <toxicity> found or empty.\n",
            "duvakitug: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "rocbrutinib: No <indication> found or empty.\n",
            "rocbrutinib: No <toxicity> found or empty.\n",
            "rocbrutinib: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "tulmimetostat: No <indication> found or empty.\n",
            "tulmimetostat: No <toxicity> found or empty.\n",
            "tulmimetostat: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "raludotatug deruxtecan: No <indication> found or empty.\n",
            "raludotatug deruxtecan: No <toxicity> found or empty.\n",
            "raludotatug deruxtecan: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "tdi-01: No <indication> found or empty.\n",
            "tdi-01: No <toxicity> found or empty.\n",
            "tdi-01: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "ibuzatrelvir: No <indication> found or empty.\n",
            "ibuzatrelvir: No <toxicity> found or empty.\n",
            "ibuzatrelvir: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "exidavnemab: No <indication> found or empty.\n",
            "exidavnemab: No <toxicity> found or empty.\n",
            "exidavnemab: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "imciromab pentetate: No <indication> found or empty.\n",
            "imciromab pentetate: No <toxicity> found or empty.\n",
            "imciromab pentetate: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "cetyl oleate: No <indication> found or empty.\n",
            "cetyl oleate: No <toxicity> found or empty.\n",
            "cetyl oleate: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "cetyl myristoleate: No <indication> found or empty.\n",
            "cetyl myristoleate: No <toxicity> found or empty.\n",
            "cetyl myristoleate: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "cetyl palmitoleate: No <indication> found or empty.\n",
            "cetyl palmitoleate: No <toxicity> found or empty.\n",
            "cetyl palmitoleate: No specific <adverse-effects> field; using <toxicity> as fallback.\n",
            "Sample Drug Entry (lepirudin):\n",
            "{'indications': 'Not specified', 'dosage': 'Not specified', 'contraindications': 'Not specified', 'interactions': 'Not specified', 'side_effects': 'Not specified'}\n",
            "Raw XML for lepirudin:\n",
            "<drug xmlns=\"http://www.drugbank.ca\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\" type=\"biotech\" created=\"2005-06-13\" updated=\"2024-11-03\">\n",
            "  <drugbank-id primary=\"true\">DB00001</drugbank-id>\n",
            "  <drugbank-id>BTD00024</drugbank-id>\n",
            "  <drugbank-id>BIOD00024</drugbank-id>\n",
            "  <name>Lepirudin</name>\n",
            "  <description>Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).[A246609] &#13;\n",
            "&#13;\n",
            "Lepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]</description>\n",
            "  <cas-number>138068-37-8</cas-number>\n",
            "  <unii>Y43GF64R34</unii>\n",
            "  <state>solid</state>\n",
            "  <groups>\n",
            "    <group>approved</group>\n",
            "    <group>withdrawn</group>\n",
            "  </groups>\n",
            "  <general-references>\n",
            "    <articles>\n",
            "      <article>\n",
            "        <ref-id>A1</ref-id>\n",
            "        <pubmed-id>16244762</pubmed-id>\n",
            "        <citation>Smythe MA, Stephens JL, Koerber JM, Mattson JC: A comparison of lepirudin and argatroban outcomes. Clin Appl Thromb Hemost. 2005 Oct;11(4):371-4.</citation>\n",
            "      </article>\n",
            "      <article>\n",
            "        <ref-id>A2</ref-id>\n",
            "        <pubmed-id>16690967</pubmed-id>\n",
            "        <citation>Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V: Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006 Sep 1;108(5):1492-6. Epub 2006 May 11.</citation>\n",
            "      </article>\n",
            "      <article>\n",
            "        <ref-id>A3</ref-id>\n",
            "        <pubmed-id>16241940</pubmed-id>\n",
            "        <citation>Lubenow N, Eichler P, Lietz T, Greinacher A: Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005 Nov;3(11):2428-36.</citation>\n",
            "      </article>\n",
            "      <article>\n",
            "        <ref-id>A246609</ref-id>\n",
            "        <pubmed-id>19707378</pubmed-id>\n",
            "        <citation>Petros S: Lepirudin in the management of patients with heparin-induced thrombocytopenia. Biologics. 2008 Sep;2(3):481-90. doi: 10.2147/btt.s3415.</citation>\n",
            "      </article>\n",
            "      <article>\n",
            "        <ref-id>A246624</ref-id>\n",
            "        <pubmed-id>25294122</pubmed-id>\n",
            "        <citation>Chapin JC, Hajjar KA: Fibrinolysis and the control of blood coagulation. Blood Rev. 2015 Jan;29(1):17-24. doi: 10.1016/j.blre.2014.09.003. Epub 2014 Sep 16.</citation>\n",
            "      </article>\n",
            "    </articles>\n",
            "    <textbooks/>\n",
            "    <links>\n",
            "      <link>\n",
            "        <ref-id>L48</ref-id>\n",
            "        <title>Google books</title>\n",
            "        <url>http://books.google.com/books?id=iadLoXoQkWEC&amp;pg=PA440</url>\n",
            "      </link>\n",
            "      <link>\n",
            "        <ref-id>L41539</ref-id>\n",
            "        <title>Health Canada Approved Drug Products: Refludan (lepirudin) lyophilized powder for intravenous injection</title>\n",
            "        <url>https://pdf.hres.ca/dpd_pm/00004023.PDF</url>\n",
            "      </link>\n",
            "      <link>\n",
            "        <ref-id>L41544</ref-id>\n",
            "        <title>FDA Clinical Pharmacology and Biopharmaceutics Review: Refludan (lepirudin) lyophilized powder for intravenous injection</title>\n",
            "        <url>https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20807_Refludan_biopharmr.pdf</url>\n",
            "      </link>\n",
            "      <link>\n",
            "        <ref-id>L41569</ref-id>\n",
            "        <title>EMA Summary of Product Characteristics: Refludan (lepirudin) powder for intravenous injection or infusion</title>\n",
            "        <url>https://www.ema.europa.eu/en/documents/product-information/refludan-epar-product-information_en.pdf</url>\n",
            "      </link>\n",
            "      <link>\n",
            "        <ref-id>L41574</ref-id>\n",
            "        <title>Bayer HealthCare: Discontinuation of Refludan [lepirudin (rDNA) for injection]</title>\n",
            "        <url>https://www.hrsa.gov/sites/default/files/opa/programrequirements/manufacturerletters/2012/refludan05312012.pdf</url>\n",
            "      </link>\n",
            "    </links>\n",
            "    <attachments/>\n",
            "  </general-references>\n",
            "  <synthesis-reference>Recombinant hirudin expressed by using yeast secretary (China Patent No. CN1371994A, 2001). China National Intellectual Property Administration. https://patents.google.com/patent/CN1371994A/en</synthesis-reference>\n",
            "  <indication>Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation. In patients with ACS, lepirudin is intended for use with [aspirin].[L41539] Lepirudin is also indicated for anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease in order to prevent further thromboembolic complications.[L41539]</indication>\n",
            "  <pharmacodynamics>Lepirudin is a recombinant hirudin that acts as a highly specific thrombin inhibitor. Its activity is measured by anti-thrombin units (ATUs) that correspond to the amount of lepirudin required to neutralize a unit of the World Health Organization α-thrombin (89/588) standard. The activity of lepirudin is 16,000 ATU/mg.[L41539,L41569] A single molecule of lepirudin binds to a molecule of thrombin, blocking its thrombogenic activity. This drug increases activated partial thromboplastin time (aPTT)  and PT (INR) values in a dose-dependent manner, and its mode of action is independent of antithrombin III.[L41539,L41569] Platelet factor 4 does not inhibit lepirudin.[L41539,L41569]&#13;\n",
            "&#13;\n",
            "The pharmacodynamic effect of lepirudin was evaluated by measuring an increase in aPTT. No saturable effect was observed at the highest tested dose (0.5 mg/kg, IV bolus).[L41539] Thrombin time was considered an unsuitable routine test for lepirudin monitoring due to the high values detected (200 seconds) even at low doses.[L41539] The concomitant use of thrombolytic therapy and lepirudin is not recommended due to the high risk of bleeding that may be life-threatening. In patients with a risk of bleeding, a physician should weigh the risks of lepirudin administration against its benefits.  There is also an especially high risk of bleeding in patients who weigh less than 50 kg, and a lower dosage is required. Patients with renal impairment have a higher risk of hemorrhagic adverse events.[L41539]</pharmacodynamics>\n",
            "  <mechanism-of-action>Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicated.[L41539,A3] Thrombin is a serine protease that participates in the blood-clotting cascade, and it is formed by the cleavage of pro-thrombin. Active thrombin cleaves fibrinogen and generates fibrin monomers that polymerize to form fibrin clots.[A246624]&#13;\n",
            "&#13;\n",
            "Lepirudin binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex.[A246609] This blocks the protease activity of thrombin and inhibits the coagulation process. Each molecule of lepirudin binds to a single molecule of thrombin,[L41539] and unlike [heparin], it is able to inhibit thrombin in both its clot-bound or free states.[A246609]</mechanism-of-action>\n",
            "  <toxicity>The acute toxicity of intravenous lepirudin was evaluated in mice (0.1-1000 mg/kg), rats (1-1000 mg/kg), and monkeys (1-100 mg/kg), and toxicity was not detected at the doses investigated.[L41539] The acute toxicity of lepirudin administered subcutaneously was also evaluated in mice (1-1250 mg/kg) and rats (1-500 mg/kg), and no toxicity was detected.[L41539] One rat (100 mg/kg) died of rapid blood loss after the subcutaneous administration of lepirudin. Reactions to local injections such as hemorrhages, hematomas and/or nodules were detected in mice and rats given subcutaneous doses of lepirudin equal or higher than 500 mg/kg and 10 mg/kg, respectively.[L41539] &#13;\n",
            "&#13;\n",
            "Chronic toxicity was evaluated in rats and monkeys given lepirudin for up to 3 months. Most of the effects observed were due to the antithrombotic action of lepirudin. After 3 months, hemosiderin deposits in the spleen and moderate sinus histiocytosis in the lymph node were observed in rats. In monkeys, external and internal hemorrhages and hematomas were detected.[L41539] Lepidurin was reported as not mutagenic.[L41539]&#13;\n",
            "&#13;\n",
            "Relative overdose may occur in patients with renal impairment, therefore, bolus dose and rate of infusion must be reduced in case of known or suspected renal insufficiency.[L41539] Excessively high activated partial thromboplastin time (aPTT) values suggest an overdose and a risk of bleeding. Lepirudin has no known antidote. In case of life-threatening bleeding and if excessive plasma levels of lepirudin are suspected: 1)stop the administration of lepirudin immediately, 2) determine aPTT and coagulation parameters, 3) determine hemoglobin, and prepare for a transfusion, 4) follow the treatment guidelines for patients with shock.[L41539] Hemofiltration or hemodialysis may be useful in case of overdose, based in single case reports and animal data.[L41539]</toxicity>\n",
            "  <metabolism>As a polypeptide, lepirudin is expected to be metabolized by the sequential cleavage of amino acids by kidney exoproteases, which have carboxypeptidase and dipeptidase-like activity.[L41539,L41544] The C-terminal cleavage of lepirudin aminoacids (aminoacids 1 to 65) produces four metabolites with anti-thrombotic activity: M1 (aminoacids 1 to 64), M2 (aminoacids 1 to 63), M3 (aminoacids 1 to 62), and M4 (aminoacids 1 to 61).[L41544]</metabolism>\n",
            "  <absorption>Lepirudin administered as a single intravenous bolus injection of 0.4 mg/kg in 9 healthy volunteers (male and female) resulted in a C&lt;sub&gt;max&lt;/sub&gt; of 2924 ng/mL, a t&lt;sub&gt;max&lt;/sub&gt; of 0.17 h and an AUC&lt;sub&gt;0-∞&lt;/sub&gt; of 2500 ng•h/mL.[L41539] When 0.1, 0.15 and 0.2 mg/kg of lepirudin was administered as a single intravenous infusion over 6 hours in healthy male volunteers, lepirudin had a corresponding C&lt;sub&gt;max&lt;/sub&gt; of 111, 203, and 2446 ng/mL and a corresponding AUC of 612, 1184, and 1446 ng•h/mL.[L41544] Bioavailability is 100% following injection. Also, it has been reported that following subcutaneous (sc) administration, the bioavailability of lepirudin is almost 100%.[A246609]</absorption>\n",
            "  <half-life>Lepirudin has an initial half-life of approximately 10 minutes, and in young healthy volunteers, it has a terminal half-time of 1.3 hours.[L41539] Lepirudin has a first-order elimination kinetic; plasma concentration increases proportionally as the lepirudin intravenous dose is increased. Elimination half-life values of up to 2 days were detected in patients with marked renal insufficiency (creatinine clearance &lt; 15 mL/min).[L41539]</half-life>\n",
            "  <protein-binding>In human plasma, the protein binding of lepirudin was approximately 3%.[L41539]</protein-binding>\n",
            "  <route-of-elimination>Lepirudin is mostly excreted through urine (48.3%). About 35% of lepirudin is excreted unchanged, while metabolites are found in a smaller proportion (2.5% of M1, 5.4% of M2, 3.9% of M3 and 1.6% of M4).[L41544]</route-of-elimination>\n",
            "  <volume-of-distribution>The volume of distribution of lepirudin at steady state was 12.2 L in healthy young subjects (n=18, 18-60 years), 18.7 L in healthy elderly subjects (n=10, 65-80 years), 18.0 L in renally impaired subjects (n=16, creatinine clearance &lt; 80 mL/min, and 32.1 L in heparin-induced thrombocytopenia patients (n=73).[L41539] The distribution of lepirudin is mainly restricted to extracellular fluids.[L41539]</volume-of-distribution>\n",
            "  <clearance>The clearance of lepirudin is proportional to the glomerular filtration rate. On average, lepirudin clearance was 164 mL/min in healthy young subjects (n=18, 18-60 years) and 25% lower in women than in men. In healthy elderly subjects (n=10, 65-80 years), clearance was 139 mL/min, about 20% lower than in younger patients.[L41539] This is possibly due to the lower creatinine clearance in elderly patients. In renally impaired subjects (n=16, creatinine clearance &lt; 80 mL/min), clearance was 61 mL/min, and in heparin-induced thrombocytopenia patients (n=73), it was 114 mL/min.[L41539]</clearance>\n",
            "  <classification>\n",
            "    <description/>\n",
            "    <direct-parent>Peptides</direct-parent>\n",
            "    <kingdom>Organic Compounds</kingdom>\n",
            "    <superclass>Organic Acids</superclass>\n",
            "    <class>Carboxylic Acids and Derivatives</class>\n",
            "    <subclass>Amino Acids, Peptides, and Analogues</subclass>\n",
            "  </classification>\n",
            "  <salts/>\n",
            "  <synonyms>\n",
            "    <synonym language=\"english\" coder=\"\">[Leu1, Thr2]-63-desulfohirudin</synonym>\n",
            "    <synonym language=\"english\" coder=\"\">Desulfatohirudin</synonym>\n",
            "    <synonym language=\"english\" coder=\"\">Hirudin variant-1</synonym>\n",
            "    <synonym language=\"english\" coder=\"inn\">Lepirudin</synonym>\n",
            "    <synonym language=\"english\" coder=\"\">Lepirudin recombinant</synonym>\n",
            "    <synonym language=\"english\" coder=\"\">R-hirudin</synonym>\n",
            "  </synonyms>\n",
            "  <products>\n",
            "    <product>\n",
            "      <name>Refludan</name>\n",
            "      <labeller>Bayer Ag</labeller>\n",
            "      <ndc-id/>\n",
            "      <ndc-product-code>50419-150</ndc-product-code>\n",
            "      <dpd-id/>\n",
            "      <ema-product-code/>\n",
            "      <ema-ma-number/>\n",
            "      <started-marketing-on>1998-03-06</started-marketing-on>\n",
            "      <ended-marketing-on>2013-06-30</ended-marketing-on>\n",
            "      <dosage-form>Powder</dosage-form>\n",
            "      <strength>50 mg/1mL</strength>\n",
            "      <route>Intravenous</route>\n",
            "      <fda-application-number>NDA020807</fda-application-number>\n",
            "      <generic>false</generic>\n",
            "      <over-the-counter>false</over-the-counter>\n",
            "      <approved>true</approved>\n",
            "      <country>US</country>\n",
            "      <source>FDA NDC</source>\n",
            "    </product>\n",
            "    <product>\n",
            "      <name>Refludan</name>\n",
            "      <labeller>Bayer Ag</labeller>\n",
            "      <ndc-id/>\n",
            "      <ndc-product-code/>\n",
            "      <dpd-id>02240996</dpd-id>\n",
            "      <ema-product-code/>\n",
            "      <ema-ma-number/>\n",
            "      <started-marketing-on>2000-01-31</started-marketing-on>\n",
            "      <ended-marketing-on>2013-07-26</ended-marketing-on>\n",
            "      <dosage-form>Powder, for solution</dosage-form>\n",
            "      <strength>50 mg / vial</strength>\n",
            "      <route>Intravenous</route>\n",
            "      <fda-application-number/>\n",
            "      <generic>false</generic>\n",
            "      <over-the-counter>false</over-the-counter>\n",
            "      <approved>true</approved>\n",
            "      <country>Canada</country>\n",
            "      <source>DPD</source>\n",
            "    </product>\n",
            "    <product>\n",
            "      <name>Refludan</name>\n",
            "      <labeller>Celgene Corporation</labeller>\n",
            "      <ndc-id/>\n",
            "      <ndc-product-code/>\n",
            "      <dpd-id/>\n",
            "      <ema-product-code>EMEA/H/C/000122</ema-product-code>\n",
            "      <ema-ma-number>EU/1/97/035/001</ema-ma-number>\n",
            "      <started-marketing-on>2016-09-08</started-marketing-on>\n",
            "      <ended-marketing-on>2012-04-24</ended-marketing-on>\n",
            "      <dosage-form>Injection, solution, concentrate</dosage-form>\n",
            "      <strength>50 mg</strength>\n",
            "      <route>Intravenous</route>\n",
            "      <fda-application-number/>\n",
            "      <generic>false</generic>\n",
            "      <over-the-counter>false</over-the-counter>\n",
            "      <approved>false</approved>\n",
            "      <country>EU</country>\n",
            "      <source>EMA</source>\n",
            "    </product>\n",
            "    <product>\n",
            "      <name>Refludan</name>\n",
            "      <labeller>Celgene Corporation</labeller>\n",
            "      <ndc-id/>\n",
            "      <ndc-product-code/>\n",
            "      <dpd-id/>\n",
            "      <ema-product-code>EMEA/H/C/000122</ema-product-code>\n",
            "      <ema-ma-number>EU/1/97/035/002</ema-ma-number>\n",
            "      <started-marketing-on>2016-09-08</started-marketing-on>\n",
            "      <ended-marketing-on>2012-04-24</ended-marketing-on>\n",
            "      <dosage-form>Injection, solution, concentrate</dosage-form>\n",
            "      <strength>50 mg</strength>\n",
            "      <route>Intravenous</route>\n",
            "      <fda-application-number/>\n",
            "      <generic>false</generic>\n",
            "      <over-the-counter>false</over-the-counter>\n",
            "      <approved>false</approved>\n",
            "      <country>EU</country>\n",
            "      <source>EMA</source>\n",
            "    </product>\n",
            "    <product>\n",
            "      <name>Refludan</name>\n",
            "      <labeller>Celgene Corporation</labeller>\n",
            "      <ndc-id/>\n",
            "      <ndc-product-code/>\n",
            "      <dpd-id/>\n",
            "      <ema-product-code>EMEA/H/C/000122</ema-product-code>\n",
            "      <ema-ma-number>EU/1/97/035/003</ema-ma-number>\n",
            "      <started-marketing-on>2016-09-08</started-marketing-on>\n",
            "      <ended-marketing-on>2012-04-24</ended-marketing-on>\n",
            "      <dosage-form>Injection, solution, concentrate</dosage-form>\n",
            "      <strength>20 mg</strength>\n",
            "      <route>Intravenous</route>\n",
            "      <fda-application-number/>\n",
            "      <generic>false</generic>\n",
            "      <over-the-counter>false</over-the-counter>\n",
            "      <approved>false</approved>\n",
            "      <country>EU</country>\n",
            "      <source>EMA</source>\n",
            "    </product>\n",
            "    <product>\n",
            "      <name>Refludan</name>\n",
            "      <labeller>Celgene Corporation</labeller>\n",
            "      <ndc-id/>\n",
            "      <ndc-product-code/>\n",
            "      <dpd-id/>\n",
            "      <ema-product-code>EMEA/H/C/000122</ema-product-code>\n",
            "      <ema-ma-number>EU/1/97/035/004</ema-ma-number>\n",
            "      <started-marketing-on>2016-09-08</started-marketing-on>\n",
            "      <ended-marketing-on>2012-04-24</ended-marketing-on>\n",
            "      <dosage-form>Injection, solution, concentrate</dosage-form>\n",
            "      <strength>20 mg</strength>\n",
            "      <route>Intravenous</route>\n",
            "      <fda-application-number/>\n",
            "      <generic>false</generic>\n",
            "      <over-the-counter>false</over-the-counter>\n",
            "      <approved>false</approved>\n",
            "      <country>EU</country>\n",
            "      <source>EMA</source>\n",
            "    </product>\n",
            "  </products>\n",
            "  <international-brands/>\n",
            "  <mixtures/>\n",
            "  <packagers>\n",
            "    <packager>\n",
            "      <name>Bayer Healthcare</name>\n",
            "      <url>http://www.bayerhealthcare.com</url>\n",
            "    </packager>\n",
            "    <packager>\n",
            "      <name>Berlex Labs</name>\n",
            "      <url>http://www.berlex.com</url>\n",
            "    </packager>\n",
            "  </packagers>\n",
            "  <manufacturers>\n",
            "    <manufacturer generic=\"false\" url=\"\">Bayer healthcare pharmaceuticals inc</manufacturer>\n",
            "  </manufacturers>\n",
            "  <prices>\n",
            "    <price>\n",
            "      <description>Refludan 50 mg vial</description>\n",
            "      <cost currency=\"USD\">273.19</cost>\n",
            "      <unit>vial</unit>\n",
            "    </price>\n",
            "  </prices>\n",
            "  <categories>\n",
            "    <category>\n",
            "      <category>Amino Acids, Peptides, and Proteins</category>\n",
            "      <mesh-id>D000602</mesh-id>\n",
            "    </category>\n",
            "    <category>\n",
            "      <category>Anticoagulants</category>\n",
            "      <mesh-id>D000925</mesh-id>\n",
            "    </category>\n",
            "    <category>\n",
            "      <category>Antithrombin Proteins</category>\n",
            "      <mesh-id>D058833</mesh-id>\n",
            "    </category>\n",
            "    <category>\n",
            "      <category>Antithrombins</category>\n",
            "      <mesh-id>D000991</mesh-id>\n",
            "    </category>\n",
            "    <category>\n",
            "      <category>Blood and Blood Forming Organs</category>\n",
            "      <mesh-id/>\n",
            "    </category>\n",
            "    <category>\n",
            "      <category>Cardiovascular Agents</category>\n",
            "      <mesh-id>D002317</mesh-id>\n",
            "    </category>\n",
            "    <category>\n",
            "      <category>Enzyme Inhibitors</category>\n",
            "      <mesh-id>D004791</mesh-id>\n",
            "    </category>\n",
            "    <category>\n",
            "      <category>Fibrin Modulating Agents</category>\n",
            "      <mesh-id>D050299</mesh-id>\n",
            "    </category>\n",
            "    <category>\n",
            "      <category>Hematologic Agents</category>\n",
            "      <mesh-id>D006401</mesh-id>\n",
            "    </category>\n",
            "    <category>\n",
            "      <category>Peptides</category>\n",
            "      <mesh-id>D010455</mesh-id>\n",
            "    </category>\n",
            "    <category>\n",
            "      <category>Protease Inhibitors</category>\n",
            "      <mesh-id>D011480</mesh-id>\n",
            "    </category>\n",
            "    <category>\n",
            "      <category>Proteins</category>\n",
            "      <mesh-id>D011506</mesh-id>\n",
            "    </category>\n",
            "    <category>\n",
            "      <category>Serine Protease Inhibitors</category>\n",
            "      <mesh-id>D015842</mesh-id>\n",
            "    </category>\n",
            "    <category>\n",
            "      <category>Serpins</category>\n",
            "      <mesh-id>D015843</mesh-id>\n",
            "    </category>\n",
            "    <category>\n",
            "      <category>Thrombin Inhibitors</category>\n",
            "      <mesh-id/>\n",
            "    </category>\n",
            "  </categories>\n",
            "  <affected-organisms>\n",
            "    <affected-organism>Humans and other mammals</affected-organism>\n",
            "  </affected-organisms>\n",
            "  <dosages>\n",
            "    <dosage>\n",
            "      <form>Injection, powder, for suspension</form>\n",
            "      <route>Intravenous</route>\n",
            "      <strength>5000000 mg</strength>\n",
            "    </dosage>\n",
            "    <dosage>\n",
            "      <form>Injection, solution, concentrate</form>\n",
            "      <route>Intravenous</route>\n",
            "      <strength>20 mg</strength>\n",
            "    </dosage>\n",
            "    <dosage>\n",
            "      <form>Injection, solution, concentrate</form>\n",
            "      <route>Intravenous</route>\n",
            "      <strength>50 mg</strength>\n",
            "    </dosage>\n",
            "    <dosage>\n",
            "      <form>Powder</form>\n",
            "      <route>Intravenous</route>\n",
            "      <strength/>\n",
            "    </dosage>\n",
            "    <dosage>\n",
            "      <form>Powder</form>\n",
            "      <route>Intravenous</route>\n",
            "      <strength>50 mg/1mL</strength>\n",
            "    </dosage>\n",
            "    <dosage>\n",
            "      <form>Powder, for solution</form>\n",
            "      <route>Intravenous</route>\n",
            "      <strength>50 mg / vial</strength>\n",
            "    </dosage>\n",
            "  </dosages>\n",
            "  <atc-codes>\n",
            "    <atc-code code=\"B01AE02\">\n",
            "      <level code=\"B01AE\">Direct thrombin inhibitors</level>\n",
            "      <level code=\"B01A\">ANTITHROMBOTIC AGENTS</level>\n",
            "      <level code=\"B01\">ANTITHROMBOTIC AGENTS</level>\n",
            "      <level code=\"B\">BLOOD AND BLOOD FORMING ORGANS</level>\n",
            "    </atc-code>\n",
            "  </atc-codes>\n",
            "  <ahfs-codes/>\n",
            "  <pdb-entries/>\n",
            "  <patents>\n",
            "    <patent>\n",
            "      <number>5180668</number>\n",
            "      <country>United States</country>\n",
            "      <approved>1993-01-19</approved>\n",
            "      <expires>2010-01-19</expires>\n",
            "      <pediatric-extension>false</pediatric-extension>\n",
            "    </patent>\n",
            "  </patents>\n",
            "  <food-interactions>\n",
            "    <food-interaction>Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include chamomile, garlic, ginger, ginkgo and ginseng.</food-interaction>\n",
            "  </food-interactions>\n",
            "  <drug-interactions>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06605</drugbank-id>\n",
            "      <name>Apixaban</name>\n",
            "      <description>Apixaban may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06695</drugbank-id>\n",
            "      <name>Dabigatran etexilate</name>\n",
            "      <description>Dabigatran etexilate may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01254</drugbank-id>\n",
            "      <name>Dasatinib</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01609</drugbank-id>\n",
            "      <name>Deferasirox</name>\n",
            "      <description>The risk or severity of gastrointestinal bleeding can be increased when Lepirudin is combined with Deferasirox.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01586</drugbank-id>\n",
            "      <name>Ursodeoxycholic acid</name>\n",
            "      <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Ursodeoxycholic acid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB02123</drugbank-id>\n",
            "      <name>Glycochenodeoxycholic Acid</name>\n",
            "      <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Glycochenodeoxycholic Acid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB02659</drugbank-id>\n",
            "      <name>Cholic Acid</name>\n",
            "      <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Cholic Acid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB02691</drugbank-id>\n",
            "      <name>Glycocholic acid</name>\n",
            "      <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Glycocholic acid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB03619</drugbank-id>\n",
            "      <name>Deoxycholic acid</name>\n",
            "      <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Deoxycholic acid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04348</drugbank-id>\n",
            "      <name>Taurocholic acid</name>\n",
            "      <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Taurocholic acid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB05990</drugbank-id>\n",
            "      <name>Obeticholic acid</name>\n",
            "      <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Obeticholic acid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06777</drugbank-id>\n",
            "      <name>Chenodeoxycholic acid</name>\n",
            "      <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Chenodeoxycholic acid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08833</drugbank-id>\n",
            "      <name>Taurochenodeoxycholic acid</name>\n",
            "      <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Taurochenodeoxycholic acid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08834</drugbank-id>\n",
            "      <name>Tauroursodeoxycholic acid</name>\n",
            "      <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Tauroursodeoxycholic acid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08857</drugbank-id>\n",
            "      <name>Bamet-UD2</name>\n",
            "      <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Bamet-UD2.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11622</drugbank-id>\n",
            "      <name>Dehydrocholic acid</name>\n",
            "      <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Dehydrocholic acid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11789</drugbank-id>\n",
            "      <name>Hyodeoxycholic Acid</name>\n",
            "      <description>The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Hyodeoxycholic Acid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09075</drugbank-id>\n",
            "      <name>Edoxaban</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Edoxaban is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09053</drugbank-id>\n",
            "      <name>Ibrutinib</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08935</drugbank-id>\n",
            "      <name>Obinutuzumab</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Obinutuzumab.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06228</drugbank-id>\n",
            "      <name>Rivaroxaban</name>\n",
            "      <description>Lepirudin may increase the anticoagulant activities of Rivaroxaban.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06206</drugbank-id>\n",
            "      <name>Sugammadex</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Sugammadex.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09070</drugbank-id>\n",
            "      <name>Tibolone</name>\n",
            "      <description>Tibolone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00932</drugbank-id>\n",
            "      <name>Tipranavir</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00013</drugbank-id>\n",
            "      <name>Urokinase</name>\n",
            "      <description>Urokinase may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00163</drugbank-id>\n",
            "      <name>Vitamin E</name>\n",
            "      <description>Vitamin E may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09030</drugbank-id>\n",
            "      <name>Vorapaxar</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01381</drugbank-id>\n",
            "      <name>Ginkgo biloba</name>\n",
            "      <description>Ginkgo biloba may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01181</drugbank-id>\n",
            "      <name>Ifosfamide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Ifosfamide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00468</drugbank-id>\n",
            "      <name>Quinine</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Quinine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00908</drugbank-id>\n",
            "      <name>Quinidine</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Quinidine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00675</drugbank-id>\n",
            "      <name>Tamoxifen</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Tamoxifen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00539</drugbank-id>\n",
            "      <name>Toremifene</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Toremifene is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00806</drugbank-id>\n",
            "      <name>Pentoxifylline</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Pentoxifylline.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00686</drugbank-id>\n",
            "      <name>Pentosan polysulfate</name>\n",
            "      <description>Pentosan polysulfate may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00583</drugbank-id>\n",
            "      <name>Levocarnitine</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Levocarnitine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00255</drugbank-id>\n",
            "      <name>Diethylstilbestrol</name>\n",
            "      <description>Diethylstilbestrol may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00269</drugbank-id>\n",
            "      <name>Chlorotrianisene</name>\n",
            "      <description>Chlorotrianisene may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00286</drugbank-id>\n",
            "      <name>Conjugated estrogens</name>\n",
            "      <description>Conjugated estrogens may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01357</drugbank-id>\n",
            "      <name>Mestranol</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Mestranol is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04574</drugbank-id>\n",
            "      <name>Estrone sulfate</name>\n",
            "      <description>Estrone sulfate may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04575</drugbank-id>\n",
            "      <name>Quinestrol</name>\n",
            "      <description>Quinestrol may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB07931</drugbank-id>\n",
            "      <name>Hexestrol</name>\n",
            "      <description>Hexestrol may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09317</drugbank-id>\n",
            "      <name>Synthetic Conjugated Estrogens, A</name>\n",
            "      <description>Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09318</drugbank-id>\n",
            "      <name>Synthetic Conjugated Estrogens, B</name>\n",
            "      <description>Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09369</drugbank-id>\n",
            "      <name>Polyestradiol phosphate</name>\n",
            "      <description>Polyestradiol phosphate may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09381</drugbank-id>\n",
            "      <name>Esterified estrogens</name>\n",
            "      <description>Esterified estrogens may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11478</drugbank-id>\n",
            "      <name>Zeranol</name>\n",
            "      <description>Zeranol may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11674</drugbank-id>\n",
            "      <name>Equol</name>\n",
            "      <description>Equol may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13143</drugbank-id>\n",
            "      <name>Methallenestril</name>\n",
            "      <description>Methallenestril may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13386</drugbank-id>\n",
            "      <name>Epimestrol</name>\n",
            "      <description>Epimestrol may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13418</drugbank-id>\n",
            "      <name>Moxestrol</name>\n",
            "      <description>Moxestrol may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13952</drugbank-id>\n",
            "      <name>Estradiol acetate</name>\n",
            "      <description>Estradiol acetate may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13953</drugbank-id>\n",
            "      <name>Estradiol benzoate</name>\n",
            "      <description>Estradiol benzoate may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13954</drugbank-id>\n",
            "      <name>Estradiol cypionate</name>\n",
            "      <description>Estradiol cypionate may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13956</drugbank-id>\n",
            "      <name>Estradiol valerate</name>\n",
            "      <description>Estradiol valerate may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB15334</drugbank-id>\n",
            "      <name>Biochanin A</name>\n",
            "      <description>Biochanin A may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB15335</drugbank-id>\n",
            "      <name>Formononetin</name>\n",
            "      <description>Formononetin may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04573</drugbank-id>\n",
            "      <name>Estriol</name>\n",
            "      <description>Estriol may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09211</drugbank-id>\n",
            "      <name>Limaprost</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Limaprost is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00159</drugbank-id>\n",
            "      <name>Icosapent</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00244</drugbank-id>\n",
            "      <name>Mesalazine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Mesalazine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00328</drugbank-id>\n",
            "      <name>Indomethacin</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00461</drugbank-id>\n",
            "      <name>Nabumetone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00465</drugbank-id>\n",
            "      <name>Ketorolac</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00469</drugbank-id>\n",
            "      <name>Tenoxicam</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00482</drugbank-id>\n",
            "      <name>Celecoxib</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00500</drugbank-id>\n",
            "      <name>Tolmetin</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00533</drugbank-id>\n",
            "      <name>Rofecoxib</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00554</drugbank-id>\n",
            "      <name>Piroxicam</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00573</drugbank-id>\n",
            "      <name>Fenoprofen</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00580</drugbank-id>\n",
            "      <name>Valdecoxib</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00586</drugbank-id>\n",
            "      <name>Diclofenac</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00605</drugbank-id>\n",
            "      <name>Sulindac</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00712</drugbank-id>\n",
            "      <name>Flurbiprofen</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00749</drugbank-id>\n",
            "      <name>Etodolac</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00784</drugbank-id>\n",
            "      <name>Mefenamic acid</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00788</drugbank-id>\n",
            "      <name>Naproxen</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00795</drugbank-id>\n",
            "      <name>Sulfasalazine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00812</drugbank-id>\n",
            "      <name>Phenylbutazone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00814</drugbank-id>\n",
            "      <name>Meloxicam</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00821</drugbank-id>\n",
            "      <name>Carprofen</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00861</drugbank-id>\n",
            "      <name>Diflunisal</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00936</drugbank-id>\n",
            "      <name>Salicylic acid</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00939</drugbank-id>\n",
            "      <name>Meclofenamic acid</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00991</drugbank-id>\n",
            "      <name>Oxaprozin</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01009</drugbank-id>\n",
            "      <name>Ketoprofen</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01014</drugbank-id>\n",
            "      <name>Balsalazide</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01250</drugbank-id>\n",
            "      <name>Olsalazine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Olsalazine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01283</drugbank-id>\n",
            "      <name>Lumiracoxib</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01397</drugbank-id>\n",
            "      <name>Magnesium salicylate</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01399</drugbank-id>\n",
            "      <name>Salsalate</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01401</drugbank-id>\n",
            "      <name>Choline magnesium trisalicylate</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01419</drugbank-id>\n",
            "      <name>Antrafenine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01424</drugbank-id>\n",
            "      <name>Aminophenazone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01435</drugbank-id>\n",
            "      <name>Antipyrine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01600</drugbank-id>\n",
            "      <name>Tiaprofenic acid</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01628</drugbank-id>\n",
            "      <name>Etoricoxib</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB02224</drugbank-id>\n",
            "      <name>Taxifolin</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB03585</drugbank-id>\n",
            "      <name>Oxyphenbutazone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04725</drugbank-id>\n",
            "      <name>Licofelone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Licofelone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04812</drugbank-id>\n",
            "      <name>Benoxaprofen</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Benoxaprofen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04828</drugbank-id>\n",
            "      <name>Zomepirac</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Zomepirac is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB05095</drugbank-id>\n",
            "      <name>Cimicoxib</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Cimicoxib is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06725</drugbank-id>\n",
            "      <name>Lornoxicam</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Lornoxicam is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06736</drugbank-id>\n",
            "      <name>Aceclofenac</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06737</drugbank-id>\n",
            "      <name>Zaltoprofen</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Zaltoprofen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB07402</drugbank-id>\n",
            "      <name>Azapropazone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Azapropazone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08439</drugbank-id>\n",
            "      <name>Parecoxib</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08797</drugbank-id>\n",
            "      <name>Salicylamide</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Salicylamide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08940</drugbank-id>\n",
            "      <name>Kebuzone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Kebuzone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08942</drugbank-id>\n",
            "      <name>Isoxicam</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08951</drugbank-id>\n",
            "      <name>Indoprofen</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Indoprofen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08955</drugbank-id>\n",
            "      <name>Ibuproxam</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Ibuproxam is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08976</drugbank-id>\n",
            "      <name>Floctafenine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Floctafenine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08981</drugbank-id>\n",
            "      <name>Fenbufen</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Fenbufen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08984</drugbank-id>\n",
            "      <name>Etofenamate</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Etofenamate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08991</drugbank-id>\n",
            "      <name>Epirizole</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Epirizole is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09084</drugbank-id>\n",
            "      <name>Benzydamine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Benzydamine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09214</drugbank-id>\n",
            "      <name>Dexketoprofen</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Dexketoprofen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09215</drugbank-id>\n",
            "      <name>Droxicam</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Droxicam is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09216</drugbank-id>\n",
            "      <name>Tolfenamic acid</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Tolfenamic acid is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09217</drugbank-id>\n",
            "      <name>Firocoxib</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Firocoxib is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09218</drugbank-id>\n",
            "      <name>Clonixin</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Clonixin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09285</drugbank-id>\n",
            "      <name>Morniflumate</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Morniflumate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09288</drugbank-id>\n",
            "      <name>Propacetamol</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Propacetamol is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09295</drugbank-id>\n",
            "      <name>Talniflumate</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Talniflumate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11455</drugbank-id>\n",
            "      <name>Robenacoxib</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Robenacoxib is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11466</drugbank-id>\n",
            "      <name>Tepoxalin</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Tepoxalin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11518</drugbank-id>\n",
            "      <name>Flunixin</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Flunixin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12399</drugbank-id>\n",
            "      <name>Polmacoxib</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Polmacoxib is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12610</drugbank-id>\n",
            "      <name>Ebselen</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Ebselen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13001</drugbank-id>\n",
            "      <name>Tinoridine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Tinoridine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13167</drugbank-id>\n",
            "      <name>Alclofenac</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Alclofenac is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13217</drugbank-id>\n",
            "      <name>Fentiazac</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Fentiazac is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13232</drugbank-id>\n",
            "      <name>Suxibuzone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Suxibuzone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13286</drugbank-id>\n",
            "      <name>Bumadizone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Bumadizone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13314</drugbank-id>\n",
            "      <name>Alminoprofen</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Alminoprofen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13371</drugbank-id>\n",
            "      <name>Difenpiramide</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Difenpiramide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13407</drugbank-id>\n",
            "      <name>Nifenazone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Nifenazone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13432</drugbank-id>\n",
            "      <name>Lonazolac</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Lonazolac is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13481</drugbank-id>\n",
            "      <name>Tenidap</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Tenidap is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13524</drugbank-id>\n",
            "      <name>Propyphenazone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Propyphenazone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13527</drugbank-id>\n",
            "      <name>Proglumetacin</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Proglumetacin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13538</drugbank-id>\n",
            "      <name>Guacetisal</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Guacetisal is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13544</drugbank-id>\n",
            "      <name>Ethenzamide</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Ethenzamide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13612</drugbank-id>\n",
            "      <name>Carbaspirin calcium</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Carbaspirin calcium is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13629</drugbank-id>\n",
            "      <name>Mofebutazone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Mofebutazone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13649</drugbank-id>\n",
            "      <name>Proquazone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Proquazone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13657</drugbank-id>\n",
            "      <name>Benorilate</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Benorilate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13722</drugbank-id>\n",
            "      <name>Pirprofen</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Pirprofen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13860</drugbank-id>\n",
            "      <name>Imidazole salicylate</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Imidazole salicylate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14059</drugbank-id>\n",
            "      <name>SC-236</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when SC-236 is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14060</drugbank-id>\n",
            "      <name>NS-398</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when NS-398 is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14938</drugbank-id>\n",
            "      <name>Flurbiprofen axetil</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen axetil is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09212</drugbank-id>\n",
            "      <name>Loxoprofen</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Loxoprofen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04552</drugbank-id>\n",
            "      <name>Niflumic acid</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Niflumic acid is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04865</drugbank-id>\n",
            "      <name>Omacetaxine mepesuccinate</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Omacetaxine mepesuccinate.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11133</drugbank-id>\n",
            "      <name>Omega-3 fatty acids</name>\n",
            "      <description>Omega-3 fatty acids may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00081</drugbank-id>\n",
            "      <name>Tositumomab</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Tositumomab.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00048</drugbank-id>\n",
            "      <name>Collagenase clostridium histolyticum</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Collagenase clostridium histolyticum.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00389</drugbank-id>\n",
            "      <name>Carbimazole</name>\n",
            "      <description>Carbimazole may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00550</drugbank-id>\n",
            "      <name>Propylthiouracil</name>\n",
            "      <description>Propylthiouracil may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00763</drugbank-id>\n",
            "      <name>Methimazole</name>\n",
            "      <description>Methimazole may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB03374</drugbank-id>\n",
            "      <name>3,5-Diiodotyrosine</name>\n",
            "      <description>3,5-Diiodotyrosine may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06715</drugbank-id>\n",
            "      <name>Potassium Iodide</name>\n",
            "      <description>Potassium Iodide may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB07637</drugbank-id>\n",
            "      <name>Dibromotyrosine</name>\n",
            "      <description>Dibromotyrosine may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09418</drugbank-id>\n",
            "      <name>Potassium perchlorate</name>\n",
            "      <description>Potassium perchlorate may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13644</drugbank-id>\n",
            "      <name>Methylthiouracil</name>\n",
            "      <description>Methylthiouracil may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13804</drugbank-id>\n",
            "      <name>Benzylthiouracil</name>\n",
            "      <description>Benzylthiouracil may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04682</drugbank-id>\n",
            "      <name>Octylphenoxy polyethoxyethanol</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Octylphenoxy polyethoxyethanol.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB05830</drugbank-id>\n",
            "      <name>Trestolone</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Trestolone.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08867</drugbank-id>\n",
            "      <name>Ulipristal</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ulipristal.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11507</drugbank-id>\n",
            "      <name>Cloprostenol</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cloprostenol.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13044</drugbank-id>\n",
            "      <name>Gossypol</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Gossypol.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00294</drugbank-id>\n",
            "      <name>Etonogestrel</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Etonogestrel.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00378</drugbank-id>\n",
            "      <name>Dydrogesterone</name>\n",
            "      <description>Dydrogesterone may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00396</drugbank-id>\n",
            "      <name>Progesterone</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Progesterone.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01431</drugbank-id>\n",
            "      <name>Allylestrenol</name>\n",
            "      <description>Allylestrenol may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06713</drugbank-id>\n",
            "      <name>Norelgestromin</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Norelgestromin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06789</drugbank-id>\n",
            "      <name>Hydroxyprogesterone caproate</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydroxyprogesterone caproate.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09124</drugbank-id>\n",
            "      <name>Medrogestone</name>\n",
            "      <description>Medrogestone may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11372</drugbank-id>\n",
            "      <name>Altrenogest</name>\n",
            "      <description>Altrenogest may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11636</drugbank-id>\n",
            "      <name>Nomegestrol</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Nomegestrol.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13230</drugbank-id>\n",
            "      <name>Gestonorone</name>\n",
            "      <description>Gestonorone may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13533</drugbank-id>\n",
            "      <name>Methylestrenolone</name>\n",
            "      <description>Methylestrenolone may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13602</drugbank-id>\n",
            "      <name>Promegestone</name>\n",
            "      <description>Promegestone may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13866</drugbank-id>\n",
            "      <name>Etynodiol</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Etynodiol.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14570</drugbank-id>\n",
            "      <name>Hydroxyprogesterone</name>\n",
            "      <description>Hydroxyprogesterone may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14679</drugbank-id>\n",
            "      <name>Quingestanol acetate</name>\n",
            "      <description>Quingestanol acetate may decrease the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00233</drugbank-id>\n",
            "      <name>Aminosalicylic acid</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01294</drugbank-id>\n",
            "      <name>Bismuth subsalicylate</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Bismuth subsalicylate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06251</drugbank-id>\n",
            "      <name>Dersalazine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Dersalazine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06807</drugbank-id>\n",
            "      <name>Phenyl aminosalicylate</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09543</drugbank-id>\n",
            "      <name>Methyl salicylate</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Methyl salicylate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11079</drugbank-id>\n",
            "      <name>Trolamine salicylate</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Trolamine salicylate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13509</drugbank-id>\n",
            "      <name>Aloxiprin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Aloxiprin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14006</drugbank-id>\n",
            "      <name>Choline salicylate</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Choline salicylate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14026</drugbank-id>\n",
            "      <name>Thiosalicylic acid</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Thiosalicylic acid is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00054</drugbank-id>\n",
            "      <name>Abciximab</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Abciximab is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00063</drugbank-id>\n",
            "      <name>Eptifibatide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Eptifibatide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00208</drugbank-id>\n",
            "      <name>Ticlopidine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Ticlopidine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00261</drugbank-id>\n",
            "      <name>Anagrelide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Anagrelide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00758</drugbank-id>\n",
            "      <name>Clopidogrel</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Clopidogrel is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00775</drugbank-id>\n",
            "      <name>Tirofiban</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Tirofiban is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00975</drugbank-id>\n",
            "      <name>Dipyridamole</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Dipyridamole is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01088</drugbank-id>\n",
            "      <name>Iloprost</name>\n",
            "      <description>Iloprost may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01138</drugbank-id>\n",
            "      <name>Sulfinpyrazone</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01166</drugbank-id>\n",
            "      <name>Cilostazol</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Cilostazol is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01207</drugbank-id>\n",
            "      <name>Ridogrel</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Ridogrel is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01240</drugbank-id>\n",
            "      <name>Epoprostenol</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Epoprostenol is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB02709</drugbank-id>\n",
            "      <name>Resveratrol</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Resveratrol is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04743</drugbank-id>\n",
            "      <name>Nimesulide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Nimesulide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04905</drugbank-id>\n",
            "      <name>Tesmilifene</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Tesmilifene is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04932</drugbank-id>\n",
            "      <name>Defibrotide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Defibrotide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB05229</drugbank-id>\n",
            "      <name>Beraprost</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Beraprost is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB05266</drugbank-id>\n",
            "      <name>Ibudilast</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Ibudilast is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB05767</drugbank-id>\n",
            "      <name>Andrographolide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Andrographolide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06081</drugbank-id>\n",
            "      <name>Caplacizumab</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Caplacizumab is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06209</drugbank-id>\n",
            "      <name>Prasugrel</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Prasugrel is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06441</drugbank-id>\n",
            "      <name>Cangrelor</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Cangrelor is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB07615</drugbank-id>\n",
            "      <name>Tranilast</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Tranilast is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08814</drugbank-id>\n",
            "      <name>Triflusal</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Triflusal is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08816</drugbank-id>\n",
            "      <name>Ticagrelor</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Ticagrelor is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08887</drugbank-id>\n",
            "      <name>Icosapent ethyl</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09283</drugbank-id>\n",
            "      <name>Trapidil</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Trapidil is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12092</drugbank-id>\n",
            "      <name>Naftopidil</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Naftopidil is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12163</drugbank-id>\n",
            "      <name>Sarpogrelate</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Sarpogrelate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12321</drugbank-id>\n",
            "      <name>Ifetroban</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Ifetroban is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12445</drugbank-id>\n",
            "      <name>Nitroaspirin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Nitroaspirin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12545</drugbank-id>\n",
            "      <name>Indobufen</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Indobufen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12749</drugbank-id>\n",
            "      <name>Butylphthalide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Butylphthalide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12771</drugbank-id>\n",
            "      <name>Hydroxytyrosol</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13036</drugbank-id>\n",
            "      <name>Ramatroban</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Ramatroban is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13327</drugbank-id>\n",
            "      <name>Picotamide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Picotamide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13367</drugbank-id>\n",
            "      <name>Cloricromen</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Cloricromen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13400</drugbank-id>\n",
            "      <name>Linsidomine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Linsidomine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13510</drugbank-id>\n",
            "      <name>Buflomedil</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Buflomedil is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13929</drugbank-id>\n",
            "      <name>Relcovaptan</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Relcovaptan is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB15786</drugbank-id>\n",
            "      <name>Maritime pine extract</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Maritime pine extract is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00374</drugbank-id>\n",
            "      <name>Treprostinil</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Treprostinil is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB03404</drugbank-id>\n",
            "      <name>Hemin</name>\n",
            "      <description>Hemin may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13783</drugbank-id>\n",
            "      <name>Acemetacin</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Lepirudin is combined with Acemetacin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00624</drugbank-id>\n",
            "      <name>Testosterone</name>\n",
            "      <description>Testosterone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01420</drugbank-id>\n",
            "      <name>Testosterone propionate</name>\n",
            "      <description>Testosterone propionate may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01481</drugbank-id>\n",
            "      <name>1-Testosterone</name>\n",
            "      <description>1-Testosterone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01485</drugbank-id>\n",
            "      <name>4-Hydroxytestosterone</name>\n",
            "      <description>4-Hydroxytestosterone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01510</drugbank-id>\n",
            "      <name>Dehydrochloromethyltestosterone</name>\n",
            "      <description>Dehydrochloromethyltestosterone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01541</drugbank-id>\n",
            "      <name>Boldenone</name>\n",
            "      <description>Boldenone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01543</drugbank-id>\n",
            "      <name>18-methyl-19-nortestosterone</name>\n",
            "      <description>18-methyl-19-nortestosterone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01564</drugbank-id>\n",
            "      <name>Calusterone</name>\n",
            "      <description>Calusterone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01569</drugbank-id>\n",
            "      <name>Formebolone</name>\n",
            "      <description>Formebolone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01572</drugbank-id>\n",
            "      <name>Methyl-1-testosterone</name>\n",
            "      <description>Methyl-1-testosterone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB07447</drugbank-id>\n",
            "      <name>5beta-dihydrotestosterone</name>\n",
            "      <description>5beta-dihydrotestosterone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08619</drugbank-id>\n",
            "      <name>Testosterone succinate</name>\n",
            "      <description>Testosterone succinate may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11429</drugbank-id>\n",
            "      <name>Mibolerone</name>\n",
            "      <description>Mibolerone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13943</drugbank-id>\n",
            "      <name>Testosterone cypionate</name>\n",
            "      <description>Testosterone cypionate may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13944</drugbank-id>\n",
            "      <name>Testosterone enanthate</name>\n",
            "      <description>Testosterone enanthate may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13946</drugbank-id>\n",
            "      <name>Testosterone undecanoate</name>\n",
            "      <description>Testosterone undecanoate may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13947</drugbank-id>\n",
            "      <name>Testosterone enantate benzilic acid hydrazone</name>\n",
            "      <description>Testosterone enantate benzilic acid hydrazone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13951</drugbank-id>\n",
            "      <name>Stanolone acetate</name>\n",
            "      <description>Stanolone acetate may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13958</drugbank-id>\n",
            "      <name>Trestolone acetate</name>\n",
            "      <description>Trestolone acetate may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14093</drugbank-id>\n",
            "      <name>(1,2,6,7-3H)Testosterone</name>\n",
            "      <description>(1,2,6,7-3H)Testosterone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14655</drugbank-id>\n",
            "      <name>Drostanolone propionate</name>\n",
            "      <description>Drostanolone propionate may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB02901</drugbank-id>\n",
            "      <name>Stanolone</name>\n",
            "      <description>Stanolone may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11051</drugbank-id>\n",
            "      <name>Azficel-T</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Lepirudin is combined with Azficel-T.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09568</drugbank-id>\n",
            "      <name>Omega-3-carboxylic acids</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be increased when used in combination with Omega-3-carboxylic acids.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00025</drugbank-id>\n",
            "      <name>Antihemophilic factor, human recombinant</name>\n",
            "      <description>The therapeutic efficacy of Antihemophilic factor, human recombinant can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00036</drugbank-id>\n",
            "      <name>Coagulation factor VIIa Recombinant Human</name>\n",
            "      <description>The therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00100</drugbank-id>\n",
            "      <name>Coagulation Factor IX (Recombinant)</name>\n",
            "      <description>The therapeutic efficacy of Coagulation Factor IX (Recombinant) can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01373</drugbank-id>\n",
            "      <name>Calcium</name>\n",
            "      <description>The therapeutic efficacy of Calcium can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01783</drugbank-id>\n",
            "      <name>Pantothenic acid</name>\n",
            "      <description>The therapeutic efficacy of Pantothenic acid can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01942</drugbank-id>\n",
            "      <name>Formic acid</name>\n",
            "      <description>The therapeutic efficacy of Formic acid can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB02261</drugbank-id>\n",
            "      <name>Platelet Activating Factor</name>\n",
            "      <description>The therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09109</drugbank-id>\n",
            "      <name>Turoctocog alfa</name>\n",
            "      <description>The therapeutic efficacy of Turoctocog alfa can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09222</drugbank-id>\n",
            "      <name>Fibrinogen human</name>\n",
            "      <description>The therapeutic efficacy of Fibrinogen human can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09310</drugbank-id>\n",
            "      <name>Catridecacog</name>\n",
            "      <description>The therapeutic efficacy of Catridecacog can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09329</drugbank-id>\n",
            "      <name>Antihemophilic factor (recombinant), PEGylated</name>\n",
            "      <description>The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11311</drugbank-id>\n",
            "      <name>Prothrombin</name>\n",
            "      <description>The therapeutic efficacy of Prothrombin can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11330</drugbank-id>\n",
            "      <name>Factor IX Complex (Human)</name>\n",
            "      <description>The therapeutic efficacy of Factor IX Complex (Human) can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11606</drugbank-id>\n",
            "      <name>Susoctocog alfa</name>\n",
            "      <description>The therapeutic efficacy of Susoctocog alfa can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11608</drugbank-id>\n",
            "      <name>Eftrenonacog alfa</name>\n",
            "      <description>The therapeutic efficacy of Eftrenonacog alfa can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11668</drugbank-id>\n",
            "      <name>Rusalatide acetate</name>\n",
            "      <description>The therapeutic efficacy of Rusalatide acetate can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12409</drugbank-id>\n",
            "      <name>Vatreptacog alfa</name>\n",
            "      <description>The therapeutic efficacy of Vatreptacog alfa can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12909</drugbank-id>\n",
            "      <name>Factor XIII (human)</name>\n",
            "      <description>The therapeutic efficacy of Factor XIII (human) can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13133</drugbank-id>\n",
            "      <name>Von Willebrand factor human</name>\n",
            "      <description>The therapeutic efficacy of Von Willebrand factor human can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13148</drugbank-id>\n",
            "      <name>Coagulation factor X human</name>\n",
            "      <description>The therapeutic efficacy of Coagulation factor X human can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13150</drugbank-id>\n",
            "      <name>Coagulation factor VII human</name>\n",
            "      <description>The therapeutic efficacy of Coagulation factor VII human can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13151</drugbank-id>\n",
            "      <name>Anti-inhibitor coagulant complex</name>\n",
            "      <description>The therapeutic efficacy of Anti-inhibitor coagulant complex can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13152</drugbank-id>\n",
            "      <name>Coagulation Factor IX Human</name>\n",
            "      <description>The therapeutic efficacy of Coagulation Factor IX Human can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13192</drugbank-id>\n",
            "      <name>Antihemophilic factor human</name>\n",
            "      <description>The therapeutic efficacy of Antihemophilic factor human can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13197</drugbank-id>\n",
            "      <name>Kallidinogenase</name>\n",
            "      <description>The therapeutic efficacy of Kallidinogenase can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13201</drugbank-id>\n",
            "      <name>Trenonacog alfa</name>\n",
            "      <description>The therapeutic efficacy of Trenonacog alfa can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13884</drugbank-id>\n",
            "      <name>Albutrepenonacog alfa</name>\n",
            "      <description>The therapeutic efficacy of Albutrepenonacog alfa can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13923</drugbank-id>\n",
            "      <name>Emicizumab</name>\n",
            "      <description>The therapeutic efficacy of Emicizumab can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13933</drugbank-id>\n",
            "      <name>Nonacog beta pegol</name>\n",
            "      <description>The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13999</drugbank-id>\n",
            "      <name>Moroctocog alfa</name>\n",
            "      <description>The therapeutic efficacy of Moroctocog alfa can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14473</drugbank-id>\n",
            "      <name>Beroctocog alfa</name>\n",
            "      <description>The therapeutic efficacy of Beroctocog alfa can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14562</drugbank-id>\n",
            "      <name>Andexanet alfa</name>\n",
            "      <description>The therapeutic efficacy of Andexanet alfa can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14577</drugbank-id>\n",
            "      <name>Calcium cation</name>\n",
            "      <description>The therapeutic efficacy of Calcium cation can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14700</drugbank-id>\n",
            "      <name>Damoctocog alfa pegol</name>\n",
            "      <description>The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14738</drugbank-id>\n",
            "      <name>Turoctocog alfa pegol</name>\n",
            "      <description>The therapeutic efficacy of Turoctocog alfa pegol can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00176</drugbank-id>\n",
            "      <name>Fluvoxamine</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00215</drugbank-id>\n",
            "      <name>Citalopram</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Citalopram.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00472</drugbank-id>\n",
            "      <name>Fluoxetine</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00715</drugbank-id>\n",
            "      <name>Paroxetine</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Paroxetine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01149</drugbank-id>\n",
            "      <name>Nefazodone</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Nefazodone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04832</drugbank-id>\n",
            "      <name>Zimelidine</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Zimelidine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04884</drugbank-id>\n",
            "      <name>Dapoxetine</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Dapoxetine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06731</drugbank-id>\n",
            "      <name>Seproxetine</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Seproxetine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08953</drugbank-id>\n",
            "      <name>Indalpine</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Indalpine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12693</drugbank-id>\n",
            "      <name>Ritanserin</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Ritanserin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13233</drugbank-id>\n",
            "      <name>Alaproclate</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Alaproclate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00476</drugbank-id>\n",
            "      <name>Duloxetine</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Duloxetine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01105</drugbank-id>\n",
            "      <name>Sibutramine</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Sibutramine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04896</drugbank-id>\n",
            "      <name>Milnacipran</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Milnacipran is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06700</drugbank-id>\n",
            "      <name>Desvenlafaxine</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08918</drugbank-id>\n",
            "      <name>Levomilnacipran</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Levomilnacipran.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00285</drugbank-id>\n",
            "      <name>Venlafaxine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Venlafaxine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00601</drugbank-id>\n",
            "      <name>Linezolid</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00614</drugbank-id>\n",
            "      <name>Furazolidone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Furazolidone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00721</drugbank-id>\n",
            "      <name>Procaine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00752</drugbank-id>\n",
            "      <name>Tranylcypromine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00780</drugbank-id>\n",
            "      <name>Phenelzine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00805</drugbank-id>\n",
            "      <name>Minaprine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01037</drugbank-id>\n",
            "      <name>Selegiline</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01168</drugbank-id>\n",
            "      <name>Procarbazine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01171</drugbank-id>\n",
            "      <name>Moclobemide</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01247</drugbank-id>\n",
            "      <name>Isocarboxazid</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01367</drugbank-id>\n",
            "      <name>Rasagiline</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01626</drugbank-id>\n",
            "      <name>Pargyline</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04017</drugbank-id>\n",
            "      <name>Clorgiline</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Clorgiline is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04818</drugbank-id>\n",
            "      <name>Iproniazid</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Iproniazid is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04820</drugbank-id>\n",
            "      <name>Nialamide</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06654</drugbank-id>\n",
            "      <name>Safinamide</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08550</drugbank-id>\n",
            "      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09241</drugbank-id>\n",
            "      <name>Methylene blue</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09243</drugbank-id>\n",
            "      <name>Hydracarbazine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Hydracarbazine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09244</drugbank-id>\n",
            "      <name>Pirlindole</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Pirlindole is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09245</drugbank-id>\n",
            "      <name>Toloxatone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Toloxatone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09246</drugbank-id>\n",
            "      <name>Benmoxin</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Benmoxin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09248</drugbank-id>\n",
            "      <name>Mebanazine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Mebanazine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09249</drugbank-id>\n",
            "      <name>Octamoxin</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Octamoxin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09250</drugbank-id>\n",
            "      <name>Pheniprazine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Pheniprazine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09251</drugbank-id>\n",
            "      <name>Phenoxypropazine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Phenoxypropazine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09252</drugbank-id>\n",
            "      <name>Pivhydrazine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Pivhydrazine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09253</drugbank-id>\n",
            "      <name>Safrazine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Safrazine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09254</drugbank-id>\n",
            "      <name>Caroxazone</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13875</drugbank-id>\n",
            "      <name>Harmaline</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Harmaline is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13876</drugbank-id>\n",
            "      <name>Brofaromine</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Brofaromine is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00006</drugbank-id>\n",
            "      <name>Bivalirudin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Bivalirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00266</drugbank-id>\n",
            "      <name>Dicoumarol</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Dicoumarol is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00278</drugbank-id>\n",
            "      <name>Argatroban</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Argatroban.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00407</drugbank-id>\n",
            "      <name>Ardeparin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Ardeparin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00498</drugbank-id>\n",
            "      <name>Phenindione</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Phenindione.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00569</drugbank-id>\n",
            "      <name>Fondaparinux</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Fondaparinux.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00682</drugbank-id>\n",
            "      <name>Warfarin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Warfarin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00946</drugbank-id>\n",
            "      <name>Phenprocoumon</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Phenprocoumon is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00974</drugbank-id>\n",
            "      <name>Edetic acid</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Edetic acid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01109</drugbank-id>\n",
            "      <name>Heparin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Heparin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01225</drugbank-id>\n",
            "      <name>Enoxaparin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Enoxaparin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01418</drugbank-id>\n",
            "      <name>Acenocoumarol</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Acenocoumarol is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04898</drugbank-id>\n",
            "      <name>Ximelagatran</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Ximelagatran.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB05099</drugbank-id>\n",
            "      <name>Ancrod</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Ancrod is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06271</drugbank-id>\n",
            "      <name>Sulodexide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Sulodexide is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06406</drugbank-id>\n",
            "      <name>Idraparinux</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Idraparinux.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06635</drugbank-id>\n",
            "      <name>Otamixaban</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Otamixaban.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06754</drugbank-id>\n",
            "      <name>Danaparoid</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Danaparoid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06779</drugbank-id>\n",
            "      <name>Dalteparin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Dalteparin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08794</drugbank-id>\n",
            "      <name>Ethyl biscoumacetate</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08813</drugbank-id>\n",
            "      <name>Nadroparin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Nadroparin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09255</drugbank-id>\n",
            "      <name>Dextran</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Dextran.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11095</drugbank-id>\n",
            "      <name>Desirudin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Desirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11268</drugbank-id>\n",
            "      <name>Protocatechualdehyde</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Protocatechualdehyde.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11312</drugbank-id>\n",
            "      <name>Protein C</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Protein C is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11598</drugbank-id>\n",
            "      <name>Antithrombin III human</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Antithrombin III human.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11984</drugbank-id>\n",
            "      <name>Letaxaban</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Letaxaban.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12289</drugbank-id>\n",
            "      <name>Darexaban</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Darexaban.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12598</drugbank-id>\n",
            "      <name>Nafamostat</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Nafamostat.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12831</drugbank-id>\n",
            "      <name>Gabexate</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Gabexate.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13124</drugbank-id>\n",
            "      <name>Troxerutin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Troxerutin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13136</drugbank-id>\n",
            "      <name>Fluindione</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Fluindione.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13149</drugbank-id>\n",
            "      <name>Protein S human</name>\n",
            "      <description>The therapeutic efficacy of Protein S human can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13616</drugbank-id>\n",
            "      <name>Melagatran</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Melagatran.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09154</drugbank-id>\n",
            "      <name>Sodium citrate</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Sodium citrate.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00031</drugbank-id>\n",
            "      <name>Tenecteplase</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Tenecteplase is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00055</drugbank-id>\n",
            "      <name>Drotrecogin alfa</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06822</drugbank-id>\n",
            "      <name>Tinzaparin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Tinzaparin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13199</drugbank-id>\n",
            "      <name>Brinase</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Brinase is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13646</drugbank-id>\n",
            "      <name>Saruplase</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Saruplase is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00086</drugbank-id>\n",
            "      <name>Streptokinase</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Streptokinase is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04925</drugbank-id>\n",
            "      <name>Desmoteplase</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Desmoteplase is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06543</drugbank-id>\n",
            "      <name>Astaxanthin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Astaxanthin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08994</drugbank-id>\n",
            "      <name>Ditazole</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Ditazole.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09258</drugbank-id>\n",
            "      <name>Bemiparin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Bemiparin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09260</drugbank-id>\n",
            "      <name>Parnaparin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Parnaparin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13275</drugbank-id>\n",
            "      <name>Clorindione</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Clorindione.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13347</drugbank-id>\n",
            "      <name>Diphenadione</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Diphenadione.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13451</drugbank-id>\n",
            "      <name>Tioclomarol</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Tioclomarol.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00009</drugbank-id>\n",
            "      <name>Alteplase</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Alteplase is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00015</drugbank-id>\n",
            "      <name>Reteplase</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Reteplase is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00029</drugbank-id>\n",
            "      <name>Anistreplase</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Anistreplase is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14094</drugbank-id>\n",
            "      <name>Tocopherylquinone</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Tocopherylquinone.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06679</drugbank-id>\n",
            "      <name>Amediplase</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Amediplase is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB03410</drugbank-id>\n",
            "      <name>4-hydroxycoumarin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when 4-hydroxycoumarin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08496</drugbank-id>\n",
            "      <name>(R)-warfarin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with (R)-warfarin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14055</drugbank-id>\n",
            "      <name>(S)-Warfarin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with (S)-Warfarin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12364</drugbank-id>\n",
            "      <name>Betrixaban</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Betrixaban.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11166</drugbank-id>\n",
            "      <name>Antithrombin Alfa</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Antithrombin Alfa.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04665</drugbank-id>\n",
            "      <name>Coumarin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Coumarin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14726</drugbank-id>\n",
            "      <name>Dabigatran</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Dabigatran.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06294</drugbank-id>\n",
            "      <name>Semuloparin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Semuloparin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12726</drugbank-id>\n",
            "      <name>Monteplase</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Monteplase is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09259</drugbank-id>\n",
            "      <name>Reviparin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Reviparin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB15880</drugbank-id>\n",
            "      <name>Dermatan sulfate</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Dermatan sulfate.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB05361</drugbank-id>\n",
            "      <name>SR-123781A</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with SR-123781A.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00203</drugbank-id>\n",
            "      <name>Sildenafil</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Lepirudin is combined with Sildenafil.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00008</drugbank-id>\n",
            "      <name>Peginterferon alfa-2a</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2a.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00011</drugbank-id>\n",
            "      <name>Interferon alfa-n1</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n1.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00018</drugbank-id>\n",
            "      <name>Interferon alfa-n3</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-n3.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00022</drugbank-id>\n",
            "      <name>Peginterferon alfa-2b</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon alfa-2b.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00033</drugbank-id>\n",
            "      <name>Interferon gamma-1b</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon gamma-1b.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00034</drugbank-id>\n",
            "      <name>Interferon alfa-2a</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-2a.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00041</drugbank-id>\n",
            "      <name>Aldesleukin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Aldesleukin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00056</drugbank-id>\n",
            "      <name>Gemtuzumab ozogamicin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Gemtuzumab ozogamicin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00068</drugbank-id>\n",
            "      <name>Interferon beta-1b</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon beta-1b.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00069</drugbank-id>\n",
            "      <name>Interferon alfacon-1</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfacon-1.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00073</drugbank-id>\n",
            "      <name>Rituximab</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Rituximab.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00078</drugbank-id>\n",
            "      <name>Ibritumomab tiuxetan</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Ibritumomab tiuxetan.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00087</drugbank-id>\n",
            "      <name>Alemtuzumab</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Alemtuzumab.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00105</drugbank-id>\n",
            "      <name>Interferon alfa-2b</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa-2b.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00120</drugbank-id>\n",
            "      <name>Phenylalanine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Phenylalanine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00188</drugbank-id>\n",
            "      <name>Bortezomib</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Bortezomib.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00242</drugbank-id>\n",
            "      <name>Cladribine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Cladribine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00262</drugbank-id>\n",
            "      <name>Carmustine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Carmustine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00276</drugbank-id>\n",
            "      <name>Amsacrine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Amsacrine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00291</drugbank-id>\n",
            "      <name>Chlorambucil</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Chlorambucil.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00293</drugbank-id>\n",
            "      <name>Raltitrexed</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Raltitrexed.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00305</drugbank-id>\n",
            "      <name>Mitomycin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Mitomycin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00307</drugbank-id>\n",
            "      <name>Bexarotene</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Bexarotene.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00309</drugbank-id>\n",
            "      <name>Vindesine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Vindesine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00322</drugbank-id>\n",
            "      <name>Floxuridine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Floxuridine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00352</drugbank-id>\n",
            "      <name>Tioguanine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Tioguanine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00361</drugbank-id>\n",
            "      <name>Vinorelbine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Vinorelbine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00380</drugbank-id>\n",
            "      <name>Dexrazoxane</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Dexrazoxane.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00398</drugbank-id>\n",
            "      <name>Sorafenib</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Sorafenib.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00428</drugbank-id>\n",
            "      <name>Streptozocin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Streptozocin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00441</drugbank-id>\n",
            "      <name>Gemcitabine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Gemcitabine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00444</drugbank-id>\n",
            "      <name>Teniposide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Teniposide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00445</drugbank-id>\n",
            "      <name>Epirubicin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Epirubicin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00446</drugbank-id>\n",
            "      <name>Chloramphenicol</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Chloramphenicol.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00480</drugbank-id>\n",
            "      <name>Lenalidomide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Lenalidomide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00488</drugbank-id>\n",
            "      <name>Altretamine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Altretamine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00495</drugbank-id>\n",
            "      <name>Zidovudine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Zidovudine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00515</drugbank-id>\n",
            "      <name>Cisplatin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Cisplatin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00526</drugbank-id>\n",
            "      <name>Oxaliplatin</name>\n",
            "      <description>The risk or severity of hemorrhage can be increased when Oxaliplatin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00531</drugbank-id>\n",
            "      <name>Cyclophosphamide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Cyclophosphamide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00544</drugbank-id>\n",
            "      <name>Fluorouracil</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Fluorouracil.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00552</drugbank-id>\n",
            "      <name>Pentostatin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Pentostatin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00563</drugbank-id>\n",
            "      <name>Methotrexate</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Methotrexate.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00564</drugbank-id>\n",
            "      <name>Carbamazepine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Carbamazepine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00570</drugbank-id>\n",
            "      <name>Vinblastine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Vinblastine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00619</drugbank-id>\n",
            "      <name>Imatinib</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Imatinib.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00631</drugbank-id>\n",
            "      <name>Clofarabine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Clofarabine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00642</drugbank-id>\n",
            "      <name>Pemetrexed</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Pemetrexed.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00694</drugbank-id>\n",
            "      <name>Daunorubicin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Daunorubicin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00762</drugbank-id>\n",
            "      <name>Irinotecan</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Irinotecan.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00773</drugbank-id>\n",
            "      <name>Etoposide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Etoposide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00851</drugbank-id>\n",
            "      <name>Dacarbazine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Dacarbazine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00853</drugbank-id>\n",
            "      <name>Temozolomide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Temozolomide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00859</drugbank-id>\n",
            "      <name>Penicillamine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Penicillamine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00864</drugbank-id>\n",
            "      <name>Tacrolimus</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Tacrolimus.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00877</drugbank-id>\n",
            "      <name>Sirolimus</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Sirolimus.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00888</drugbank-id>\n",
            "      <name>Mechlorethamine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Mechlorethamine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00928</drugbank-id>\n",
            "      <name>Azacitidine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Azacitidine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00958</drugbank-id>\n",
            "      <name>Carboplatin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Carboplatin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00970</drugbank-id>\n",
            "      <name>Dactinomycin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Dactinomycin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00987</drugbank-id>\n",
            "      <name>Cytarabine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Cytarabine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00997</drugbank-id>\n",
            "      <name>Doxorubicin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Doxorubicin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01005</drugbank-id>\n",
            "      <name>Hydroxyurea</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Hydroxyurea.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01008</drugbank-id>\n",
            "      <name>Busulfan</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Busulfan.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01030</drugbank-id>\n",
            "      <name>Topotecan</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Topotecan.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01033</drugbank-id>\n",
            "      <name>Mercaptopurine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Mercaptopurine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01041</drugbank-id>\n",
            "      <name>Thalidomide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Thalidomide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01042</drugbank-id>\n",
            "      <name>Melphalan</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Melphalan.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01073</drugbank-id>\n",
            "      <name>Fludarabine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Fludarabine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01099</drugbank-id>\n",
            "      <name>Flucytosine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Flucytosine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01101</drugbank-id>\n",
            "      <name>Capecitabine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Capecitabine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01169</drugbank-id>\n",
            "      <name>Arsenic trioxide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Arsenic trioxide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01177</drugbank-id>\n",
            "      <name>Idarubicin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Idarubicin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01204</drugbank-id>\n",
            "      <name>Mitoxantrone</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Mitoxantrone.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01206</drugbank-id>\n",
            "      <name>Lomustine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Lomustine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01229</drugbank-id>\n",
            "      <name>Paclitaxel</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Paclitaxel.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01248</drugbank-id>\n",
            "      <name>Docetaxel</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Docetaxel.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01262</drugbank-id>\n",
            "      <name>Decitabine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Decitabine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01280</drugbank-id>\n",
            "      <name>Nelarabine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Nelarabine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01590</drugbank-id>\n",
            "      <name>Everolimus</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Everolimus.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB02546</drugbank-id>\n",
            "      <name>Vorinostat</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Vorinostat.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04572</drugbank-id>\n",
            "      <name>Thiotepa</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Thiotepa.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04845</drugbank-id>\n",
            "      <name>Ixabepilone</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Ixabepilone.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04868</drugbank-id>\n",
            "      <name>Nilotinib</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Nilotinib.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB05015</drugbank-id>\n",
            "      <name>Belinostat</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Belinostat.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB05109</drugbank-id>\n",
            "      <name>Trabectedin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Trabectedin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB05258</drugbank-id>\n",
            "      <name>Interferon alfa</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Interferon alfa.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB05472</drugbank-id>\n",
            "      <name>Human interferon omega-1</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Human interferon omega-1.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB05773</drugbank-id>\n",
            "      <name>Trastuzumab emtansine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Trastuzumab emtansine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06287</drugbank-id>\n",
            "      <name>Temsirolimus</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Temsirolimus.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06616</drugbank-id>\n",
            "      <name>Bosutinib</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Bosutinib.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06769</drugbank-id>\n",
            "      <name>Bendamustine</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Bendamustine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06772</drugbank-id>\n",
            "      <name>Cabazitaxel</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Cabazitaxel.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08871</drugbank-id>\n",
            "      <name>Eribulin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Eribulin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08877</drugbank-id>\n",
            "      <name>Ruxolitinib</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Ruxolitinib.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08889</drugbank-id>\n",
            "      <name>Carfilzomib</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Carfilzomib.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08895</drugbank-id>\n",
            "      <name>Tofacitinib</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Tofacitinib.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08901</drugbank-id>\n",
            "      <name>Ponatinib</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Ponatinib.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB08910</drugbank-id>\n",
            "      <name>Pomalidomide</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Pomalidomide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09042</drugbank-id>\n",
            "      <name>Tedizolid phosphate</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Tedizolid phosphate.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09052</drugbank-id>\n",
            "      <name>Blinatumomab</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Blinatumomab.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09073</drugbank-id>\n",
            "      <name>Palbociclib</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Palbociclib.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09074</drugbank-id>\n",
            "      <name>Olaparib</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Olaparib.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09077</drugbank-id>\n",
            "      <name>Dinutuximab</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Dinutuximab.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09122</drugbank-id>\n",
            "      <name>Peginterferon beta-1a</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Peginterferon beta-1a.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12814</drugbank-id>\n",
            "      <name>Cepeginterferon alfa-2B</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Cepeginterferon alfa-2B.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00229</drugbank-id>\n",
            "      <name>Cefotiam</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotiam.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00267</drugbank-id>\n",
            "      <name>Cefmenoxime</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefmenoxime.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00274</drugbank-id>\n",
            "      <name>Cefmetazole</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefmetazole.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00430</drugbank-id>\n",
            "      <name>Cefpiramide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpiramide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00438</drugbank-id>\n",
            "      <name>Ceftazidime</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftazidime.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00447</drugbank-id>\n",
            "      <name>Loracarbef</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Loracarbef.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00456</drugbank-id>\n",
            "      <name>Cefalotin</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefalotin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00493</drugbank-id>\n",
            "      <name>Cefotaxime</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotaxime.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00535</drugbank-id>\n",
            "      <name>Cefdinir</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefdinir.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00567</drugbank-id>\n",
            "      <name>Cephalexin</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cephalexin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00671</drugbank-id>\n",
            "      <name>Cefixime</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefixime.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00689</drugbank-id>\n",
            "      <name>Cephaloglycin</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cephaloglycin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00833</drugbank-id>\n",
            "      <name>Cefaclor</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefaclor.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00923</drugbank-id>\n",
            "      <name>Ceforanide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceforanide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01066</drugbank-id>\n",
            "      <name>Cefditoren</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefditoren.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01112</drugbank-id>\n",
            "      <name>Cefuroxime</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefuroxime.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01139</drugbank-id>\n",
            "      <name>Cefapirin</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefapirin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01140</drugbank-id>\n",
            "      <name>Cefadroxil</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefadroxil.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01150</drugbank-id>\n",
            "      <name>Cefprozil</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefprozil.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01212</drugbank-id>\n",
            "      <name>Ceftriaxone</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftriaxone.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01326</drugbank-id>\n",
            "      <name>Cefamandole</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefamandole.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01327</drugbank-id>\n",
            "      <name>Cefazolin</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefazolin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01328</drugbank-id>\n",
            "      <name>Cefonicid</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefonicid.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01329</drugbank-id>\n",
            "      <name>Cefoperazone</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefoperazone.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01330</drugbank-id>\n",
            "      <name>Cefotetan</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefotetan.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01331</drugbank-id>\n",
            "      <name>Cefoxitin</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefoxitin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01332</drugbank-id>\n",
            "      <name>Ceftizoxime</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftizoxime.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01333</drugbank-id>\n",
            "      <name>Cefradine</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefradine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01413</drugbank-id>\n",
            "      <name>Cefepime</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefepime.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01414</drugbank-id>\n",
            "      <name>Cefacetrile</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefacetrile.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01415</drugbank-id>\n",
            "      <name>Ceftibuten</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftibuten.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01416</drugbank-id>\n",
            "      <name>Cefpodoxime</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpodoxime.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04570</drugbank-id>\n",
            "      <name>Latamoxef</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Latamoxef.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04918</drugbank-id>\n",
            "      <name>Ceftobiprole</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftobiprole.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06590</drugbank-id>\n",
            "      <name>Ceftaroline fosamil</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftaroline fosamil.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09008</drugbank-id>\n",
            "      <name>Cefaloridine</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefaloridine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09050</drugbank-id>\n",
            "      <name>Ceftolozane</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftolozane.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09062</drugbank-id>\n",
            "      <name>Cefminox</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefminox.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11367</drugbank-id>\n",
            "      <name>Cefroxadine</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefroxadine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11935</drugbank-id>\n",
            "      <name>Flomoxef</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Flomoxef.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13266</drugbank-id>\n",
            "      <name>Cefatrizine</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefatrizine.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13461</drugbank-id>\n",
            "      <name>Cefcapene</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefcapene.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13470</drugbank-id>\n",
            "      <name>Cefodizime</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefodizime.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13499</drugbank-id>\n",
            "      <name>Cefsulodin</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefsulodin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13504</drugbank-id>\n",
            "      <name>Cefetamet</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefetamet.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13638</drugbank-id>\n",
            "      <name>Cefbuperazone</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefbuperazone.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13667</drugbank-id>\n",
            "      <name>Cefozopran</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefozopran.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13682</drugbank-id>\n",
            "      <name>Cefpirome</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefpirome.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13778</drugbank-id>\n",
            "      <name>Cefazedone</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefazedone.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13821</drugbank-id>\n",
            "      <name>Ceftezole</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftezole.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14725</drugbank-id>\n",
            "      <name>Cefamandole nafate</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cefamandole nafate.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00254</drugbank-id>\n",
            "      <name>Doxycycline</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Doxycycline is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00207</drugbank-id>\n",
            "      <name>Azithromycin</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Azithromycin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09539</drugbank-id>\n",
            "      <name>Omega-3-acid ethyl esters</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00945</drugbank-id>\n",
            "      <name>Acetylsalicylic acid</name>\n",
            "      <description>Acetylsalicylic acid may increase the anticoagulant activities of Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01606</drugbank-id>\n",
            "      <name>Tazobactam</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Tazobactam is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00199</drugbank-id>\n",
            "      <name>Erythromycin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Erythromycin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00656</drugbank-id>\n",
            "      <name>Trazodone</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Trazodone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00620</drugbank-id>\n",
            "      <name>Triamcinolone</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Triamcinolone.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09079</drugbank-id>\n",
            "      <name>Nintedanib</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Nintedanib is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01175</drugbank-id>\n",
            "      <name>Escitalopram</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Escitalopram is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01104</drugbank-id>\n",
            "      <name>Sertraline</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Sertraline is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00232</drugbank-id>\n",
            "      <name>Methyclothiazide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Methyclothiazide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00436</drugbank-id>\n",
            "      <name>Bendroflumethiazide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Bendroflumethiazide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00562</drugbank-id>\n",
            "      <name>Benzthiazide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Benzthiazide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00606</drugbank-id>\n",
            "      <name>Cyclothiazide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cyclothiazide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00774</drugbank-id>\n",
            "      <name>Hydroflumethiazide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydroflumethiazide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00880</drugbank-id>\n",
            "      <name>Chlorothiazide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Chlorothiazide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00999</drugbank-id>\n",
            "      <name>Hydrochlorothiazide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Hydrochlorothiazide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01021</drugbank-id>\n",
            "      <name>Trichlormethiazide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Trichlormethiazide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01324</drugbank-id>\n",
            "      <name>Polythiazide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Polythiazide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13430</drugbank-id>\n",
            "      <name>Mebutizide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Mebutizide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13532</drugbank-id>\n",
            "      <name>Cyclopenthiazide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Cyclopenthiazide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB15861</drugbank-id>\n",
            "      <name>Buthiazide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Buthiazide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00783</drugbank-id>\n",
            "      <name>Estradiol</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Estradiol is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00977</drugbank-id>\n",
            "      <name>Ethinylestradiol</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Ethinylestradiol is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00834</drugbank-id>\n",
            "      <name>Mifepristone</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Mifepristone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13310</drugbank-id>\n",
            "      <name>Ormeloxifene</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Ormeloxifene is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00304</drugbank-id>\n",
            "      <name>Desogestrel</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Desogestrel is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00351</drugbank-id>\n",
            "      <name>Megestrol acetate</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Megestrol acetate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00367</drugbank-id>\n",
            "      <name>Levonorgestrel</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Levonorgestrel is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00603</drugbank-id>\n",
            "      <name>Medroxyprogesterone acetate</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Medroxyprogesterone acetate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00717</drugbank-id>\n",
            "      <name>Norethisterone</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Norethisterone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00823</drugbank-id>\n",
            "      <name>Ethynodiol diacetate</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Ethynodiol diacetate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB00957</drugbank-id>\n",
            "      <name>Norgestimate</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Norgestimate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01395</drugbank-id>\n",
            "      <name>Drospirenone</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Drospirenone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04839</drugbank-id>\n",
            "      <name>Cyproterone acetate</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Cyproterone acetate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB06730</drugbank-id>\n",
            "      <name>Gestodene</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Gestodene is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09123</drugbank-id>\n",
            "      <name>Dienogest</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Dienogest is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09371</drugbank-id>\n",
            "      <name>Norethynodrel</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Norethynodrel is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09389</drugbank-id>\n",
            "      <name>Norgestrel</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Norgestrel is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11619</drugbank-id>\n",
            "      <name>Gestrinone</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Gestrinone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12474</drugbank-id>\n",
            "      <name>Lynestrenol</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Lynestrenol is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13528</drugbank-id>\n",
            "      <name>Chlormadinone</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Chlormadinone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13563</drugbank-id>\n",
            "      <name>Norgestrienone</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Norgestrienone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13685</drugbank-id>\n",
            "      <name>Quingestanol</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Quingestanol is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13857</drugbank-id>\n",
            "      <name>Demegestone</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Demegestone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13981</drugbank-id>\n",
            "      <name>Nomegestrol acetate</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Nomegestrol acetate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14678</drugbank-id>\n",
            "      <name>Norethindrone enanthate</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Norethindrone enanthate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB15775</drugbank-id>\n",
            "      <name>Algestone acetophenide</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Algestone acetophenide.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12235</drugbank-id>\n",
            "      <name>Estetrol</name>\n",
            "      <description>The risk or severity of adverse effects can be increased when Estetrol is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11201</drugbank-id>\n",
            "      <name>Menthyl salicylate</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Menthyl salicylate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11323</drugbank-id>\n",
            "      <name>Glycol salicylate</name>\n",
            "      <description>The risk or severity of bleeding and hemorrhage can be increased when Glycol salicylate is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB15119</drugbank-id>\n",
            "      <name>Ropeginterferon alfa-2b</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Ropeginterferon alfa-2b.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB15575</drugbank-id>\n",
            "      <name>Padeliporfin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Padeliporfin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB16007</drugbank-id>\n",
            "      <name>Rurioctocog alfa pegol</name>\n",
            "      <description>The therapeutic efficacy of Rurioctocog alfa pegol can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14733</drugbank-id>\n",
            "      <name>Ceftobiprole medocaril</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Ceftobiprole medocaril.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB01051</drugbank-id>\n",
            "      <name>Novobiocin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Novobiocin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB03966</drugbank-id>\n",
            "      <name>Clorobiocin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Clorobiocin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04571</drugbank-id>\n",
            "      <name>Trioxsalen</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Trioxsalen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB04886</drugbank-id>\n",
            "      <name>Calanolide A</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Calanolide A is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB07118</drugbank-id>\n",
            "      <name>Hymecromone</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Hymecromone is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11390</drugbank-id>\n",
            "      <name>Coumaphos</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Coumaphos is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB11419</drugbank-id>\n",
            "      <name>Haloxon</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Haloxon is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12216</drugbank-id>\n",
            "      <name>Bergapten</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Bergapten is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB12823</drugbank-id>\n",
            "      <name>Tecarfarin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Tecarfarin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13155</drugbank-id>\n",
            "      <name>Esculin</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Esculin is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13177</drugbank-id>\n",
            "      <name>4-methylumbelliferyl beta-D-glucoside</name>\n",
            "      <description>The risk or severity of bleeding can be increased when 4-methylumbelliferyl beta-D-glucoside is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13279</drugbank-id>\n",
            "      <name>Carbocromen</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Carbocromen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB13912</drugbank-id>\n",
            "      <name>Coumermycin A1</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Coumermycin A1 is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09422</drugbank-id>\n",
            "      <name>Soybean oil</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Soybean oil.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB09567</drugbank-id>\n",
            "      <name>Olive oil</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Olive oil.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB15434</drugbank-id>\n",
            "      <name>Mosunetuzumab</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Mosunetuzumab.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB17472</drugbank-id>\n",
            "      <name>Pirtobrutinib</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Pirtobrutinib.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB14713</drugbank-id>\n",
            "      <name>Inotersen</name>\n",
            "      <description>The risk or severity of thrombocytopenia can be increased when Inotersen is combined with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB16791</drugbank-id>\n",
            "      <name>Etranacogene dezaparvovec</name>\n",
            "      <description>The therapeutic efficacy of Etranacogene dezaparvovec can be decreased when used in combination with Lepirudin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB15903</drugbank-id>\n",
            "      <name>Chlormadinone acetate</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Chlormadinone acetate.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB17048</drugbank-id>\n",
            "      <name>Plumbagin</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Plumbagin.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB18000</drugbank-id>\n",
            "      <name>Algestone</name>\n",
            "      <description>The therapeutic efficacy of Lepirudin can be decreased when used in combination with Algestone.</description>\n",
            "    </drug-interaction>\n",
            "    <drug-interaction>\n",
            "      <drugbank-id>DB07767</drugbank-id>\n",
            "      <name>Ferulic acid</name>\n",
            "      <description>The risk or severity of bleeding can be increased when Lepirudin is combined with Ferulic acid.</description>\n",
            "    </drug-interaction>\n",
            "  </drug-interactions>\n",
            "  <sequences>\n",
            "    <sequence format=\"FASTA\">&gt;DB00001 sequence\n",
            "LTYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIP\n",
            "EEYLQ</sequence>\n",
            "  </sequences>\n",
            "  <experimental-properties>\n",
            "    <property>\n",
            "      <kind>Water Solubility</kind>\n",
            "      <value>Soluble</value>\n",
            "      <source>Health Canada drug label</source>\n",
            "    </property>\n",
            "    <property>\n",
            "      <kind>Melting Point</kind>\n",
            "      <value>65 °C</value>\n",
            "      <source>Otto, A. &amp; Seckler, R. Eur. J. Biochem. 202:67-73 (1991)</source>\n",
            "    </property>\n",
            "    <property>\n",
            "      <kind>Isoelectric Point</kind>\n",
            "      <value>3.7</value>\n",
            "      <source>Health Canada drug label</source>\n",
            "    </property>\n",
            "    <property>\n",
            "      <kind>Molecular Weight</kind>\n",
            "      <value>6979.0</value>\n",
            "      <source/>\n",
            "    </property>\n",
            "    <property>\n",
            "      <kind>Molecular Formula</kind>\n",
            "      <value>C287H440N80O111S6</value>\n",
            "      <source/>\n",
            "    </property>\n",
            "  </experimental-properties>\n",
            "  <external-identifiers>\n",
            "    <external-identifier>\n",
            "      <resource>Drugs Product Database (DPD)</resource>\n",
            "      <identifier>11916</identifier>\n",
            "    </external-identifier>\n",
            "    <external-identifier>\n",
            "      <resource>PubChem Substance</resource>\n",
            "      <identifier>46507011</identifier>\n",
            "    </external-identifier>\n",
            "    <external-identifier>\n",
            "      <resource>KEGG Drug</resource>\n",
            "      <identifier>D06880</identifier>\n",
            "    </external-identifier>\n",
            "    <external-identifier>\n",
            "      <resource>PharmGKB</resource>\n",
            "      <identifier>PA450195</identifier>\n",
            "    </external-identifier>\n",
            "    <external-identifier>\n",
            "      <resource>UniProtKB</resource>\n",
            "      <identifier>P01050</identifier>\n",
            "    </external-identifier>\n",
            "    <external-identifier>\n",
            "      <resource>Therapeutic Targets Database</resource>\n",
            "      <identifier>DAP000541</identifier>\n",
            "    </external-identifier>\n",
            "    <external-identifier>\n",
            "      <resource>Wikipedia</resource>\n",
            "      <identifier>Lepirudin</identifier>\n",
            "    </external-identifier>\n",
            "    <external-identifier>\n",
            "      <resource>ChEMBL</resource>\n",
            "      <identifier>CHEMBL1201666</identifier>\n",
            "    </external-identifier>\n",
            "    <external-identifier>\n",
            "      <resource>RxCUI</resource>\n",
            "      <identifier>237057</identifier>\n",
            "    </external-identifier>\n",
            "  </external-identifiers>\n",
            "  <external-links>\n",
            "    <external-link>\n",
            "      <resource>RxList</resource>\n",
            "      <url>http://www.rxlist.com/cgi/generic/lepirudin.htm</url>\n",
            "    </external-link>\n",
            "    <external-link>\n",
            "      <resource>Drugs.com</resource>\n",
            "      <url>http://www.drugs.com/cdi/lepirudin.html</url>\n",
            "    </external-link>\n",
            "  </external-links>\n",
            "  <pathways>\n",
            "    <pathway>\n",
            "      <smpdb-id>SMP0000278</smpdb-id>\n",
            "      <name>Lepirudin Action Pathway</name>\n",
            "      <category>drug_action</category>\n",
            "      <drugs>\n",
            "        <drug>\n",
            "          <drugbank-id>DB00001</drugbank-id>\n",
            "          <name>Lepirudin</name>\n",
            "        </drug>\n",
            "        <drug>\n",
            "          <drugbank-id>DB01022</drugbank-id>\n",
            "          <name>Phylloquinone</name>\n",
            "        </drug>\n",
            "        <drug>\n",
            "          <drugbank-id>DB01373</drugbank-id>\n",
            "          <name>Calcium</name>\n",
            "        </drug>\n",
            "      </drugs>\n",
            "      <enzymes>\n",
            "        <uniprot-id>P00734</uniprot-id>\n",
            "        <uniprot-id>P00748</uniprot-id>\n",
            "        <uniprot-id>P02452</uniprot-id>\n",
            "        <uniprot-id>P03952</uniprot-id>\n",
            "        <uniprot-id>P03951</uniprot-id>\n",
            "        <uniprot-id>P00740</uniprot-id>\n",
            "        <uniprot-id>P00451</uniprot-id>\n",
            "        <uniprot-id>P12259</uniprot-id>\n",
            "        <uniprot-id>P00742</uniprot-id>\n",
            "        <uniprot-id>P02671</uniprot-id>\n",
            "        <uniprot-id>P02675</uniprot-id>\n",
            "        <uniprot-id>P02679</uniprot-id>\n",
            "        <uniprot-id>P00488</uniprot-id>\n",
            "        <uniprot-id>P05160</uniprot-id>\n",
            "        <uniprot-id>P00747</uniprot-id>\n",
            "        <uniprot-id>P00750</uniprot-id>\n",
            "        <uniprot-id>P08709</uniprot-id>\n",
            "        <uniprot-id>P13726</uniprot-id>\n",
            "        <uniprot-id>Q9BQB6</uniprot-id>\n",
            "        <uniprot-id>P38435</uniprot-id>\n",
            "      </enzymes>\n",
            "    </pathway>\n",
            "  </pathways>\n",
            "  <reactions>\n",
            "    <reaction>\n",
            "      <sequence>1</sequence>\n",
            "      <left-element>\n",
            "        <drugbank-id>DB00001</drugbank-id>\n",
            "        <name>Lepirudin</name>\n",
            "      </left-element>\n",
            "      <right-element>\n",
            "        <drugbank-id>DBMET03462</drugbank-id>\n",
            "        <name>M1 (1-64)</name>\n",
            "      </right-element>\n",
            "      <enzymes/>\n",
            "    </reaction>\n",
            "    <reaction>\n",
            "      <sequence>2</sequence>\n",
            "      <left-element>\n",
            "        <drugbank-id>DBMET03462</drugbank-id>\n",
            "        <name>M1 (1-64)</name>\n",
            "      </left-element>\n",
            "      <right-element>\n",
            "        <drugbank-id>DBMET03463</drugbank-id>\n",
            "        <name>M2 (1-63)</name>\n",
            "      </right-element>\n",
            "      <enzymes/>\n",
            "    </reaction>\n",
            "    <reaction>\n",
            "      <sequence>3</sequence>\n",
            "      <left-element>\n",
            "        <drugbank-id>DBMET03463</drugbank-id>\n",
            "        <name>M2 (1-63)</name>\n",
            "      </left-element>\n",
            "      <right-element>\n",
            "        <drugbank-id>DBMET03464</drugbank-id>\n",
            "        <name>M3 (1-62)</name>\n",
            "      </right-element>\n",
            "      <enzymes/>\n",
            "    </reaction>\n",
            "    <reaction>\n",
            "      <sequence>4</sequence>\n",
            "      <left-element>\n",
            "        <drugbank-id>DBMET03464</drugbank-id>\n",
            "        <name>M3 (1-62)</name>\n",
            "      </left-element>\n",
            "      <right-element>\n",
            "        <drugbank-id>DBMET03465</drugbank-id>\n",
            "        <name>M4 (1-61)</name>\n",
            "      </right-element>\n",
            "      <enzymes/>\n",
            "    </reaction>\n",
            "  </reactions>\n",
            "  <snp-effects/>\n",
            "  <snp-adverse-drug-reactions/>\n",
            "  <targets>\n",
            "    <target position=\"1\">\n",
            "      <id>BE0000048</id>\n",
            "      <name>Prothrombin</name>\n",
            "      <organism>Humans</organism>\n",
            "      <actions>\n",
            "        <action>inhibitor</action>\n",
            "      </actions>\n",
            "      <references>\n",
            "        <articles>\n",
            "          <article>\n",
            "            <ref-id>A1703</ref-id>\n",
            "            <pubmed-id>10505536</pubmed-id>\n",
            "            <citation>Turpie AG: Anticoagulants in acute coronary syndromes. Am J Cardiol. 1999 Sep 2;84(5A):2M-6M.</citation>\n",
            "          </article>\n",
            "          <article>\n",
            "            <ref-id>A1705</ref-id>\n",
            "            <pubmed-id>10912644</pubmed-id>\n",
            "            <citation>Warkentin TE: Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med. 2000 Jul;6(4):343-51.</citation>\n",
            "          </article>\n",
            "          <article>\n",
            "            <ref-id>A1707</ref-id>\n",
            "            <pubmed-id>11055889</pubmed-id>\n",
            "            <citation>Eriksson BI: New therapeutic options in deep vein thrombosis prophylaxis. Semin Hematol. 2000 Jul;37(3 Suppl 5):7-9.</citation>\n",
            "          </article>\n",
            "          <article>\n",
            "            <ref-id>A1709</ref-id>\n",
            "            <pubmed-id>11467439</pubmed-id>\n",
            "            <citation>Fabrizio MC: Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Technol. 2001 May;33(2):117-25.</citation>\n",
            "          </article>\n",
            "          <article>\n",
            "            <ref-id>A1711</ref-id>\n",
            "            <pubmed-id>11807012</pubmed-id>\n",
            "            <citation>Szaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002 Feb 1;99(3):1053-9.</citation>\n",
            "          </article>\n",
            "          <article>\n",
            "            <ref-id>A264250</ref-id>\n",
            "            <pubmed-id>37713619</pubmed-id>\n",
            "            <citation>Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.</citation>\n",
            "          </article>\n",
            "        </articles>\n",
            "        <textbooks/>\n",
            "        <links>\n",
            "          <link>\n",
            "            <ref-id>L41539</ref-id>\n",
            "            <title>Health Canada Approved Drug Products: Refludan (lepirudin) lyophilized powder for intravenous injection</title>\n",
            "            <url>https://pdf.hres.ca/dpd_pm/00004023.PDF</url>\n",
            "          </link>\n",
            "        </links>\n",
            "        <attachments/>\n",
            "      </references>\n",
            "      <known-action>yes</known-action>\n",
            "      <polypeptide id=\"P00734\" source=\"Swiss-Prot\">\n",
            "        <name>Prothrombin</name>\n",
            "        <general-function>Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing. Activates coagulation factor XI (F11); activation is promoted by the contact with negatively charged surfaces (PubMed:2019570, PubMed:21976677). Triggers the production of pro-inflammatory cytokines, such as MCP-1/CCL2 and IL8/CXCL8, in endothelial cells (PubMed:30568593, PubMed:9780208)</general-function>\n",
            "        <specific-function>calcium ion binding</specific-function>\n",
            "        <gene-name>F2</gene-name>\n",
            "        <locus>11p11.2</locus>\n",
            "        <cellular-location>Secreted, extracellular space</cellular-location>\n",
            "        <transmembrane-regions/>\n",
            "        <signal-regions>1-24</signal-regions>\n",
            "        <theoretical-pi>5.7</theoretical-pi>\n",
            "        <molecular-weight>70036.295</molecular-weight>\n",
            "        <chromosome-location>11</chromosome-location>\n",
            "        <organism ncbi-taxonomy-id=\"9606\">Humans</organism>\n",
            "        <external-identifiers>\n",
            "          <external-identifier>\n",
            "            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>\n",
            "            <identifier>HGNC:3535</identifier>\n",
            "          </external-identifier>\n",
            "          <external-identifier>\n",
            "            <resource>GenAtlas</resource>\n",
            "            <identifier>F2</identifier>\n",
            "          </external-identifier>\n",
            "          <external-identifier>\n",
            "            <resource>GeneCards</resource>\n",
            "            <identifier>F2</identifier>\n",
            "          </external-identifier>\n",
            "          <external-identifier>\n",
            "            <resource>GenBank Gene Database</resource>\n",
            "            <identifier>M17262</identifier>\n",
            "          </external-identifier>\n",
            "          <external-identifier>\n",
            "            <resource>GenBank Protein Database</resource>\n",
            "            <identifier>339641</identifier>\n",
            "          </external-identifier>\n",
            "          <external-identifier>\n",
            "            <resource>Guide to Pharmacology</resource>\n",
            "            <identifier>2362</identifier>\n",
            "          </external-identifier>\n",
            "          <external-identifier>\n",
            "            <resource>UniProtKB</resource>\n",
            "            <identifier>P00734</identifier>\n",
            "          </external-identifier>\n",
            "          <external-identifier>\n",
            "            <resource>UniProt Accession</resource>\n",
            "            <identifier>THRB_HUMAN</identifier>\n",
            "          </external-identifier>\n",
            "        </external-identifiers>\n",
            "        <synonyms>\n",
            "          <synonym>3.4.21.5</synonym>\n",
            "          <synonym>Coagulation factor II</synonym>\n",
            "        </synonyms>\n",
            "        <amino-acid-sequence format=\"FASTA\">&gt;lcl|BSEQ0016004|Prothrombin\n",
            "MAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\n",
            "VEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\n",
            "NITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\n",
            "CSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\n",
            "QAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\n",
            "DGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\n",
            "DGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\n",
            "DLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\n",
            "VCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\n",
            "RIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\n",
            "GFYTHVFRLKKWIQKVIDQFGE</amino-acid-sequence>\n",
            "        <gene-sequence format=\"FASTA\">&gt;lcl|BSEQ0016005|Prothrombin (F2)\n",
            "ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\n",
            "CTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\n",
            "GTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC\n",
            "GTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\n",
            "GATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\n",
            "GCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\n",
            "AACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\n",
            "GAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\n",
            "GACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\n",
            "TGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\n",
            "GGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\n",
            "TACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\n",
            "CAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\n",
            "TTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\n",
            "GGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\n",
            "GATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\n",
            "CAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\n",
            "CTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\n",
            "GACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\n",
            "CTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\n",
            "GTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\n",
            "GACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG\n",
            "ATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\n",
            "CGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\n",
            "GTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\n",
            "GTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\n",
            "AGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\n",
            "CGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\n",
            "GGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\n",
            "CGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\n",
            "GGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\n",
            "GGAGAGTAG</gene-sequence>\n",
            "        <pfams>\n",
            "          <pfam>\n",
            "            <identifier>PF00051</identifier>\n",
            "            <name>Kringle</name>\n",
            "          </pfam>\n",
            "          <pfam>\n",
            "            <identifier>PF00089</identifier>\n",
            "            <name>Trypsin</name>\n",
            "          </pfam>\n",
            "          <pfam>\n",
            "            <identifier>PF09396</identifier>\n",
            "            <name>Thrombin_light</name>\n",
            "          </pfam>\n",
            "          <pfam>\n",
            "            <identifier>PF00594</identifier>\n",
            "            <name>Gla</name>\n",
            "          </pfam>\n",
            "        </pfams>\n",
            "        <go-classifiers>\n",
            "          <go-classifier>\n",
            "            <category>component</category>\n",
            "            <description>collagen-containing extracellular matrix</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>function</category>\n",
            "            <description>heparin binding</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>function</category>\n",
            "            <description>lipopolysaccharide binding</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>function</category>\n",
            "            <description>receptor ligand activity</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>function</category>\n",
            "            <description>signaling receptor binding</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>antimicrobial humoral immune response mediated by antimicrobial peptide</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>cytolysis by host of symbiont cells</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>G protein-coupled receptor signaling pathway</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>ligand-gated ion channel signaling pathway</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>negative regulation of blood coagulation</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>negative regulation of cytokine production involved in inflammatory response</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>neutrophil-mediated killing of gram-negative bacterium</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>positive regulation of cell population proliferation</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>positive regulation of insulin secretion</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>positive regulation of lipid kinase activity</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>positive regulation of protein localization to nucleus</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>positive regulation of receptor signaling pathway via JAK-STAT</description>\n",
            "          </go-classifier>\n",
            "          <go-classifier>\n",
            "            <category>process</category>\n",
            "            <description>regulation of cytosolic calcium ion concentration</description>\n",
            "          </go-classifier>\n",
            "        </go-classifiers>\n",
            "      </polypeptide>\n",
            "    </target>\n",
            "  </targets>\n",
            "  <enzymes/>\n",
            "  <carriers/>\n",
            "  <transporters/>\n",
            "</drug>\n",
            "\n",
            "\n",
            "'calpol' in drug_data: False\n",
            "'paracetamol' in drug_data: False\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Step 5: Embedding and Semantic Retrieval\n",
        "\n",
        "Index DrugBank drug names into a FAISS vector store for semantic retrieval. Test retrieval with the detected drug name or a fallback query."
      ],
      "metadata": {
        "id": "Mx1PyOrnW7WA"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def initialize_vector_store(drug_data: Dict[str, Dict]) -> tuple:\n",
        "    \"\"\"Index DrugBank data into a FAISS vector store.\"\"\"\n",
        "    drug_names = list(drug_data.keys())\n",
        "    embeddings = embedder.encode(drug_names, convert_to_numpy=True)\n",
        "\n",
        "    # FAISS Index\n",
        "    dimension = embeddings.shape[1]\n",
        "    index = faiss.IndexFlatL2(dimension)\n",
        "    index.add(embeddings)\n",
        "    return index, drug_names, embeddings\n",
        "\n",
        "def retrieve_drug_info(query: str, index, drug_names: List[str], drug_data: Dict[str, Dict], top_k: int = 3) -> List[Dict]:\n",
        "    \"\"\"Retrieve top-k similar drug entries.\"\"\"\n",
        "    query_embedding = embedder.encode([query], convert_to_numpy=True)\n",
        "    distances, indices = index.search(query_embedding, top_k)\n",
        "    results = []\n",
        "    for i, idx in enumerate(indices[0]):\n",
        "        drug_name = drug_names[idx]\n",
        "        similarity = 1 - (distances[0][i] / np.linalg.norm(query_embedding))  # Normalize to [0,1]\n",
        "        if similarity >= SIMILARITY_THRESHOLD:\n",
        "            results.append({\"name\": drug_name, \"info\": drug_data[drug_name], \"similarity\": similarity})\n",
        "    return results\n",
        "\n",
        "# Initialize vector store\n",
        "index, drug_names, _ = initialize_vector_store(drug_data)\n",
        "\n",
        "# Test retrieval\n",
        "test_query = drug_entities[0] if drug_entities else \"aspirin\"  # Use detected entity or fallback\n",
        "retrieved_info = retrieve_drug_info(test_query, index, drug_names, drug_data)\n",
        "print(f\"Retrieved Info for '{test_query}':\")\n",
        "for item in retrieved_info:\n",
        "    print(f\"- {item['name']} (Similarity: {item['similarity']:.2f}): {item['info']}\")"
      ],
      "metadata": {
        "id": "pMhitV9mW8qv"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Step 6: Response Generation\n",
        "\n",
        "Generate a concise drug summary using OpenAI GPT-3.5-turbo. Test with the retrieved drug information."
      ],
      "metadata": {
        "id": "kL6ajgIhW-cI"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def generate_response(drug_info: List[Dict]) -> str:\n",
        "    \"\"\"Generate a concise drug summary using OpenAI.\"\"\"\n",
        "    if not drug_info:\n",
        "        return \"No information found for this drug.\"\n",
        "\n",
        "    drug = drug_info[0]  # Take top match\n",
        "    info = drug[\"info\"]\n",
        "    prompt = f\"\"\"\n",
        "    Provide a concise summary of the following drug information:\n",
        "    Drug: {drug['name']}\n",
        "    Usage: {info.get('indications', 'Not specified')}\n",
        "    Dosage: {info.get('dosage', 'Not specified')}\n",
        "    Warnings: {info.get('contraindications', 'Not specified')}\n",
        "    Interactions: {info.get('interactions', 'Not specified')}\n",
        "    Side Effects: {info.get('side_effects', 'Not specified')}\n",
        "    Include all available fields in a readable format. If insufficient data, return 'No detailed information available.'\n",
        "    \"\"\"\n",
        "    response = openai.ChatCompletion.create(\n",
        "        model=\"gpt-3.5-turbo\",\n",
        "        messages=[{\"role\": \"user\", \"content\": prompt}],\n",
        "        max_tokens=200\n",
        "    )\n",
        "    return response.choices[0].message[\"content\"]\n",
        "\n",
        "# Test response generation\n",
        "response = generate_response(retrieved_info)\n",
        "print(\"Generated Response:\")\n",
        "print(response)"
      ],
      "metadata": {
        "id": "Z0WLY7pGW_z6"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "markdown",
      "source": [
        "## Step 7: Full Pipeline\n",
        "\n",
        "Combine all steps to process the medicine image and retrieve drug facts. Print intermediate outputs to debug and verify each stage."
      ],
      "metadata": {
        "id": "3GtdEknTXBdZ"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "def process_medicine_image(image_path: str, drug_data: Dict[str, Dict], index, drug_names: List[str]) -> str:\n",
        "    \"\"\"Full pipeline for medicine identification and drug facts retrieval.\"\"\"\n",
        "    # Preprocess and extract text\n",
        "    preprocessed_img = preprocess_image(image_path)\n",
        "    raw_text = extract_text(preprocessed_img)\n",
        "    print(\"Extracted Text:\", raw_text)\n",
        "\n",
        "    # Clean text and extract entities\n",
        "    drug_entities = clean_and_extract_entities(raw_text)\n",
        "    if not drug_entities:\n",
        "        return \"No drug name identified in the image.\"\n",
        "    print(\"Detected Drug Entities:\", drug_entities)\n",
        "\n",
        "    # Retrieve and generate response\n",
        "    query = drug_entities[0]  # Use first detected drug name\n",
        "    drug_info = retrieve_drug_info(query, index, drug_names, drug_data)\n",
        "    print(\"Retrieved Info:\", [{\"name\": item[\"name\"], \"similarity\": item[\"similarity\"]} for item in drug_info])\n",
        "    response = generate_response(drug_info)\n",
        "\n",
        "    return response\n",
        "\n",
        "# Run the pipeline\n",
        "result = process_medicine_image(IMAGE_PATH, drug_data, index, drug_names)\n",
        "print(\"Drug Facts Summary:\")\n",
        "print(result)"
      ],
      "metadata": {
        "id": "ABJkrrX_XDg2"
      },
      "execution_count": null,
      "outputs": []
    }
  ]
}